donepezil has been researched along with Acute Confusional Senile Dementia in 1573 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer's disease." | 9.27 | A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study. ( Barker, S; Crutch, S; Cutler, D; Douglas, J; Epie, N; Frost, C; Knight, W; Kukkastenvehmas, R; Ridha, BH; Rossor, MN; Warrington, EK, 2018) |
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 9.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| "APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy." | 9.22 | Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. ( De Beaumont, L; Dea, D; Lamarre-Théroux, L; Pelleieux, S; Poirier, J, 2016) |
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 9.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| "The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to explore which tests and their measures are able to detect cognitive change after a single dose of donepezil in Alzheimer disease (AD) patients." | 9.20 | Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease. ( Kaubrys, G; Kuzmickienė, J, 2015) |
| "Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD)." | 9.17 | Concentration of donepezil to the cognitive response in Alzheimer disease. ( Chen, CH; Chen, SH; Chou, MC; Li, CH; Liu, CK; Yang, YH, 2013) |
| "To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial." | 9.15 | SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. ( Dixon, R; Gold, M; Hopton, G; Hunter, J; Jacobs, G; Maher-Edwards, G; Williams, P, 2011) |
| " Twenty-three patients with mild-to-moderate Alzheimer disease and apnea-hypopnea index (AHI) > 5/h were allocated to two groups: donepezil treated (n = 11) and placebo treated (n = 12)." | 9.13 | Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. ( Guilleminault, C; Moraes, W; Poyares, D; Sukys-Claudino, L; Tufik, S, 2008) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 9.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 9.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 9.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "Examine the effects of donepezil on sleep and rapid eye movement (REM) sleep electroencephalogram (EEG) in patients with Alzheimer disease, using polysomnography, and the correlation between REM sleep EEG parameters and cognitive scores." | 9.12 | The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. ( Bertolucci, PH; Guilleminault, C; Moraes, Wdos S; Poyares, DR; Ramos, LR; Tufik, S, 2006) |
| "The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses." | 9.12 | A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. ( Olin, JT; Schmitt, FA; van Dyck, CH, 2006) |
| "To evaluate the clinical efficacy and safety of akatinol memantine in the treatment of patients with mild to moderate Alzheimer disease (AD)." | 9.12 | [Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial]. ( Hu, HT; Ji, CJ; Tang, HC; Wang, YH; Xu, T; Yao, JL; Yu, HZ; Zhang, ZX, 2006) |
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 9.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| "To examine whether the presence of domain-specific cognitive impairments would predict a response to donepezil medication in patients with mild-to-moderate Alzheimer disease (AD)." | 9.12 | Cognitive predictors of donepezil therapy response in Alzheimer disease. ( Bergman, H; Chertkow, H; Murtha, S; Phillips, N; Saumier, D; Whitehead, V, 2007) |
| "To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)." | 9.12 | Donepezil preserves cognition and global function in patients with severe Alzheimer disease. ( Black, SE; Doody, R; Jambor, KM; Li, H; McRae, T; Perdomo, CA; Richardson, S; Sun, Y; Xu, Y, 2007) |
| "To determine the efficacy of donepezil in the treatment of neuropsychiatric symptoms in patients with Alzheimer disease (AD) in a randomized withdrawal study." | 9.11 | The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. ( Clare, C; Damms, J; Dean, C; Hogg, F; Holmes, C; Langley, A; Olivieri, S; Pandita-Gunawardena, ND; Vethanayagam, S; Wilkinson, D, 2004) |
| "To investigate the costs to society of Alzheimer disease (AD) care in a multinational, randomized, placebo-controlled trial of donepezil in patients with moderate to severe AD." | 9.11 | Economic evaluation of donepezil in moderate to severe Alzheimer disease. ( Feldman, H; Gauthier, S; Hecker, J; Hux, M; Mastey, V; Schwam, EM; Shah, S; Vellas, B; Xu, Y, 2004) |
| "To evaluate the efficacy of donepezil in patients with early-stage Alzheimer disease." | 9.11 | Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. ( Goldman, R; Ieni, J; Kumar, D; Nunez, M; Richardson, S; Seltzer, B; Zolnouni, P, 2004) |
| " Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer's Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant." | 9.11 | Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? ( Hashimoto, M; Kazui, H; Matsumoto, K; Mori, E; Nakano, Y; Yasuda, M, 2005) |
| "To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment." | 9.10 | Down syndrome and Alzheimer disease: response to donepezil. ( Doran, E; Lott, IT; Nelson, L; Osann, K, 2002) |
| "Donepezil hydrochloride is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderately severe Alzheimer disease (AD)." | 9.09 | Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. ( Doody, RS; Geldmacher, DS; Gordon, B; Perdomo, CA; Pratt, RD, 2001) |
| "Donepezil hydrochloride (Aricept) is a selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer disease." | 9.08 | Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. ( Doody, RS; Friedhoff, LT; Mohs, RC; Rogers, SL, 1998) |
| "This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions." | 8.95 | Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. ( Chan, PT; Chang, PC; Chen, CY; Chen, R; Chou, KR; Chu, H; Lin, YC, 2017) |
| "We herein report an 81-year-old woman with Alzheimer's disease (AD) in who donepezil, a cholinesterase inhibitor (ChEI), caused cervical dystonia." | 8.90 | Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors. ( Hanashiro, S; Ikeda, K; Iwasaki, Y; Kawabe, K; Sawada, M; Yanagihashi, M, 2014) |
| "To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug-drug interactions, and the therapeutic issues concerning the use of donepezil in patients with Alzheimer disease." | 8.80 | Donepezil use in Alzheimer disease. ( Barner, EL; Gray, SL, 1998) |
| "Providing evidence on donepezil and memantine administration as extemporaneous combination (DM-EXT) to treat Alzheimer Disease (AD) in Italy, and describing demographic and clinical features of AD patients prescribed DM-EXT." | 8.31 | Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data. ( Falato, S; Padovani, A; Pegoraro, V, 2023) |
| "To investigate the clinical effect of donepezil combined with hydrogen-oxygen mixture inhalation in the treatment of patients with Alzheimer disease (AD), a total of 273 AD patients admitted to our hospital from March 2018 to March 2022 were retrospectively analyzed and assigned into an observation group (n = 138) and a control group (n = 135) according to the different treatment that they received." | 8.31 | Efficacy of donepezil plus hydrogen-oxygen mixture inhalation for treatment of patients with Alzheimer disease: A retrospective study. ( Dan, Z; Li, H; Xie, J, 2023) |
| "In this study, a Drosophila AD model and SH-SY5Y clles were used to assess the toxicity of SIP3, and APPswe/PS1dE9 (APP/PS1) transgenic mice were used to evaluate the cognitive-behavioral and depression-like behavior effect of SIP3 and donepezil co-treatment on symptoms of AD." | 8.12 | Co-Treatment with the Herbal Medicine SIP3 and Donepezil Improves Memory and Depression in the Mouse Model of Alzheimer's Disease. ( Chin, YW; Choi, H; Kanmani, S; Kim, KK; Kim, KW; Kim, SN; Kim, YM; Koo, BS; Liu, QF; Son, T, 2022) |
| "When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 8.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
| "Donepezil is one of the most commonly prescribed drugs for the treatment of Alzheimer disease." | 8.02 | Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients With Alzheimer Disease. ( Kagawa, Y; Maeda, T; Obi, T; Ueno, A; Yamamoto, Y, 2021) |
| "Over the 48-week treatment period, donepezil combined NBP group had slower cognitive decline and better activities of daily living in patients with mild to moderate AD." | 8.02 | Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study. ( Gao, F; Guo, X; Liu, J; Lu, W; Ma, L; Qu, Q; Quan, Q; Su, H; Wang, J; Zhang, H, 2021) |
| "The purpose of the paper is to systematically investigate the association between the occurrence of bradycardia in adults and the usage of donepezil using clinical data derived from the FDA Adverse Event Reporting System (FAERS) database." | 8.02 | Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Eckhoff, K; Jose, RP; Luboff, H; Morris, R; Pham, M; Rohlsen-Neal, D, 2021) |
| "Patients prescribed rivastigmine were more likely to report pneumonia as an adverse event than many drugs except galantamine." | 8.02 | The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Morris, R; Umeukeje, G, 2021) |
| "This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD)." | 7.96 | Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option. ( Han, W; Li, H; Yang, H, 2020) |
| "Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports." | 7.91 | Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. ( Fleet, JL; Garg, AX; McArthur, E; Montero-Odasso, M; Patel, A; Weir, MA, 2019) |
| "The results of this study suggested that early induction of donepezil treatment was necessary when apparent cognitive decline was identified during the treatment of geriatric depression." | 7.83 | Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression. ( Hoshino, R; Inoue, J; Ishida, W; Nojima, H; Okamoto, N, 2016) |
| "Donepezil is a drug usually administered by oral route for Alzheimer disease treatment, but several gastric side effects have been reported as diarrhea, nausea, and anorexia." | 7.83 | Exploring the Phase Behavior of Monoolein/Oleic Acid/Water Systems for Enhanced Donezepil Administration for Alzheimer Disease Treatment. ( Carvalho, FC; Pereira, GR; Ruela, AL, 2016) |
| "To compare the outcome of donepezil treatment in ethnically diverse Alzheimer disease (AD) patients with ethnically diverse AD patients who did not receive donepezil." | 7.81 | Donepezil treatment in ethnically diverse patients with Alzheimer disease. ( Ashford, JW; Kraemer, HC; O'Hara, R; Ringman, JM; Taylor, JL; Tinklenberg, JR; Yaffe, K; Yesavage, JA, 2015) |
| "An 80-year-old Greek woman with Alzheimer disease was admitted to the hospital with a sudden onset of myoclonus in both upper and lower extremities after receiving 30 mg of donepezil daily for 25 days." | 7.80 | Donepezil-induced myoclonus in a patient with Alzheimer disease. ( Anagnostou, E; Bougea, A; Gerakoulis, S; Kapaki, E; Kararizou, E; Paraskevas, G, 2014) |
| "We have previously demonstrated that the chronic intervention in the cholinergic system by donepezil, an acetylcholinesterase inhibitor, plays a beneficial role in suppressing long-term cardiac remodeling after myocardial infarction (MI)." | 7.77 | Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice. ( Arikawa, M; Handa, T; Kakinuma, Y; Sato, T; Yamasaki, F, 2011) |
| "To evaluate the influence of the single nucleotide polymorphism rs1080985 in the cytochrome P450 2D6 (CYP2D6) gene on the efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD)." | 7.75 | Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. ( Bizzarro, A; Cascavilla, L; D'Onofrio, G; Dallapiccola, B; Daniele, A; Franceschi, M; Mangialasche, F; Masullo, C; Matera, MG; Mecocci, P; Paris, F; Pilotto, A; Seripa, D, 2009) |
| "To determine if results from randomized clinical trials of donepezil in Alzheimer disease (AD) patients can be applied to AD patients in clinical practice by comparing the findings from a Nordic one-year randomized AD donepezil trial with data from a one-year prospective, observational study of AD patients." | 7.74 | Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? ( Ashford, JW; Kraemer, HC; Ross, L; Sheikh, J; Taylor, JL; Tinklenberg, JR; Yaffe, K; Yesavage, JA, 2007) |
| "The comparative effects of a newly described specific alpha7 nAChR partial agonist, S 24795, and a cholinesterase inhibitor, donepezil, currently used as a symptomatic Alzheimer's disease treatment were studied in two mouse models of aging-related memory deficits." | 7.74 | Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. ( Desmedt, A; Marighetto, A; Morain, P; Philippin, JN; Trocmé-Thibierge, C; Valerio, S, 2008) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 7.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "In patients with AD treated with donepezil, a noninvasive evaluation identified a probable cause of syncope in over two-thirds of patients." | 7.73 | Causes of syncope in patients with Alzheimer's disease treated with donepezil. ( Bordier, P; Garrigue, S; Gencel, L; Lafitte, A; Lanusse, S; Reynard, C; Robert, F, 2005) |
| "The goal of this study was to investigate whether donepezil treatment is associated with reduced mortality in nursing home residents who have dementia." | 7.73 | Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? ( Gasper, MC; Lapane, KL; Ott, BR, 2005) |
| "The purpose of this study was to estimate the impact of donepezil use on health care costs and utilization in patients with mild to moderate AD and related dementias." | 7.73 | Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. ( Fillit, H; Hill, J; Lu, S, 2005) |
| "Donepezil, a selective acetylcholinesterase (AChE) inhibitor, has been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbit eyes." | 7.73 | Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients. ( Berkhoff, M; Cattapan-Ludewig, K; Daepp, GC; Estermann, S; Frueh, BE; Goldblum, D, 2006) |
| "To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer's disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy." | 7.72 | Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. ( Abe, K; Hanyu, H; Sakurai, H; Takasaki, M; Tanaka, Y, 2003) |
| "A case of hypnopompic hallucinations associated with donepezil is described." | 7.70 | Hypnopompic hallucinations with donepezil. ( Gray, R; Yorston, GA, 2000) |
| "Donepezil 23 mg is considered for Alzheimer's disease (AD) to optimize cognitive benefits; however, increased adverse events (AEs) can negatively influence drug adherence." | 7.01 | Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. ( Han, HJ; Hong, YJ; Kim, HJ; Kim, S; Kwon, M; Lee, JH; Lee, Y; Park, KW; Yang, DW; Youn, YC, 2021) |
| "Donepezil is widely used to treat Alzheimer's disease (AD), but detecting early response remains challenging for clinicians." | 6.90 | Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial. ( Berger, JT; Foldi, NS; Kaplan, L; Ly, JJ; Macina, LO; Stewart, JL; Van Dyk, K; Vila-Castelar, C, 2019) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 6.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| "Donepezil 5 mg/day was started after initial hMWM testing in the treated group (n = 12), and after 28 days, the dose was increased to 10 mg/day." | 6.79 | Effect of donepezil in Alzheimer disease can be measured by a computerized human analog of the Morris water maze. ( Amlerova, J; Andel, R; Coulson, EJ; Gazova, I; Harrison, J; Hort, J; Laczó, J; Mokrisova, I; Valis, M; Windisch, M, 2014) |
| "Donepezil is a widely used cholinesterase inhibitor for the treatment of Alzheimer's disease (AD), however its cholinergic adverse side effects on the cardiovascular system are still unclear." | 6.77 | Cardiac safety of donepezil in elderly patients with Alzheimer disease. ( Aydemir, E; Bozoglu, E; Isik, AT; Yay, A; Yildiz, GB, 2012) |
| " The drug was administered at a dosage of 5 mg/day for 1 month and 10 mg/day for the following 7 months, as tolerated." | 6.72 | Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. ( Bordier, P; Garrigue, S; Gencel, L; Lafitte, A; Lanusse, S; Margaine, J; Robert, F, 2006) |
| "Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist." | 6.71 | Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. ( Farlow, MR; Gergel, I; Graham, SM; Grossberg, GT; McDonald, S; Tariot, PN, 2004) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 6.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| "Donepezil-treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal-sparing subtypes." | 5.69 | Differential response to donepezil in MRI subtypes of mild cognitive impairment. ( Cavedo, E; Diaz-Galvan, P; Dubois, B; Ferreira, D; Grothe, MJ; Hampel, H; Kantarci, K; Lista, S; Lorenzon, G; Mårtensson, G; Mohanty, R; Vergallo, A; Westman, E, 2023) |
| "The authors conducted a delayed-start study of donepezil for cognitive decline in non-demented PD patients." | 5.41 | Early-start ( Kiyohara, K; Kohsaka, M; Oeda, T; Park, K; Sawada, H; Tomita, S; Umemura, A; Yamamoto, K, 2021) |
| "Donepezil is a drug that is used to treat Alzheimer's disease." | 5.40 | A brief report on the efficacy of donepezil in pain management in Alzheimer's disease. ( Gharaei, H; Shadlou, H, 2014) |
| "When donepezil was re-prescribed, the delirium resolved and the patient's mental state stabilized." | 5.38 | Withdrawal syndrome after donepezil cessation in a patient with dementia. ( Bidzan, L; Bidzan, M, 2012) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 5.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "Donepezil was orally given at a dosage of 5 mgxkg(-1)xday(-1)." | 5.35 | Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. ( Ando, M; Arikawa, M; Handa, T; Kakinuma, Y; Katare, RG; Sasaguri, S; Sato, T; Yamasaki, F, 2009) |
| "Donepezil has been licensed for use in Japan to improve cognitive function since 1999." | 5.31 | Urinary incontinence: an unrecognised adverse effect with donepezil. ( Hashimoto, M; Imamura, T; Kazui, H; Mori, E; Tanimukai, S, 2000) |
| "The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer's disease." | 5.27 | A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study. ( Barker, S; Crutch, S; Cutler, D; Douglas, J; Epie, N; Frost, C; Knight, W; Kukkastenvehmas, R; Ridha, BH; Rossor, MN; Warrington, EK, 2018) |
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 5.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| " Mood disorders (depression, anxiety and apathy) were significantly decreased in subjects treated with donepezil and choline alphoscerate, while their severity and frequency was increased in the other group." | 5.24 | The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. ( Amenta, F; Carotenuto, A; Fasanaro, AM; Manzo, V; Rea, R; Ricci, G; Traini, E, 2017) |
| " Significant improvements were observed on the Alzheimer's Disease Assessment Scale-cognitive component-Japanese version and the Neuropsychiatric Inventory depression scores of patients who received the combined therapy with donepezil and NYT (Alzheimer's Disease Assessment Scale-cognitive component-Japanese version, 12 months: P < 0." | 5.22 | Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation. ( Arita, R; Asou, H; Honda, M; Kishi, T; Komatsu, Y; Kudoh, C; Mimura, M, 2016) |
| "We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers (France) in patients with amnestic mild cognitive impairment (MCI) receiving Donepezil 10 mg daily or placebo over 12 months, and 6 months open label follow-up." | 5.22 | Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. ( Bakardjian, H; Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Galluzzi, S; Grothe, MJ; Hampel, H; Lista, S; Teipel, SJ, 2016) |
| "APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy." | 5.22 | Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. ( De Beaumont, L; Dea, D; Lamarre-Théroux, L; Pelleieux, S; Poirier, J, 2016) |
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 5.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| "The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to explore which tests and their measures are able to detect cognitive change after a single dose of donepezil in Alzheimer disease (AD) patients." | 5.20 | Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease. ( Kaubrys, G; Kuzmickienė, J, 2015) |
| "Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD)." | 5.17 | Concentration of donepezil to the cognitive response in Alzheimer disease. ( Chen, CH; Chen, SH; Chou, MC; Li, CH; Liu, CK; Yang, YH, 2013) |
| "To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial." | 5.15 | SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. ( Dixon, R; Gold, M; Hopton, G; Hunter, J; Jacobs, G; Maher-Edwards, G; Williams, P, 2011) |
| "To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship." | 5.14 | Donepezil delays progression to AD in MCI subjects with depressive symptoms. ( Cummings, JL; Edland, SD; Lu, PH; Petersen, RC; Teng, E; Tingus, K, 2009) |
| "To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain metabolite concentrations in comparison with donepezil." | 5.14 | Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. ( Errea, JM; Fayed, N; Modrego, PJ; Pina, MA; Rios, C; Sarasa, M, 2010) |
| "Effective counseling and support interventions can reduce symptoms of depression in caregivers when patients are taking donepezil." | 5.13 | A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression. ( Brodaty, H; Burns, A; Mittelman, MS; Wallen, AS, 2008) |
| " Twenty-three patients with mild-to-moderate Alzheimer disease and apnea-hypopnea index (AHI) > 5/h were allocated to two groups: donepezil treated (n = 11) and placebo treated (n = 12)." | 5.13 | Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. ( Guilleminault, C; Moraes, W; Poyares, D; Sukys-Claudino, L; Tufik, S, 2008) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 5.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 5.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 5.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "Examine the effects of donepezil on sleep and rapid eye movement (REM) sleep electroencephalogram (EEG) in patients with Alzheimer disease, using polysomnography, and the correlation between REM sleep EEG parameters and cognitive scores." | 5.12 | The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. ( Bertolucci, PH; Guilleminault, C; Moraes, Wdos S; Poyares, DR; Ramos, LR; Tufik, S, 2006) |
| "The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses." | 5.12 | A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. ( Olin, JT; Schmitt, FA; van Dyck, CH, 2006) |
| "To evaluate the clinical efficacy and safety of akatinol memantine in the treatment of patients with mild to moderate Alzheimer disease (AD)." | 5.12 | [Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial]. ( Hu, HT; Ji, CJ; Tang, HC; Wang, YH; Xu, T; Yao, JL; Yu, HZ; Zhang, ZX, 2006) |
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 5.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| "To examine whether the presence of domain-specific cognitive impairments would predict a response to donepezil medication in patients with mild-to-moderate Alzheimer disease (AD)." | 5.12 | Cognitive predictors of donepezil therapy response in Alzheimer disease. ( Bergman, H; Chertkow, H; Murtha, S; Phillips, N; Saumier, D; Whitehead, V, 2007) |
| "To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)." | 5.12 | Donepezil preserves cognition and global function in patients with severe Alzheimer disease. ( Black, SE; Doody, R; Jambor, KM; Li, H; McRae, T; Perdomo, CA; Richardson, S; Sun, Y; Xu, Y, 2007) |
| "To determine the efficacy of donepezil in the treatment of neuropsychiatric symptoms in patients with Alzheimer disease (AD) in a randomized withdrawal study." | 5.11 | The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. ( Clare, C; Damms, J; Dean, C; Hogg, F; Holmes, C; Langley, A; Olivieri, S; Pandita-Gunawardena, ND; Vethanayagam, S; Wilkinson, D, 2004) |
| "To investigate the costs to society of Alzheimer disease (AD) care in a multinational, randomized, placebo-controlled trial of donepezil in patients with moderate to severe AD." | 5.11 | Economic evaluation of donepezil in moderate to severe Alzheimer disease. ( Feldman, H; Gauthier, S; Hecker, J; Hux, M; Mastey, V; Schwam, EM; Shah, S; Vellas, B; Xu, Y, 2004) |
| "We analysed the effects of donepezil, rivastigmine and galantamine, prescribed for the treatment of Alzheimer disease in a real-world setting in Italy." | 5.11 | An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. ( Aguglia, E; Maso, E; Onor, ML; Saina, M, 2004) |
| "To evaluate the efficacy of donepezil in patients with early-stage Alzheimer disease." | 5.11 | Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. ( Goldman, R; Ieni, J; Kumar, D; Nunez, M; Richardson, S; Seltzer, B; Zolnouni, P, 2004) |
| " Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer's Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant." | 5.11 | Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? ( Hashimoto, M; Kazui, H; Matsumoto, K; Mori, E; Nakano, Y; Yasuda, M, 2005) |
| "To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment." | 5.10 | Down syndrome and Alzheimer disease: response to donepezil. ( Doran, E; Lott, IT; Nelson, L; Osann, K, 2002) |
| "To determine the efficacy of donepezil hydrochloride for the treatment of Alzheimer disease in patients drawn from clinical practice." | 5.09 | Donepezil therapy in clinical practice: a randomized crossover study. ( Brown, LB; Corwin, C; Daffner, KR; Friedman, P; Gomez-Isla, T; Greenberg, SM; Growdon, JH; Hayden, DL; Meadows, ME; Schoenfeld, DA; Sperling, RA; Tennis, MK; Walsh, KL, 2000) |
| "Donepezil hydrochloride is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderately severe Alzheimer disease (AD)." | 5.09 | Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. ( Doody, RS; Geldmacher, DS; Gordon, B; Perdomo, CA; Pratt, RD, 2001) |
| "Donepezil hydrochloride (Aricept) is a selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer disease." | 5.08 | Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. ( Doody, RS; Friedhoff, LT; Mohs, RC; Rogers, SL, 1998) |
| "Donepezil, galantamine, and rivastigmine are the three acetylcholinesterase inhibitors (AChEIs), out of a total of only four medications prescribed in the treatment of Alzheimer's Disease (AD) and related dementias." | 5.05 | Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review. ( Alsabbagh, MW; Huang, Y, 2020) |
| "This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions." | 4.95 | Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. ( Chan, PT; Chang, PC; Chen, CY; Chen, R; Chou, KR; Chu, H; Lin, YC, 2017) |
| "The purpose of this systematic review was to review the current place in therapy of the 4 medications, donepezil, rivastigmine, galantamine, and memantine, approved for the treatment of Alzheimer disease (AD) since the publication of Phase III trials." | 4.91 | Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? ( Chamberlin, KW; Ehret, MJ, 2015) |
| "To investigate whether there is a difference in the treatment effect of donepezil on cognition in Alzheimer disease between industry-funded and independent randomised controlled trials." | 4.90 | The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis. ( Abrahams, S; Della Sala, S; Killin, LO; Russ, TC; Starr, JM, 2014) |
| "We herein report an 81-year-old woman with Alzheimer's disease (AD) in who donepezil, a cholinesterase inhibitor (ChEI), caused cervical dystonia." | 4.90 | Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors. ( Hanashiro, S; Ikeda, K; Iwasaki, Y; Kawabe, K; Sawada, M; Yanagihashi, M, 2014) |
| "Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine." | 4.88 | New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. ( Caraci, F; Drago, F; Fedotova, J; Leggio, GM; Salomone, S, 2012) |
| " Symptoms, interventions, and treatment-related adverse events addressed in this issue are management of Alzheimer's agitation with donepezil; needle-free lidocaine powder for minor painful procedures; psychostimulants in depression; anticoagulation for cancer-related venous thromboembolism; effect of waiting for acute pain treatment on risk of chronic pain; and an update on severe cutaneous reactions associated with medications." | 4.85 | Pain and palliative care pharmacotherapy literature summaries and analyses. ( Abernethy, AP; Farrell, TW, 2009) |
| "This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia." | 4.84 | Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. ( Valdovinos, MG; Williams, DC; Yoo, JH, 2007) |
| "Some randomized studies, mostly of short duration, have indicated that cholinesterase inhibitors (donepezil, rivastigmine and galantamine) may have a beneficial effect in Alzheimer's disease, vascular dementia and in dementia caused by Lewy body disease." | 4.84 | [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]. ( Landmark, K; Reikvam, A, 2008) |
| "Several clinical trials have been conducted over a period of many years reporting the benefits of donepezil for Alzheimer disease (AD) patients." | 4.82 | Update on Alzheimer drugs (donepezil). ( Smith Doody, R, 2003) |
| "To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug-drug interactions, and the therapeutic issues concerning the use of donepezil in patients with Alzheimer disease." | 4.80 | Donepezil use in Alzheimer disease. ( Barner, EL; Gray, SL, 1998) |
| "Donepezil is an effective, well-tolerated, and easily administered symptomatic treatment for mild-to-moderate Alzheimer disease (AD)." | 4.80 | Therapeutic standards in Alzheimer disease. ( Doody, RS, 1999) |
| "Providing evidence on donepezil and memantine administration as extemporaneous combination (DM-EXT) to treat Alzheimer Disease (AD) in Italy, and describing demographic and clinical features of AD patients prescribed DM-EXT." | 4.31 | Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data. ( Falato, S; Padovani, A; Pegoraro, V, 2023) |
| "To investigate the clinical effect of donepezil combined with hydrogen-oxygen mixture inhalation in the treatment of patients with Alzheimer disease (AD), a total of 273 AD patients admitted to our hospital from March 2018 to March 2022 were retrospectively analyzed and assigned into an observation group (n = 138) and a control group (n = 135) according to the different treatment that they received." | 4.31 | Efficacy of donepezil plus hydrogen-oxygen mixture inhalation for treatment of patients with Alzheimer disease: A retrospective study. ( Dan, Z; Li, H; Xie, J, 2023) |
| "In this study, a Drosophila AD model and SH-SY5Y clles were used to assess the toxicity of SIP3, and APPswe/PS1dE9 (APP/PS1) transgenic mice were used to evaluate the cognitive-behavioral and depression-like behavior effect of SIP3 and donepezil co-treatment on symptoms of AD." | 4.12 | Co-Treatment with the Herbal Medicine SIP3 and Donepezil Improves Memory and Depression in the Mouse Model of Alzheimer's Disease. ( Chin, YW; Choi, H; Kanmani, S; Kim, KK; Kim, KW; Kim, SN; Kim, YM; Koo, BS; Liu, QF; Son, T, 2022) |
| "When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 4.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
| "Donepezil is one of the most commonly prescribed drugs for the treatment of Alzheimer disease." | 4.02 | Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients With Alzheimer Disease. ( Kagawa, Y; Maeda, T; Obi, T; Ueno, A; Yamamoto, Y, 2021) |
| "Over the 48-week treatment period, donepezil combined NBP group had slower cognitive decline and better activities of daily living in patients with mild to moderate AD." | 4.02 | Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study. ( Gao, F; Guo, X; Liu, J; Lu, W; Ma, L; Qu, Q; Quan, Q; Su, H; Wang, J; Zhang, H, 2021) |
| "The purpose of the paper is to systematically investigate the association between the occurrence of bradycardia in adults and the usage of donepezil using clinical data derived from the FDA Adverse Event Reporting System (FAERS) database." | 4.02 | Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Eckhoff, K; Jose, RP; Luboff, H; Morris, R; Pham, M; Rohlsen-Neal, D, 2021) |
| "Patients prescribed rivastigmine were more likely to report pneumonia as an adverse event than many drugs except galantamine." | 4.02 | The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Morris, R; Umeukeje, G, 2021) |
| "This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD)." | 3.96 | Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option. ( Han, W; Li, H; Yang, H, 2020) |
| "Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports." | 3.91 | Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. ( Fleet, JL; Garg, AX; McArthur, E; Montero-Odasso, M; Patel, A; Weir, MA, 2019) |
| "The risk of pneumonia was higher in persons using rivastigmine patch (n = 9709) (adjusted hazard ratio (HR) 1." | 3.85 | Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease. ( Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2017) |
| " Fifty-two patients with Alzheimer disease underwent the group reminiscence approach with reality orientation, as well as the donepezil treatment." | 3.85 | Cholinesterase inhibitors are compatible with psychosocial intervention for Alzheimer disease patients suggested by neuroimaging findings. ( Meguro, K, 2017) |
| "The results of this study suggested that early induction of donepezil treatment was necessary when apparent cognitive decline was identified during the treatment of geriatric depression." | 3.83 | Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression. ( Hoshino, R; Inoue, J; Ishida, W; Nojima, H; Okamoto, N, 2016) |
| "Donepezil is a drug usually administered by oral route for Alzheimer disease treatment, but several gastric side effects have been reported as diarrhea, nausea, and anorexia." | 3.83 | Exploring the Phase Behavior of Monoolein/Oleic Acid/Water Systems for Enhanced Donezepil Administration for Alzheimer Disease Treatment. ( Carvalho, FC; Pereira, GR; Ruela, AL, 2016) |
| "Matrix type transdermal films of donepezil (DNP) as an alternative delivery approach was designed to improve patient compliance to Alzheimer disease treatment." | 3.81 | Biopolymer-based transdermal films of donepezil as an alternative delivery approach in Alzheimer's disease treatment. ( Erdal, MS; Galipoğlu, M; Güngör, S, 2015) |
| "To compare the outcome of donepezil treatment in ethnically diverse Alzheimer disease (AD) patients with ethnically diverse AD patients who did not receive donepezil." | 3.81 | Donepezil treatment in ethnically diverse patients with Alzheimer disease. ( Ashford, JW; Kraemer, HC; O'Hara, R; Ringman, JM; Taylor, JL; Tinklenberg, JR; Yaffe, K; Yesavage, JA, 2015) |
| "3-3 mg/kg) did not induce EPS signs by itself; however, it significantly potentiated bradykinesia induction with a low dose of haloperidol (0." | 3.81 | Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice. ( Fujiwara, M; Mizuguchi, Y; Morimoto, T; Ohno, Y; Shimizu, S; Sobue, A, 2015) |
| "An 80-year-old Greek woman with Alzheimer disease was admitted to the hospital with a sudden onset of myoclonus in both upper and lower extremities after receiving 30 mg of donepezil daily for 25 days." | 3.80 | Donepezil-induced myoclonus in a patient with Alzheimer disease. ( Anagnostou, E; Bougea, A; Gerakoulis, S; Kapaki, E; Kararizou, E; Paraskevas, G, 2014) |
| "All four dementia drugs available on the Swedish market (three cholinesterase inhibitors [donepezil, rivastigmine and galantamine] and memantine) were prescribed at the two dementia clinics." | 3.79 | Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres. ( Johnell, K; Sonde, L, 2013) |
| "We have previously demonstrated that the chronic intervention in the cholinergic system by donepezil, an acetylcholinesterase inhibitor, plays a beneficial role in suppressing long-term cardiac remodeling after myocardial infarction (MI)." | 3.77 | Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice. ( Arikawa, M; Handa, T; Kakinuma, Y; Sato, T; Yamasaki, F, 2011) |
| "To determine the factors associated with receiving specific treatment (cholinesterase inhibitors or/and memantine) for Alzheimer disease (AD) in elderly patients." | 3.76 | Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease. ( Formiga, F; Fort, I; Regalado, P; Robles, MJ; Rodriguez, D, 2010) |
| " Application of donepezil, a drug used for the treatment of Alzheimer disease, in a concentration of 1 μM eliminates the suppressive effect of β-amyloid peptide 1-42 on long-term posttenanic potentiation in the hippocampus." | 3.76 | Donepezil eliminates suppressive effects of β-amyloid peptide (1-42) on long-term potentiation in the hippocampus. ( Kapai, NA; Skrebitskii, VG; Solntseva, EI, 2010) |
| "To evaluate the influence of the single nucleotide polymorphism rs1080985 in the cytochrome P450 2D6 (CYP2D6) gene on the efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD)." | 3.75 | Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. ( Bizzarro, A; Cascavilla, L; D'Onofrio, G; Dallapiccola, B; Daniele, A; Franceschi, M; Mangialasche, F; Masullo, C; Matera, MG; Mecocci, P; Paris, F; Pilotto, A; Seripa, D, 2009) |
| "Cox proportional hazards with time-dependent exposures were used to evaluate the association and examine the dose effect for donepezil and bradycardia." | 3.75 | Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. ( Cantor, MD; Farwell, W; Hernandez, RK; Lawler, EV, 2009) |
| "We attempted to determine whether the pretreatment regional cerebral blood flow (rCBF) might predict cognitive changes in response to donepezil treatment, as assessed in terms of the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog), and in relation to the severity of subcortical hyperintensities (SH)." | 3.74 | SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease. ( Fukui, T; Furukawa, TA; Hongo, J; Iidaka, T; Mimura, M; Murata, Y; Nakaaki, S; Sato, J; Shinagawa, Y; Soma, T; Tatsumi, H; Tohyama, J, 2008) |
| "To determine if results from randomized clinical trials of donepezil in Alzheimer disease (AD) patients can be applied to AD patients in clinical practice by comparing the findings from a Nordic one-year randomized AD donepezil trial with data from a one-year prospective, observational study of AD patients." | 3.74 | Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? ( Ashford, JW; Kraemer, HC; Ross, L; Sheikh, J; Taylor, JL; Tinklenberg, JR; Yaffe, K; Yesavage, JA, 2007) |
| "The comparative effects of a newly described specific alpha7 nAChR partial agonist, S 24795, and a cholinesterase inhibitor, donepezil, currently used as a symptomatic Alzheimer's disease treatment were studied in two mouse models of aging-related memory deficits." | 3.74 | Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. ( Desmedt, A; Marighetto, A; Morain, P; Philippin, JN; Trocmé-Thibierge, C; Valerio, S, 2008) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 3.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "In patients with AD treated with donepezil, a noninvasive evaluation identified a probable cause of syncope in over two-thirds of patients." | 3.73 | Causes of syncope in patients with Alzheimer's disease treated with donepezil. ( Bordier, P; Garrigue, S; Gencel, L; Lafitte, A; Lanusse, S; Reynard, C; Robert, F, 2005) |
| "The goal of this study was to investigate whether donepezil treatment is associated with reduced mortality in nursing home residents who have dementia." | 3.73 | Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? ( Gasper, MC; Lapane, KL; Ott, BR, 2005) |
| "The purpose of this study was to estimate the impact of donepezil use on health care costs and utilization in patients with mild to moderate AD and related dementias." | 3.73 | Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. ( Fillit, H; Hill, J; Lu, S, 2005) |
| "In this retrospective analysis, AD patients who had symptoms suggestive of concomitant Lewy body disease appeared to show greater treatment responses to rivastigmine than to donepezil, and experienced fewer adverse events under either drug, compared with patients without Lewy body pathology." | 3.73 | Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. ( Bergman, H; Bullock, R; Lane, R; Nagel, J; Rapatz, G; Touchon, J, 2006) |
| "Donepezil, a selective acetylcholinesterase (AChE) inhibitor, has been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbit eyes." | 3.73 | Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients. ( Berkhoff, M; Cattapan-Ludewig, K; Daepp, GC; Estermann, S; Frueh, BE; Goldblum, D, 2006) |
| "To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer's disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy." | 3.72 | Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. ( Abe, K; Hanyu, H; Sakurai, H; Takasaki, M; Tanaka, Y, 2003) |
| " From a review of the literature, the optimal technique employs quantitative 15O-water PET imaging determinations of cerebral blood flow (CBF) and acetazolamide (ACZ) (1 g iv with measurements at 10- to 20-min post-administration) as the vasodilating agent." | 3.72 | Technical issues in the determination of cerebrovascular reserve in elderly subjects using 15O-water PET imaging. ( Boles Ponto, LL; Hichwa, RD; Leonard Watkins, G; Schultz, SK, 2004) |
| "We describe three cases of patients with Alzheimer's disease who presented with cardiac syncope soon after initiation of a cholinesterase inhibitor therapy (donepezil)." | 3.72 | Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. ( Barold, SS; Bordier, P; Bressolles, N; Clémenty, J; Garrigue, S; Lanusse, S, 2003) |
| " Galantamine is a novel treatment for Alzheimer disease with a dual mode of action." | 3.71 | Maintaining functional and behavioral abilities in Alzheimer disease. ( Winblad, B, 2001) |
| "A case of hypnopompic hallucinations associated with donepezil is described." | 3.70 | Hypnopompic hallucinations with donepezil. ( Gray, R; Yorston, GA, 2000) |
| "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020." | 3.69 | Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia. ( Kojima, J; Nakajima, K; Nakayama, K; Ochiai, M, 1997) |
| " However, the appropriate donepezil dosage is still a matter of debate." | 3.30 | The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease. ( Angelucci, F; Dlabkova, A; Hort, J; Karasova, JZ; Kuca, K; Novotny, M; Pavelek, Z; Pejchal, J; Valis, M, 2023) |
| "9% (n = 292) of patients reported at least one adverse event during the trial; the frequency of patients with investigator-defined drug-related adverse events was similar in all treatment groups, ranging from 15." | 3.30 | Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial. ( Blahova, Z; Garcia, M; Jessen, F; Wunderlich, G, 2023) |
| "Changes from baseline in the Alzheimer's Disease Assessment Scale-cognitive component-Japanese version at week 24 (least squares mean ± standard error) were -0." | 3.30 | Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study. ( Aoki, H; Ishikawa, I; Kikuchi, T; Kim, R; Nakamura, Y; Nishiyama, K, 2023) |
| " The incidence of adverse events at application site in the continuation group over 52 weeks was 56." | 3.30 | Efficacy and Safety of a Transdermal Donepezil Patch in Patients with Mild to Moderate Alzheimer's Disease: Open-Label, Extension Study. ( Aoki, H; Ishikawa, I; Kikuchi, T; Kim, R; Nakamura, Y; Nishiyama, K; Omori, T, 2023) |
| " No remarkable adverse events were observed for 24 weeks." | 3.11 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate ( Cho, HJ; Choi, H; Choi, SH; Han, HJ; Han, SH; Kim, BC; Kim, HJ; Kim, SY; Moon, SY; Park, KH; Park, KW; Park, MY; Shim, Y; Yang, DW; Yoon, KE; Yoon, SJ; Youn, YC, 2022) |
| "To explore the effect of resveratrol (RES) combined with donepezil hydrochloride on inflammatory factor level and cognitive function level of patients with Alzheimer's disease (AD)." | 3.11 | Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease. ( Fang, X; Wang, L; Zhang, J; Zhao, J, 2022) |
| " There were 2 cases of adverse reaction of increased stool frequency in GV-971 (5." | 3.11 | Efficacy and safety of sodium oligomannate in the treatment of Alzheimer's disease. ( Lin, PX; Xue, LH; Zhang, LF; Zhang, YP, 2022) |
| " Existing evidence shows that acupuncture has advantages in the treatment of AD, but whether the efficacy of acupuncture belongs to the placebo effect remains controversial, and there is no strict placebo-controlled clinical study to evaluate the efficacy and safety of acupuncture combined with Western medicine in the treatment of AD." | 3.11 | Clinical efficacy of acupuncture combined with Western medicine in the treatment of mild to moderate Alzheimer disease: A protocol of a randomized controlled trial. ( Guo, R; He, J; Quan, L; Zhou, K, 2022) |
| "Donepezil 23 mg is considered for Alzheimer's disease (AD) to optimize cognitive benefits; however, increased adverse events (AEs) can negatively influence drug adherence." | 3.01 | Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. ( Han, HJ; Hong, YJ; Kim, HJ; Kim, S; Kwon, M; Lee, JH; Lee, Y; Park, KW; Yang, DW; Youn, YC, 2021) |
| "Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy." | 3.01 | From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. ( Bennett, KA; Bradley, SJ; Broad, LM; Brown, AJH; Brown, GA; Brown, J; Browning, M; Bundgaard, C; Cansfield, JE; Christopoulos, A; Congreve, MS; Cooke, RM; Cross, DM; Dawson, GR; de Graaf, C; Deakin, JFW; Dias, JM; Dwomoh, L; Errey, JC; Goonawardena, AV; Hudson, BD; Hurrell, E; Jazayeri, A; Langmead, CJ; Liptrot, J; Marshall, FH; Mattedi, G; Molloy, C; Morairty, SR; Nathan, PJ; Okrasa, K; Osborne, G; Patel, JC; Perini, F; Phillips, K; Pickworth, M; Robertson, N; Rucktooa, P; Sexton, PM; Shahabi, S; Smith, RT; Tasker, T; Tehan, BG; Teobald, B; Tobin, AB; Vinson, M; Warneck, J; Weir, M, 2021) |
| "Fatigue and neurodegeneration of Alzheimer's disease could share common brain signatures (i." | 3.01 | Fatigue in Alzheimer's disease: biological basis and clinical management-a narrative review. ( Angioni, D; de Souto Barreto, P; Delrieu, J; Ousset, PJ; Raffin, J, 2023) |
| "While these drugs are known to induce classic cholinergic adverse events such as diarrhea, their potential to cause psychiatric adverse events has yet to be thoroughly examined." | 3.01 | Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. ( Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A, 2023) |
| "Based on Alzheimer's Disease Assessment Scale-Cognitive Subscale total scores from baseline up to week 12, a latent class model was used to identify heterogeneous groups." | 3.01 | Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. ( Cipriani, A; Furawaka, TA; Goldberg, Y; Iwatsubo, T; Leucht, S; Levine, SZ; Samara, M; Yoshida, K, 2021) |
| " The safety endpoints were also assessed based on adverse events, laboratory test results, vital signs, and other observations related to safety." | 3.01 | Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. ( Choi, SH; Han, HJ; Jeong, JH; Kim, BC; Kim, S; Koh, SH; Kwon, HS; Lee, AY; Lee, CN; Lee, JH; Lee, JY; Lee, KY; Na, HR; Park, JS; Park, KW; Yang, Y, 2021) |
| "This was a randomized, double-blind, placebo-controlled trial in 42 (to deliver 36 with combination treatment) healthy elderly subjects investigating the effects of oral HTL0018318 15 and 25 mg given alone and combined with donepezil 10 mg at steady state on adverse events (AEs), vital signs, saliva production, sleep quality, pulmonary function, subjective feelings, and pharmacokinetics." | 3.01 | Safety and Pharmacokinetics of HTL0018318, a Novel M ( Bakker, C; Cross, DM; Dickinson, S; Groeneveld, GJ; Klaassen, ES; Labots, G; Liptrot, J; Tasker, T; van der Aart, J, 2021) |
| "To observe the effects of Dengzhan Shengmai capsule combined with donepezil hydrochloride on cognitive function, daily living ability, and safety in patients with Alzheimer's disease." | 3.01 | Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings, randomized and controlled clinical trial. ( He, XY; Huang, P; Xu, M, 2021) |
| " Primary outcome was the incidence of adverse events (AEs)." | 2.94 | Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease. ( Chen, W; Jia, J; Jia, L; Tang, Y; Wang, F; Wei, C; Xu, L; Zhou, A, 2020) |
| "The primary outcomes were scores of Alzheimer's Disease Rating Scale-Cognitive (ADAS-Cog) and Chinese Medicine Symptom Scale (CM-SS)." | 2.94 | Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula () and Routine Western Medicine. ( Li, H; Liu, JG; Liu, NY; Pei, H; Wang, HC; Wang, ZY; Wei, Y; Yang, Y; Zhang, S, 2020) |
| "0 mA of intensity), and the needles were kept for 40 min, EA was given once a day; the donepezil hydrochloride tablet was taken orally, 5 mg, once a day, and after 4 weeks the dosage might be increased to 10 mg per day according to the specific situation." | 2.94 | [Effect of electroacupuncture at governor vessel on learning-memory ability and serum level of APP, Aβ ( Li, HL; Li, SL; Pang, J; Wang, YJ; Xia, KP; Zhang, M, 2020) |
| "Donepezil is widely used to treat Alzheimer's disease (AD), but detecting early response remains challenging for clinicians." | 2.90 | Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial. ( Berger, JT; Foldi, NS; Kaplan, L; Ly, JJ; Macina, LO; Stewart, JL; Van Dyk, K; Vila-Castelar, C, 2019) |
| "HYF is effective and safe for improving the cognitive function in mildto-moderate AD patients." | 2.90 | Effect and Safety of Huannao Yicong Formula () in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial. ( Cao, Y; Fang, JY; Li, H; Liu, JG; Liu, JP; Liu, LT; Wang, HC; Wei, Y; Yang, Y, 2019) |
| " However, the adverse events (AEs) depending on the method of dose escalation have not been clarified yet." | 2.90 | Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. ( Han, HJ; Hong, YJ; Kim, HJ; Kim, JE; Kim, S; Lee, JH; Park, KW; Yang, DW; Youn, YC, 2019) |
| "However, one study subject had epileptic seizures after IVIg." | 2.84 | Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease. ( Allsop, D; Ataka, S; Ishii, R; Kasai, T; Kondo, M; Mizuno, T; Mori, H; Nakagawa, M; Shimada, H; Tanaka, A; Taylor, M; Tokuda, T; Tomiyama, T, 2017) |
| "A total of 334 participants with Alzheimer's disease will be randomly assigned to either an electroacupuncture combined with donepezil group or a donepezil group with a ratio of 1:1." | 2.84 | The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer's disease patients: study protocol for a randomized controlled trial. ( Bin, L; Feng, Q; Liu, Z; Peng, W; Xu, M; Zhou, J, 2017) |
| "Recent studies using the mouse model of Alzheimer's disease (AD) have shown that donepezil administration reduces brain amyloid-β (Aβ) accumulation." | 2.84 | Changes in brain amyloid-β accumulation after donepezil administration. ( Ishibashi, K; Ishii, K; Ishiwata, K; Miura, Y; Wagatsuma, K, 2017) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 2.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| "Primary efficacy was measured using Alzheimer's disease Assessment Scale-Cognitive (ADAS-cog) and Clinician's Interview-Based Impression of Change-Plus (CIBIC-Plus)." | 2.84 | Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial. ( Han, J; Jia, Y; Nie, K; Shi, J; Yu, J; Yu, T; Zhang, X; Zhao, L, 2017) |
| "At 26 weeks, Alzheimer's Disease Assessment Scale Cognitive Component scores in the efficacy evaluable population improved by 0." | 2.84 | Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease. ( Chase, TN; Clarence-Smith, K; Farlow, MR, 2017) |
| "Donepezil for 24 weeks was more effective than placebo and showed good safety and tolerability in Chinese patients with severe AD." | 2.84 | Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. ( Doody, RS; Jia, J; Jia, L; Li, F; Liang, J; Shi, L; Tang, Y; Wei, C; Zhou, A, 2017) |
| "Drugs that are used in the treatment of Alzheimer's disease are donepezil, galantamine, tacrine, rivastigmine showing major adverse effects." | 2.82 | Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease. ( Natarajan, R; Raji, V; Sivaraman, B; Velmurugan, BA, 2022) |
| "The strategies to combat Alzheimer's Disease (AD) have been changing with respect to the failures of many drug candidates assessed in clinical studies, the complex pathophysiology of AD, and the limitations of the current drugs employed." | 2.82 | The Hybrid Compounds as Multi-target Ligands for the Treatment of Alzheimer's Disease: Considerations on Donepezil. ( Gulcan, HO; Kosar, M, 2022) |
| "We aimed to perform an updated umbrella review to identify an efficacious and safe treatment for AD patients." | 2.82 | The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review. ( Ai, Y; Cheng, Y; Fan, F; Liu, H; Liu, Q; Shi, X, 2022) |
| "Donepezil is a first-line drug for the treatment of Alzheimer's disease (AD)." | 2.82 | Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis. ( Han, Y; Liu, H; Liu, Y; Wang, H; Zhao, J; Zong, Y, 2022) |
| "We included trials assessing cognition with the Mini-Mental State Examination (MMSE), and adverse events." | 2.82 | Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. ( Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA, 2022) |
| " Therefore, meta-analysis is employed in this study to evaluate the efficacy and safety of using donepezil hydrochloride combined with nimodipine in treating VaD to provide references for clinical treatments." | 2.82 | A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia. ( Huang, KL; Liu, J; Ran, SM; Tan, AH; Wang, GY; Wang, MY; Yang, Q, 2022) |
| " Improvements to the approved therapies, such as easier routes of administration and reduced dosing frequencies, along with the developments of new strategies and combined treatments are expected to occur within the next decade and will positively impact the way the disease is managed." | 2.82 | Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. ( Boada, M; Jofresa, S; Morató, X; Pytel, V; Ruiz, A, 2022) |
| " Therefore, to overcome such issues, various nanoformulations of nutraceuticals have been developed, that allow their effective delivery into the brain owing to reduced particle size, increased lipophilicity, increased bioavailability and avoidance of fast hepatic metabolism." | 2.82 | Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease. ( Fazal, SA; Haque, SE; Iqubal, A; Iqubal, MK; Pottoo, FH, 2022) |
| " ABT-126 was generally well tolerated; the most common adverse events were agitation, constipation, diarrhea, fall, and headache." | 2.82 | Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. ( Florian, H; Gault, LM; Gauthier, S; Lin, Y; Lipschitz, S; Meier, A; Othman, AA; Robieson, WZ; Tang, Q, 2016) |
| "Donepezil is an established treatment for mild, moderate, and severe Alzheimer's disease (AD)." | 2.82 | Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial. ( Atarashi, H; Homma, A; Kubota, N; Nakai, K; Takase, T, 2016) |
| " A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil was evaluated for bioequivalence with co-administered commercially available memantine ER and donepezil, and for bioavailability with regard to food intake." | 2.80 | A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. ( Boinpally, R; Chen, L; Hofbauer, RK; McClure, N; Periclou, A; Zukin, SR, 2015) |
| "Donepezil was used as the standard control treatment." | 2.80 | The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. ( Cheng, Y; Du, H; Shi, FD; Wei, C; Zhang, N, 2015) |
| "Apathy is a common symptom in Alzheimer's disease (AD), but no treatment has proven to be effective, although administration of cholinesterase inhibitors has been associated with moderate improvements in the short term." | 2.80 | Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. ( Amenta, F; Carotenuto, A; Fasanaro, AM; Manzo, V; Rea, R; Traini, E, 2015) |
| "Donepezil 5 mg/day was started after initial hMWM testing in the treated group (n = 12), and after 28 days, the dose was increased to 10 mg/day." | 2.79 | Effect of donepezil in Alzheimer disease can be measured by a computerized human analog of the Morris water maze. ( Amlerova, J; Andel, R; Coulson, EJ; Gazova, I; Harrison, J; Hort, J; Laczó, J; Mokrisova, I; Valis, M; Windisch, M, 2014) |
| " Pharmacodynamic analyses of ChEIs provide paradoxical observations." | 2.79 | Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. ( Darreh-Shori, T; Hosseini, SM; Nordberg, A, 2014) |
| " Overall incidence of adverse events was similar among treatment groups." | 2.79 | Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. ( Greco, N; Katz, DA; Lenz, RA; Liu, W; Marek, GJ; Meier, A; Zhang, W, 2014) |
| "The donepezil treatment, which enhances higher-level cognitive processing time, revealed that P300 latency decreases as cognitive capability increases, especially improved in recent memory." | 2.79 | Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study. ( Chang, YS; Chen, HL; Hsu, CY; Liu, CK; Tang, SH, 2014) |
| "Treatment with donepezil plus choline alphoscerate significantly slowed changes of the different items analyzed." | 2.79 | The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment. ( Amenta, F; Carotenuto, A; Fasanaro, AM; Rea, R; Traini, E, 2014) |
| " 25 patients (seven taking placebo and 18 taking idalopirdine) discontinued treatment because of adverse events, the difference between groups being mainly due to asymptomatic transient increases in transaminase concentrations in some idalopirdine-treated patients." | 2.79 | Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. ( Colding-Jørgensen, E; Wilkinson, D; Windfeld, K, 2014) |
| "The donepezil HCl ODF has the potential to improve the compliance of Alzheimer disease patients." | 2.79 | Effect of polymer, plasticizer and filler on orally disintegrating film. ( Liew, KB; Peh, KK; Tan, YT, 2014) |
| "Donepezil treatment is associated with stabilization of connectivity of medial temporal regions during resting state and of brain efficiency during a cognitive demand, on the whole reducing progressive dysfunctional reorganizations observed during the natural course of the disease." | 2.78 | Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease. ( Bargalló, N; Bartrés-Faz, D; Bosch, B; Castellví, M; Lladó, A; Molinuevo, JL; Peña-Gómez, C; Rami, L; Sánchez-Valle, R; Solé-Padullés, C, 2013) |
| "Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses." | 2.78 | Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. ( Christensen, D; Cummings, J; Doody, R; Fain, R; Farlow, M; Liu, L; Mackell, J; Sabbagh, M, 2013) |
| "Efficacy outcomes included the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog/11), Mini-Mental State Examination (MMSE), Clinician's Interview-Based Impression of Change - Plus Caregiver's Input (CIBIC-plus) and Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)." | 2.77 | Two galantamine titration regimens in patients switched from donepezil. ( Andreasen, N; Davis, B; Engedal, K; Han, J; Richarz, U; Schäuble, B, 2012) |
| "In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months." | 2.77 | Donepezil and memantine for moderate-to-severe Alzheimer's disease. ( Adams, J; Baldwin, A; Ballard, C; Banerjee, S; Barber, R; Bentham, P; Brown, R; Burns, A; Dening, T; Findlay, D; Gray, R; Griffin, M; Hills, R; Holmes, C; Howard, R; Hughes, A; Jacoby, R; Johnson, T; Jones, R; Juszczak, E; Katona, C; Knapp, M; Lindesay, J; Macharouthu, A; McKeith, I; McShane, R; O'Brien, J; Onions, C; Passmore, P; Phillips, P; Ritchie, C; Sheehan, B, 2012) |
| "Throughout the natural progression of Alzheimer's disease (AD), the body mass index (BMI) decreases." | 2.77 | [Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer's disease: friend or foe?]. ( Drotos, G; Fazekas, CO; Feher, A; Horvath, TL; Janka, Z; Juhasz, A; Kalman, J; Kovacs, J; Pakaski, M, 2012) |
| "Donepezil is a widely used cholinesterase inhibitor for the treatment of Alzheimer's disease (AD), however its cholinergic adverse side effects on the cardiovascular system are still unclear." | 2.77 | Cardiac safety of donepezil in elderly patients with Alzheimer disease. ( Aydemir, E; Bozoglu, E; Isik, AT; Yay, A; Yildiz, GB, 2012) |
| "0) on stable donepezil dosing participated in two task-related fMRI sessions consisting of a face-name paired associative encoding memory paradigm 24 weeks apart during a randomized placebo-controlled pharmaco-fMRI drug study." | 2.77 | Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. ( Atri, A; Deluca, AN; Diamond, EL; McLaren, DG; Mitchell, MB; O'Brien, JL; Rentz, DM; Sperling, RA; Sreenivasan, A; Van Dijk, KR, 2012) |
| "Donepezil 23 mg was generally safe and well tolerated among patients receiving donepezil alone and among patients receiving a combination of donepezil and memantine therapy." | 2.77 | Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. ( Doody, RS; Farlow, MR; Geldmacher, DS; Mackell, J; Moline, M; Sun, Y, 2012) |
| "Compared with the donepezil treatment in the patients with mild-to-moderate AD, our results suggest that donepezil combined with natural hirudin may improve the treatment effects in the ADL, BPSD and cognition of the patients." | 2.77 | Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study. ( Li, DQ; Yang, H; Zhou, YP, 2012) |
| " Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent adverse events (AEs); changes in weight, electrocardiogram, vital signs, and laboratory parameters; and discontinuation due to AEs." | 2.77 | Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. ( Mackell, J; Moline, M; Salloway, S; Tariot, P; Yardley, J, 2012) |
| "Progressive neurodegeneration in Alzheimer's disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD." | 2.77 | The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design. ( Andersen, F; Engstad, TA; Halvorsen, DS; Straume, B; Viitanen, M; Wilsgaard, T, 2012) |
| "Donepezil treatment appears to have resulted in a significant reduction over 6 months of the emergence of apathy in patients with AD." | 2.76 | Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. ( Cummings, J; Gauthier, S; Jones, R; Knox, S; Lopez, O; Mackell, J; Richardson, S; Sun, Y; Waldemar, G; Wilkinson, D; Xu, Y; Zhang, R, 2011) |
| "Donepezil has not been evaluated in Korean patients with Alzheimer's disease (AD) for up to 1 year." | 2.76 | Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report. ( Bae, HJ; Choi, SH; Kim, BC; Kim, BK; Kim, JE; Kim, S; Kwon, JC; Lee, JS; Na, HR; Park, MY; Shim, YS; Yang, DW; Yoo, BG, 2011) |
| "Participants had probable or possible Alzheimer's disease, were resident in a care home, had clinically significant agitation (defined as a score of 39 or above on the Cohen Mansfield Agitation Inventory) and were free of antipsychotics and/or anticholinesterase for at least 2 weeks." | 2.76 | A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. ( Ballard, C; Burns, A; Chazot, P; Francis, P; Holmes, C; Howes, MJ; Lees, G; Morris, J; Perry, E, 2011) |
| "Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent adverse events (AEs) and their relationship to treatment initiation; changes in weight, electrocardiogram, vital signs, and laboratory parameters; and the incidence of premature study discontinuation." | 2.76 | Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. ( Bibbiani, F; Brand-Schieber, E; Farlow, M; Hsu, T; Moline, M; Satlin, A; Veloso, F; Yardley, J; Zou, H, 2011) |
| "And their effects on ADAS-Cog (Alzheimer's disease assessment scale-cognitive subscale) total and ADL (activity of daily living) scores were measured." | 2.76 | [Effects of donepezil treatment on platelets α and β secretase activities in Alzheimer's disease patients]. ( Dong, GS; Jiang, QH; Li, X; Yang, HQ, 2011) |
| "The main outcome measure was the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-cog)." | 2.75 | The long-term efficacy and tolerability of donepezil in patients with vascular dementia. ( Boundy, K; Hecker, J; Kumar, D; Posner, H; Róman, G; Salloway, S; Schindler, R; Wilkinson, D, 2010) |
| " Safety was assessed by adverse events (AEs) and laboratory tests." | 2.75 | Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities. ( Gao, J; Mackell, J; Richardson, S; Rosenblatt, A, 2010) |
| "Currently approved Alzheimer's disease (AD) treatments have been reported to provide symptomatic benefit, without proven impact on clinical progression." | 2.75 | Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. ( Brand-Schieber, E; Farlow, MR; Hsu, T; Moline, ML; Salloway, S; Satlin, A; Tariot, PN; Wang, Q; Yardley, J; Zou, H, 2010) |
| "donepezil) are known to benefit Alzheimer's disease (AD) patients." | 2.75 | Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease. ( Hara, C; Hashikai, A; Kouno, M; Matsuda, O; Saito, M; Shibuya, H; Shido, E, 2010) |
| "More donepezil-treated subjects (18." | 2.74 | Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. ( Doody, RS; Ferris, SH; Goldman, R; Murthy, AK; Salloway, S; Sun, Y; Watkins, WE; Xu, Y, 2009) |
| "Six individuals with probable Alzheimer's disease (AD) participated in a phase 1 study employing a repeated measures, parallel baseline design testing the hypothesis that error-free experience during word production practice combined with an acetyl cholinesterase inhibitor would improve confrontation naming ability." | 2.74 | Errorless practice as a possible adjuvant to donepezil in Alzheimer's disease. ( Crosson, B; Fuller, R; Heilman, KM; Kendall, D; Leon, SA; Moore, A; Nadeau, SE; Rothi, LJ; Wu, SS, 2009) |
| " Adverse events were consistent with the known donepezil safety profile." | 2.74 | Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan. ( Arimoto, I; Asada, T; Homma, A; Imai, Y; Iwamoto, T; Koma, H; Ohbayashi, T; Shigeta, M; Tago, H; Takase, T; Takita, M, 2009) |
| "To observe clinical therapeutic effect of acupuncture combined with Yizhi Jiannao Granules for treatment of Alzheimer's disease and its effects on intelligence, daily life and social activity ability." | 2.74 | [Clinical observation on acupuncture combined with Yizhi Jiannao granules for treatment of Alzheimer's disease]. ( Dong, KL; Peng, XW, 2009) |
| "Donepezil was well tolerated over the entire 162-week study period." | 2.73 | Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. ( Burns, A; Gauthier, S; Perdomo, C, 2007) |
| "To study the efficacy and safety of Reinhartdt and sea cucumber capsule (RSC) combined with donepezil in treating Alzheimer's disease (AD), and its effect on thyroid function axis." | 2.73 | [Clinical study of Reinhartdt and sea cucumber capsule combined with donepezil in treating Alzheimer's disease]. ( Liang, LZ; Yan, YX; Zhou, ZL, 2007) |
| " An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit." | 2.73 | Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. ( Cummings, J; Kurlan, R; Raman, R; Thal, L, 2007) |
| " Tolerability can be increased by use of flexible dosing and efficacy is likely to be enhanced by increasing the length of the trial from six to 12 months and by enriching the sample with subjects more likely to decline during the trial." | 2.73 | Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI. ( Correia, S; Richardson, S; Salloway, S, 2008) |
| "We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks." | 2.73 | Donepezil for the treatment of agitation in Alzheimer's disease. ( Ballard, CG; Bentham, P; Brown, RG; Bullock, R; Burns, AS; DeCesare, J; Holmes, C; Howard, RJ; Jacoby, R; Johnson, T; Jones, RW; Juszczak, E; Katona, C; Knapp, M; Lindesay, J; O'Brien, JT; Rodger, M; Wilcock, G, 2007) |
| "Donepezil was effective and well tolerated in moderate-to-severe AD patients who discontinued memantine monotherapy, including those with previous exposure to ChE inhibitors." | 2.73 | Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. ( Hager, K; Hort, J; Li, C; López Pousa, S; Sakka, P; Schwam, E; Soininen, H; Tsolaki, M, 2007) |
| "To describe a cohort of patients with Alzheimer's disease from a whole city population treated with donepezil, and to analyse outcomes over 4 years." | 2.73 | Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. ( Benbow, S; Clark, M; Grizzell, M; Jolley, D; Lyle, S; Willmott, S, 2008) |
| " Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD." | 2.73 | Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. ( Corey-Bloom, J; Doody, RS; Ieni, J; Li, H; Schindler, R; Zhang, R, 2008) |
| "Donepezil was well tolerated." | 2.73 | Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. ( Arimoto, I; Asada, T; Homma, A; Imai, Y; Iwamoto, T; Koma, H; Ohbayashi, T; Shigeta, M; Tago, H; Takita, M, 2008) |
| "Ferulic acid (FA) is a phenol derivative from natural sources and serves as a potential pharmacophore that exerts multiple pharmacological properties such as antioxidant, neuroprotection, Aβ aggregation modulation, and anti-inflammatory." | 2.72 | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease. ( Kumar, S; Mishra, S; Modi, G; Rai, H; Singh, G; Singh, GK; Singh, YP; Srikrishna, S, 2021) |
| " The effect is expressed through the characteristics of various pharmacokinetic processes." | 2.72 | [Pharmacokinetics/Pharmacodynamic Analysis to Link Pharmacokinetics to Efficacy and Drug Interaction of Alzheimer's Disease Drugs]. ( Kiriyama, A, 2021) |
| " For AD patients, the dosage regimen is also crucial due to aging and diseases." | 2.72 | An Update on the Routes for the Delivery of Donepezil. ( Chen, BZ; Guo, XD; Zhang, XP; Zhao, ZQ; Zheng, H, 2021) |
| "In patients with Alzheimer's disease, global assessment scales, such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Clinician's Interview-Based Impression Plus Caregiver Input (CIBI plus), and the Clinical Global Impression (CGI) are commonly used." | 2.72 | Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donep ( Cipriani, A; Efthimiou, O; Furakawa, TA; Goldberg, Y; Iwatsubo, T; Leucht, S; Levine, SZ; Samara, M; Yoshida, K, 2021) |
| "Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative diseases and the leading causes of dementia worldwide." | 2.72 | Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion? ( Matos, MJ, 2021) |
| "Delays in the diagnosis of Alzheimer's disease, and, therefore, delays in treatment, may have a detrimental effect on a patient's long-term well-being." | 2.72 | 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. ( Engedal, K; Haglund, A; Schindler, R; Soininen, H; Verhey, F; Waldemar, G; Wetterholm, AL; Wimo, A; Winblad, B; Zhang, R, 2006) |
| "Younger Alzheimer's disease (AD) patients appear to differ genetically and neuropathologically from older AD patients, and may experience a more aggressive disease course compared with older patients." | 2.72 | Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. ( Bergman, H; Bullock, R; Gambina, G; He, Y; Lane, R; Nagel, J; Touchon, J, 2006) |
| "Patients with mild to moderate Alzheimer's disease received open-label treatment with donepezil (5 mg/day for 4 weeks, then 10 mg/day for the remainder of the phase) for 12-24 weeks." | 2.72 | Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. ( Hampel, H; Johannsen, P; Qvitzau, S; Richardson, S; Salmon, E; Schindler, R; Xu, Y, 2006) |
| "Current outcome measures for Alzheimer's disease (AD) drugs have been criticized as insufficiently patient-centred." | 2.72 | Verbal repetition in patients with Alzheimer's disease who receive donepezil. ( Asp, E; Cloutier, F; Cook, C; Dei, DW; Fay, S; Fisk, J; Robertson, ML; Rockwood, K, 2006) |
| " The drug was administered at a dosage of 5 mg/day for 1 month and 10 mg/day for the following 7 months, as tolerated." | 2.72 | Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. ( Bordier, P; Garrigue, S; Gencel, L; Lafitte, A; Lanusse, S; Margaine, J; Robert, F, 2006) |
| "Donepezil treatment shows a spatially limited functional effect on right hippocampus and left prefrontal cortical metabolism, independently of clinical response to treatment." | 2.72 | Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. ( Bartenstein, P; Drzezga, A; Hampel, H; Möller, HJ; Schwaiger, M; Teipel, SJ, 2006) |
| "Treatment with donepezil improves cognitive function of patients with Alzheimer's disease (AD) when compared to a placebo-controlled group." | 2.72 | Regional cerebral blood flow in Alzheimer's disease: comparison between short and long-term donepezil therapy. ( Kubota, T; Mori, S; Nakai, T; Nishimura, T; Okuyama, C; Ushuijima, Y, 2006) |
| "Donepezil treatment did not improve P50 sensory gating in AD patients but decreased P50 amplitude." | 2.72 | Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease. ( Bergonzi, P; Cadore, IP; Cancelli, I; Gigli, GL; Merlino, G; Moratti, U; Valente, M; Valentinis, L, 2006) |
| "In this retrospective analysis, Alzheimer's disease patients younger than 75 with wild-type BuChE exhibited differential efficacy to rivastigmine, while BuChE K-variant carriers experienced similar long-term treatment effects with both agents." | 2.72 | Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. ( Bergman, H; Blesa, R; Bullock, R; Gambina, G; He, Y; Lane, R; Meyer, J; Nagel, J; Rapatz, G, 2006) |
| "Donepezil was well tolerated; 51% of patients experienced adverse events, most commonly diarrhea (5." | 2.72 | Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease. ( Goldman, R; Griffith, P; Lichtenberg, P; Payne-Parrish, J, 2006) |
| "Donepezil-treated patients gained functional benefits relative to placebo on the Progressive Deterioration Scale (p = 0." | 2.71 | An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. ( Chin, W; Engedal, K; Haglund, A; Mastey, V; Miceli, R; Soininen, H; Subbiah, P; Verhey, F; Waldemar, G; Wetterholm, AL; Wimo, A; Winblad, B; Zhang, R, 2003) |
| "When donepezil was taken at an effective dose for at least 9 to 12 months, conservative estimates of the time gained before NHP were 21." | 2.71 | Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. ( Geldmacher, DS; Ieni, JR; Mastey, V; McRae, T; Provenzano, G, 2003) |
| "182 patients (69 male, 113 female) with Alzheimer's disease were randomised to galantamine (n = 94) or donepezil (n = 88) for 52 weeks." | 2.71 | A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. ( Bullock, R; Coles, H; Howe, I; Kershaw, P; Lilienfeld, S; Truyen, L; Wilcock, G; Zhu, Y, 2003) |
| "Mean Alzheimer's Disease Assessment Scale cognitive subscale scores were improved after treatment with donepezil, relative to placebo, at weeks 6, 12, 18, and 24." | 2.71 | Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. ( Charles, HC; Doraiswamy, PM; Ieni, JR; Krishnan, KR; Mintzer, J; Perdomo, C; Rogers, S; Weisler, R; Yu, X, 2003) |
| "12 patients with mild to moderate Alzheimer's disease and six controls were studied." | 2.71 | A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. ( Bolt, L; Fleming, J; Hoffmann, S; Holmes, C; Kemp, PM; Thom, J; Wilkinson, DG; Wilkinson, S; Zivanovic, M, 2003) |
| " In an open-label study, we evaluated the neurophysiological effects of chronic administration of donepezil to AD patients, by means of a correlative approach between quantitative EEG (qEEG) and perfusional brain single photon emission computed tomography (SPECT)." | 2.71 | Quantitative EEG and perfusional single photon emission computed tomography correlation during long-term donepezil therapy in Alzheimer's disease. ( Calvini, P; Canfora, M; De Leo, C; Girtler, N; Nobili, F; Piccardo, A; Rodriguez, G; Vitali, P, 2004) |
| "Sertraline augmentation was well-tolerated in this sample of AD outpatients." | 2.71 | A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. ( Burt, T; Dysken, M; Finkel, SI; Krishnan, KR; McRae, T; Mintzer, JE, 2004) |
| "Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist." | 2.71 | Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. ( Farlow, MR; Gergel, I; Graham, SM; Grossberg, GT; McDonald, S; Tariot, PN, 2004) |
| "A study was performed on patients with Alzheimer's disease (AD) in order to evaluate the efficacy of a combined treatment (donepezil plus cognitive training) in both cognitive processes and affective states." | 2.71 | Effects of cholinergic drugs and cognitive training on dementia. ( Campo, P; López Ibor, JJ; López Ibor, MI; Maestú, F; Ortiz, T; Requena, C, 2004) |
| "6 %)treatment was withdrawn because of mostly gastrointestinal adverse events." | 2.71 | Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. ( Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E, 2004) |
| "Donepezil is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD)." | 2.71 | Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. ( Fukuyama, H; Hashikawa, K; Kawasaki, K; Kita, T; Namiki, C; Tanaka, M; Thuy, DH; Yoshida, H, 2004) |
| "Donepezil treatment group: basal GH levels taken at 08:30 a." | 2.71 | The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. ( Geyer, G; Huber, ER; Knechtelsdorfer, M; Mayerhofer, L; Mersich, N; Obermayr, RP; Tragl, KH, 2005) |
| "Attentional function is impaired in Alzheimer's disease (AD)." | 2.71 | Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. ( Foldi, NS; Schaefer, LA; White, RE, 2005) |
| "To characterise the population of Alzheimer's disease patients treated with acetylcholinesterase inhibitors, to analyse effectiveness and drug safety in the clinical practice, and to identify variables that may predict the response to therapy." | 2.71 | A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. ( Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N, 2005) |
| "Reality orientation therapy combined with cholinesterase inhibitors has not been evaluated in patients with Alzheimer's disease." | 2.71 | Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial. ( Bartorelli, L; Bernabei, R; Carbone, G; Frisoni, GB; Giacobini, E; Lambertucci, P; Onder, G; Silveri, MC; Zanetti, O, 2005) |
| "Outcome measures were Alzheimer's disease Assessment Scale-Cognitive Component (ADAS-Cog), the Mini Mental State Examination, Instrumental Activities of Daily Living, and the Caregiver-rated Clinical Global Impression of Change." | 2.70 | Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. ( Couderc, R; Forette, F; Latour, F; Moulin, F; Rigaud, AS; Traykov, L, 2002) |
| "The correlates of dropout, efficacy, and adverse events in the treatment of Alzheimer's disease (AD) with acetylcholinesterase inhibitors (ChEI) are unclear." | 2.70 | Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease. ( Kim, JM; Shin, IS; Yoon, JS, 2002) |
| "To understand the treatment goals of Alzheimer's disease (AD) patients, carers, and physicians; to estimate whether clinically important goals are met during treatment with donepezil; and to compare a measure of goal attainment with standard measures used to evaluate AD treatment." | 2.70 | Goal setting and attainment in Alzheimer's disease patients treated with donepezil. ( Fay, S; Graham, JE; Rockwood, K, 2002) |
| "Treatment with donepezil reduced the AChE activity (k3 values) in the AD brain by 39% in the frontal (p < 0." | 2.70 | Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. ( Järvenpää, T; Kaasinen, V; Kurki, T; Någren, K; Oikonen, V; Rinne, JO; Roivainen, A; Yu, M, 2002) |
| "Treatment with donepezil for 1 y appears to reduce the decline in rCBF, suggesting preservation of functional brain activity." | 2.70 | Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. ( Asada, T; Matsuda, H; Nakano, S; Takasaki, M; Uno, M, 2001) |
| " Safety was monitored by physical examinations, vital signs, clinical laboratory tests, electrocardiograms (ECGs), and treatment-emergent adverse events (AEs)." | 2.70 | A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. ( Cummings, JL; Katz, IR; Mintzer, J; Perdomo, CA; Schwam, EM; Tariot, PN; Whalen, E, 2001) |
| "Donepezil is a cholinesterase inhibitor which has been previously shown to affect the cognitive evoked potentials (EPs) of patients with Alzheimer's Disease (AD) during treatment with the drug." | 2.70 | The effects of donepezil on quantitative EEG in patients with Alzheimer's disease. ( Patrick, G; Reeves, RR; Struve, FA, 2002) |
| "Donepezil is a specific, reversible inhibitor of AChE, while rivastigmine is a slowly reversible (pseudoirreversible) dual cholinesterase (ChE) inhibitor, with brain-regional specificity for the cerebral cortex and hippocampus." | 2.70 | Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. ( Auriacombe, S; Loria-Kanza, Y; Pere, JJ; Vellas, B, 2002) |
| "Donepezil was well tolerated, with no evidence of hepatotoxicity." | 2.69 | Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. ( Friedhoff, LT; Rogers, SL, 1998) |
| "Treatment with donepezil had no discernible effect on auditory or visual P300 EP amplitudes." | 2.69 | The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease. ( Booker, JG; Nave, DW; Patrick, G; Reeves, RR; Struve, FA, 1999) |
| "Alzheimer's disease is associated with a loss in presynaptic cholinergic function." | 2.69 | Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy. ( Gemmell, HG; Murray, AD; Shanks, MF; Staff, RT; Venneri, A, 2000) |
| " The most common adverse events were related to the nervous and digestive systems, and were generally mild and transient, resolving without the need for dose modifications." | 2.69 | Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. ( Doody, RS; Ieni, JR; Pratt, RD; Rogers, SL, 2000) |
| "Donepezil has a mildly positive effect on emotional/behavioral symptoms in AD in addition to its effect on cognitive function." | 2.69 | Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. ( Fontaine, CS; Foster, BM; Martin-Cook, K; Saine, K; Svetlik, DA; Weiner, MF, 2000) |
| "Efficacy was assessed by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory-carer Distress Scale (NPI-D)." | 2.69 | Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. ( Korbey, J; Matthews, HP; Rowden, J; Wilkinson, DG, 2000) |
| " The plasma elimination half-life of the beta-phase (t 1/2 beta) and time to maximum peak plasma concentration (tmax) were significantly longer in the elderly than in the young: t 1/2 beta, 103." | 2.67 | Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ( Hasegawa, J; Kamakura, H; Mihara, M; Morishita, N; Ohnishi, A; Tanaka, T; Tomono, Y; Yamazaki, K, 1993) |
| " Three separate studies were conducted to evaluate the safety and to establish the pharmacokinetic profile of E2020 after oral administration to healthy male subjects." | 2.67 | Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ( Hasegawa, J; Mihara, M; Morishita, N; Ohnishi, A; Shimamura, Y; Tomono, Y; Yamazaki, K, 1993) |
| " Besides, transdermal drug delivery systems seem to provide hope for the management of various diseases, due to the advantages that they offer in comparison with oral dosage forms." | 2.66 | Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management. ( Bülbül, EÖ; Karantas, ID; Mutlu, G; Okur, ME; Okur, NÜ; Siafaka, PI, 2020) |
| "Memantine was more acceptable than placebo (MD 0." | 2.66 | Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. ( Guo, J; Huang, Y; Liu, R; Wang, Z; Zhang, N; Zhang, R, 2020) |
| "During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline." | 2.61 | Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning. ( Ahmed, M; Aleya, L; Ashraf, GM; Barreto, GE; Begum, MM; Kabir, MT; Mathew, B; Rahman, MS; Thangapandiyan, S; Uddin, MS, 2019) |
| "Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden." | 2.61 | A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease. ( Benek, O; Juza, R; Kaping, D; Korabecny, J; Mezeiova, E; Soukup, O; Spilovska, K, 2019) |
| "Elderly patients with Alzheimer's disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions." | 2.58 | Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease. ( Kaushik, V; Mikobi, E; Raji, MA; Smith, ST, 2018) |
| "Meta-analyses were conducted for Alzheimer's Disease Assessment Scale-cognitive subscale and/or Mini-Mental State Examination (MMSE)." | 2.58 | Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes. ( Chang, SY; Dong, L; Feng, M; Guo, X; Hügel, H; Hyde, AJ; Lu, C; May, BH; Xue, CC; Zhang, AL, 2018) |
| "Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment." | 2.58 | The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis. ( Chang, YC; Perng, CH; Tzang, RF, 2018) |
| "Alzheimer's disease is debilitating neurodegenerative disorder in the elderly." | 2.58 | Profiling donepezil template into multipotent hybrids with antioxidant properties. ( Dolezal, R; Gorecki, L; Janockova, J; Jun, D; Korabecny, J; Kuca, K; Malinak, D; Mezeiova, E; Nepovimova, E; Soukup, O; Spilovska, K, 2018) |
| " Presence of drug in the olfactory bulb, in turn, increases the drug bioavailability in the brain and reduces the drug degradation as well as wastage of the drug through` systemic clearance." | 2.58 | Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. ( Agrawal, M; Alexander, A; Antimisiaris, SG; Chougule, MB; Saraf, S; Shoyele, SA, 2018) |
| "Donepezil is a cholinesterase inhibitor." | 2.58 | Donepezil for dementia due to Alzheimer's disease. ( Birks, JS; Harvey, RJ, 2018) |
| "Donepezil was found to benefit patients in cognition and global functioning." | 2.58 | A review of clinical treatment considerations of donepezil in severe Alzheimer's disease. ( Adlimoghaddam, A; Albensi, BC; Neuendorff, M; Roy, B, 2018) |
| " Although memantine monotherapy and combination therapy are associated with a few individual adverse events such as somnolence, it is well-tolerated and its safety (all-cause discontinuation) is comparable or superior to that of the placebo (agitation)." | 2.58 | The efficacy and safety of memantine for the treatment of Alzheimer's disease. ( Ikuta, T; Iwata, N; Kishi, T; Matsunaga, S; Nomura, I; Okuya, M; Sakuma, K, 2018) |
| " Based on these studies, donepezil has been shown to be effective and safe in Chinese AD patients and may impact AD biomarkers, such as hippocampal atrophy, Aβ, and tau." | 2.58 | Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients. ( Gordon, ML; Zhang, N, 2018) |
| "The increasing prevalence of Alzheimer's disease (AD) demands more effective drugs, which are still unclear." | 2.58 | Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review. ( Hang, L; Jia, R; Li, J; Liang, J; Wang, Y; Wu, R; Xu, Y; Zhang, H, 2018) |
| " Acetylcholinesterase inhibitors (AChEIs) aim to provide symptomatic benefit for cognitive decline, however these drugs are not without adverse events (AEs)." | 2.55 | Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. ( Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D, 2017) |
| "Donepezil has demonstrated a range of effects, including protecting against amyloid β, ischaemia and glutamate toxicity; slowing of progression of hippocampal atrophy; and up-regulation of nicotinic acetylcholine receptors." | 2.55 | Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. ( Dash, A; Hsu, JL; Kandiah, N; Kim, SH; Suthisisang, C; Udommongkol, C, 2017) |
| "Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors." | 2.55 | Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. ( Agbaba, D; Benchekroun, M; Brindisi, M; Brogi, S; Butini, S; Campiani, G; Esteban, G; Filipic, S; Gemma, S; Ismaili, L; Marco-Contelles, J; Nikolic, K; Refouvelet, B; Unzeta, M, 2017) |
| "The most prevalent of all dementias is Alzheimer's disease, a progressive neurodegenerative disease that presents with deficits in memory, cognition, motor skills, and a general decline in the quality of life." | 2.55 | Alzheimer's disease in the zebrafish: where can we take it? ( Caramillo, EM; Echevarria, DJ, 2017) |
| "Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD)." | 2.53 | Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. ( Lewis, SJ; Szeto, JY, 2016) |
| " Withdrawals due to adverse events and number of patients experiencing nausea, vomiting, diarrhoea and dizziness were examined as safety profiles." | 2.53 | The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. ( Kobayashi, H; Nakagawa, R; Ohnishi, T; Yoshizawa, K, 2016) |
| "Alzheimer's disease is a multifactorial syndrome, for which effective cures are urgently needed." | 2.53 | Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics. ( Caporaso, R; Minarini, A; Rosini, M; Simoni, E, 2016) |
| " To alleviate the pill burden and swallowing difficulties associated with the condition, a fixed drug combination of extended-release memantine and donepezil was developed." | 2.53 | Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia. ( Owen, RT, 2016) |
| "Using Alzheimer's disease as an example, this review employs a networks-based method to assess repeatability of outcomes across species, by intervention and mechanism." | 2.52 | Improving the predictive value of interventional animal models data. ( Zeiss, CJ, 2015) |
| "Donepezil is an acetylcholinesterase inhibitor approved for use across the full spectrum of mild, moderate, and severe AD." | 2.52 | Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance. ( Dash, A; Jeong, SK; Kim, BC; Lee, JH; Park, KW, 2015) |
| "His only medical history was mild Alzheimer's disease diagnosed 6 months prior." | 2.52 | Upper gastrointestinal bleed associated with cholinesterase inhibitor use. ( Kok, KS; Loke, Y; Southgate, J, 2015) |
| " Compared with placebo, more dropouts and adverse events occurred with the cholinesterase inhibitors, but not with memantine." | 2.50 | Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. ( Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC, 2014) |
| "Donepezil is a highly selective acetylcholinesterase inhibitor and one of the only four drugs currently approved for treatment of Alzheimer's dementia." | 2.50 | Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. ( Prvulovic, D; Schneider, B, 2014) |
| "Memantine is a non-competitive low-affinity antagonist of the NMDA receptor with a t(1/2) of 70 h." | 2.49 | Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. ( Eap, CB; Noetzli, M, 2013) |
| "Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing." | 2.49 | Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. ( Farlow, M; Ferris, SH, 2013) |
| "Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes." | 2.49 | Atypical aging in Down syndrome. ( Zigman, WB, 2013) |
| "Treatment with memantine/ChEI combination therapy in moderate-to-severe AD produces consistent benefits that appear to increase over time, and that are beyond those of ChEI treatment alone." | 2.49 | Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. ( Gauthier, S; Molinuevo, JL, 2013) |
| "Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs." | 2.48 | Reviewing the role of donepezil in the treatment of Alzheimer's disease. ( Cummings, JL; Doody, RS; Farlow, MR, 2012) |
| "In randomized clinical trials, adverse events (AEs) are reported for the drug under evaluation and compared with the placebo group." | 2.48 | A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. ( Amanzio, M; Benedetti, F; Vase, L, 2012) |
| "Treatment with memantine in addition to donepezil versus treatment with donepezil alone showed an ICER range from a dominant value to 6818." | 2.48 | Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. ( Dams, J; Dodel, R; Neumann, A; Pouryamout, L; Wasem, J, 2012) |
| "Alzheimer's disease is a progressive disorder with the moderate to severe stages generally characterized by significant cognitive, functional, and behavioral dysfunction." | 2.47 | Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. ( Cummings, J; Sabbagh, M, 2011) |
| "Down syndrome is probably believed too special and therefore many clinicians seems to hesitate to attend them or scare to give wrong treatment." | 2.46 | [Care continuity for patients with Down syndrome during transition from childhood to adulthood]. ( Hasegawa, T, 2010) |
| " Safety outcomes included adverse events (AEs), discontinuations caused by AEs and serious AEs (SAEs)." | 2.46 | Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. ( Farlow, MR; Meng, X; Olin, JT; Sadowsky, CH, 2010) |
| "Donepezil is a mixed competitive and noncompetitive acetylcholinesterase inhibitor that shows a relative selectivity for acetylcholinesterase inhibitor compared with butyrylcholinesterase." | 2.45 | Donepezil in the treatment of patients with Alzheimer's disease. ( Tsuno, N, 2009) |
| "Donepezil was the most widely studied treatment and galantamine the least widely prescribed therapy." | 2.45 | Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. ( Kelly, S; Lockhart, IA; Mitchell, SA, 2009) |
| " In silico predicted ADME and physicochemical properties of conjugates showed good CNS bioavailability and safety parameters." | 2.44 | Piperazine-2-carboxylic acid derivatives as MTDLs anti-Alzheimer agents: Anticholinesterase activity, mechanistic aspect, and molecular modeling studies. ( Abd El-Wahab, HAA; Akincioglu, H; Gülçin, İ; Omar, FA; Soliman, AM, 2024) |
| "The pathogenesis of Alzheimer's disease (AD) is complex, resulting in unsatisfactory effects of single-target therapeutic drugs." | 2.44 | Ginsenoside RK1 improves cognitive impairments and pathological changes in Alzheimer's disease via stimulation of the AMPK/Nrf2 signaling pathway. ( Li, A; Li, L; Liang, G; Ren, J; She, L; Sun, J; Wang, W; Wu, H; Xiong, L; Zhao, X, 2024) |
| " However, we found that their survival could be promoted by the long-term administration of donepezil, an acetylcholinesterase inhibitor that is widely used for the treatment of Alzheimer's disease." | 2.44 | [Neuronal migration in the adult brain]. ( Kaneko, N; Sawamoto, K, 2008) |
| " Across trials, the incidence of adverse events was generally lowest for donepezil and highest for rivastigmine." | 2.44 | Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. ( Gartlehner, G; Hansen, RA; Jonas, DE; Moore, CG; Morgan, LC; Webb, AP, 2008) |
| "Donepezil has numerous cellular and molecular effects that should influence AD progression." | 2.44 | Donepezil: potential neuroprotective and disease-modifying effects. ( Jacobson, SA; Sabbagh, MN, 2008) |
| "Moderate-to-severe stage Alzheimer's disease (AD) is a clinically diagnosable entity that represents a substantial burden to our healthcare system in terms of its prevalence, symptomatology, caregiver stress and economics." | 2.44 | Pharmacological treatment in moderate-to-severe Alzheimer's disease. ( Feldman, HH; Hsiung, GY, 2008) |
| "Studies on Alzheimer's disease and Lewy body dementias show that cholinesterase inhibitors are still first line treatment for these diseases and memantine is indicated in moderate/severe Alzheimer's disease, whereas there is as yet no standard available treatment for frontotemporal dementias." | 2.44 | Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence? ( Engelhardt, E; Laks, J, 2008) |
| "Delirium is very common in the elderly." | 2.44 | [Delirium]. ( Derouesné, C; Lacomblez, L, 2007) |
| "Available data from Alzheimer's Disease Cooperative Study (ADCS) randomized controlled clinical trials and from randomized controlled industry-sponsored trials for four cognitive enhancers (donepezil, galantamine, rivastigmine and sabeluzole) were pooled to assess the numbers of non-Caucasian participants." | 2.44 | Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. ( Aerssens, J; Alvidrez, J; Anand, R; Faison, WE; Farrer, LA; Jarvik, L; Manly, J; McRae, T; Mintzer, JE; Murphy, GM; Olin, JT; Regier, D; Sano, M; Schultz, SK, 2007) |
| " We found that long-term administration of donepezil, an acetylcholinesterase inhibitor clinically used for the treatment of Alzheimer's disease, promotes the survival of newly-generated neurons in the OB and the DG." | 2.44 | [Neuronal migration in the adult brain]. ( Kaneko, N; Sawamoto, K, 2007) |
| "Alzheimer's disease (AD) and vascular dementia (VaD) are both associated with deficits in cholinergic neurotransmission that are amenable to therapeutic intervention." | 2.43 | Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. ( Bayer, AJ; Passmore, AP; Steinhagen-Thiessen, E, 2005) |
| " The author provides information on recommended dosing for all three medications, noting that cholinesterase inhibitors must be titrated carefully." | 2.43 | Cholinesterase inhibitors in the treatment of dementia. ( Ellis, JM, 2005) |
| "Pharmacological treatment of Alzheimer's disease focuses on correcting the cholinergic deficiency in the central nervous system with cholinesterase inhibitors." | 2.43 | Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. ( Beck-Bornholdt, HP; Kaduszkiewicz, H; van den Bussche, H; Zimmermann, T, 2005) |
| "Treatment with donepezil, rivastigmine or galantamine resulted in significantly better cognitive performance using the ADAS-cog scale when compared with placebo." | 2.43 | A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. ( Clegg, A; Green, C; Kirby, J; Loveman, E; Payne, E; Picot, J; Takeda, A, 2006) |
| "Therapies for Alzheimer's disease (AD) at present augment the deteriorating cholinergic system, are reasonably well tolerated, and are convenient, given once or twice a day." | 2.43 | Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy. ( Davis, B; Sadik, K, 2006) |
| "Alzheimer's disease is the most common cause of dementia in older people." | 2.43 | Donepezil for dementia due to Alzheimer's disease. ( Birks, J; Harvey, RJ, 2006) |
| "Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005)." | 2.43 | Cholinesterase inhibitors for Alzheimer's disease. ( Birks, J, 2006) |
| "Donepezil is a selective acetylcholinesterase inhibitor that is widely prescribed for Alzheimer's disease (AD)." | 2.43 | Donepezil: a review. ( Seltzer, B, 2005) |
| "Familial Alzheimer's disease is a very rare autosomal dominant disease with early onset, caused by mutations in the amyloid precursor protein and presenilin genes, both linked to Abeta metabolism." | 2.43 | Alzheimer's disease. ( Blennow, K; de Leon, MJ; Zetterberg, H, 2006) |
| "Alzheimer's disease is the most common cause of dementia in older people." | 2.42 | Donepezil for dementia due to Alzheimer's disease. ( Birks, JS; Harvey, R, 2003) |
| "Therefore, additional therapies for Alzheimer's disease still need to be developed that include more tolerable agents with alternative mechanisms of action and broader efficacy." | 2.42 | Current treatments for Alzheimer's disease: cholinesterase inhibitors. ( Doody, RS, 2003) |
| "Donepezil does not cause liver toxicity or significant drug interactions and is relatively well-tolerated." | 2.42 | Donepezil: a clinical review of current and emerging indications. ( Rogers, SJ; Román, GC, 2004) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 2.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| "Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development." | 2.42 | NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. ( Farlow, MR, 2004) |
| "At the present time interventions for Alzheimer's disease are limited to those that modify the manifestations of the disease, and foremost amongst the candidates available are the cholinesterase inhibitors." | 2.42 | Evidence-based pharmacotherapy of Alzheimer's disease. ( Birks, J; Evans, JG; Wilcock, G, 2004) |
| "Donepezil was well tolerated; adverse events were cholinergic in nature and generally of mild severity and brief in duration." | 2.42 | Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. ( Birks, J; Evans, JG; Perdomo, C; Pratt, RD; Whitehead, A; Wilcock, GK, 2004) |
| "Donepezil is a representative acetylcholinesterase inhibitor (AChEI) and is a great success among the AChEI drugs." | 2.42 | [Scope and limitations of acetylcholinesterase inhibitors]. ( Sugimoto, H, 2004) |
| " Three head-to-head trials of ChEIs in the treatment of AD have been published to date, but are limited due to their open-label design, rates of titration, and the drug dosage levels utilised." | 2.42 | The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. ( Herrmann, N; Lanctôt, KL; Thompson, S, 2004) |
| "Donepezil is a potent, selective inhibitor of acetylcholinesterase, and selective inhibition of central as opposed to peripheral ChEs might be expected to reduce the incidence of AEs, thus this may explain the lower incidence of cholinergic AEs observed following treatment with donepezil, compared with nonselective ChE inhibitors." | 2.42 | The safety and tolerability of donepezil in patients with Alzheimer's disease. ( Ham, RJ; Jackson, S; Wilkinson, D, 2004) |
| "Nefiracetam has been shown to potentiate ACh currents in the alpha4beta2 receptor of rat cortical neurons with a bell-shaped dose-response relationship and the maximum effect at 1 nM." | 2.42 | Mechanisms of action of cognitive enhancers on neuroreceptors. ( Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2004) |
| "Donepezil (Aricept) is a highly selective acetylcholinesterase inhibitors with a pharmacokinetic profile allowing once-daily dosing." | 2.42 | Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. ( Geldmacher, DS, 2004) |
| "Tacrine was the first cholinesterase inhibitor approved by regulatory agencies, followed by donepezil, rivastigmine and recently galantamine." | 2.41 | Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. ( Jann, MW; Shirley, KL; Small, GW, 2002) |
| " Adverse events, physical examinations and clinical laboratory tests were assessed." | 2.41 | Donepezil: tolerability and safety in Alzheimer's disease. ( Ieni, JR; Perdomo, CA; Pratt, RD; Surick, IW, 2002) |
| "100 of the cases as announcing an Alzheimer's Disease (AD)." | 2.41 | [Mild Cognitive Impairment: potential therapeutics]. ( Allain, H; Belliard, S; Bentue-Ferrer, D; Djemaï, M; Merienne, M; Reymann, JM, 2002) |
| "Alzheimer's disease is the most common cause of dementia and is a primary degenerative disease of the brain of unknown cause." | 2.41 | Donepezil for mild and moderate Alzheimer's disease. ( Birks J, S; Melzer, D, 2000) |
| "Donepezil (E-2020) is a reversible, noncompetitive, piperidine-type cholinesterase inhibitor." | 2.41 | Donepezil: a review of its use in Alzheimer's disease. ( Dooley, M; Lamb, HM, 2000) |
| " In order to maximize and prolong positive drug effects, it is important to start early and adjust dosage during the treatment." | 2.41 | Cholinesterase inhibitors stabilize Alzheimer's disease. ( Giacobini, E, 2000) |
| "The estimated prevalence of Alzheimer's disease for a standard health authority (500,000 people) is about 3330." | 2.41 | Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. ( Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N, 2001) |
| "Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings." | 2.41 | Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. ( Duttagupta, S; Fillit, HM; Knopman, DS; Lloyd, JR; Max, W; Rice, DP, 2001) |
| "During the last years, treatment of Alzheimer's disease has improved following a better detection of this disease and, more importantly, following a better knowledge of its physiopathogeny." | 2.41 | [Anticholinesterase agents in Alzheimer's disease]. ( Sternon, J; Ventura, M, 2001) |
| "Donepezil is a piperidine-based, reversible acetylcholinesterase inhibitor, that is chemically unrelated to other cholinesterase inhibitors." | 2.41 | Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. ( Homma, A; Shigeta, M, 2001) |
| "A guide for drug prescription in Alzheimer's disease is thus warranted and becomes clearer, sure that, in the next future modifications and new strategies will appear." | 2.41 | [Perspectives for drug treatment in Alzheimer's disease]. ( Allain, H; Bentue-Ferrer, D; Lecavorzin, P; Polard, E; Reymann, JM; Tribut, O, 2001) |
| "Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed." | 2.41 | Guidelines for managing Alzheimer's disease: Part II. Treatment. ( Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B, 2002) |
| "Donepezil is a specific and potent acetylcholinesterase inhibitor according to in vitro data." | 2.40 | Donepezil. ( Benfield, P; Bryson, HM, 1997) |
| "Alzheimer's disease is the most common dementing illness affecting over 4 million Americans." | 2.40 | Providing dental care for patients diagnosed with Alzheimer's disease. ( Henry, RG; Wekstein, DR, 1997) |
| "Donepezil is a synthetic noncovalent reversible inhibitor of acetylcholinesterase (AChE) for the treatment of mild to moderate dementia associated with Alzheimer's disease." | 2.40 | Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. ( Shintani, EY; Uchida, KM, 1997) |
| "Donepezil HCI is a piperidine-based reversible acetylcholinesterase (AChE) inhibitor, chemically distinct from other cholinesterase (ChE) inhibitors and rationally designed to treat the symptoms of Alzheimer's disease (AD)." | 2.40 | Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. ( Rogers, SL, 1998) |
| " Furthermore, its long half-life supports a simple and convenient once-daily dosing regimen." | 2.40 | Clinical profile of donepezil in the treatment of Alzheimer's disease. ( Doody, RS, 1999) |
| "Because Alzheimer's disease is a heterogeneous disorder, the range of treatment responses likely will remain variable." | 2.40 | What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. ( Larson, EB; Shadlen, MF, 1999) |
| " These benefits, as well as a simple, once-daily dosing regimen, make donepezil a viable therapeutic option for AD patients." | 2.40 | Clinical benefits of a new piperidine-class AChE inhibitor. ( Doody, RS, 1999) |
| "The rapid growth of the world's Alzheimer's disease (AD) population has resulted in a tremendous financial burden on society, a situation exacerbated by the fact that the funding of health and social services faces increasing restrictions in the coming years." | 2.40 | An economic perspective on Alzheimer's disease. ( Trabucchi, M, 1999) |
| "Donepezil is a specific acetylcholinesterase inhibitor that can improve symptoms in patients with mild-to-moderate Alzheimer's disease; cognitive function is maintained above baseline levels for up to 1 year and normal decline of cognitive function is slowed." | 2.40 | Donepezil. Pharmacoeconomic implications of therapy. ( Foster, RH; Plosker, GL, 1999) |
| "Donepezil is a piperidine based, potent, specific, non-competitive and reversible inhibitor of acetylcholinesterase (AChE)." | 2.40 | The pharmacology of donepezil: a new treatment of Alzheimer's disease. ( Wilkinson, DG, 1999) |
| "Donepezil has become the focal point of anti-AD drug discovery projects." | 1.91 | A Recent Appraisal of Small-Organic Molecules as Anti-Alzheimer's Agents. ( Gupta, M; Khan, SK; Kumar, A; Nain, S; Ojha, M, 2023) |
| "Donepezil was superior to bromelain in improving locomotor activity." | 1.91 | Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway. ( Abo El-Magd, NF; Eraky, SM; Ramadan, NM, 2023) |
| "Donepezil was increased to 10 mg, and 2 months later, the patient developed dropped head syndrome." | 1.91 | [Abnormal posture of the trunk related to donepezil hydrochloride: report of 2 cases]. ( Komatsu, K; Takahashi, M; Ueda, A, 2023) |
| "Developing drugs for Alzheimer's disease (AD) is an extremely challenging task due to its devastating pathology." | 1.91 | Lobeline: A multifunctional alkaloid modulates cholinergic and glutamatergic activities. ( Dileep, KV; Omkumar, RV; Remya, C; Sadasivan, C; Variyar, EJ, 2023) |
| "Experiments on transgenic mice with an Alzheimer's disease model (APP/PS1) demonstrated that the intranasal administration of liposomes within 21 days resulted in enhanced learning abilities and a reduction in the formation rate of Aβ plaques in the entorhinal cortex and hippocampus of the brain." | 1.91 | Mitochondria-Targeted Delivery Strategy of Dual-Loaded Liposomes for Alzheimer's Disease Therapy. ( Belyaev, G; Bushmeleva, K; Gaynanova, G; Petrov, K; Samigullin, D; Sibgatullina, G; Sinyashin, O; Valeeva, F; Vasileva, L; Vyshtakalyuk, A; Zakharova, L; Zueva, I, 2023) |
| " After drug treatment, the results showed that AD patients with HLJD combined with DON treatment didn't increase the adverse effects and had good compliance." | 1.91 | Efficacy evaluation and metabolomics analysis of Huanglian Jiedu decoction in combination with donepezil for Alzheimer's disease treatment. ( Huang, J; Xu, M; Yue, Y, 2023) |
| "As of 2022, according to the Alzheimer's Disease Association, there were over 6." | 1.91 | A causal inference study: The impact of the combined administration of Donepezil and Memantine on decreasing hospital and emergency department visits of Alzheimer's disease patients. ( Ehwerhemuepha, L; Lu, H; Patel, YM; Pierce, A; Rakovski, C; Rezaie, A; Sajjadi, SA; Yaghmaei, E, 2023) |
| "4% (6/64) discontinued due to adverse events." | 1.91 | Long-Term Safety, Tolerability, and Efficacy of a Transdermal Donepezil Patch in Patients with Severe Alzheimer's Disease. ( Aoki, H; Ishikawa, I; Kikuchi, T; Kim, R; Nakamura, Y; Narita, K; Nishiyama, K, 2023) |
| "Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers." | 1.91 | Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD). ( Bortnichak, EA; DiBello, JR; Liaw, KL; Liu, X; Lu, Y; Swartz, J; Zhong, W, 2023) |
| "Donepezil and memantine were the most consumed drugs, with the highest growth in consumption from 2014 to 2020." | 1.91 | Consumption of drugs for Alzheimer's disease on the Brazilian private market. ( Calil-Elias, S; Erbisti, RS; Freitas, EL; Grinberg-Weller, B; Miranda, ES, 2023) |
| "Early-response was based on Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) change scores under minus four from baseline to week six, otherwise classified non-response; then subgrouped by donepezil or placebo." | 1.72 | Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. ( Cipriani, A; Furukawa, TA; Goldberg, Y; Iwatsubo, T; Leucht, S; Levine, SZ; Samara, M; Yoshida, K, 2022) |
| " This study evaluated the risk of serious adverse events (SAEs) associated with individual ChEIs in older adults with dementia and also examined sex-based and dose-based effects on this risk." | 1.72 | Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. ( Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML; Masurkar, PP; Sherer, JT, 2022) |
| "Alzheimer's disease is the most common cause of dementia in the elderly population." | 1.72 | Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin. ( Ali, RH; Ali, SK, 2022) |
| "Drug delivery systems that not only show efficacy through multiple therapeutic pathways but also facilitate patient drug use and exhibit a high bioavailability profile represent a promising strategy in the treatment of Alzheimer's disease (AD)." | 1.72 | A novel multi-target strategy for Alzheimer's disease treatment via sublingual route: Donepezil/memantine/curcumin-loaded nanofibers. ( Aydemir, O; Bocekci, VG; Cam, ME; Duruksu, G; Ertas, B; Guler, E; Gunduz, O; Gurbuz, F; Ozcan, GS; Sahin Cam, C; Topal, F; Yazir, Y, 2022) |
| "Donepezil is frequently used to treat Alzheimer's disease (AD) symptoms but is associated with early discontinuation." | 1.72 | Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer's Disease Patients in Japan: LIFE Study. ( Fukuda, H; Maeda, M; Murata, F; Murata, Y, 2022) |
| " Most of the selected hybrid donepezils revealed good bioavailability, drug-likeness properties and pharmacokinetics; however, some need improved pharmacokinetic properties." | 1.72 | Roles of hybrid donepezil scaffolds as potent human acetylcholinesterase inhibitors using in silico interaction analysis, drug-likeness, and pharmacokinetics prediction. ( Hannongbua, S; Honorio, P; Saparpakorn, P, 2022) |
| "Alzheimer's disease is one of the most common neurodegenerative diseases worldwide and carries a huge social burden." | 1.72 | [Capabilities of combined therapy of Alzheimer's disease]. ( Levin, OS; Vasenina, EE; Veryugina, NI, 2022) |
| "Donepezil is an acetylcholinesterase inhibitor (AChEI) in use to treat symptomatic patients of mild to moderate Alzheimer's disease (AD)." | 1.72 | Understanding binding between donepezil and human ferritin: molecular docking and molecular dynamics simulation approach. ( Husain, FM; Khan, MS; Shahwan, M; Shamsi, A, 2022) |
| "Donepezil was approved for the treatment of Alzheimer's disease (AD) but causes variable therapeutic responses." | 1.72 | Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease. ( Chou, PS; Hour, TC; Huang, LC; Yang, YH; Yen, CW, 2022) |
| "Alzheimer's disease is a progressive brain disorder with characteristic symptoms and several pathological hallmarks." | 1.62 | 2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease. ( Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M, 2021) |
| "The multifactorial nature of Alzheimer's disease (AD) is a reason for the lack of effective drugs as well as a basis for the development of "multi-target-directed ligands" (MTDLs)." | 1.62 | Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. ( Angeloni, C; Bartolini, M; Bergamini, C; Bolognesi, ML; Chantegreil, F; de Camargo Nascente, L; de Melo Viana Teixeira, S; Freschi, M; Hrelia, S; Malaguti, M; Nachon, F; Prchal, L; Rossi, M; Salerno, A; Soares Romeiro, LA; Soukup, O, 2021) |
| "Liquiritigenin has been isolated and identified from Sargassum pallidum." | 1.62 | Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity. ( Guan, L; Jia, J; Jiang, H; Peng, D; Zhang, L, 2021) |
| "The pharmacokinetic (PK) change in a drug by co-administered herbal products can alter the efficacy and toxicity." | 1.62 | Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice. ( Bae, M; Chin, YW; Cho, J; Choi, YH; Han, SY; Kim, ES; Kim, YM; You, BH, 2021) |
| "Treatment with donepezil was administered from the 4th to the 6th month of life." | 1.62 | Donepezil improves vascular function in a mouse model of Alzheimer's disease. ( Antonioli, L; Baldacci, F; Bernardini, N; Blandizzi, C; D'Antongiovanni, V; Duranti, E; Fornai, M; Masi, S; Pellegrini, C; Taddei, S; Virdis, A, 2021) |
| "The modulatory effects of piperine on drug metabolizing enzymes play an important role in the control of pharmacokinetic and the bioavailability properties of the administered drugs." | 1.62 | The functional effects of piperine and piperine plus donepezil on hippocampal synaptic plasticity impairment in rat model of Alzheimer's disease. ( Ashrafpoor, M; Esfahani, DE; Nazifi, M; Oryan, S, 2021) |
| " T-006 improved cognitive ability after long-term administration in two AD mouse models and targeted mitochondrial-related protein alpha-F1-ATP synthase (ATP5A)." | 1.62 | The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease. ( Chen, H; Cheng, J; Guo, B; Huang, C; Su, Z; Sun, Y; Wang, Y; Wu, J; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhu, Z, 2021) |
| "Donepezil is a drug administered orally in the treatment of Alzheimer's disease, and with gastrointestinal side effects that are typical of acetylcholinesterase inhibitors." | 1.62 | The liquid crystalline phase behaviour of a nasal formulation modifies the brain disposition of donepezil in rats in the treatment of Alzheimer's disease. ( Boralli, VB; Carvalho, FC; de Souza, IFF; Dos Santos, TQ; Mangerona, BA; Pereira, GR; Placido, RV; Ruela, ALM, 2021) |
| "Eleven patients with Alzheimer's disease were treated with donepezil for 6 months." | 1.62 | Effects of donepezil on the amplitude of low-frequency fluctuations in the brain of patients with Alzheimer's disease: evidence from resting-state functional magnetic resonance imaging. ( Cheng, J; Yang, H; Zhang, J, 2021) |
| "Complex pathomechanism of Alzheimer's disease (AD) prompts researchers to develop multifunctional molecules in order to find effective therapy against AD." | 1.56 | 1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease. ( Gobec, S; Godyń, J; Jończyk, J; Knez, D; Malawska, B; Panek, D; Pasieka, A; Sabaté, R; Valdivieso, ÁDR; Wichur, T; Więckowska, A; Więckowski, K, 2020) |
| "Donepezil is a second generation acetylcholinesterase (AChE) inhibitor for treatment of Alzheimer's disease (AD)." | 1.56 | Donepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature. ( Kiametis, AS; Silva, MA; Treptow, W, 2020) |
| " In conclusion, in mice donepezil's brain bioavailability depends on P-gp." | 1.56 | Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice. ( Namendorf, C; Namendorf, T; Spieler, D; Uhr, M; von Cube, M, 2020) |
| " Here, we report an extrapyramidal adverse reaction to donepezil in an elderly patient with AD." | 1.56 | Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report. ( Li, HC; Luo, KX; Wang, JS; Wang, QX, 2020) |
| "Sixty-five outpatients with Alzheimer's disease or mixed dementia being treated with donepezil were assessed at baseline and over 27 months." | 1.56 | Are cytochrome P4502D6 and apolipoprotein E genotypes associated with long-term cognitive and functional changes in patients treated with donepezil? ( Coin, A; De Rui, M; Devita, M; Girardi, A; Manzato, E; Pamio, MV; Pigozzo, S; Sergi, G; Trevisan, C, 2020) |
| " There are few medications available as oral and suspension dosage forms for the management of AD." | 1.56 | Treatment of Alzheimer's diseases using donepezil nanoemulsion: an intranasal approach. ( Awasthy, S; Bhatnagar, I; Dang, S; Kaur, A; Nigam, K; Shankar, S; Sukhpal, H; Tyagi, A, 2020) |
| "To investigate the effect of electroacupuncture (EA) combined with Donepezil on learning-memory ability and gene expression of β-amyloid (Aβ) clearance-related factors in the hippocampus in senescence-accelerated mouse prone 8 (SAMP8) mice, so as to explore their synthetic effect in improving dementia of Alzheimer's disease (AD)．." | 1.56 | [Effect of electroacupuncture combined with Donepezil on learning-memory ability and expression of hippocampal β-amyloid clearance-related genes in SAMP8 mice]. ( An, HY; Li, XH; Qiu, L; Tang, CL; Wu, MJ; Yang, YH; Yang, ZX; Zhu, ZW, 2020) |
| "Alzheimer's disease is type of dementia in which cognitive functions get declined." | 1.56 | Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease. ( Awasthi, A; Corrie, L; Gulati, M; Kumar Singh, S; Vishwas, S, 2020) |
| " Medical charts were reviewed, including diagnosis, dosage of antidementia medicines, neuropsychological testing scores, and the further questionnaires were conducted via face-to-face or telephone, included duration of treatment, types of antidementia drugs, and reasons for treatment discontinuation." | 1.56 | Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China. ( Lü, Y; Yang, W; Yu, W; Yu, X, 2020) |
| " 3xTg-AD mice (10-month-old) were dosed intraperitoneally with 9R (daily 3, 10 or 30 mg/kg) for a month." | 1.56 | 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model. ( Ju, Y; Tam, KY, 2020) |
| "Dementia was diagnosed in 132 (32." | 1.56 | Dementia Diagnoses and Treatment in Geriatric Ward Patients: A Cross-Sectional Study in Poland. ( Wojszel, ZB, 2020) |
| " Among all AChEIs donepezil possesses lowest adverse effects, it can treat mildmoderate- severe AD and only once-daily dosing is required." | 1.56 | De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents. ( Pandey, S; Singh, BK, 2020) |
| "Facing the complexity of Alzheimer's disease (AD), it is now currently admitted that a therapeutic pleiotropic intervention is needed to alter its progression." | 1.51 | Novel multi target-directed ligands targeting 5-HT ( Bergamini, C; Bolognesi, ML; Claeysen, S; Dallemagne, P; Davis, A; Hatat, B; Lanthier, C; Lecoutey, C; Liparulo, I; Payan, H; Rochais, C; Since, M, 2019) |
| "The diverse nature of Alzheimer's disease (AD) has prompted researchers to develop multi-functional agents." | 1.51 | Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ( Choubey, PK; Krishnamurthy, S; Prajapati, SK; Seth, A; Sharma, P; Shrivastava, SK; Tripathi, A; Tripathi, MK; Tripathi, PN, 2019) |
| "Donepezil treatment increased cell membrane surface expression of APP in SNX33 expression-dependent manner." | 1.51 | Donepezil modulates amyloid precursor protein endocytosis and reduction by up-regulation of SNX33 expression in primary cortical neurons. ( Akaike, A; Izumi, Y; Kimata, R; Kume, T; Mizukawa, Y; Nakagawa, S; Nao, Y; Takada-Takatori, Y; Tsuchida, K; Urushidani, T, 2019) |
| "Donepezil is an acetylcholinesterase inhibitor used for the symptomatic treatment of AD." | 1.51 | Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery. ( Alexander, A; Dubey, SK; Kanojia, N; Krishna, KV; Kukreti, R; Saha, RN; Singhvi, G; Wadhwa, G, 2019) |
| "Many factors are involved in Alzheimer's Disease (AD) such as amyloid plaques, neurofibrillary tangles, cholinergic deficit and oxidative stress." | 1.51 | Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer's Disease Therapy. ( Andrys, R; Benchekroun, M; Iriepa, I; Ismaili, L; Malek, R; Marco-Contelles, J; Moraleda, I; Musilek, K; Refouvelet, B, 2019) |
| "Late-onset Alzheimer's disease (AD) differs substantially from early-onset AD." | 1.51 | rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine. ( Iyo, M; Oda, Y; Okubo, T; Sato, K; Shirayama, Y; Takahashi, M; Yoshino, K, 2019) |
| "Donepezil is an acetylcholinesterase inhibitor (AChI) that improves cognitive function in Alzheimer's disease (AD) patients." | 1.51 | Donepezil decreases heart rate in elderly patients with Alzheimer's disease. ( Lin, Y; Pu, Z; Shen, J; Sun, Y; Xu, W, 2019) |
| "Among neurodegenerative disorders, Alzheimer's disease (AD) is one of the most common disorders showing slow progressive cognitive decline." | 1.51 | Metal based donepezil analogues designed to inhibit human acetylcholinesterase for Alzheimer's disease. ( Halim, MA; Hossain, MK; Islam, N; Junaid, M; Ullah, MO, 2019) |
| " After the 15-day treatment, the Morris water maze test, micro-PET(positron-emission tomography), H&E (haematoxylin and eosin) staining, and immunohistochemistry were used to study the differences between donepezil (SAMP8+D), acupuncture (SAMP8+MA), and donepezil combined with acupuncture (SAMP8+D+MA) therapy for the treatment of Alzheimer's disease." | 1.51 | Effects of manual acupuncture combined with donepezil in a mouse model of Alzheimer's disease. ( Jiang, J; Li, Y; Li, Z; Liu, G; Shi, S, 2019) |
| "Overall the number of Alzheimer's disease outpatients of sampling days increased from 10 239 in 2012 to 20 546 in 2017." | 1.51 | Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017. ( Chen, X; Yu, L; Yu, Z, 2019) |
| " Further drug-like property analysis demonstrated that the optimized compound, 8d (WI-1758), had liver microsomal metabolic stability, was well tolerated (>2000 mg/kg), and had a rational pharmacokinetic profile, as well as an oral bioavailability of 14." | 1.48 | Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease. ( Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X, 2018) |
| "The multifactorial nature of Alzheimer's disease (AD) calls for the development of multitarget agents addressing key pathogenic processes." | 1.48 | Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties. ( Cai, P; Fang, SQ; Kong, LY; Liu, QH; Wang, XB; Yang, HL; Yang, XL, 2018) |
| "Among 418 patients with Alzheimer's disease receiving donepezil, 196 patients were eligible for analysis." | 1.48 | Location of white matter changes and response to donepezil in patients with Alzheimer's disease: A retrospective and observational study. ( Chou, PS; Kao, LL; Kao, YH; Lin, TC; Wu, MN; Yang, YH, 2018) |
| "Donepezil is an acetylcholine esterase inhibitor approved for use for all AD stages." | 1.48 | Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-β load and related toxicity in a mouse model of Alzheimer's disease. ( Batarseh, YS; Kaddoumi, A, 2018) |
| " The adverse drug effects and discontinuation rates were investigated with self-reported complaint after starting or increasing anti-dementia drugs." | 1.48 | Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia. ( Cho, AH; Kim, JS; Lim, EY; Yang, DW, 2018) |
| " The aim of the current study was to assess the impact of the long-term use of ChEIs on mortality in patients with AD." | 1.48 | The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease. ( Gkioka, M; Kazmierski, J; Messini-Zachou, C; Tsolaki, M, 2018) |
| "Donepezil is a first-line acetylcholinesterase inhibitor used for the treatment of AD that has been found, in addition to its potent acetylcholinesterase inhibitory effect, to act through other non-cholinergic mechanisms such as affecting mitochondrial biogenesis through peroxisome proliferator-activated receptor gamma coactivator (PGC1α)." | 1.48 | Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer's Disease. ( Chen, L; Fu, J; Guo, C; Huang, J; Huo, Y; Lu, J; Wan, L; Xin, B; Yang, Q; Zhong, Y, 2018) |
| " A transdermal physiologically based pharmacokinetic (TPBPK) model was developed and was integrated in a compartmental pharmacokinetic model to predict the plasma drug concentrations in rats." | 1.48 | In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro/in Vivo Correlations. ( Arfi, S; Bhatta, RS; Mishra, PR; Mittapelly, N; Pandey, G; Tulsankar, SL, 2018) |
| "Donepezil is a commonly prescribed cholinesterase inhibitor in Alzheimer's dementia." | 1.48 | Acute inability to mobilise resulting from probable donepezil-induced myoclonus. ( Henderson, EJ; Huffman, AJ; Whateley, JM, 2018) |
| "Ellagic acid (EA) is a phenolic phytoconstituent obtained from grains and fruits, having evident antioxidant effects and known to modulate several endogenous molecular signals in humans in a beneficial way." | 1.48 | Ellagic acid: Insights into its neuroprotective and cognitive enhancement effects in sporadic Alzheimer's disease. ( Jha, AB; Panchal, SS; Shah, A, 2018) |
| "Translational research in Alzheimer's disease (AD) pathology provides evidence that accumulation of amyloid-β and hyperphosphorylated tau, neuropathological hallmarks of AD, is associated with complex disturbances in synaptic and neuronal function leading to oscillatory abnormalities in the neuronal networks that support memory and cognition." | 1.48 | Neurophysiological signals as predictive translational biomarkers for Alzheimer's disease treatment: effects of donepezil on neuronal network oscillations in TgF344-AD rats. ( Hajós, M; Horvath, TL; Kelley, C; Stoiljkovic, M, 2018) |
| "Over 44 million people live with Alzheimer's disease (AD) worldwide." | 1.46 | A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease. ( Anjum, R; Bernhardt, PV; Hibbs, D; Kalinowski, DS; Lin, HY; Palanimuthu, D; Poon, R; Richardson, DR; Sahni, S, 2017) |
| "The clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) subscale change is disputed." | 1.46 | Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. ( Hoffman, D; Howlett, SE; Mitnitski, A; Rockwood, K; Schindler, R, 2017) |
| "Examples from Alzheimer's disease (AD) clinical studies of solanezumab and donepezil using the composite Integrated AD Rating Scale (iADRS) and its components, the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and AD Cooperative Study-Activities of Daily Living inventory, instrumental items (ADCS-iADL) were consistent with the theoretical statistical properties." | 1.46 | Statistical properties of continuous composite scales and implications for drug development. ( Aisen, P; Andersen, S; Case, M; Hendrix, S; Holdridge, KC; Liu-Seifert, H; Siemers, E; Sparks, J; Wessels, AM, 2017) |
| "Depression is one of the most frequent psychiatric disorders of Alzheimer's disease (AD)." | 1.46 | Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus. ( Cui, L; Hattori, S; Hayashi, T; Ikejima, T; Liu, B; Liu, W; Song, X; Tashiro, SI; Ushiki-Kaku, Y; Xu, F; Zhou, B, 2017) |
| "Our results suggest that the developed formulation has a potential to replace the current daily dosing regimen to a less frequent dosing schedule." | 1.46 | Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study. ( Arya, A; Banala, VT; Mishra, PR; Mishra, S; Mitra, K; Mittapelly, N; Pandey, G; Sharma, S; Shukla, S; Thalla, M, 2017) |
| "Treatment with donepezil or BPCT significantly decreased the prolonged 2nd retention transfer latency and 2nd retention latency time values of the SADM group in the EPM and MWM tests, respectively." | 1.46 | A benzothiazole/piperazine derivative with acetylcholinesterase inhibitory activity: Improvement in streptozotocin-induced cognitive deficits in rats. ( Can, ÖD; Demir Özkay, Ü; Sağlık, BN; Turan, N, 2017) |
| "Also, reduction of amyloid plaque burden and gliosis in the cortex and hippocampus was assessed." | 1.46 | The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. ( Fernandez, AP; Futch, HS; Herrero-Labrador, R; Marco-Contelles, J; Martínez-Murillo, R; Romero, A; Samadi, A; Serrano, J; Serrano, MP; Unzeta, M, 2017) |
| "Neurodegenerative diseases including Alzheimer's disease are complex to tackle because of the complexity of the brain, both in structure and function." | 1.46 | Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases. ( Emon, MA; Hofmann-Apitius, M; Karki, R; Kodamullil, AT; Younesi, E, 2017) |
| "We retrospectively enrolled 171 Alzheimer's disease patients, whose ChEI medication was changed." | 1.46 | Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease. ( Abe, K; Darwish, M; Hishikawa, N; Ohta, Y; Sato, K; Takemoto, M; Yamashita, T, 2017) |
| "Rolipram treatment significantly attenuated STZ induced and age related memory deficits, biochemical and histopathological alterations." | 1.46 | Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type. ( Kumar, A; Singh, N, 2017) |
| "The effects of AD-35 on cognitive impairments and neuroinflammatory changes caused by intracerebroventricular injection of Aβ25-35 were studied in rats." | 1.46 | Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease. ( Cai, J; Feng, N; Feng, R; Gong, Y; Li, J; Li, L; Liu, L; Peng, Y; Wang, L; Wang, X; Xu, S; Zhao, X, 2017) |
| "A total of 551 Alzheimer's disease patients (201 men and 350 women) were divided into four subgroups based on their PVH severity (0-III)." | 1.46 | Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity. ( Abe, K; Fukui, Y; Hishikawa, N; Ichinose, J; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T, 2017) |
| " The method was successfully applied to a pharmacokinetic study involving intramuscular application of 3." | 1.43 | An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ( Korabecny, J; Kuca, K; Mzik, M; Nepovimova, E; Palička, V; Voříšek, V; Zdarova Karasova, J, 2016) |
| "Treatment with vanillin in different doses and donepezil have significantly ameliorated i." | 1.43 | Protective effect of transient receptor potential vanilloid subtype 1 (TRPV1) modulator, against behavioral, biochemical and structural damage in experimental models of Alzheimer's disease. ( Jayant, S; Sharma, B; Sharma, BM, 2016) |
| "Donepezil was well tolerated, but haloperidol administration was followed by development of severe dystonia." | 1.43 | DatSCAN In Differential Diagnostics of Lewy Body Disease. ( Ivanova, K; Luzny, J, 2016) |
| "Donepezil (DNPZ) is a drug commonly used for Alzheimer's disease (AD) that may favour a T helper 2 phenotype leading to increased naturally occurring auto-antibodies (NAb) against beta-amyloid (Aβ)." | 1.43 | Donepezil modulates the endogenous immune response: implications for Alzheimer's disease. ( Aliprandi, A; Appollonio, I; Casati, M; Conti, E; Dominici, R; Ferrarese, C; Radice, I; Salmaggi, A; Santarone, ME; Tironi, M; Tremolizzo, L; Zoia, CP, 2016) |
| "Alzheimer's disease is a fatal neurodegenerative disorder with a complex etiology." | 1.42 | Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents. ( Bajda, M; Brus, B; Gobec, S; Guzior, N; Malawska, B; Rakoczy, J, 2015) |
| "Due to the complex nature of Alzheimer's disease, multi-target-directed ligand approaches are one of the most promising strategies in the search for effective treatments." | 1.42 | Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. ( Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K, 2015) |
| "The standards of care for Alzheimer's disease, acetylcholinesterase inhibitors such as donepezil (Aricept®), are dose-limited due to adverse side-effects." | 1.42 | Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. ( Cannon, CE; Dancho, M; Koser, A; Kuduk, SD; Puri, V; Renger, JJ; Uslaner, JM; Vardigan, JD; Wittmann, M, 2015) |
| "Due to the complex nature of Alzheimer's disease, there is a renewed and growing search for multitarget drugs." | 1.42 | Donepezil-ferulic acid hybrids as anti-Alzheimer drugs. ( Benchekroun, M; Gharbi, T; Ismaili, L; Luzet, V; Marco-Contelles, J; Pudlo, M; Refouvelet, B, 2015) |
| "To describe ChEI related ADRs in Alzheimer's disease (donepezil, rivastigmine, and galantamine) and characterize their seriousness as reported by national pharmacovigilance systems to VigiBase, a World Health Organization International Drug Monitoring Program database, between 1998 and 2013." | 1.42 | Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase. ( Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Laroche, ML; Mouls, M; Souverein, P; van Marum, R; Wilchesky, M, 2015) |
| "Memantine is a low-affinity voltage-dependent noncompetitive antagonist at glutamatergic NMDA receptors." | 1.42 | Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. ( Akishita, M; Ogawa, S; Ota, H; Ouchi, Y, 2015) |
| "Donepezil is an inhibitor of acetylcholinesterase used for the treatment of Alzheimer's disease." | 1.42 | Drug-induced lupus erythematosus associated with donepezil: a case report. ( Manzo, C; Putignano, S, 2015) |
| "A total of 77 Han Chinese patients with Alzheimer's disease were recruited to confirm these results, by measuring their steady-state plasma concentrations of S-donepezil." | 1.42 | Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. ( Chen, P; Guo, C; Han, Y; Li, W; Lu, J; Miao, Y; Wan, L; Wang, B; Yu, Q; Zhong, Y, 2015) |
| "This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia." | 1.42 | Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. ( Abagyan, R; Ali, TB; Chen, WY; Reilly, BM; Schleret, TR, 2015) |
| "The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness." | 1.40 | Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease. ( Adam, BL; Gao, J; Terry, AV, 2014) |
| "Both the Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measures for clinical trials in Alzheimer's disease and are approved also for regulatory purposes." | 1.40 | Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. ( Annas, P; Hannesdottir, K; Jaeger, J; Karin, A; Karlsson, P; Miller, F; Segerdahl, M; Sjögren, N; von Rosen, T, 2014) |
| "Donepezil is a drug that is used to treat Alzheimer's disease." | 1.40 | A brief report on the efficacy of donepezil in pain management in Alzheimer's disease. ( Gharaei, H; Shadlou, H, 2014) |
| "The donepezil concentration was estimated in the brain homogenate using HPLC method." | 1.40 | Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. ( Ali, J; Ali, M; Ali, R; Baboota, S; Bhatnagar, A; Md, S, 2014) |
| "Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease (AD)." | 1.40 | The potentially protective effect of donepezil in Alzheimer's disease. ( Ishiwata, A; Katayama, Y; Mishina, M; Mizumura, S; Yamazaki, M, 2014) |
| "Currently available treatment used in Alzheimer's disease is based on acetylcholinesterase inhibitors, e." | 1.39 | Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids. ( Mikiciuk-Olasik, E; Szymański, P; Zurek, E, 2013) |
| "Donepezil enantiomers were separated and determined by LC-MS/MS using D5-donepezil as an internal standard on a Sepax Chiralomix SB-5 column." | 1.39 | Steady-state plasma concentration of donepezil enantiomers and its stereoselective metabolism and transport in vitro. ( Cheng, G; Dan, L; Lili, W; Qi, Y; Xueli, Z; Yan, L; Yuan, Z; Zhiyong, Z, 2013) |
| "Because cognitive function showed improvement after increasing the dose of donepezil, the dosage of this drug should probably be adjusted based on the overall severity of Alzheimer's disease as well as the progression of cognitive dysfunction." | 1.39 | Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study. ( Hashimoto, M; Honda, K; Ikeda, M; Kaneda, K; Ogawa, Y; Yatabe, Y; Yuuki, S, 2013) |
| "As life expectancy increases, it is imperative that health care providers recognize the importance of safe medication use within an aging geriatric population." | 1.39 | Donepezil 23 mg: a brief insight on efficacy and safety concerns. ( Nguyen, MD; Salbu, RL, 2013) |
| "Donepezil was able to fully reverse the effects of biperiden on N50 sensory gating, but had residual effects when combined with scopolamine; i." | 1.39 | Cholinergic gating of hippocampal auditory evoked potentials in freely moving rats. ( Blokland, A; Klinkenberg, I; Sambeth, A, 2013) |
| "Alzheimer's disease is characterized by a progressive decline in cognitive function and involves β-amyloid (Aβ) in its pathogenesis." | 1.39 | Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. ( Matsuoka, N; Nagakura, A; Shitaka, Y; Yarimizu, J, 2013) |
| "Diagnosing and treating patients with Alzheimer's disease (AD) at an early stage should improve the quality of life of the patient and caregiver." | 1.38 | An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. ( Blume, S; Getsios, D; Hernández, L; Ishak, KJ; Maclaine, G, 2012) |
| "When donepezil was re-prescribed, the delirium resolved and the patient's mental state stabilized." | 1.38 | Withdrawal syndrome after donepezil cessation in a patient with dementia. ( Bidzan, L; Bidzan, M, 2012) |
| "Current treatment of Alzheimer's disease rests on cholinergic and anti-glutamatergic substances." | 1.38 | Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease. ( Neumeister, KL; Riepe, MW, 2012) |
| "This sequence of dosage and symptoms suggests acetylcholinesterase inhibition was the trigger for release of these memories, which are otherwise mostly chronically repressed in this individual." | 1.38 | Case report: Post-traumatic memories triggered by donepezil in a dose-dependent pattern. ( Wolff, ML, 2012) |
| "Donepezil used for the treatment of Alzheimer's disease inhibits decomposition of acetylcholine." | 1.38 | [Interaction of donepezil with rocuronium]. ( Pautola, L; Reinikainen, M, 2012) |
| " Mini-Mental State Examination and Alzheimer's Disease Assessment Scale (ADAS) scores were determined before and after the donepezil dosage increase." | 1.38 | Efficacy of a high dosage of donepezil for Alzheimer's disease as examined by single-photon emission computed tomography imaging. ( Abe, S; Fujii, H; Iwamoto, T; Kanaya, K; Koizumi, K; Sakai, M, 2012) |
| "Donepezil was the most widely used CED (66%), followed by galantamine (27%) then memantine (4%)." | 1.37 | Prescribing trends in cognition enhancing drugs in Australia. ( Byrne, GJ; Hollingworth, SA, 2011) |
| "Donepezil has been approved for the treatment for mild-to-moderate Alzheimer's disease (AD), but the therapeutic response rate varies from 20 to 60%." | 1.37 | Plasma concentration of donepezil to the therapeutic response of Alzheimer's disease in Taiwanese. ( Chen, SH; Chou, MC; Lai, CL; Liu, CK; Wu, SL; Yang, YH, 2011) |
| "Several mouse models of Alzheimer's disease (AD) with abundant β-amyloid and/or aberrantly phosphorylated tau develop memory impairments." | 1.37 | Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). ( Bussey, TJ; Mattson, MP; Mughal, MR; Romberg, C; Saksida, LM, 2011) |
| " Their known adverse effects include bradycardia." | 1.37 | Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. ( , 2011) |
| "Cognition was assessed with Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog)." | 1.37 | 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease. ( Bajs, M; Henigsberg, N; Hrabać, P; Kalember, P; Kovavić, Z; Loncar, M; Madzar, T; Rados, M, 2011) |
| " The results showed that piperine at all dosage range used in this study significantly improved memory impairment and neurodegeneration in hippocampus." | 1.36 | Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease. ( Chonpathompikunlert, P; Muchimapura, S; Wattanathorn, J, 2010) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 1.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "Donepezil was the most frequently prescribed active ingredient (37." | 1.36 | Prescribing of drugs for Alzheimer's disease: a South African database analysis. ( Truter, I, 2010) |
| "Treatment with donepezil (maximum dose, 10 mg/day) was recently approved in Japan for severe Alzheimer's disease (AD)." | 1.36 | Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease. ( Kobayashi, H; Mimura, M; Nakano, Y; Tomioka, H; Watanabe, T; Yamagata, B, 2010) |
| " Repeated (3 days) daily dosing of ABT-107 increased extracellular cortical acetylcholine in rats, whereas acute administration increased cortical extracellular signal-regulated kinase and cAMP response element-binding protein phosphorylation in mice, neurochemical and biochemical events germane to cognitive function." | 1.36 | In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. ( Anderson, DJ; Bitner, RS; Browman, K; Buccafusco, J; Bunnelle, WH; Decker, MW; Drescher, KU; Gopalakrishnan, M; Kohlhaas, KL; Markosyan, S; Marsh, KC; Nikkel, AL; Radek, R, 2010) |
| " For 10 mg and 5 mg donepezil once-daily dosing, the estimated forgiveness of donepezil was 80% and 90% daily compliance or two and one dosage omissions at steady state, respectively." | 1.36 | Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals. ( Freiberg, I; Kloft, C; Scheerans, C; Schmidt-Pokrzywniak, A; Schwalbe, O; Stang, A, 2010) |
| "Older age, longer time between Alzheimer's disease diagnosis and first ChEI dispensing, lower dose of ChEI at treatment initiation and the presence of baseline depression and neuropsychiatric symptoms were associated with a significantly increased likelihood of antipsychotic drug use." | 1.36 | Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. ( Duh, MS; Kahler, KH; Lefebvre, P; Mody-Patel, N; Scharre, DW; Vekeman, F, 2010) |
| "A total of 18 patients with Alzheimer's disease and 12 patients with amnesic syndrome received study-test sessions under four different study conditions: errorless/errorful and effortless/effortful." | 1.36 | Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome. ( Komatsu, S; Mimura, M, 2010) |
| "Donepezil is a reversible, primarily non-competitive, selective inhibitor of AChE used in patients with Alzheimer's disease for the improvement of cognitive deficits." | 1.35 | Prolonged treatment with donepezil increases acetylcholinesterase expression in the central nervous system. ( Pregelj, P; Zivin, M, 2008) |
| "Hypersexuality in Alzheimer's disease (AD) has been rarely investigated." | 1.35 | Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008) |
| "The donepezil-treated patients taking psychotropic drugs showed significantly greater improvement on the SIB, less deterioration on the ADCS-ADL, and had higher Clinical Global Impression of Improvement scores and a trend towards lower NPI scores." | 1.35 | Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis. ( Haglund, A; Jelic, V; Kowalski, J; Langworth, S; Winblad, B, 2008) |
| " Most patients tolerated the treatment well, with only 2 discontinuing because of adverse events." | 1.35 | Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study. ( Kassalow, LM; Li, H; Lopez, OL; Mackell, JA; McRae, T; Sun, Y; Xu, Y, 2008) |
| "Clinical course is typical for Alzheimer's disease with decline on the Mini-Mental Status Examination from a score of 25 to 19 over 3." | 1.35 | Possible Alzheimer's disease in an apolipoprotein E2 homozygote. ( Belden, C; Connor, D; Ignatov, I; Jacobson, S; Sabbagh, MN, 2009) |
| "Available treatments for Alzheimer's disease (AD) need to be evaluated in order to determine whether the clinical benefits justify their additional costs." | 1.35 | Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. ( García-Pérez, L; Hart, W; Linertová, R; López-Bastida, J, 2009) |
| " In this study, we sought to determine whether long-term administration of donepezil would slow amyloid plaque deposition or confer neuronal protection in a mouse model of AD." | 1.35 | Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. ( Coughlan, CA; Csernansky, JG; Dong, H; Murphy, KM; Yuede, CM, 2009) |
| "Donepezil was orally given at a dosage of 5 mgxkg(-1)xday(-1)." | 1.35 | Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. ( Ando, M; Arikawa, M; Handa, T; Kakinuma, Y; Katare, RG; Sasaguri, S; Sato, T; Yamasaki, F, 2009) |
| "The objective was to investigate the frequency of adverse events (AE) as a cause for discontinuation of donepezil treatment for Alzheimer's dementia (DAT) in a geriatric memory unit." | 1.35 | [Adverse events causing discontinuation of donepezil for Alzheimer's dementia]. ( Carøe, TK; Moe, C, 2009) |
| "Donepezil is a drug used for treatment in patients with Alzheimer's disease (AD)." | 1.35 | Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. ( Fuh, JL; Wang, SJ, 2008) |
| "Dementia was diagnosed in 134, and specifically Alzheimer's disease (AD) in 79, by an expert consensus panel." | 1.35 | Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. ( Baker, AS; Brandt, J; Lyketsos, CG; Mayer, LS; McNabney, M; Onyike, CU; Rosenblatt, A; Samus, QM, 2008) |
| "Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand 123I-5-IA-85380." | 1.35 | alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis. ( Best, J; Donaghey, C; Dougall, N; Ebmeier, KP; Herrmann, L; Lonie, J; Patterson, J; Pimlott, S; Sharman, M; Strachan, M; Terrière, E; Wyper, D, 2008) |
| "Celecoxib/STZ treatments produced a significant loss of learning and memory." | 1.35 | Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. ( Sharma, B; Singh, M; Singh, N, 2008) |
| "Donepezil was frequently discontinued, and the rate of discontinuation was higher in patients with advanced dementia." | 1.35 | Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. ( Itoh, A; Nabeshima, T; Suzuki, Y; Umegaki, H, 2008) |
| "With the goal of developing Alzheimer's disease therapeutics, we have designed and synthesized new piperidine derivatives having dual action of acetylcholinesterase (AChE) and beta-amyloid peptide (Abeta) aggregation inhibition." | 1.34 | Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. ( Chae, BS; Eun, JS; Kim, DK; Kim, KH; Kwon, YE; Lee, SK; Leem, JY; No, KT; Park, JY; Shin, JH; Shin, TY; Yang, JH, 2007) |
| "One of the characteristics of Alzheimer's disease (AD) that hinders the discovery of effective disease-modifying therapies is the multifactorial nature of its etiopathology." | 1.34 | Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. ( Andrisano, V; Banzi, R; Bartolini, M; Bergamini, C; Bolognesi, ML; Cattaneo, A; Cavalli, A; Fato, R; Hrelia, P; Lenaz, G; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tarozzi, A; Tumiatti, V, 2007) |
| "donepezil) in Alzheimer's disease (AD)." | 1.34 | Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil. ( Matsuda, O, 2007) |
| " Higher dosages often did not exert beneficial effects in accordance with inverted U-shaped dose-response curves described for cholinomimetics." | 1.33 | Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. ( Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D, 2005) |
| "54 mg kg-1 D-1 dosage as a positive control drug, DZXYS in 12." | 1.33 | [Protective effect of Danzhi-xiaoyao San on rat brain energy or material metabolism (correction of matebolism) dealt with D-galactose]. ( Cai, DY; Chen, JX; Huang, QF; Sun, LP; Wang, X; Zhang, JJ; Zhang, W, 2005) |
| " These results suggest that donepezil exerts a neuroprotective effect by reducing the amount of the toxic form of Abeta fibrils in septal neuron cultures." | 1.33 | Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. ( Akasofu, S; Kimura, M; Ogura, H; Sawada, K, 2005) |
| "Donepezil was well tolerated, with 85 of 913 (9." | 1.33 | Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study. ( Ibach, B; Kamleiter, M; Klinger, T; Mielke, R; Schoenknecht, P; Schroeder, J; Silver, G, 2005) |
| "Donepezil therapy was started after baseline evaluation." | 1.33 | Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. ( Acciarri, A; Bizzarro, A; Brahe, C; Marra, C; Masullo, C; Tiziano, FD; Valenza, A, 2005) |
| "Currently, medications for Alzheimer's disease constitute the largest category of appeals." | 1.33 | Appeals system and its outcomes in national health insurance in Taiwan. ( Kuo, SC; Lin, SJ; Yang, YH, 2006) |
| "few studies have analysed the effect of the long-term use of cholinesterase inhibitors (ChEIs) on mortality." | 1.33 | Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. ( Cors, OS; Estrada, AT; Franch, JV; Gelada-Batlle, E; López-Pousa, S; Nierga, IP; Olmo, JG, 2006) |
| "Donepezil is a reversible inhibitor of acetylcholinesterase." | 1.33 | Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. ( Abdulkadir, G; Ozlem, S; Suleyman, T; Tevfik, P, 2006) |
| "Donepeziltreated residents had a significantly shorter mean time to effective dose than rivastigmine- and galantamine-treated residents (1." | 1.33 | Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. ( Dybicz, SB; Erwin, WG; Keohane, DJ; McRae, T; Shah, SN, 2006) |
| "SPECT studies and Alzheimer's Disease Assessment Scale Japan cognitive Subscale function test ADAS-Jcog, as recognitive function test were performed for 22 patients (16 females, 6 males mean age = 73." | 1.33 | 3DSRT evaluation of responses of Alzheimer type dementia to donepezil hydrochloride therapy. ( Akiyama, H; Hashimoto, H; Higashiyama, S; Inoue, K; Inoue, Y; Kawabe, J; Kawamura, E; Kiriike, N; Shiomi, S; Torii, K, 2006) |
| "A 75-years-old man with Alzheimer's disease, treated with the cholinesterase inhibitor donepezil for 14 months, was scheduled for left colectomy under general anesthesia." | 1.32 | [Interaction of donepezil and muscular blockers in Alzheimer's disease]. ( Demartini Ferrari, A; Roca de Togores López, A; Sánchez Morillo, J, 2003) |
| " It is important to prevent dosing errors in cooperation with medical providers, patients and families." | 1.32 | [A case of acute cholinergic adverse effects induced by donepezil overdose: a follow-up of clinical course and plasma concentration of donepezil]. ( Fukuhara, Y; Kowa, H; Nakashima, K; Wada, K; Yano, H, 2003) |
| "Donepezil treatment resulted in statistically significant improvements in cognition and patient activity and social behaviour, and was generally well tolerated despite high levels of comorbid illness and concomitant medication use." | 1.32 | Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. ( Bahra, R; Baloyannis, S; Boada-Rovira, M; Brodaty, H; Cras, P; Emre, M; Zhang, R, 2004) |
| " Dose-response curves for tremor (central effect) and salivation (peripheral effect) showed that donepezil and icopezil possess a more favourable therapeutic index than the nonselective inhibitors, tacrine and heptylphysostigmine." | 1.32 | Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. ( Chapin, D; Hubbard, ST; Jones, SB; Liston, DR; Nason, D; Nielsen, JA; Ramirez, A; Shalaby, IA; Villalobos, A; White, WF, 2004) |
| "Fourteen inpatients with Alzheimer's disease received donepezil 5 mg/day, supplemented with extracts of Ginkgo biloba 90 mg/day for 30 days." | 1.32 | The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. ( Furukori, H; Kaneda, A; Kaneko, S; Tateishi, T; Yasui-Furukori, N, 2004) |
| "Donepezil use was associated with cognitive impairment, behavioral problems and the use of psychotropic drugs including anti-psychotics and anti-depressants." | 1.32 | Donepezil use in US nursing homes. ( Bernabei, R; Lapane, KL; Mor, V; Pedone, C, 2004) |
| "Muscle fasciculation appeared only after donepezil with a dose-dependent incidence and intensity." | 1.32 | Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. ( Liang, YQ; Tang, XC, 2004) |
| " At concentrations that include their prescribed dosage ranges, donepezil (1-1000 nM) and galantamine (50-1000 nM) increase action potential-dependent dopamine release." | 1.32 | Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. ( Dani, JA; Zhang, L; Zhou, FM, 2004) |
| "Control subjects were diagnosed with Alzheimer's disease (AD) at some point after the initial 6-month period." | 1.32 | Impact of rivastigmine use on the risk of nursing home placement in a US sample. ( Arcona, S; Beusterien, KM; Gause, D; Kimel, M; Mirski, D; Thomas, SK, 2004) |
| "Donepezil has been shown to improve aspects of cognitive functioning in persons with Alzheimer's disease (AD), but its impact on instrumental activities of daily living has received little attention." | 1.31 | Comparison of functional and cognitive donepezil effects in Alzheimer's disease. ( Cullum, CM; Hynan, L; Martin-Cook, K; Saine, K; Svetlik, DA; Weiner, MF, 2002) |
| "Donepezil is a cholinesterase inhibitor used for the treatment of Alzheimer's disease." | 1.31 | Responses to donepezil in Alzheimer's disease and Parkinson's disease. ( Mori, S, 2002) |
| "Donepezil (Aricept) is a reversible acetylcholinesterase inhibitor which is indicated for the treatment of mild to moderate dementia of the Alzheimer's type." | 1.31 | Use of donepezil in elderly patients with Alzheimer's disease--a Hawaii based study. ( Alagiakrishnan, K; Blanchette, PL; Wong, W, 2000) |
| "The cholinergic hypothesis of Alzheimer's disease is the basis of a new class of drugs: acetylcholinesterase inhibitors." | 1.31 | [Extra-pyramidal syndrome induced by donepezil]. ( Alt, M; Carcenac, D; Demuynck-Roegel, C; Kiesmann, M; Kuntzmann, F; Martin-Hunyadi, C, 2000) |
| "Donepezil has been licensed for use in Japan to improve cognitive function since 1999." | 1.31 | Urinary incontinence: an unrecognised adverse effect with donepezil. ( Hashimoto, M; Imamura, T; Kazui, H; Mori, E; Tanimukai, S, 2000) |
| "Comprehensive Alzheimer's disease (AD) treatment should address caregiver well-being." | 1.31 | Impact of donepezil on caregiving burden for patients with Alzheimer's disease. ( Brooks, RL; Fillit, HM; Gutterman, EM, 2000) |
| "Treatment with sertraline was initiated in February 1998." | 1.31 | Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. ( Nace, DA; Towers, AL; Verrico, MM, 2000) |
| "Donepezil is an acetylcholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate Alzheimer's disease." | 1.31 | Adverse effects associated with the use of donepezil in general practice in England. ( Dunn, NR; Pearce, GL; Shakir, SA, 2000) |
| " Specifically, certain metabolic parameters (ie, half-life and route of metabolism/elimination) can affect a drug's tolerability and become important when a switch from one agent to another is contemplated." | 1.31 | Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. ( Farlow, MR, 2001) |
| "Patients with a diagnosis of Alzheimer's disease or related dementia were identified from the claims-and-encounter records of the plan." | 1.31 | The effect of donepezil therapy on health costs in a Medicare managed care plan. ( Fillit, H; Futterman, R; Hill, JW; Mastey, V, 2002) |
| "Donepezil treatment might have a beneficial impact on patients with severe renal dysfunction." | 1.31 | New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient. ( Kamata, K; Nishijima, T; Sano, M; Suwata, J; Yoshikawa, T, 2002) |
| "Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | 1.30 | [Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998) |
| "Donepezil is a new drug recently approved in the United States and Canada for the treatment of Alzheimer's disease (AD)." | 1.30 | Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. ( Blackhouse, G; Gagnon, M; Gauthier, S; Goeree, R; Hux, M; Iskedjian, M; O'Brien, BJ, 1999) |
| "Donepezil has psychotropic properties, and pretreatment behaviors help predict patients' responses to treatment." | 1.30 | The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. ( Barclay, TR; Cummings, JL; Masterman, DM; Mega, MS; O'Connor, SM, 1999) |
| " The first large-scale study designed to evaluate the efficacy of Aricept administered at a daily dosage of 5 to 10 mg was conducted over 14 weeks." | 1.30 | [Cholinergic hypothesis and Alzheimer's disease: the place of donepezil (Aricept)]. ( Bertogliati, C; Gokalsing, E; Robert, PH, 1999) |
| "Donepezil treatment was associated with a decrease in medical costs, particularly in the outpatient components of health care." | 1.30 | Donepezil use in managed Medicare: effect on health care costs and utilization. ( Fillit, H; Gutterman, EM; Lewis, B, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 103 (6.55) | 18.2507 |
| 2000's | 588 (37.38) | 29.6817 |
| 2010's | 616 (39.16) | 24.3611 |
| 2020's | 266 (16.91) | 2.80 |
| Authors | Studies |
|---|---|
| Perola, E | 1 |
| Cellai, L | 1 |
| Brufani, M | 1 |
| Piazzi, L | 2 |
| Rampa, A | 2 |
| Bisi, A | 1 |
| Gobbi, S | 2 |
| Belluti, F | 1 |
| Cavalli, A | 4 |
| Bartolini, M | 14 |
| Andrisano, V | 10 |
| Valenti, P | 1 |
| Recanatini, M | 4 |
| Muñoz-Ruiz, P | 1 |
| Rubio, L | 1 |
| García-Palomero, E | 1 |
| Dorronsoro, I | 1 |
| del Monte-Millán, M | 1 |
| Valenzuela, R | 1 |
| Usán, P | 1 |
| de Austria, C | 1 |
| Bidon-Chanal, A | 2 |
| Orozco, M | 1 |
| Luque, FJ | 5 |
| Medina, M | 1 |
| Martínez, A | 5 |
| Kwon, YE | 1 |
| Park, JY | 1 |
| No, KT | 1 |
| Shin, JH | 1 |
| Lee, SK | 1 |
| Eun, JS | 1 |
| Yang, JH | 1 |
| Shin, TY | 1 |
| Kim, DK | 2 |
| Chae, BS | 1 |
| Leem, JY | 1 |
| Kim, KH | 1 |
| Bolognesi, ML | 8 |
| Banzi, R | 1 |
| Tarozzi, A | 4 |
| Minarini, A | 3 |
| Rosini, M | 3 |
| Tumiatti, V | 2 |
| Bergamini, C | 4 |
| Fato, R | 3 |
| Lenaz, G | 1 |
| Hrelia, P | 1 |
| Cattaneo, A | 1 |
| Melchiorre, C | 2 |
| Bembenek, SD | 1 |
| Keith, JM | 1 |
| Letavic, MA | 1 |
| Apodaca, R | 1 |
| Barbier, AJ | 1 |
| Dvorak, L | 1 |
| Aluisio, L | 1 |
| Miller, KL | 1 |
| Lovenberg, TW | 1 |
| Carruthers, NI | 1 |
| Zhu, Y | 4 |
| Xiao, K | 1 |
| Ma, L | 4 |
| Xiong, B | 1 |
| Fu, Y | 5 |
| Yu, H | 3 |
| Wang, W | 3 |
| Wang, X | 8 |
| Hu, D | 1 |
| Peng, H | 1 |
| Li, J | 15 |
| Gong, Q | 5 |
| Chai, Q | 1 |
| Tang, X | 2 |
| Zhang, H | 10 |
| Shen, J | 2 |
| Marco-Contelles, J | 17 |
| León, R | 3 |
| de los Ríos, C | 5 |
| Samadi, A | 10 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Rodríguez-Franco, MI | 7 |
| López, B | 1 |
| López, MG | 3 |
| García, AG | 2 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 3 |
| Ali, MA | 2 |
| Yar, MS | 1 |
| Hasan, MZ | 1 |
| Ahsan, MJ | 1 |
| Pandian, S | 2 |
| Rizzo, S | 1 |
| Ceccarini, L | 1 |
| Egea, J | 3 |
| Iriepa, I | 12 |
| Moraleda, I | 12 |
| Gálvez, E | 2 |
| Romero, A | 5 |
| Ismail, R | 2 |
| Choon, TS | 2 |
| Yoon, YK | 1 |
| Wei, AC | 1 |
| Kumar, RS | 2 |
| Osman, H | 2 |
| Manogaran, E | 1 |
| Al-Rashid, ZF | 1 |
| Hsung, RP | 1 |
| Tasso, B | 1 |
| Catto, M | 5 |
| Nicolotti, O | 2 |
| Novelli, F | 1 |
| Tonelli, M | 1 |
| Giangreco, I | 1 |
| Pisani, L | 2 |
| Sparatore, A | 1 |
| Boido, V | 1 |
| Carotti, A | 3 |
| Sparatore, F | 1 |
| Huang, W | 1 |
| Tang, L | 3 |
| Shi, Y | 4 |
| Huang, S | 1 |
| Xu, L | 3 |
| Sheng, R | 2 |
| Wu, P | 1 |
| Zhou, N | 2 |
| Hu, Y | 5 |
| Bolea, I | 3 |
| Juárez-Jiménez, J | 1 |
| Chioua, M | 4 |
| Pouplana, R | 1 |
| Unzeta, M | 7 |
| Valderas, C | 1 |
| Meng, FC | 1 |
| Mao, F | 4 |
| Shan, WJ | 1 |
| Qin, F | 1 |
| Huang, L | 8 |
| Li, XS | 1 |
| Mohamed, T | 2 |
| Yeung, JC | 1 |
| Vasefi, MS | 2 |
| Beazely, MA | 2 |
| Rao, PP | 3 |
| Estrada, M | 2 |
| Pérez, C | 9 |
| Leonetti, F | 1 |
| Pesce, P | 1 |
| Stefanachi, A | 1 |
| Cellamare, S | 1 |
| de la Fuente Revenga, M | 1 |
| Sun, Y | 14 |
| Chen, J | 2 |
| Chen, X | 7 |
| Li, X | 14 |
| Luo, Z | 2 |
| Sheng, J | 2 |
| Lu, C | 2 |
| Yan, J | 1 |
| Liu, A | 1 |
| Luo, HB | 1 |
| González-Naranjo, P | 1 |
| Pérez-Macias, N | 1 |
| Campillo, NE | 3 |
| Arán, VJ | 1 |
| Girón, R | 1 |
| Sánchez-Robles, E | 1 |
| Martín, MI | 1 |
| Gómez-Cañas, M | 1 |
| García-Arencibia, M | 1 |
| Fernández-Ruiz, J | 1 |
| Páez, JA | 1 |
| Liang, L | 4 |
| Pang, Y | 1 |
| Bautista-Aguilera, OM | 4 |
| Esteban, G | 4 |
| Nikolic, K | 3 |
| Agbaba, D | 3 |
| Soriano, E | 3 |
| Gao, J | 3 |
| Adam, BL | 1 |
| Terry, AV | 2 |
| Qiang, X | 13 |
| Sang, Z | 20 |
| Yuan, W | 2 |
| Li, Y | 21 |
| Liu, Q | 9 |
| Bai, P | 5 |
| Ang, W | 2 |
| Tan, Z | 24 |
| Deng, Y | 17 |
| Pudlo, M | 2 |
| Luzet, V | 3 |
| Ismaïli, L | 7 |
| Tomassoli, I | 1 |
| Iutzeler, A | 1 |
| Refouvelet, B | 5 |
| Wang, L | 5 |
| Ojima, M | 1 |
| Inokuchi, T | 1 |
| Youdim, MB | 1 |
| Herrero, R | 1 |
| Fernández Fernández, AP | 1 |
| Peng, P | 1 |
| Khan, I | 1 |
| Ibrar, A | 1 |
| Zaib, S | 1 |
| Ahmad, S | 1 |
| Furtmann, N | 2 |
| Hameed, S | 1 |
| Simpson, J | 1 |
| Bajorath, J | 3 |
| Iqbal, J | 3 |
| Miao, H | 1 |
| Meng, F | 1 |
| McEneny-King, A | 1 |
| Edginton, AN | 1 |
| Meena, P | 4 |
| Nemaysh, V | 1 |
| Khatri, M | 1 |
| Manral, A | 5 |
| Luthra, PM | 1 |
| Tiwari, M | 9 |
| Guzior, N | 1 |
| Bajda, M | 4 |
| Rakoczy, J | 1 |
| Brus, B | 2 |
| Gobec, S | 7 |
| Malawska, B | 10 |
| Luo, Y | 2 |
| Rochais, C | 6 |
| Lecoutey, C | 6 |
| Gaven, F | 1 |
| Giannoni, P | 1 |
| Hamidouche, K | 1 |
| Hedou, D | 1 |
| Dubost, E | 1 |
| Genest, D | 1 |
| Yahiaoui, S | 1 |
| Freret, T | 2 |
| Bouet, V | 1 |
| Dauphin, F | 1 |
| Sopkova de Oliveira Santos, J | 2 |
| Ballandonne, C | 1 |
| Corvaisier, S | 2 |
| Malzert-Fréon, A | 1 |
| Legay, R | 3 |
| Boulouard, M | 2 |
| Claeysen, S | 4 |
| Dallemagne, P | 6 |
| Więckowska, A | 5 |
| Więckowski, K | 3 |
| Sałat, K | 2 |
| Czerwińska, P | 1 |
| Filipek, B | 1 |
| Hameed, A | 2 |
| Zehra, ST | 2 |
| Shah, SJ | 1 |
| Khan, KM | 2 |
| Alharthy, RD | 1 |
| Tahir, MN | 1 |
| Kanhed, AM | 1 |
| Sinha, A | 1 |
| Machhi, J | 2 |
| Tripathi, A | 5 |
| Parikh, ZS | 1 |
| Pillai, PP | 1 |
| Giridhar, R | 1 |
| Yadav, MR | 2 |
| Saini, V | 4 |
| Luo, XT | 1 |
| Wang, CM | 1 |
| Liu, Y | 11 |
| Huang, ZG | 1 |
| Wang, Z | 6 |
| Wang, Y | 13 |
| Wang, B | 3 |
| Li, W | 6 |
| Yerdelen, KO | 1 |
| Koca, M | 1 |
| Anil, B | 1 |
| Sevindik, H | 1 |
| Kasap, Z | 1 |
| Halici, Z | 1 |
| Turkaydin, K | 1 |
| Gunesacar, G | 1 |
| Shaik, JB | 1 |
| Palaka, BK | 1 |
| Penumala, M | 1 |
| Kotapati, KV | 1 |
| Devineni, SR | 1 |
| Eadlapalli, S | 1 |
| Darla, MM | 1 |
| Ampasala, DR | 1 |
| Vadde, R | 1 |
| Amooru, GD | 1 |
| Abbas, S | 1 |
| Nisa, RU | 1 |
| Mahmood, T | 1 |
| Ayub, K | 1 |
| Al-Rashida, M | 1 |
| Xie, SS | 5 |
| Lan, JS | 4 |
| Wang, ZM | 4 |
| Jiang, N | 2 |
| Li, F | 5 |
| Wu, JJ | 6 |
| Wang, J | 8 |
| Kong, LY | 7 |
| Yang, X | 9 |
| Luo, L | 6 |
| Xiao, G | 5 |
| Cao, Z | 10 |
| Zha, GF | 1 |
| Zhang, CP | 1 |
| Qin, HL | 3 |
| Jantan, I | 2 |
| Sher, M | 2 |
| Amjad, MW | 2 |
| Hussain, MA | 2 |
| Hussain, Z | 1 |
| Bukhari, SN | 2 |
| Maqbool, M | 3 |
| Jameel, E | 3 |
| Kumar, J | 5 |
| Shandilya, A | 2 |
| Hoda, N | 6 |
| Jayaram, B | 3 |
| Singh, A | 5 |
| Mobashir, M | 1 |
| Shidore, M | 1 |
| Shingala, K | 1 |
| Murumkar, P | 1 |
| Sharma, MK | 1 |
| Agrawal, N | 1 |
| Parikh, Z | 1 |
| Pillai, P | 1 |
| Herrera-Arozamena, C | 2 |
| Viña, D | 2 |
| Morales-García, JA | 2 |
| Pérez-Castillo, A | 2 |
| Osman, W | 1 |
| Sit, VM | 1 |
| Hroch, L | 1 |
| Benek, O | 2 |
| Guest, P | 1 |
| Aitken, L | 1 |
| Soukup, O | 13 |
| Janockova, J | 4 |
| Musil, K | 1 |
| Dohnal, V | 1 |
| Dolezal, R | 5 |
| Kuca, K | 8 |
| Smith, TK | 1 |
| Gunn-Moore, F | 1 |
| Musilek, K | 3 |
| Mishra, CB | 2 |
| Kumari, S | 2 |
| Dighe, SN | 1 |
| Deora, GS | 1 |
| De la Mora, E | 1 |
| Nachon, F | 6 |
| Chan, S | 1 |
| Parat, MO | 1 |
| Brazzolotto, X | 6 |
| Ross, BP | 2 |
| Leng, J | 1 |
| Zhu, K | 1 |
| Naeem-Ul-Hassan, M | 1 |
| Ahmad, W | 1 |
| Li, XM | 1 |
| Wang, XB | 6 |
| Cai, P | 4 |
| Liu, QH | 3 |
| Xu, DQ | 1 |
| Yang, XL | 4 |
| Wang, H | 10 |
| Lu, Z | 1 |
| Zheng, X | 2 |
| Ni, W | 1 |
| Zhu, J | 4 |
| Lian, F | 1 |
| Zhang, N | 4 |
| Kołaczkowski, M | 2 |
| Bucki, A | 2 |
| Godyń, J | 7 |
| Marcinkowska, M | 1 |
| Zaręba, P | 2 |
| Siwek, A | 3 |
| Kazek, G | 1 |
| Głuch-Lutwin, M | 3 |
| Mierzejewski, P | 1 |
| Bienkowski, P | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Knez, D | 5 |
| Wichur, T | 4 |
| Prakash, A | 1 |
| Lynn, AM | 1 |
| Chen, Z | 2 |
| Digiacomo, M | 2 |
| Tu, Y | 1 |
| Gu, Q | 1 |
| Wang, S | 7 |
| Chu, J | 1 |
| Chen, Q | 2 |
| Han, Y | 3 |
| Nesi, G | 2 |
| Sestito, S | 2 |
| Macchia, M | 1 |
| Rapposelli, S | 2 |
| Pi, R | 3 |
| Joubert, J | 1 |
| Foka, GB | 1 |
| Repsold, BP | 1 |
| Oliver, DW | 1 |
| Kapp, E | 1 |
| Malan, SF | 1 |
| Midde, N | 1 |
| McInnes, C | 1 |
| Chapman, JM | 1 |
| van Greunen, DG | 2 |
| Cordier, W | 2 |
| Nell, M | 2 |
| van der Westhuyzen, C | 1 |
| Steenkamp, V | 2 |
| Panayides, JL | 2 |
| Riley, DL | 2 |
| Zheng, Y | 3 |
| Su, F | 1 |
| Ai, J | 1 |
| Park, B | 1 |
| Nam, JH | 1 |
| Kim, JH | 3 |
| Kim, HJ | 6 |
| Onnis, V | 1 |
| Balboni, G | 1 |
| Lee, KT | 1 |
| Park, JH | 4 |
| Lee, JY | 3 |
| Nirogi, R | 2 |
| Shinde, A | 1 |
| Kambhampati, RS | 1 |
| Mohammed, AR | 2 |
| Saraf, SK | 1 |
| Badange, RK | 1 |
| Bandyala, TR | 1 |
| Bhatta, V | 1 |
| Bojja, K | 1 |
| Reballi, V | 1 |
| Subramanian, R | 2 |
| Benade, V | 2 |
| Palacharla, RC | 1 |
| Bhyrapuneni, G | 1 |
| Jayarajan, P | 2 |
| Goyal, V | 1 |
| Jasti, V | 1 |
| Xu, R | 6 |
| Song, Q | 10 |
| Xia, CL | 1 |
| Wang, N | 2 |
| Guo, QL | 1 |
| Liu, ZQ | 1 |
| Wu, JQ | 1 |
| Huang, SL | 1 |
| Ou, TM | 1 |
| Tan, JH | 1 |
| Wang, HG | 1 |
| Li, D | 2 |
| Huang, ZS | 1 |
| Monjas, L | 1 |
| Arce, MP | 1 |
| Gil, C | 1 |
| Conde, S | 1 |
| Pan, W | 2 |
| Wang, K | 12 |
| Ma, Q | 6 |
| Yu, L | 7 |
| Yang, Y | 6 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Liu, W | 21 |
| Dias, KS | 1 |
| de Paula, CT | 1 |
| Dos Santos, T | 1 |
| Souza, IN | 1 |
| Boni, MS | 1 |
| Guimarães, MJ | 1 |
| da Silva, FM | 1 |
| Castro, NG | 2 |
| Neves, GA | 2 |
| Veloso, CC | 1 |
| Coelho, MM | 1 |
| de Melo, IS | 1 |
| Giusti, FC | 1 |
| Giusti-Paiva, A | 2 |
| da Silva, ML | 1 |
| Dardenne, LE | 3 |
| Guedes, IA | 2 |
| Pruccoli, L | 3 |
| Morroni, F | 1 |
| Viegas, C | 4 |
| Zhang, T | 3 |
| Yang, J | 8 |
| Liu, J | 6 |
| Miao, ZY | 1 |
| Ding, Y | 3 |
| Wang, T | 2 |
| Zhang, X | 5 |
| Liu, H | 10 |
| Ahmed, W | 1 |
| Mumtazuddin, S | 1 |
| Peauger, L | 2 |
| Azzouz, R | 2 |
| Gembus, V | 2 |
| Ţînţaş, ML | 2 |
| Sopková-de Oliveira Santos, J | 3 |
| Bohn, P | 1 |
| Papamicaël, C | 2 |
| Levacher, V | 2 |
| Zhao, XJ | 2 |
| Gong, DM | 1 |
| Jiang, YR | 2 |
| Guo, D | 2 |
| Deng, YC | 1 |
| Zhou, LY | 1 |
| Kang, P | 1 |
| Hou, JW | 1 |
| Zhang, XY | 1 |
| Jalili-Baleh, L | 2 |
| Nadri, H | 4 |
| Moradi, A | 3 |
| Bukhari, SNA | 2 |
| Shakibaie, M | 1 |
| Jafari, M | 2 |
| Golshani, M | 1 |
| Homayouni Moghadam, F | 1 |
| Firoozpour, L | 1 |
| Asadipour, A | 2 |
| Emami, S | 2 |
| Khoobi, M | 2 |
| Foroumadi, A | 2 |
| De Simone, A | 2 |
| Baschieri, A | 1 |
| Apperley, KYP | 1 |
| Chen, HH | 1 |
| Guardigni, M | 1 |
| Montanari, S | 1 |
| Kobrlova, T | 3 |
| Valgimigli, L | 1 |
| Keillor, JW | 1 |
| Basso, M | 1 |
| Milelli, A | 1 |
| Palanimuthu, D | 1 |
| Poon, R | 1 |
| Sahni, S | 1 |
| Anjum, R | 1 |
| Hibbs, D | 1 |
| Lin, HY | 1 |
| Bernhardt, PV | 1 |
| Kalinowski, DS | 1 |
| Richardson, DR | 1 |
| Chierrito, TPC | 2 |
| Pedersoli-Mantoani, S | 1 |
| Roca, C | 1 |
| Requena, C | 2 |
| Sebastian-Perez, V | 1 |
| Castillo, WO | 1 |
| Moreira, NCS | 1 |
| Sakamoto-Hojo, ET | 4 |
| Takahashi, CS | 1 |
| Jiménez-Barbero, J | 2 |
| Cañada, FJ | 2 |
| Carvalho, I | 6 |
| Ye, M | 2 |
| Han, X | 2 |
| Singh, M | 2 |
| Kaur, M | 1 |
| Singh, N | 6 |
| Silakari, O | 1 |
| Xu, YX | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Wang, TD | 1 |
| Tang, Y | 4 |
| Zhang, HY | 2 |
| Huang, Q | 1 |
| Liang, N | 1 |
| Li, Q | 7 |
| Hu, J | 4 |
| Feng, X | 1 |
| Chan, ASC | 1 |
| Dias Viegas, FP | 2 |
| de Freitas Silva, M | 3 |
| Divino da Rocha, M | 1 |
| Castelli, MR | 2 |
| Riquiel, MM | 2 |
| Machado, RP | 1 |
| Vaz, SM | 1 |
| Simões de Lima, LM | 1 |
| Mancini, KC | 1 |
| Marques de Oliveira, PC | 1 |
| Morais, ÉP | 1 |
| Gontijo, VS | 1 |
| da Silva, FMR | 1 |
| D'Alincourt da Fonseca Peçanha, D | 1 |
| Vilela, FC | 1 |
| Orlandi, L | 1 |
| Camps, I | 1 |
| Veloso, MP | 1 |
| Leomil Coelho, LF | 1 |
| Ionta, M | 1 |
| Ferreira-Silva, GÁ | 1 |
| Pereira, RM | 1 |
| de Oliveira Carneiro Junior, W | 1 |
| Quaglio Bellozi, PM | 1 |
| Pinheiro de Oliveira, AC | 1 |
| Ferreira, FF | 1 |
| Gurjar, AS | 1 |
| Darekar, MN | 1 |
| Yeong, KY | 1 |
| Ooi, L | 1 |
| Yang, Z | 2 |
| Kumar, D | 4 |
| Gupta, SK | 1 |
| Ganeshpurkar, A | 2 |
| Gutti, G | 2 |
| Krishnamurthy, S | 5 |
| Modi, G | 4 |
| Singh, SK | 2 |
| Hepnarova, V | 2 |
| Korabecny, J | 10 |
| Matouskova, L | 1 |
| Jost, P | 2 |
| Muckova, L | 3 |
| Hrabinova, M | 3 |
| Vykoukalova, N | 1 |
| Kerhartova, M | 1 |
| Kucera, T | 1 |
| Nepovimova, E | 7 |
| Spilovska, K | 3 |
| Mezeiova, E | 7 |
| Pham, NL | 1 |
| Jun, D | 3 |
| Staud, F | 1 |
| Kaping, D | 2 |
| Forootanfar, H | 1 |
| Küçükkılınç, TT | 1 |
| Abdolahi, Z | 1 |
| Ameri, A | 1 |
| Ayazgok, B | 1 |
| Baeeri, M | 1 |
| Rahimifard, M | 1 |
| Abbas Bukhari, SN | 1 |
| Abdollahi, M | 1 |
| Ganjali, MR | 1 |
| Zhao, Y | 7 |
| Ye, F | 1 |
| Xu, J | 5 |
| Liao, Q | 1 |
| Chen, L | 5 |
| Zhang, W | 4 |
| Sun, H | 7 |
| Feng, F | 5 |
| Qu, W | 2 |
| Budni, J | 2 |
| Mina, F | 1 |
| Medeiros, EB | 2 |
| Deuther-Conrad, W | 1 |
| Entrena, JM | 1 |
| López-Muñoz, F | 1 |
| Estrada Valencia, M | 1 |
| de Andrés, L | 1 |
| Ramos, E | 1 |
| Yáñez, M | 1 |
| Laurini, E | 1 |
| Pricl, S | 1 |
| Coquelle, N | 1 |
| Pišlar, A | 1 |
| Žakelj, S | 1 |
| Jukič, M | 2 |
| Sova, M | 1 |
| Mravljak, J | 1 |
| Kos, J | 1 |
| Colletier, JP | 1 |
| Fang, SQ | 2 |
| Yang, HL | 1 |
| Ghobadian, R | 1 |
| Mahdavi, M | 2 |
| Asadi, M | 1 |
| Akbarzadeh, T | 1 |
| Khaleghzadeh-Ahangar, H | 1 |
| Sharifzadeh, M | 1 |
| Amini, M | 1 |
| Reis, J | 1 |
| Cagide, F | 1 |
| Valencia, ME | 1 |
| Teixeira, J | 1 |
| Bagetta, D | 1 |
| Uriarte, E | 1 |
| Oliveira, PJ | 1 |
| Ortuso, F | 1 |
| Alcaro, S | 2 |
| Borges, F | 2 |
| Lalut, J | 3 |
| Santoni, G | 1 |
| Karila, D | 1 |
| Davis, A | 5 |
| Silman, I | 2 |
| Sussman, J | 1 |
| Weik, M | 1 |
| Maurice, T | 1 |
| Tian, C | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 6 |
| Mishra, P | 1 |
| Kumar, A | 6 |
| Panda, G | 1 |
| de Andrade, P | 1 |
| Mantoani, SP | 1 |
| Gonçalves Nunes, PS | 1 |
| Magadán, CR | 1 |
| Xavier, DJ | 1 |
| Hojo, ETS | 1 |
| AlFadly, ED | 1 |
| Elzahhar, PA | 1 |
| Tramarin, A | 2 |
| Elkazaz, S | 1 |
| Shaltout, H | 1 |
| Abu-Serie, MM | 1 |
| Ghareeb, DA | 1 |
| El-Yazbi, AF | 1 |
| Rafeh, RW | 1 |
| Bakkar, NZ | 1 |
| Kobeissy, F | 1 |
| Saudi, MNS | 1 |
| Belal, ASF | 1 |
| He, Y | 7 |
| Ye, C | 1 |
| Sharma, P | 6 |
| Tripathi, PN | 3 |
| Prajapati, SK | 3 |
| Seth, A | 2 |
| Tripathi, MK | 3 |
| Srivastava, P | 2 |
| Tiwari, V | 2 |
| Shrivastava, SK | 6 |
| Wang, D | 2 |
| Hu, M | 1 |
| Zhang, D | 5 |
| Chen, C | 3 |
| Fu, J | 4 |
| Shao, S | 1 |
| Shi, G | 1 |
| Zhou, Y | 6 |
| Wu, S | 1 |
| Chalupova, K | 2 |
| Monti, B | 1 |
| Lamba, D | 1 |
| Caliandro, R | 1 |
| Pesaresi, A | 1 |
| Gastellier, AJ | 1 |
| Pejchal, J | 3 |
| Jarosova, M | 1 |
| Zdarova Karasova, J | 2 |
| Mzik, M | 2 |
| Kristofikova, Z | 1 |
| Misik, J | 3 |
| Benkova, M | 1 |
| Setnicka, V | 1 |
| Habartova, L | 1 |
| Chvojkova, M | 1 |
| Kleteckova, L | 1 |
| Vales, K | 1 |
| Uliassi, E | 2 |
| Valis, M | 4 |
| Umar, T | 2 |
| Shalini, S | 2 |
| Raza, MK | 3 |
| Gusain, S | 2 |
| Seth, P | 1 |
| Hosseini, F | 1 |
| Ramazani, A | 1 |
| Mohammadi-Khanaposhtani, M | 1 |
| Barazandeh Tehrani, M | 1 |
| Larijani, B | 1 |
| Wu, M | 1 |
| Ma, J | 1 |
| Ji, L | 1 |
| Wang, M | 1 |
| Han, J | 3 |
| Kumar, B | 2 |
| Kumar, V | 2 |
| Prashar, V | 1 |
| Saini, S | 1 |
| Dwivedi, AR | 1 |
| Bajaj, B | 1 |
| Mehta, D | 1 |
| Parkash, J | 1 |
| Shi, J | 11 |
| Johan van der Westhuizen, C | 1 |
| Stander, A | 1 |
| Zhang, P | 4 |
| Xu, M | 4 |
| Peng, Y | 2 |
| Zhu, L | 1 |
| Ji, J | 1 |
| Rakesh, KP | 1 |
| Xu, Y | 17 |
| Zhang, Z | 4 |
| Jiang, X | 7 |
| Alsulami, H | 1 |
| Tang, W | 2 |
| Lanthier, C | 1 |
| Payan, H | 2 |
| Liparulo, I | 1 |
| Hatat, B | 2 |
| Since, M | 2 |
| Kakarla, R | 1 |
| Beohar, M | 1 |
| Zhu, G | 6 |
| Yang, D | 1 |
| Fan, X | 1 |
| Choubey, PK | 2 |
| Cheng, X | 4 |
| Zhang, Q | 2 |
| Zheng, C | 2 |
| Cheng, Y | 3 |
| Lu, X | 1 |
| Łażewska, D | 1 |
| Kuder, K | 1 |
| Hagenow, S | 1 |
| Łątka, K | 1 |
| Stawarska, E | 1 |
| Stark, H | 1 |
| Kieć-Kononowicz, K | 2 |
| Malek, R | 2 |
| Arribas, RL | 1 |
| Palomino-Antolin, A | 1 |
| Totoson, P | 1 |
| Demougeot, C | 1 |
| Diez-Iriepa, D | 2 |
| Panek, D | 4 |
| Mordyl, B | 2 |
| Chabchoub, F | 1 |
| Jończyk, J | 2 |
| Valdivieso, ÁDR | 1 |
| Pasieka, A | 3 |
| Sabaté, R | 2 |
| do Carmo Carreiras, M | 1 |
| Wei, R | 2 |
| Yun, Y | 1 |
| Miao, Y | 3 |
| Sun, J | 3 |
| Qiao, Z | 2 |
| Wu, A | 4 |
| Huang, XF | 1 |
| Dong, YH | 1 |
| Wang, JH | 1 |
| Ke, HM | 1 |
| Song, GQ | 1 |
| Xu, DF | 1 |
| Lan, Y | 1 |
| Wang, C | 4 |
| Singh, YP | 3 |
| Tej, GNVC | 1 |
| Pandey, A | 1 |
| Priya, K | 1 |
| Pandey, P | 1 |
| Shankar, G | 2 |
| Nayak, PK | 1 |
| Rai, G | 1 |
| Chittiboyina, AG | 1 |
| Doerksen, RJ | 1 |
| Vishwakarma, S | 1 |
| Rodríguez-Lavado, J | 1 |
| Gallardo-Garrido, C | 2 |
| Mallea, M | 1 |
| Bustos, V | 1 |
| Osorio, R | 1 |
| Hödar-Salazar, M | 1 |
| Chung, H | 2 |
| Araya-Maturana, R | 2 |
| Lorca, M | 1 |
| Pessoa-Mahana, CD | 2 |
| Mella-Raipán, J | 1 |
| Saitz, C | 1 |
| Jaque, P | 1 |
| Reyes-Parada, M | 1 |
| Iturriaga-Vásquez, P | 2 |
| Pessoa-Mahana, H | 2 |
| Le-Nhat-Thuy, G | 1 |
| Nguyen Thi, N | 1 |
| Pham-The, H | 1 |
| Dang Thi, TA | 1 |
| Nguyen Thi, H | 1 |
| Nguyen Thi, TH | 1 |
| Nguyen Hoang, S | 1 |
| Nguyen, TV | 1 |
| Sharma, S | 3 |
| Arora, S | 1 |
| Attri, S | 1 |
| Kaur, P | 1 |
| Kaur Gulati, H | 1 |
| Bhagat, K | 1 |
| Kumar, N | 2 |
| Singh, H | 1 |
| Vir Singh, J | 1 |
| Mohinder Singh Bedi, P | 1 |
| Gabr, MT | 3 |
| Brogi, S | 2 |
| Du, H | 3 |
| Ma, M | 1 |
| Xu, H | 1 |
| Liu, S | 1 |
| Ma, F | 2 |
| Dai, B | 1 |
| Ma, X | 1 |
| Guo, S | 1 |
| Lu, S | 2 |
| Wang, G | 1 |
| Toublet, FX | 1 |
| Liu, C | 3 |
| Xing, C | 1 |
| Lyu, W | 3 |
| Chen, T | 2 |
| Chen, Y | 4 |
| Andrys, R | 3 |
| Simunkova, M | 1 |
| Handl, J | 1 |
| Micankova, P | 1 |
| Capek, J | 1 |
| Rousar, T | 1 |
| Marco-Contelles, JL | 1 |
| Valko, M | 1 |
| Erdogan, M | 1 |
| Kilic, B | 1 |
| Sagkan, RI | 1 |
| Aksakal, F | 1 |
| Ercetin, T | 1 |
| Gulcan, HO | 2 |
| Dogruer, DS | 1 |
| Yin, W | 2 |
| Bai, F | 1 |
| Xu, S | 3 |
| Peng, T | 1 |
| Hong, Y | 2 |
| Xu, HE | 1 |
| Jiang, H | 2 |
| Manzoor, S | 1 |
| Majumdar, S | 1 |
| Kumar, S | 4 |
| Pal, K | 1 |
| Rashid, H | 1 |
| Yu, G | 2 |
| Liu, Z | 9 |
| Cong, S | 1 |
| Rai, H | 1 |
| Singh, G | 3 |
| Singh, GK | 2 |
| Mishra, S | 2 |
| Srikrishna, S | 2 |
| Zhang, L | 6 |
| Rossi, M | 1 |
| Freschi, M | 1 |
| de Camargo Nascente, L | 1 |
| Salerno, A | 1 |
| de Melo Viana Teixeira, S | 1 |
| Chantegreil, F | 2 |
| Prchal, L | 2 |
| Malaguti, M | 1 |
| Angeloni, C | 1 |
| Hrelia, S | 1 |
| Soares Romeiro, LA | 1 |
| Szałaj, N | 1 |
| Latacz, G | 2 |
| Tabor, J | 1 |
| Dias, J | 3 |
| Lu, J | 5 |
| Höfner, G | 1 |
| Wanner, K | 1 |
| Chowdhury, SR | 1 |
| Gu, J | 1 |
| Lei, S | 1 |
| Tavallaie, MS | 1 |
| Lam, C | 1 |
| Lu, D | 1 |
| Jiang, F | 1 |
| Fu, L | 1 |
| Alzweiri, M | 1 |
| S Alsegiani, A | 1 |
| Karaj, E | 1 |
| A Almarghalani, D | 1 |
| Tabaza, Y | 1 |
| A Shah, Z | 1 |
| Tillekeratne, LMV | 1 |
| Zou, M | 2 |
| Xie, H | 3 |
| Lin, T | 1 |
| Guan, L | 1 |
| Peng, D | 1 |
| Jia, J | 3 |
| Zuo, J | 2 |
| Wu, C | 1 |
| Zha, L | 1 |
| Liu, XH | 1 |
| Zhang, J | 4 |
| Schwarthoff, S | 1 |
| Tischer, N | 1 |
| Sager, H | 1 |
| Schätz, B | 1 |
| Rohrbach, MM | 1 |
| Raztsou, I | 1 |
| Robaa, D | 1 |
| Gaube, F | 1 |
| Arndt, HD | 1 |
| Winckler, T | 2 |
| Pont, C | 1 |
| Ginex, T | 1 |
| Griñán-Ferré, C | 2 |
| Scheiner, M | 1 |
| Mattellone, A | 1 |
| Martínez, N | 1 |
| Arce, EM | 1 |
| Soriano-Fernández, Y | 1 |
| Naldi, M | 1 |
| Barenys, M | 1 |
| Gómez-Catalán, J | 1 |
| Pérez, B | 1 |
| Loza, MI | 1 |
| Brea, J | 1 |
| Decker, M | 1 |
| Pallàs, M | 2 |
| Muñoz-Torrero, D | 3 |
| Jahan, S | 1 |
| Barik, A | 1 |
| Upadhyay, P | 2 |
| Singh, L | 1 |
| Kamble, K | 1 |
| Tiwari, S | 2 |
| Garg, P | 1 |
| Gupta, S | 3 |
| Góral, I | 1 |
| Śniecikowska, J | 1 |
| Walczak, M | 1 |
| Liu, T | 2 |
| Chen, S | 2 |
| Du, J | 1 |
| Xing, S | 1 |
| Li, R | 1 |
| Huang, Y | 4 |
| Huang, J | 4 |
| You, H | 1 |
| Liu, D | 1 |
| Yin, G | 1 |
| Shi, T | 1 |
| Liu, X | 5 |
| Gao, Y | 3 |
| Wu, L | 2 |
| Chen, H | 3 |
| Zhou, L | 1 |
| Xu, Z | 3 |
| Zhao, Q | 3 |
| Zhong, F | 1 |
| Mi, J | 3 |
| Waly, OM | 1 |
| Saad, KM | 1 |
| El-Subbagh, HI | 1 |
| Bayomi, SM | 1 |
| Ghaly, MA | 1 |
| Xi, M | 1 |
| Feng, C | 1 |
| Du, K | 1 |
| Lv, W | 1 |
| Du, C | 2 |
| Shen, R | 1 |
| Sun, X | 1 |
| Lei, Z | 2 |
| Yue, S | 1 |
| Uras, G | 1 |
| Onuwaje, I | 1 |
| Yao, H | 1 |
| Phillips, J | 1 |
| Allen, S | 1 |
| Zhu, Z | 2 |
| Brunetti, L | 2 |
| Leuci, R | 1 |
| Carrieri, A | 2 |
| Occhineri, S | 1 |
| Vinci, G | 1 |
| Gambacorta, L | 1 |
| Baltrukevich, H | 1 |
| Chaves, S | 5 |
| Laghezza, A | 2 |
| Altomare, CD | 2 |
| Tortorella, P | 2 |
| Santos, MA | 5 |
| Loiodice, F | 2 |
| Piemontese, L | 5 |
| Liu, L | 4 |
| Zheng, L | 1 |
| Feng, KW | 1 |
| Wang, HT | 1 |
| Xu, JP | 1 |
| Zhou, ZZ | 1 |
| Macedo Vaz, S | 1 |
| Dos Reis Rosa Franco, G | 1 |
| Jorge R Guimarães, M | 1 |
| Motta R da Silva, F | 1 |
| Gonçalves Castro, N | 1 |
| Alvim Guedes, I | 1 |
| Amaral Alves, M | 1 |
| Garrett da Costa, R | 1 |
| Beserra Pinheiro, G | 1 |
| Germino Veras, L | 1 |
| Renata Mortari, M | 1 |
| Knorz, AL | 1 |
| Quante, A | 1 |
| Pisani, S | 1 |
| Mueller, C | 1 |
| Huntley, J | 1 |
| Aarsland, D | 2 |
| Kempton, MJ | 1 |
| Bae, M | 1 |
| Han, SY | 1 |
| Kim, ES | 1 |
| You, BH | 1 |
| Kim, YM | 2 |
| Cho, J | 1 |
| Chin, YW | 2 |
| Choi, YH | 1 |
| Zhang, B | 1 |
| Fang, L | 2 |
| Gou, S | 1 |
| Hong, YJ | 3 |
| Han, HJ | 4 |
| Youn, YC | 3 |
| Park, KW | 8 |
| Yang, DW | 6 |
| Kim, S | 5 |
| Lee, Y | 1 |
| Kwon, M | 1 |
| Lee, JH | 7 |
| Sivaraman, B | 1 |
| Raji, V | 1 |
| Velmurugan, BA | 1 |
| Natarajan, R | 1 |
| Kim, J | 1 |
| Lee, HJ | 2 |
| Park, SK | 1 |
| Jeong, HR | 1 |
| Lee, S | 2 |
| Lee, H | 2 |
| Seol, E | 2 |
| Hoe, HS | 2 |
| Morris, JK | 1 |
| McCoin, CS | 1 |
| Fuller, KN | 1 |
| John, CS | 1 |
| Wilkins, HM | 1 |
| Green, ZD | 1 |
| Burns, JM | 1 |
| Vidoni, ED | 1 |
| Mahnken, JD | 1 |
| Shankar, K | 1 |
| Swerdlow, RH | 1 |
| Thyfault, JP | 1 |
| Pellegrini, C | 1 |
| D'Antongiovanni, V | 1 |
| Fornai, M | 1 |
| Duranti, E | 1 |
| Baldacci, F | 1 |
| Bernardini, N | 1 |
| Taddei, S | 1 |
| Virdis, A | 1 |
| Blandizzi, C | 1 |
| Masi, S | 1 |
| Antonioli, L | 1 |
| Parween, F | 1 |
| Hossain, MS | 1 |
| Singh, KP | 1 |
| Gupta, RD | 1 |
| Yang, SQ | 1 |
| Fan, DH | 1 |
| Yuan, ZX | 1 |
| Su, MY | 1 |
| Zhang, ZN | 1 |
| Lin, Y | 3 |
| Lin, HG | 1 |
| Kosar, M | 1 |
| Brown, AJH | 1 |
| Bradley, SJ | 1 |
| Marshall, FH | 1 |
| Brown, GA | 1 |
| Bennett, KA | 1 |
| Brown, J | 1 |
| Cansfield, JE | 1 |
| Cross, DM | 2 |
| de Graaf, C | 1 |
| Hudson, BD | 1 |
| Dwomoh, L | 1 |
| Dias, JM | 1 |
| Errey, JC | 1 |
| Hurrell, E | 1 |
| Liptrot, J | 2 |
| Mattedi, G | 1 |
| Molloy, C | 1 |
| Nathan, PJ | 1 |
| Okrasa, K | 1 |
| Osborne, G | 1 |
| Patel, JC | 1 |
| Pickworth, M | 1 |
| Robertson, N | 1 |
| Shahabi, S | 1 |
| Bundgaard, C | 2 |
| Phillips, K | 2 |
| Broad, LM | 1 |
| Goonawardena, AV | 1 |
| Morairty, SR | 1 |
| Browning, M | 1 |
| Perini, F | 1 |
| Dawson, GR | 1 |
| Deakin, JFW | 1 |
| Smith, RT | 1 |
| Sexton, PM | 1 |
| Warneck, J | 1 |
| Vinson, M | 1 |
| Tasker, T | 2 |
| Tehan, BG | 1 |
| Teobald, B | 1 |
| Christopoulos, A | 1 |
| Langmead, CJ | 1 |
| Jazayeri, A | 1 |
| Cooke, RM | 1 |
| Rucktooa, P | 1 |
| Congreve, MS | 1 |
| Weir, M | 1 |
| Tobin, AB | 1 |
| Bago Rožanković, P | 1 |
| Rožanković, M | 1 |
| Badžak, J | 1 |
| Stojić, M | 1 |
| Šušak Sporiš, I | 1 |
| Ge, Q | 1 |
| Yan, S | 1 |
| Paranjpe, MD | 1 |
| Hu, S | 1 |
| Fan, F | 1 |
| Shi, X | 2 |
| Ai, Y | 1 |
| Ren, G | 1 |
| Cui, Y | 2 |
| Rotstein, A | 1 |
| Levine, SZ | 5 |
| Samara, M | 5 |
| Yoshida, K | 6 |
| Goldberg, Y | 5 |
| Cipriani, A | 6 |
| Iwatsubo, T | 6 |
| Leucht, S | 6 |
| Furukawa, TA | 5 |
| Zong, Y | 1 |
| Zhao, J | 4 |
| Jiang, J | 2 |
| Tian, H | 1 |
| Saeedi, M | 1 |
| Mehranfar, F | 1 |
| Shim, Y | 1 |
| Kim, BC | 6 |
| Park, KH | 1 |
| Park, MY | 3 |
| Moon, SY | 1 |
| Choi, SH | 6 |
| Yoon, SJ | 1 |
| Kim, SY | 4 |
| Choi, H | 2 |
| Yoon, KE | 1 |
| Cho, HJ | 1 |
| Han, SH | 2 |
| Byun, J | 1 |
| Lee, DY | 1 |
| Jeong, CW | 1 |
| Kim, Y | 3 |
| Rhee, HY | 1 |
| Moon, KW | 1 |
| Heo, J | 1 |
| Kim, WJ | 1 |
| Nam, SJ | 1 |
| Choi, HS | 1 |
| Park, JI | 1 |
| Chun, IK | 1 |
| Bak, SH | 1 |
| Lee, K | 2 |
| Byeon, GH | 1 |
| Kim, KL | 1 |
| Kim, JA | 1 |
| Park, YJ | 1 |
| Lee, EJ | 1 |
| Lee, SA | 1 |
| Kwon, SO | 1 |
| Park, SW | 1 |
| Kasani, PH | 1 |
| Kim, JK | 1 |
| Jang, JW | 1 |
| Fang, X | 1 |
| Haji Ali, S | 1 |
| Osmaniye, D | 2 |
| Sağlık, BN | 3 |
| Levent, S | 2 |
| Özkay, Y | 2 |
| Kaplancıklı, ZA | 2 |
| Liu, QF | 2 |
| Son, T | 1 |
| Kanmani, S | 1 |
| Kim, SN | 1 |
| Kim, KK | 2 |
| Kim, KW | 3 |
| Koo, BS | 3 |
| Şahin, S | 1 |
| Hutten, DR | 1 |
| Bos, JHJ | 1 |
| de Vos, S | 1 |
| Hak, E | 1 |
| Veroniki, AA | 1 |
| Ashoor, HM | 1 |
| Rios, P | 1 |
| Seitidis, G | 1 |
| Stewart, L | 1 |
| Clarke, M | 1 |
| Tudur-Smith, C | 1 |
| Mavridis, D | 1 |
| Hemmelgarn, BR | 1 |
| Holroyd-Leduc, J | 1 |
| Straus, SE | 1 |
| Tricco, AC | 1 |
| Larkin, HD | 1 |
| Naik, SP | 1 |
| Sachin, C | 1 |
| Soniya, P | 1 |
| Harishchandra, N | 1 |
| Venkatesh, S | 1 |
| Shilpa, T | 1 |
| Shivlingarao, MD | 1 |
| Zúñiga Santamaría, T | 1 |
| Yescas Gómez, P | 1 |
| Fricke Galindo, I | 1 |
| González González, M | 1 |
| Ortega Vázquez, A | 1 |
| López López, M | 1 |
| Parsons, C | 1 |
| Lim, WY | 1 |
| Loy, C | 1 |
| McGuinness, B | 1 |
| Passmore, P | 5 |
| Ward, SA | 1 |
| Hughes, C | 1 |
| Masurkar, PP | 1 |
| Chatterjee, S | 1 |
| Sherer, JT | 1 |
| Johnson, ML | 1 |
| Aparasu, RR | 1 |
| Huang, LP | 1 |
| Zhong, XQ | 1 |
| Zhou, XY | 1 |
| Deng, MQ | 1 |
| Wu, MJ | 2 |
| Deng, MZ | 1 |
| Eissa, KI | 3 |
| Kamel, MM | 3 |
| Mohamed, LW | 4 |
| Galal, MA | 1 |
| Kassab, AE | 3 |
| Zhang, LF | 1 |
| Zhang, YP | 1 |
| Lin, PX | 1 |
| Xue, LH | 1 |
| Ali, SK | 1 |
| Ali, RH | 1 |
| Ban, Y | 1 |
| Choi, HJ | 1 |
| Jeong, YJ | 1 |
| Hwang, JW | 1 |
| Kim, IW | 1 |
| Cha, BY | 1 |
| Seo, J | 1 |
| Moon, M | 1 |
| Majidazar, R | 1 |
| Rezazadeh-Gavgani, E | 1 |
| Sadigh-Eteghad, S | 1 |
| Naseri, A | 1 |
| Sharma, A | 1 |
| Nuthakki, VK | 1 |
| Gairola, S | 1 |
| Singh, B | 1 |
| Bharate, SB | 1 |
| Khasawneh, RR | 1 |
| Abu-El-Rub, E | 1 |
| Alzu'bi, A | 1 |
| Abdelhady, GT | 1 |
| Al-Soudi, HS | 1 |
| Topal, F | 1 |
| Ertas, B | 1 |
| Guler, E | 1 |
| Gurbuz, F | 1 |
| Ozcan, GS | 1 |
| Aydemir, O | 1 |
| Bocekci, VG | 1 |
| Duruksu, G | 1 |
| Sahin Cam, C | 1 |
| Yazir, Y | 1 |
| Gunduz, O | 1 |
| Cam, ME | 1 |
| Yang, Q | 5 |
| Huang, KL | 1 |
| Wang, GY | 1 |
| Wang, MY | 1 |
| Tan, AH | 1 |
| Ran, SM | 1 |
| Bu, K | 3 |
| Patel, D | 1 |
| Morris, R | 3 |
| Han, W | 2 |
| Umeukeje, G | 2 |
| Zhu, T | 1 |
| Cheng, F | 3 |
| Miao, S | 1 |
| He, Q | 1 |
| Li, C | 2 |
| Wu, Y | 1 |
| Liu, M | 1 |
| Qi, S | 1 |
| Gong, K | 1 |
| Fu, QH | 1 |
| Pei, J | 1 |
| Zhou, HG | 1 |
| Zhan, YJ | 1 |
| Tao, L | 1 |
| Zhou, Q | 1 |
| Wang, LY | 1 |
| Seo, M | 1 |
| Sahker, E | 1 |
| Efthimiou, O | 3 |
| Morató, X | 1 |
| Pytel, V | 1 |
| Jofresa, S | 1 |
| Ruiz, A | 2 |
| Boada, M | 3 |
| Ayaz, M | 1 |
| Nawaz, A | 1 |
| Naz, F | 1 |
| Ullah, F | 1 |
| Sadiq, A | 1 |
| Islam, ZU | 1 |
| Mohamed, KO | 1 |
| Sayed, HS | 1 |
| Mahmoud, Z | 1 |
| Shen, S | 2 |
| Patel, P | 1 |
| Faldu, K | 1 |
| Borisa, A | 1 |
| Bhatt, H | 1 |
| Shah, J | 1 |
| Tariot, PN | 8 |
| Braeckman, R | 1 |
| Oh, C | 1 |
| Wiatrak, B | 1 |
| Krzyżak, E | 1 |
| Szczęśniak-Sięga, B | 1 |
| Szandruk-Bender, M | 1 |
| Szeląg, A | 1 |
| Nowak, B | 1 |
| Hussain, R | 1 |
| Ullah, H | 1 |
| Rahim, F | 1 |
| Sarfraz, M | 1 |
| Taha, M | 1 |
| Iqbal, R | 1 |
| Rehman, W | 1 |
| Khan, S | 1 |
| Shah, SAA | 1 |
| Hyder, S | 1 |
| Alhomrani, M | 1 |
| Alamri, AS | 1 |
| Abdulaziz, O | 1 |
| Abdelaziz, MA | 1 |
| Gupta, M | 1 |
| Ojha, M | 1 |
| Khan, SK | 1 |
| Nain, S | 1 |
| Alvarez, XA | 3 |
| Winston, CN | 1 |
| Barlow, JW | 1 |
| Sarsoza, FM | 1 |
| Alvarez, I | 2 |
| Aleixandre, M | 3 |
| Linares, C | 3 |
| García-Fantini, M | 2 |
| Kastberger, B | 1 |
| Winter, S | 2 |
| Rissman, RA | 2 |
| Wang, Q | 2 |
| Koo, SH | 1 |
| Shin, BS | 1 |
| Zhou, K | 1 |
| He, J | 1 |
| Quan, L | 1 |
| Guo, R | 1 |
| Yue, J | 1 |
| Li, XL | 1 |
| Gao, RX | 1 |
| Li, A | 2 |
| Zhao, WW | 1 |
| Li, SL | 2 |
| Vieira, ADC | 1 |
| Zabot, GC | 1 |
| Pereira, NS | 1 |
| do Nascimento, NB | 1 |
| Lidio, AV | 1 |
| Scheffer, ÂK | 1 |
| Rempel, LCT | 1 |
| Macarini, BMN | 1 |
| Costa, MA | 1 |
| Gonçalves, CL | 1 |
| Kucharska, E | 1 |
| Rodrigues, MS | 1 |
| Moreira, JCF | 1 |
| de Oliveira, J | 1 |
| Vidal, B | 1 |
| Pereira, M | 1 |
| Valdebenito, M | 1 |
| Vidal, L | 1 |
| Mouthon, F | 1 |
| Zimmer, L | 1 |
| Charvériat, M | 1 |
| Droguerre, M | 1 |
| Fukuda, H | 1 |
| Maeda, M | 2 |
| Murata, F | 1 |
| Murata, Y | 2 |
| Jo, JK | 1 |
| Lee, G | 1 |
| Nguyen, CD | 2 |
| Park, SE | 1 |
| Kim, EJ | 1 |
| Kim, HW | 1 |
| Seo, SH | 1 |
| Cho, KM | 1 |
| Kwon, SJ | 1 |
| Son, HS | 1 |
| Honorio, P | 1 |
| Hannongbua, S | 1 |
| Saparpakorn, P | 1 |
| Pang, L | 1 |
| Quan, YS | 1 |
| Sui, HH | 1 |
| Jia, Y | 3 |
| Chen, F | 1 |
| Lee, JJ | 1 |
| Liu, P | 2 |
| Quan, ZS | 1 |
| Shen, QK | 1 |
| Guo, HY | 1 |
| Taheri, P | 1 |
| Yaghmaei, P | 1 |
| Hajebrahimi, Z | 1 |
| Parivar, K | 1 |
| Nguyen, HD | 1 |
| Nielsen, RE | 3 |
| Grøntved, S | 3 |
| Lolk, A | 3 |
| Andersen, K | 3 |
| Valentin, JB | 3 |
| Wang, XC | 3 |
| Chu, CL | 3 |
| Lu, K | 3 |
| Jin, XQ | 3 |
| Quan, SJ | 3 |
| Vasenina, EE | 3 |
| Veryugina, NI | 3 |
| Levin, OS | 3 |
| Quintana-Hernández, DJ | 3 |
| Rojas-Hernández, J | 3 |
| Santana-Del Pino, A | 3 |
| Céspedes Suárez, C | 3 |
| Pellejero Silva, M | 3 |
| Miró-Barrachina, MT | 3 |
| Ibáñez Fernández, I | 3 |
| Estupiñán López, JA | 3 |
| Borkel, LF | 3 |
| Dos Santos, A | 3 |
| Teixeira, FC | 3 |
| da Silva, DS | 3 |
| Veleda, TA | 3 |
| de Mello, JE | 3 |
| Luduvico, KP | 3 |
| Tavares, RG | 3 |
| Stefanello, FM | 3 |
| Cunico, W | 3 |
| Spanevello, RM | 3 |
| Zhao, ZQ | 5 |
| Hu, LF | 3 |
| He, YT | 3 |
| Jing, LY | 3 |
| Chen, BZ | 4 |
| Guo, XD | 4 |
| Eraky, SM | 3 |
| Ramadan, NM | 3 |
| Abo El-Magd, NF | 3 |
| Yamali, C | 3 |
| Donmez, S | 3 |
| Moreira, NCDS | 3 |
| Tamarozzi, ER | 2 |
| Lima, JEBF | 3 |
| Piassi, LO | 2 |
| Passos, GA | 2 |
| Dlabkova, A | 1 |
| Hort, J | 4 |
| Angelucci, F | 1 |
| Pavelek, Z | 1 |
| Karasova, JZ | 2 |
| Novotny, M | 1 |
| Koly, HK | 1 |
| Sutradhar, K | 1 |
| Rahman, MS | 2 |
| Wunderlich, G | 1 |
| Blahova, Z | 1 |
| Garcia, M | 1 |
| Jessen, F | 1 |
| Ueda, A | 1 |
| Komatsu, K | 1 |
| Takahashi, M | 2 |
| Padovani, A | 8 |
| Falato, S | 1 |
| Pegoraro, V | 1 |
| Kiriyama, A | 2 |
| Kimura, S | 2 |
| Yamashita, S | 1 |
| Nakamura, Y | 6 |
| Kim, R | 3 |
| Nishiyama, K | 3 |
| Kikuchi, T | 3 |
| Ishikawa, I | 3 |
| Aoki, H | 3 |
| Grandhi, VR | 1 |
| Medapati, R | 1 |
| Ganuga, N | 1 |
| Abraham, R | 1 |
| Thentu, JB | 1 |
| Palacharla, VRC | 1 |
| Petlu, S | 1 |
| Srirangavaram, M | 1 |
| Ravella, SR | 1 |
| Gagginapally, SR | 1 |
| Doghish, AS | 1 |
| Alnajjar, R | 1 |
| Al-Karmalawy, AA | 1 |
| Girgin, M | 1 |
| Isik, S | 1 |
| Kantarci-Carsibasi, N | 1 |
| Yamada, M | 3 |
| Ezzat, MAF | 2 |
| Abdelhamid, SM | 1 |
| Fouad, MA | 1 |
| Abdel-Aziz, HA | 1 |
| Allam, HA | 1 |
| Huang, H | 2 |
| Fang, C | 1 |
| Niu, H | 1 |
| Yin, X | 1 |
| Ruan, J | 1 |
| Wei, M | 1 |
| Mutlay, F | 1 |
| Kaya, D | 1 |
| Isik, AT | 3 |
| Fanizza, F | 1 |
| Boeri, L | 1 |
| Donnaloja, F | 1 |
| Perottoni, S | 1 |
| Forloni, G | 2 |
| Giordano, C | 1 |
| Albani, D | 2 |
| Omori, T | 1 |
| Remya, C | 1 |
| Dileep, KV | 1 |
| Variyar, EJ | 1 |
| Omkumar, RV | 1 |
| Sadasivan, C | 1 |
| Asgarshamsi, MH | 1 |
| Fassihi, A | 1 |
| Dehkordi, MM | 1 |
| Diaz-Galvan, P | 1 |
| Lorenzon, G | 1 |
| Mohanty, R | 1 |
| Mårtensson, G | 1 |
| Cavedo, E | 5 |
| Lista, S | 5 |
| Vergallo, A | 1 |
| Kantarci, K | 1 |
| Hampel, H | 10 |
| Dubois, B | 6 |
| Grothe, MJ | 3 |
| Ferreira, D | 1 |
| Westman, E | 1 |
| Angioni, D | 1 |
| Raffin, J | 1 |
| Ousset, PJ | 3 |
| Delrieu, J | 2 |
| de Souto Barreto, P | 1 |
| Teng, X | 1 |
| Vasileva, L | 1 |
| Gaynanova, G | 1 |
| Valeeva, F | 1 |
| Belyaev, G | 1 |
| Zueva, I | 2 |
| Bushmeleva, K | 1 |
| Sibgatullina, G | 1 |
| Samigullin, D | 1 |
| Vyshtakalyuk, A | 1 |
| Petrov, K | 2 |
| Zakharova, L | 2 |
| Sinyashin, O | 1 |
| Etemadi, A | 1 |
| Hemmati, S | 1 |
| Shahrivar-Gargari, M | 1 |
| Abibiglue, YT | 1 |
| Bavili, A | 1 |
| Hamzeh-Mivehroud, M | 1 |
| Dastmalchi, S | 1 |
| Anoush, M | 1 |
| Bijani, S | 1 |
| Moslemifar, F | 1 |
| Jahanpour, F | 1 |
| Kalantari-Hesari, A | 1 |
| Hosseini, MJ | 1 |
| Burke, JF | 1 |
| Kerber, KA | 1 |
| Langa, KM | 1 |
| Albin, RL | 1 |
| Kotagal, V | 1 |
| Dan, Z | 1 |
| Li, H | 9 |
| Xie, J | 2 |
| Kiran, PVR | 1 |
| Waiker, DK | 1 |
| Verma, A | 1 |
| Saraf, P | 1 |
| Bhardwaj, B | 1 |
| Kumar, H | 1 |
| Kumar, P | 1 |
| Trigun, SK | 1 |
| Shehata, MK | 1 |
| Ismail, AA | 1 |
| Kamel, MA | 1 |
| Olazarán, J | 2 |
| Carnero-Pardo, C | 1 |
| Fortea, J | 1 |
| Sánchez-Juan, P | 1 |
| García-Ribas, G | 1 |
| Viñuela, F | 1 |
| Martínez-Lage, P | 1 |
| Adeniyi, IA | 1 |
| Oregbesan, PO | 1 |
| Adesanya, A | 1 |
| Olubori, MA | 1 |
| Olayinka, GS | 1 |
| Ajayi, AM | 1 |
| Onasanwo, SA | 1 |
| Yue, Y | 1 |
| Abd El-Karim, SS | 1 |
| Anwar, MM | 1 |
| Ahmed, NS | 1 |
| Syam, YM | 1 |
| Elseginy, SA | 1 |
| Aly, HF | 1 |
| Younis, EA | 1 |
| Khalil, WKB | 1 |
| Ahmed, KA | 1 |
| Mohammed, FF | 1 |
| Rizk, M | 1 |
| Bittner, N | 1 |
| Funk, CSM | 1 |
| Schmidt, A | 1 |
| Bermpohl, F | 1 |
| Brandl, EJ | 1 |
| Algharably, EEA | 1 |
| Kreutz, R | 1 |
| Riemer, TG | 1 |
| Maiuolo, J | 1 |
| Costanzo, P | 1 |
| Masullo, M | 1 |
| D'Errico, A | 1 |
| Nasso, R | 1 |
| Bonacci, S | 1 |
| Mollace, V | 1 |
| Oliverio, M | 1 |
| Arcone, R | 1 |
| Yaghmaei, E | 1 |
| Pierce, A | 1 |
| Lu, H | 1 |
| Patel, YM | 1 |
| Ehwerhemuepha, L | 1 |
| Rezaie, A | 1 |
| Sajjadi, SA | 1 |
| Rakovski, C | 1 |
| Narita, K | 1 |
| Pouramiri, B | 1 |
| Rashidi, M | 1 |
| Lotfi, S | 1 |
| Mohammadi, M | 1 |
| Rabiei, K | 1 |
| Soliman, AM | 1 |
| Abd El-Wahab, HAA | 1 |
| Akincioglu, H | 2 |
| Gülçin, İ | 2 |
| Omar, FA | 1 |
| Kim, JS | 2 |
| Kim, MG | 1 |
| Ryu, JE | 1 |
| Lee, YB | 1 |
| Cho, SH | 1 |
| Shin, SJ | 1 |
| Choi, HK | 1 |
| She, L | 1 |
| Xiong, L | 1 |
| Li, L | 4 |
| Wu, H | 1 |
| Ren, J | 1 |
| Liang, G | 1 |
| Zhao, X | 3 |
| DiBello, JR | 1 |
| Lu, Y | 2 |
| Swartz, J | 2 |
| Bortnichak, EA | 1 |
| Liaw, KL | 1 |
| Zhong, W | 1 |
| Freitas, EL | 1 |
| Calil-Elias, S | 1 |
| Erbisti, RS | 1 |
| Grinberg-Weller, B | 1 |
| Miranda, ES | 1 |
| Al-Rifai, NM | 1 |
| Al-Khalileh, NM | 1 |
| Zahra, JA | 1 |
| El-Barghouthi, MI | 1 |
| Darras, FH | 1 |
| Mesiti, F | 1 |
| Chavarria, D | 1 |
| Gaspar, A | 1 |
| Takada-Takatori, Y | 2 |
| Nakagawa, S | 1 |
| Kimata, R | 1 |
| Nao, Y | 1 |
| Mizukawa, Y | 1 |
| Urushidani, T | 1 |
| Izumi, Y | 1 |
| Akaike, A | 1 |
| Tsuchida, K | 1 |
| Kume, T | 1 |
| Krishna, KV | 2 |
| Wadhwa, G | 1 |
| Alexander, A | 2 |
| Kanojia, N | 1 |
| Saha, RN | 2 |
| Kukreti, R | 1 |
| Singhvi, G | 1 |
| Dubey, SK | 4 |
| Tepmongkol, S | 1 |
| Hemrungrojn, S | 2 |
| Dupont, P | 1 |
| Tunvirachaisakul, C | 1 |
| Aniwattanapong, D | 1 |
| Likitjareon, Y | 1 |
| Supasitthumrong, T | 1 |
| Tawankanjanachot, I | 1 |
| Siritranon, N | 1 |
| Chuchuen, P | 1 |
| Natsawang, B | 1 |
| Tangwongchai, S | 1 |
| Yokoyama, S | 1 |
| Yoshinaga, T | 1 |
| Matsuzaki, J | 1 |
| Suzuki, H | 1 |
| Fleet, JL | 1 |
| McArthur, E | 1 |
| Patel, A | 1 |
| Weir, MA | 1 |
| Montero-Odasso, M | 3 |
| Garg, AX | 1 |
| Pourshojaei, Y | 1 |
| Eskandari, K | 1 |
| El-Sayed, NA | 1 |
| Farag, AE | 1 |
| Abou-Seri, SM | 1 |
| Kabir, MT | 1 |
| Uddin, MS | 1 |
| Begum, MM | 1 |
| Thangapandiyan, S | 1 |
| Aleya, L | 1 |
| Mathew, B | 1 |
| Ahmed, M | 1 |
| Barreto, GE | 1 |
| Ashraf, GM | 1 |
| Benchekroun, M | 3 |
| Shih, CC | 1 |
| Chen, PY | 1 |
| Chen, MF | 1 |
| Lee, TJF | 1 |
| Haake, A | 1 |
| Nguyen, K | 1 |
| Friedman, L | 1 |
| Chakkamparambil, B | 1 |
| Grossberg, GT | 11 |
| Guo, Y | 1 |
| Yang, H | 4 |
| Huang, Z | 1 |
| Tian, S | 1 |
| Wei, C | 3 |
| Chen, W | 1 |
| Jia, L | 2 |
| Zhou, A | 2 |
| Wang, F | 1 |
| Honjo, Y | 1 |
| Ide, K | 1 |
| Takechi, H | 1 |
| Cao, Y | 2 |
| Qian, L | 1 |
| Yu, W | 2 |
| Li, T | 1 |
| Mao, S | 1 |
| Han, G | 1 |
| Pang, J | 2 |
| Hou, J | 1 |
| Zhou, Z | 1 |
| Ren, M | 1 |
| Mo, Y | 1 |
| Yang, G | 2 |
| Qu, Z | 1 |
| Hanazawa, T | 1 |
| Kamijo, Y | 1 |
| Yoshizawa, T | 1 |
| Fujita, Y | 1 |
| Usui, K | 1 |
| Haga, Y | 1 |
| Potasiewicz, A | 1 |
| Krawczyk, M | 1 |
| Gzielo, K | 1 |
| Popik, P | 1 |
| Nikiforuk, A | 1 |
| Silva, MA | 1 |
| Kiametis, AS | 1 |
| Treptow, W | 1 |
| Resta, S | 1 |
| Rinaldo, F | 1 |
| Costa, M | 1 |
| Josselin, R | 1 |
| Gwizdala, K | 2 |
| Capriati, V | 2 |
| Pereira-Santos, AR | 1 |
| Cardoso, SM | 4 |
| Spieler, D | 1 |
| Namendorf, C | 1 |
| Namendorf, T | 1 |
| von Cube, M | 1 |
| Uhr, M | 1 |
| Talia, S | 1 |
| Benarous, K | 1 |
| Lamrani, M | 1 |
| Yousfi, M | 1 |
| Qi, Y | 2 |
| Jing, H | 1 |
| Yan, T | 1 |
| Xiao, F | 1 |
| Wu, B | 1 |
| Bi, K | 1 |
| Govind, N | 1 |
| Li, HC | 1 |
| Luo, KX | 1 |
| Wang, JS | 1 |
| Wang, QX | 1 |
| Wang, HC | 2 |
| Liu, NY | 1 |
| Zhang, S | 1 |
| Wang, ZY | 1 |
| Wei, Y | 3 |
| Liu, JG | 3 |
| Pei, H | 1 |
| Pamio, MV | 3 |
| Trevisan, C | 1 |
| Pigozzo, S | 1 |
| De Rui, M | 1 |
| Devita, M | 1 |
| Girardi, A | 2 |
| Manzato, E | 2 |
| Sergi, G | 2 |
| Coin, A | 3 |
| Xia, KP | 1 |
| Zhang, M | 1 |
| Li, HL | 1 |
| Wang, YJ | 2 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Bhatnagar, I | 1 |
| Sukhpal, H | 1 |
| Awasthy, S | 1 |
| Shankar, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Yang, ZX | 1 |
| Tang, CL | 1 |
| Li, XH | 1 |
| Zhu, ZW | 1 |
| Qiu, L | 1 |
| An, HY | 1 |
| Yang, YH | 9 |
| Mimura, Y | 1 |
| Kurose, S | 1 |
| Takata, T | 1 |
| Tabuchi, H | 1 |
| Mimura, M | 7 |
| Funayama, M | 1 |
| Avgerinos, KI | 1 |
| Vrysis, C | 1 |
| Chaitidis, N | 1 |
| Kolotsiou, K | 1 |
| Myserlis, PG | 1 |
| Kapogiannis, D | 1 |
| Vishwas, S | 1 |
| Awasthi, A | 1 |
| Corrie, L | 1 |
| Kumar Singh, S | 1 |
| Gulati, M | 1 |
| Yu, X | 2 |
| Yang, W | 1 |
| Traini, E | 6 |
| Carotenuto, A | 5 |
| Fasanaro, AM | 6 |
| Amenta, F | 7 |
| Barthold, D | 1 |
| Joyce, G | 1 |
| Ferido, P | 1 |
| Drabo, EF | 1 |
| Marcum, ZA | 1 |
| Gray, SL | 2 |
| Zissimopoulos, J | 1 |
| Siafaka, PI | 1 |
| Bülbül, EÖ | 1 |
| Mutlu, G | 1 |
| Okur, ME | 1 |
| Karantas, ID | 1 |
| Okur, NÜ | 1 |
| Gomaa, AA | 1 |
| Makboul, RM | 1 |
| El-Mokhtar, MA | 1 |
| Abdel-Rahman, EA | 1 |
| Ahmed, EA | 1 |
| Nicola, MA | 1 |
| Kho, J | 2 |
| Ioannou, A | 2 |
| Mandal, AKJ | 2 |
| Cox, A | 1 |
| Nasim, A | 1 |
| Metaxa, S | 1 |
| Missouris, CG | 2 |
| Kim, GW | 1 |
| Park, KS | 1 |
| Jeong, GW | 2 |
| Romero, I | 1 |
| Benito, C | 1 |
| Suarez, I | 1 |
| Mourente, S | 1 |
| Fantini, M | 1 |
| Figueroa, J | 1 |
| Muresanu, D | 1 |
| Moessler, H | 2 |
| Jin, N | 1 |
| Ziyatdinova, S | 1 |
| Gureviciene, I | 1 |
| Tanila, H | 1 |
| Ghai, R | 1 |
| Nagarajan, K | 1 |
| Arora, M | 1 |
| Grover, P | 1 |
| Ali, N | 1 |
| Kapoor, G | 1 |
| Alsabbagh, MW | 1 |
| Perone, R | 1 |
| Albertini, C | 1 |
| Di Pietri, F | 1 |
| de Sena Murteira Pinheiro, P | 1 |
| Petralla, S | 1 |
| Rizzardi, N | 1 |
| Pulkrabkova, L | 1 |
| Caratelli, V | 1 |
| Ciampaglia, A | 1 |
| Guiducci, J | 1 |
| Sancesario, G | 1 |
| Moscone, D | 1 |
| Arduini, F | 1 |
| Sawada, H | 1 |
| Oeda, T | 1 |
| Kohsaka, M | 1 |
| Tomita, S | 1 |
| Umemura, A | 1 |
| Park, K | 1 |
| Yamamoto, K | 1 |
| Kiyohara, K | 1 |
| Guo, J | 2 |
| Liu, R | 1 |
| Zhang, R | 14 |
| Semwal, BC | 1 |
| Garabadu, D | 1 |
| Akhoon, BA | 1 |
| Choudhary, S | 1 |
| Tiwari, H | 1 |
| Barik, MR | 1 |
| Rathor, L | 1 |
| Pandey, R | 1 |
| Nargotra, A | 1 |
| Ongnok, B | 1 |
| Khuanjing, T | 1 |
| Chunchai, T | 1 |
| Kerdphoo, S | 1 |
| Jaiwongkam, T | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Acar Çevik, U | 1 |
| Kaya Çavuşoğlu, B | 1 |
| Marucci, G | 1 |
| Buccioni, M | 1 |
| Ben, DD | 1 |
| Lambertucci, C | 1 |
| Volpini, R | 1 |
| Ju, Y | 1 |
| Tam, KY | 1 |
| Kagawa, Y | 1 |
| Yamamoto, Y | 2 |
| Ueno, A | 1 |
| Maeda, T | 1 |
| Obi, T | 1 |
| Rong, X | 1 |
| Jiang, L | 1 |
| Qu, M | 1 |
| Hassan, SSU | 1 |
| Wojszel, ZB | 1 |
| Shahwan, M | 1 |
| Khan, MS | 1 |
| Husain, FM | 1 |
| Shamsi, A | 1 |
| Nazifi, M | 1 |
| Oryan, S | 1 |
| Esfahani, DE | 1 |
| Ashrafpoor, M | 1 |
| Murchison, CF | 1 |
| Kennedy, RE | 1 |
| McConathy, JE | 1 |
| Roberson, ED | 1 |
| Przybyłowska, M | 1 |
| Dzierzbicka, K | 1 |
| Kowalski, S | 1 |
| Chmielewska, K | 1 |
| Inkielewicz-Stepniak, I | 1 |
| Guieu, B | 1 |
| Zhang, G | 3 |
| Wu, J | 1 |
| Huang, C | 1 |
| Cheng, J | 2 |
| Su, Z | 1 |
| Guo, B | 1 |
| Roughead, EE | 1 |
| Han, E | 1 |
| Lee, J | 1 |
| Kalisch Ellett, L | 1 |
| D'Onofrio, G | 5 |
| Nabavi, SM | 1 |
| Sancarlo, D | 1 |
| Greco, A | 2 |
| Pieretti, S | 1 |
| Miles, JA | 1 |
| Ng, JH | 1 |
| Sreenivas, BY | 1 |
| Courageux, C | 1 |
| Igert, A | 1 |
| McGeary, RP | 1 |
| Poliseno, V | 1 |
| Magalhães, JD | 2 |
| David, B | 1 |
| Schneider, P | 1 |
| Schäfer, P | 1 |
| Pietruszka, J | 1 |
| Gohlke, H | 1 |
| Guo, X | 2 |
| Lu, W | 1 |
| Quan, Q | 1 |
| Su, H | 1 |
| Gao, F | 1 |
| Qu, Q | 1 |
| Furawaka, TA | 1 |
| Iqubal, A | 1 |
| Iqubal, MK | 1 |
| Fazal, SA | 1 |
| Pottoo, FH | 1 |
| Haque, SE | 1 |
| Koh, SH | 1 |
| Kwon, HS | 1 |
| Jeong, JH | 2 |
| Na, HR | 4 |
| Lee, CN | 1 |
| Lee, AY | 1 |
| Park, JS | 1 |
| Lee, KY | 1 |
| Luboff, H | 1 |
| Jose, RP | 1 |
| Eckhoff, K | 1 |
| Pham, M | 1 |
| Rohlsen-Neal, D | 1 |
| de Souza, IFF | 1 |
| Dos Santos, TQ | 1 |
| Placido, RV | 1 |
| Mangerona, BA | 1 |
| Carvalho, FC | 2 |
| Boralli, VB | 1 |
| Ruela, ALM | 1 |
| Pereira, GR | 2 |
| Queda, F | 1 |
| Calò, S | 1 |
| Vasilopoulou, F | 1 |
| Rodríguez-Arévalo, S | 1 |
| Bagán, A | 1 |
| Escolano, C | 1 |
| Halminen, O | 1 |
| Vesikansa, A | 1 |
| Mehtälä, J | 1 |
| Hörhammer, I | 1 |
| Mikkola, T | 1 |
| Virta, LJ | 1 |
| Ylisaukko-Oja, T | 1 |
| Linna, M | 1 |
| Stanley, J | 1 |
| Howlett, SE | 2 |
| Dunn, T | 1 |
| Rockwood, K | 7 |
| Zhang, XP | 1 |
| Zheng, H | 1 |
| Chou, PS | 2 |
| Huang, LC | 1 |
| Hour, TC | 1 |
| Yen, CW | 1 |
| Furakawa, TA | 1 |
| Matos, MJ | 1 |
| Bakker, C | 1 |
| van der Aart, J | 1 |
| Labots, G | 1 |
| Klaassen, ES | 1 |
| Dickinson, S | 1 |
| Groeneveld, GJ | 1 |
| Soma, S | 1 |
| Suematsu, N | 1 |
| Sato, AY | 1 |
| Tsunoda, K | 1 |
| Bramian, A | 1 |
| Reddy, A | 1 |
| Takabatake, K | 1 |
| Karube, F | 1 |
| Fujiyama, F | 1 |
| Shimegi, S | 1 |
| Huang, P | 1 |
| He, XY | 1 |
| Nisha, SA | 1 |
| Devi, KP | 1 |
| Hoffman, D | 1 |
| Schindler, R | 8 |
| Mitnitski, A | 1 |
| Chintamaneni, PK | 1 |
| Krishnamurthy, PT | 1 |
| Rao, PV | 1 |
| Pindiprolu, SS | 1 |
| Kasai, T | 1 |
| Kondo, M | 1 |
| Ishii, R | 1 |
| Tanaka, A | 1 |
| Ataka, S | 1 |
| Shimada, H | 1 |
| Tomiyama, T | 1 |
| Mori, H | 2 |
| Taylor, M | 1 |
| Allsop, D | 2 |
| Nakagawa, M | 1 |
| Mizuno, T | 1 |
| Tokuda, T | 1 |
| Liu-Seifert, H | 1 |
| Andersen, S | 1 |
| Case, M | 1 |
| Sparks, J | 1 |
| Holdridge, KC | 1 |
| Wessels, AM | 1 |
| Hendrix, S | 1 |
| Aisen, P | 1 |
| Siemers, E | 2 |
| Lawler, E | 1 |
| Avila, A | 1 |
| Atukeren, P | 1 |
| Cengiz, M | 1 |
| Yavuzer, H | 1 |
| Gelisgen, R | 1 |
| Altunoglu, E | 1 |
| Oner, S | 1 |
| Erdenen, F | 1 |
| Yuceakın, D | 1 |
| Derici, H | 1 |
| Cakatay, U | 1 |
| Uzun, H | 1 |
| Havolli, E | 1 |
| Hill, MD | 1 |
| Godley, A | 1 |
| Goetghebeur, PJ | 1 |
| Lee, C | 1 |
| Ryu, SH | 1 |
| Moon, SW | 1 |
| Han, C | 1 |
| Lee, YM | 1 |
| Kim, SG | 1 |
| Lee, DW | 1 |
| Lee, SY | 1 |
| Bae, JN | 1 |
| Jung, YE | 1 |
| Kim, JL | 1 |
| Kim, BS | 1 |
| Shin, IS | 2 |
| Kim, YH | 2 |
| Kim, BJ | 1 |
| Kang, HS | 1 |
| Myung, W | 1 |
| Carroll, BJ | 1 |
| Pourmand, A | 1 |
| Shay, C | 1 |
| Redha, W | 1 |
| Aalam, A | 1 |
| Mazer-Amirshahi, M | 1 |
| Peng, W | 1 |
| Zhou, J | 3 |
| Feng, Q | 1 |
| Bin, L | 1 |
| Mohammad, D | 1 |
| Chan, P | 1 |
| Bradley, J | 1 |
| Lanctôt, K | 1 |
| Herrmann, N | 4 |
| Prasad, S | 1 |
| Chand, K | 2 |
| Kamble, SS | 1 |
| Gautam, HK | 1 |
| Sharma, SK | 1 |
| Ali, MR | 1 |
| Sadoqi, M | 1 |
| Møller, SG | 1 |
| Boutajangout, A | 1 |
| Mezei, M | 1 |
| Song, X | 1 |
| Liu, B | 1 |
| Cui, L | 1 |
| Zhou, B | 1 |
| Xu, F | 1 |
| Hayashi, T | 1 |
| Hattori, S | 1 |
| Ushiki-Kaku, Y | 1 |
| Tashiro, SI | 1 |
| Ikejima, T | 1 |
| Lai, CY | 1 |
| Wu, MY | 1 |
| Chiang, JH | 1 |
| Sun, MF | 1 |
| Chen, YH | 1 |
| Chang, CT | 1 |
| Lin, JG | 1 |
| Yen, HR | 1 |
| Hong, H | 1 |
| Mittapelly, N | 2 |
| Thalla, M | 1 |
| Pandey, G | 2 |
| Banala, VT | 1 |
| Arya, A | 1 |
| Mitra, K | 1 |
| Shukla, S | 1 |
| Mishra, PR | 2 |
| Chen, R | 1 |
| Chan, PT | 1 |
| Chu, H | 1 |
| Lin, YC | 1 |
| Chang, PC | 1 |
| Chen, CY | 1 |
| Chou, KR | 1 |
| Wu, MN | 1 |
| Kao, YH | 1 |
| Lin, TC | 1 |
| Kao, LL | 1 |
| Costa, AC | 1 |
| Joaquim, HPG | 1 |
| Nunes, VS | 1 |
| Kerr, DS | 1 |
| Ferreira, GS | 1 |
| Forlenza, OV | 3 |
| Gattaz, WF | 3 |
| Talib, LL | 3 |
| Ishibashi, K | 1 |
| Miura, Y | 1 |
| Wagatsuma, K | 1 |
| Ishiwata, K | 1 |
| Ishii, K | 2 |
| Erbayraktar, Z | 1 |
| Evlice, A | 1 |
| Yener, G | 1 |
| Ulusu, NN | 1 |
| Kim, SH | 1 |
| Kandiah, N | 2 |
| Hsu, JL | 1 |
| Suthisisang, C | 1 |
| Udommongkol, C | 1 |
| Dash, A | 4 |
| Colliot, O | 4 |
| Chupin, M | 4 |
| Dormont, D | 4 |
| Houot, M | 1 |
| Lehéricy, S | 3 |
| Teipel, S | 1 |
| Rahman, A | 1 |
| Lamberty, Y | 1 |
| Schenker, E | 1 |
| Cella, M | 1 |
| Languille, S | 1 |
| Bordet, R | 1 |
| Richardson, J | 1 |
| Pifferi, F | 1 |
| Aujard, F | 1 |
| Fernandes, TB | 1 |
| Cunha, MR | 1 |
| Sakata, RP | 1 |
| Candido, TM | 1 |
| Baby, AR | 1 |
| Tavares, MT | 1 |
| Barbosa, EG | 1 |
| Almeida, WP | 1 |
| Parise-Filho, R | 1 |
| Agunloye, OM | 1 |
| Oboh, G | 1 |
| Kaushik, V | 1 |
| Smith, ST | 1 |
| Mikobi, E | 1 |
| Raji, MA | 1 |
| Xie, M | 1 |
| Hei, XX | 1 |
| Biswas, J | 1 |
| Verma, DK | 1 |
| Gupta, P | 1 |
| Goswami, P | 1 |
| Singh, S | 1 |
| Demir Özkay, Ü | 1 |
| Can, ÖD | 1 |
| Turan, N | 1 |
| Naharci, MI | 1 |
| Abdel-Megied, AM | 1 |
| Hanafi, RS | 1 |
| Aboul-Enein, HY | 1 |
| Bretin, S | 1 |
| Krazem, A | 1 |
| Henkous, N | 1 |
| Froger-Colleaux, C | 1 |
| Mocaer, E | 1 |
| Louis, C | 1 |
| Perdaems, N | 1 |
| Marighetto, A | 2 |
| Beracochea, D | 1 |
| May, BH | 1 |
| Feng, M | 1 |
| Hyde, AJ | 1 |
| Hügel, H | 1 |
| Chang, SY | 1 |
| Dong, L | 1 |
| Zhang, AL | 1 |
| Xue, CC | 1 |
| Shirayama, Y | 1 |
| Oda, Y | 1 |
| Yoshino, K | 1 |
| Sato, K | 7 |
| Okubo, T | 1 |
| Iyo, M | 1 |
| Yu, J | 1 |
| Yu, T | 1 |
| Zhao, L | 1 |
| Nie, K | 1 |
| Espinoza, LC | 1 |
| Vacacela, M | 1 |
| Clares, B | 1 |
| Garcia, ML | 1 |
| Fabrega, MJ | 1 |
| Calpena, AC | 1 |
| Atri, A | 5 |
| Frölich, L | 6 |
| Ballard, C | 9 |
| Molinuevo, JL | 4 |
| Boneva, N | 2 |
| Windfeld, K | 2 |
| Raket, LL | 2 |
| Cummings, JL | 16 |
| Rapp, M | 1 |
| Burkart, M | 1 |
| Kohlmann, T | 1 |
| Bohlken, J | 2 |
| Saba, K | 1 |
| Veeraiah, P | 1 |
| Jose, J | 1 |
| Lakhotia, SC | 1 |
| Patel, AB | 1 |
| Batarseh, YS | 1 |
| Kaddoumi, A | 1 |
| Kokras, N | 1 |
| Stamouli, E | 1 |
| Sotiropoulos, I | 1 |
| Katirtzoglou, EA | 1 |
| Siarkos, KT | 1 |
| Dalagiorgou, G | 1 |
| Alexandraki, KI | 1 |
| Coulocheri, S | 1 |
| Piperi, C | 1 |
| Politis, AM | 1 |
| Perng, CH | 1 |
| Chang, YC | 1 |
| Tzang, RF | 1 |
| Yoshii, F | 1 |
| Kawaguchi, C | 1 |
| Kohara, S | 1 |
| Shimizu, M | 1 |
| Onaka, H | 1 |
| Ryo, M | 1 |
| Takahashi, W | 1 |
| Gorecki, L | 2 |
| Malinak, D | 2 |
| Zhong, Y | 5 |
| Huo, Y | 2 |
| Wan, L | 5 |
| Guo, C | 4 |
| Méndez-Rojas, C | 1 |
| Quiroz, G | 1 |
| Faúndez, M | 1 |
| Gallardo-Toledo, E | 1 |
| Saitz-Barría, C | 1 |
| Kogan, MJ | 1 |
| Zúñiga-López, MC | 1 |
| Valenzuela-Gutiérrez, C | 1 |
| Fullerton, T | 1 |
| Binneman, B | 1 |
| David, W | 1 |
| Delnomdedieu, M | 1 |
| Kupiec, J | 1 |
| Lockwood, P | 1 |
| Mancuso, J | 1 |
| Miceli, J | 1 |
| Bell, J | 1 |
| Vila-Castelar, C | 1 |
| Ly, JJ | 1 |
| Kaplan, L | 1 |
| Van Dyk, K | 1 |
| Berger, JT | 1 |
| Macina, LO | 1 |
| Stewart, JL | 1 |
| Foldi, NS | 2 |
| Hiremathad, A | 2 |
| Keri, RS | 1 |
| Ridha, BH | 1 |
| Crutch, S | 1 |
| Cutler, D | 1 |
| Frost, C | 1 |
| Knight, W | 1 |
| Barker, S | 1 |
| Epie, N | 1 |
| Warrington, EK | 1 |
| Kukkastenvehmas, R | 1 |
| Douglas, J | 1 |
| Rossor, MN | 1 |
| Lim, EY | 1 |
| Cho, AH | 1 |
| Kazmierski, J | 1 |
| Messini-Zachou, C | 1 |
| Gkioka, M | 1 |
| Tsolaki, M | 3 |
| Juza, R | 1 |
| Agrawal, M | 1 |
| Saraf, S | 2 |
| Antimisiaris, SG | 1 |
| Chougule, MB | 1 |
| Shoyele, SA | 1 |
| Xin, B | 1 |
| Tulsankar, SL | 1 |
| Arfi, S | 1 |
| Bhatta, RS | 1 |
| Birks, JS | 2 |
| Harvey, RJ | 3 |
| Chang, YS | 2 |
| Wu, YH | 1 |
| Wang, CJ | 1 |
| Tang, SH | 2 |
| Chen, HL | 2 |
| Whateley, JM | 1 |
| Huffman, AJ | 1 |
| Henderson, EJ | 1 |
| Abdel-Raziq, MS | 1 |
| Xiao, H | 1 |
| Wen, J | 1 |
| Yuan, F | 1 |
| Arai, H | 6 |
| Hashimoto, N | 1 |
| Sumitomo, K | 2 |
| Takase, T | 4 |
| Ishii, M | 1 |
| Petit, E | 1 |
| Bailly, L | 1 |
| Gravitz, L | 1 |
| Adlimoghaddam, A | 1 |
| Neuendorff, M | 1 |
| Roy, B | 1 |
| Albensi, BC | 1 |
| Liu, JP | 1 |
| Fang, JY | 1 |
| Liu, LT | 2 |
| Tomás, D | 1 |
| Candeias, E | 1 |
| Jha, AB | 1 |
| Panchal, SS | 1 |
| Shah, A | 2 |
| Matsunaga, S | 1 |
| Kishi, T | 2 |
| Nomura, I | 1 |
| Sakuma, K | 2 |
| Okuya, M | 1 |
| Ikuta, T | 1 |
| Iwata, N | 1 |
| He, S | 1 |
| Calhoun, A | 1 |
| King, C | 1 |
| Khoury, R | 1 |
| Markowicz-Piasecka, M | 1 |
| Huttunen, KM | 1 |
| Sikora, J | 1 |
| Stoiljkovic, M | 1 |
| Kelley, C | 1 |
| Horvath, TL | 2 |
| Hajós, M | 1 |
| Gordon, ML | 1 |
| Brewster, JT | 1 |
| Dell'Acqua, S | 1 |
| Thach, DQ | 1 |
| Sessler, JL | 1 |
| Pu, Z | 1 |
| Xu, W | 3 |
| Liang, J | 2 |
| Jia, R | 1 |
| Wu, R | 1 |
| Hang, L | 1 |
| Ragab, GH | 1 |
| Bahgat, EA | 1 |
| Goschorska, M | 1 |
| Gutowska, I | 1 |
| Baranowska-Bosiacka, I | 1 |
| Piotrowska, K | 1 |
| Metryka, E | 1 |
| Safranow, K | 1 |
| Chlubek, D | 1 |
| Jiangbo, N | 1 |
| Liyun, Z | 1 |
| Geist, MA | 1 |
| Yu, M | 2 |
| Zhao, Z | 1 |
| Cheng, H | 1 |
| Ji, Y | 1 |
| Jin, Y | 1 |
| Sun, B | 1 |
| Jackson, EG | 1 |
| Stowe, S | 1 |
| Pachón-Angona, I | 1 |
| Martin, H | 1 |
| Oset-Gasque, MJ | 1 |
| Junaid, M | 1 |
| Islam, N | 1 |
| Hossain, MK | 1 |
| Ullah, MO | 1 |
| Halim, MA | 1 |
| Son, M | 1 |
| Park, C | 1 |
| Rampogu, S | 1 |
| Zeb, A | 1 |
| Lee, KW | 1 |
| Pandey, S | 1 |
| Singh, BK | 1 |
| Liu, G | 1 |
| Shi, S | 1 |
| Zambrano, P | 1 |
| Suwalsky, M | 1 |
| Jemiola-Rzeminska, M | 1 |
| Strzalka, K | 1 |
| Sepúlveda, B | 1 |
| Gallardo, MJ | 1 |
| Aguilar, LF | 1 |
| Kim, JE | 2 |
| Ma, SL | 1 |
| Tang, NLS | 1 |
| Wat, KHY | 1 |
| Tang, JHY | 1 |
| Lau, KH | 1 |
| Law, CB | 1 |
| Chiu, J | 1 |
| Tam, CCW | 1 |
| Poon, TK | 1 |
| Lin, KL | 1 |
| Kng, CPL | 1 |
| Kong, HL | 1 |
| Chan, TY | 1 |
| Chan, WC | 1 |
| Lam, LCW | 1 |
| Lushchekina, S | 1 |
| Semenov, V | 1 |
| Mukhamedyarov, M | 1 |
| Pashirova, T | 1 |
| Babaev, V | 1 |
| Petrova, N | 1 |
| Nurullin, L | 1 |
| Ilyin, V | 1 |
| Masson, P | 1 |
| Ghosh, S | 1 |
| Jana, K | 1 |
| Ganguly, B | 1 |
| Al Harthi, S | 1 |
| Alavi, SE | 1 |
| Radwan, MA | 1 |
| El Khatib, MM | 1 |
| AlSarra, IA | 1 |
| Yu, Z | 1 |
| Kostev, K | 1 |
| Kurylo, P | 1 |
| Kosik, J | 1 |
| Jacob, L | 1 |
| Noetzli, M | 1 |
| Eap, CB | 1 |
| Di Santo, SG | 1 |
| Prinelli, F | 1 |
| Adorni, F | 1 |
| Caltagirone, C | 1 |
| Musicco, M | 1 |
| Solé-Padullés, C | 1 |
| Bartrés-Faz, D | 1 |
| Lladó, A | 1 |
| Bosch, B | 1 |
| Peña-Gómez, C | 1 |
| Castellví, M | 1 |
| Rami, L | 1 |
| Bargalló, N | 1 |
| Sánchez-Valle, R | 1 |
| Sato, T | 8 |
| Nakatsuka, H | 1 |
| Sonde, L | 1 |
| Johnell, K | 1 |
| Zurek, E | 1 |
| Szymański, P | 1 |
| Mikiciuk-Olasik, E | 1 |
| Geldmacher, D | 2 |
| Farlow, M | 5 |
| Sabbagh, M | 3 |
| Christensen, D | 2 |
| Betz, P | 1 |
| Toda, N | 1 |
| Peters, JL | 1 |
| Anderson, R | 2 |
| Hoyle, M | 2 |
| Hyde, C | 2 |
| Marcelo, F | 1 |
| Dias, C | 1 |
| Martins, A | 1 |
| Madeira, PJ | 1 |
| Jorge, T | 1 |
| Florêncio, MH | 1 |
| Cabrita, EJ | 1 |
| Rauter, AP | 1 |
| Richardson, C | 1 |
| Gard, PR | 1 |
| Klugman, A | 2 |
| Isaac, M | 2 |
| Tabet, N | 2 |
| Chen, CH | 2 |
| Chou, MC | 3 |
| Li, CH | 1 |
| Liu, CK | 3 |
| Chen, SH | 4 |
| Kroker, KS | 1 |
| Moreth, J | 1 |
| Kussmaul, L | 1 |
| Rast, G | 1 |
| Rosenbrock, H | 1 |
| Wattmo, C | 7 |
| Paulsson, E | 1 |
| Minthon, L | 12 |
| Londos, E | 4 |
| Lazzeroni, LC | 1 |
| Halbauer, JD | 1 |
| Ashford, JW | 3 |
| Noda, A | 1 |
| Hernandez, B | 1 |
| Azor, V | 1 |
| Hozack, N | 1 |
| Hasson, N | 1 |
| Henderson, VW | 1 |
| Yesavage, JA | 4 |
| Tinklenberg, JR | 3 |
| Peters, KR | 1 |
| Cummings, J | 12 |
| Doody, R | 4 |
| Mackell, J | 9 |
| Fain, R | 1 |
| Karin, A | 1 |
| Hannesdottir, K | 1 |
| Jaeger, J | 1 |
| Annas, P | 1 |
| Segerdahl, M | 1 |
| Karlsson, P | 1 |
| Sjögren, N | 1 |
| von Rosen, T | 1 |
| Miller, F | 1 |
| Easton, A | 1 |
| Sankaranarayanan, S | 1 |
| Tanghe, A | 1 |
| Terwel, D | 1 |
| Lin, AX | 1 |
| Hoque, N | 1 |
| Bourin, C | 1 |
| Gu, H | 1 |
| Ahlijanian, M | 1 |
| Bristow, L | 1 |
| Lili, W | 1 |
| Cheng, G | 1 |
| Zhiyong, Z | 1 |
| Yan, L | 1 |
| Dan, L | 1 |
| Xueli, Z | 1 |
| Yuan, Z | 1 |
| Yatabe, Y | 2 |
| Hashimoto, M | 5 |
| Kaneda, K | 2 |
| Honda, K | 2 |
| Ogawa, Y | 1 |
| Yuuki, S | 1 |
| Ikeda, M | 3 |
| Ferris, SH | 3 |
| Zigman, WB | 1 |
| Pákáski, M | 2 |
| Fehér, A | 2 |
| Juhász, A | 2 |
| Drótos, G | 2 |
| Fazekas, OC | 1 |
| Kovács, J | 2 |
| Janka, Z | 2 |
| Kálmán, J | 2 |
| Damulin, IV | 1 |
| Schmitt, FA | 3 |
| Saxton, J | 1 |
| Sonali, N | 1 |
| Tripathi, M | 2 |
| Sagar, R | 1 |
| Velpandian, T | 1 |
| Subbiah, V | 1 |
| Scacchi, R | 2 |
| Gambina, G | 5 |
| Broggio, E | 1 |
| Corbo, RM | 2 |
| Cumbo, E | 1 |
| Ligori, LD | 1 |
| Andel, R | 1 |
| Mokrisova, I | 1 |
| Gazova, I | 1 |
| Amlerova, J | 1 |
| Coulson, EJ | 1 |
| Harrison, J | 1 |
| Windisch, M | 1 |
| Laczó, J | 1 |
| Darreh-Shori, T | 3 |
| Hosseini, SM | 1 |
| Nordberg, A | 3 |
| Mao, Y | 1 |
| Wang, R | 2 |
| Guo, T | 1 |
| Jin, L | 1 |
| Song, R | 1 |
| Zhang, Y | 2 |
| Hu, R | 1 |
| Niu, G | 1 |
| Irwin, DM | 1 |
| Tan, H | 1 |
| Rodrigues Simões, MC | 1 |
| Moreira, MS | 1 |
| da Rosa, PM | 1 |
| dos Santos, MH | 1 |
| Soares, MG | 1 |
| Molino, I | 1 |
| Colucci, L | 1 |
| Shimohama, S | 2 |
| Omori, C | 1 |
| Kaneko, M | 1 |
| Nakajima, E | 1 |
| Akatsu, H | 1 |
| Waragai, M | 1 |
| Morishima-Kawashima, M | 1 |
| Saito, Y | 1 |
| Nakaya, T | 1 |
| Taru, H | 1 |
| Yamamoto, T | 1 |
| Asada, T | 4 |
| Hata, S | 1 |
| Suzuki, T | 2 |
| Pelton, GH | 1 |
| Andrews, H | 1 |
| Roose, SP | 1 |
| Marcus, SM | 1 |
| D'Antonio, K | 1 |
| Husn, H | 1 |
| Petrella, JR | 1 |
| Zannas, AS | 1 |
| Doraiswamy, PM | 4 |
| Devanand, DP | 1 |
| Nguyen, MD | 1 |
| Salbu, RL | 1 |
| Ishimaru, T | 1 |
| Ochi, S | 1 |
| Matsumoto, T | 1 |
| Yoshida, T | 2 |
| Abe, M | 1 |
| Toyota, Y | 1 |
| Fukuhara, R | 1 |
| Tanimukai, S | 2 |
| Ueno, S | 1 |
| Marek, GJ | 2 |
| Katz, DA | 1 |
| Meier, A | 4 |
| Greco, N | 1 |
| Lenz, RA | 3 |
| Araki, T | 1 |
| Wake, R | 1 |
| Miyaoka, T | 2 |
| Kawakami, K | 1 |
| Nagahama, M | 1 |
| Furuya, M | 1 |
| Limoa, E | 1 |
| Liaury, K | 1 |
| Hashioka, S | 1 |
| Murotani, K | 1 |
| Horiguchi, J | 3 |
| Gharaei, H | 1 |
| Shadlou, H | 1 |
| Hsu, CY | 1 |
| Liew, KB | 3 |
| Tan, YT | 3 |
| Peh, KK | 3 |
| Shahani, L | 1 |
| Ponnayyan Sulochana, S | 1 |
| Sharma, K | 1 |
| Mullangi, R | 1 |
| Sukumaran, SK | 1 |
| Taipale, H | 2 |
| Tanskanen, A | 2 |
| Koponen, M | 1 |
| Tolppanen, AM | 2 |
| Tiihonen, J | 2 |
| Hartikainen, S | 2 |
| Gareri, P | 1 |
| Putignano, D | 1 |
| Castagna, A | 1 |
| Cotroneo, AM | 1 |
| De Palo, G | 1 |
| Fabbo, A | 1 |
| Forgione, L | 1 |
| Giacummo, A | 1 |
| Lacava, R | 1 |
| Marino, S | 1 |
| Simone, M | 1 |
| Zurlo, A | 1 |
| Putignano, S | 2 |
| Tan, CC | 1 |
| Yu, JT | 1 |
| Wang, HF | 1 |
| Tan, MS | 1 |
| Meng, XF | 1 |
| Jiang, T | 1 |
| Zhu, XC | 1 |
| Tan, L | 1 |
| Md, S | 1 |
| Ali, M | 1 |
| Ali, R | 1 |
| Bhatnagar, A | 1 |
| Baboota, S | 1 |
| Ali, J | 1 |
| Killin, LO | 1 |
| Russ, TC | 1 |
| Starr, JM | 3 |
| Abrahams, S | 1 |
| Della Sala, S | 1 |
| Testi, S | 1 |
| Peluso, S | 1 |
| Fabrizi, GM | 1 |
| Antenora, A | 1 |
| Russo, CV | 1 |
| Pappatà, S | 1 |
| Ferrarini, M | 1 |
| Filla, A | 1 |
| Meguro, K | 9 |
| Kasai, M | 4 |
| Akanuma, K | 5 |
| Meguro, M | 4 |
| Ishii, H | 3 |
| Yamaguchi, S | 5 |
| Ishiwata, A | 1 |
| Mizumura, S | 1 |
| Mishina, M | 1 |
| Yamazaki, M | 1 |
| Katayama, Y | 1 |
| Prvulovic, D | 1 |
| Schneider, B | 1 |
| Ikeda, K | 1 |
| Yanagihashi, M | 1 |
| Sawada, M | 1 |
| Hanashiro, S | 1 |
| Kawabe, K | 1 |
| Iwasaki, Y | 1 |
| Shoji, M | 1 |
| Beauchet, O | 1 |
| Launay, CP | 1 |
| Allali, G | 1 |
| Annweiler, C | 1 |
| Wade, L | 1 |
| Forlini, C | 1 |
| Racine, E | 1 |
| Rea, R | 4 |
| Martis, EA | 1 |
| Chandarana, RC | 1 |
| Shaikh, MS | 1 |
| Ambre, PK | 1 |
| D'Souza, JS | 1 |
| Iyer, KR | 1 |
| Coutinho, EC | 1 |
| Nandan, SR | 1 |
| Pissurlenkar, RR | 1 |
| Dhanjal, NS | 2 |
| Wise, RJ | 2 |
| Wu, CR | 1 |
| Lin, HC | 1 |
| Su, MH | 1 |
| Balla, C | 1 |
| Maertens de Noordhout, A | 1 |
| Pepin, JL | 1 |
| Laursen, B | 1 |
| Mørk, A | 1 |
| Kristiansen, U | 1 |
| Bastlund, JF | 2 |
| Haig, GM | 1 |
| Pritchett, Y | 2 |
| Othman, AA | 3 |
| Hall, C | 1 |
| Gault, LM | 4 |
| Utsumi, K | 2 |
| Yu, D | 1 |
| Tao, BB | 1 |
| Yang, YY | 1 |
| Du, LS | 1 |
| Yang, SS | 1 |
| He, XJ | 1 |
| Zhu, YW | 1 |
| Yan, JK | 1 |
| Muir-Hunter, SW | 1 |
| Oteng-Amoako, A | 1 |
| Gopaul, K | 1 |
| Islam, A | 1 |
| Borrie, M | 2 |
| Wells, J | 2 |
| Speechley, M | 1 |
| Bougea, A | 1 |
| Gerakoulis, S | 1 |
| Anagnostou, E | 1 |
| Paraskevas, G | 1 |
| Kapaki, E | 1 |
| Kararizou, E | 1 |
| Galipoğlu, M | 1 |
| Erdal, MS | 1 |
| Güngör, S | 1 |
| Wilkinson, D | 10 |
| Colding-Jørgensen, E | 1 |
| Donohue, MC | 1 |
| Moghadam, SH | 1 |
| Roe, AD | 1 |
| Sun, CK | 1 |
| Edland, SD | 2 |
| Thomas, RG | 4 |
| Petersen, RC | 6 |
| Sano, M | 5 |
| Galasko, D | 3 |
| Aisen, PS | 5 |
| Bulut, E | 1 |
| Şanlı, O | 1 |
| Sadhu, A | 1 |
| Agrawal, A | 1 |
| Ilango, K | 1 |
| Karmakar, D | 1 |
| Singh, GP | 1 |
| Dubey, GP | 1 |
| Chew, AP | 1 |
| Lim, WS | 1 |
| Tan, KT | 1 |
| Paroni, G | 2 |
| Seripa, D | 4 |
| Fontana, A | 1 |
| Gravina, C | 1 |
| Urbano, M | 1 |
| Cascavilla, L | 3 |
| Pellegrini, F | 1 |
| Pilotto, A | 6 |
| Chang, YP | 1 |
| Yang, CH | 1 |
| Hefner, G | 1 |
| Brueckner, A | 1 |
| Hiemke, C | 1 |
| Fellgiebel, A | 1 |
| Zeiss, CJ | 1 |
| Vardigan, JD | 2 |
| Cannon, CE | 1 |
| Puri, V | 2 |
| Dancho, M | 1 |
| Koser, A | 1 |
| Wittmann, M | 1 |
| Kuduk, SD | 2 |
| Renger, JJ | 1 |
| Uslaner, JM | 2 |
| Ouchi, Y | 3 |
| Safar, MM | 1 |
| Arab, HH | 1 |
| Rizk, SM | 1 |
| El-Maraghy, SA | 1 |
| Bag, S | 1 |
| Tulsan, R | 1 |
| Sood, A | 1 |
| Cho, H | 1 |
| Redjeb, H | 1 |
| Zhou, W | 3 |
| LeVine, H | 1 |
| Török, B | 1 |
| Török, M | 1 |
| Gharbi, T | 1 |
| Camargo, CH | 1 |
| Justus, FF | 1 |
| Retzlaff, G | 1 |
| Croisile, B | 2 |
| Louis Tisserand, G | 1 |
| Touchon, J | 6 |
| Bonafe, A | 2 |
| Ait Ameur, A | 1 |
| Rouaud, O | 2 |
| Ricolfi, F | 2 |
| Vighetto, A | 2 |
| Pasquier, F | 2 |
| Delmaire, C | 2 |
| Ceccaldi, M | 2 |
| Girard, N | 2 |
| Dufouil, C | 1 |
| Tonelli, I | 1 |
| Duveau, F | 2 |
| Garnero, L | 1 |
| Sarazin, M | 2 |
| Moreno-Grau, S | 1 |
| Barneda, B | 1 |
| Carriba, P | 1 |
| Marín, J | 1 |
| Sotolongo-Grau, O | 1 |
| Hernández, I | 1 |
| Rosende-Roca, M | 1 |
| Mauleón, A | 1 |
| Vargas, L | 1 |
| Espinosa, A | 1 |
| Alegret, M | 1 |
| Rodriguez, O | 1 |
| Ortega, G | 1 |
| Fernández, MV | 1 |
| López-Arrieta, J | 1 |
| Tárraga, L | 1 |
| Antúnez, C | 1 |
| López, J | 1 |
| Comella, JX | 1 |
| Matsuzono, K | 4 |
| Hishikawa, N | 6 |
| Ohta, Y | 5 |
| Yamashita, T | 7 |
| Deguchi, K | 4 |
| Nakano, Y | 6 |
| Abe, K | 10 |
| Takao, Y | 1 |
| Wakutani, Y | 1 |
| Jeong, SK | 1 |
| Sui, Y | 1 |
| Shen, X | 1 |
| Pei, G | 1 |
| Ding, J | 1 |
| Gavrilova, SI | 2 |
| Kolykhalov, IV | 1 |
| Segrec, N | 1 |
| Zaman, R | 1 |
| Pregelj, P | 2 |
| Ye, CY | 1 |
| Lei, Y | 1 |
| Tang, XC | 3 |
| Kraemer, HC | 2 |
| Yaffe, K | 4 |
| O'Hara, R | 2 |
| Ringman, JM | 2 |
| Taylor, JL | 2 |
| Sola, I | 1 |
| Viayna, E | 2 |
| Gómez, T | 2 |
| Galdeano, C | 2 |
| Cassina, M | 1 |
| Camps, P | 2 |
| Romeo, M | 1 |
| Diomede, L | 1 |
| Salmona, M | 1 |
| Franco, P | 1 |
| Schaeffer, M | 1 |
| Colantuono, D | 1 |
| Robin, D | 1 |
| Brunner, D | 1 |
| Taub, N | 1 |
| Hutter-Paier, B | 1 |
| Bachyns'ka, NIu | 1 |
| Rozheliuk, IF | 1 |
| Kholyn, VO | 1 |
| Pishel', IM | 1 |
| Leonov, IuI | 1 |
| Shimizu, S | 4 |
| Mizuguchi, Y | 1 |
| Sobue, A | 1 |
| Fujiwara, M | 1 |
| Morimoto, T | 1 |
| Ohno, Y | 1 |
| Kudoh, C | 1 |
| Arita, R | 1 |
| Honda, M | 1 |
| Komatsu, Y | 1 |
| Asou, H | 1 |
| Inoue, J | 2 |
| Hoshino, R | 2 |
| Nojima, H | 2 |
| Ishida, W | 2 |
| Okamoto, N | 2 |
| Hototian, SR | 1 |
| Joaquim, HP | 2 |
| Boinpally, R | 1 |
| Zukin, SR | 1 |
| McClure, N | 1 |
| Hofbauer, RK | 1 |
| Periclou, A | 1 |
| Shi, FD | 1 |
| Tagawa, R | 2 |
| Hashimoto, H | 3 |
| Nakanishi, A | 2 |
| Kawarada, Y | 2 |
| Muramatsu, T | 1 |
| Matsuda, Y | 1 |
| Kataoka, K | 2 |
| Shimada, A | 2 |
| Uchida, K | 1 |
| Yoshida, A | 1 |
| Higashiyama, S | 3 |
| Kawabe, J | 3 |
| Kai, T | 3 |
| Shiomi, S | 3 |
| Inoue, K | 3 |
| Ghumatkar, PJ | 1 |
| Patil, SP | 1 |
| Jain, PD | 1 |
| Tambe, RM | 1 |
| Sathaye, S | 1 |
| Lin, C | 1 |
| Gu, Y | 1 |
| Wu, D | 2 |
| Song, W | 1 |
| Sakata, Y | 1 |
| Daidoji, K | 1 |
| Toyoda, T | 1 |
| Oka, M | 1 |
| Nakaaki, S | 2 |
| Negi, A | 1 |
| Miyata, J | 1 |
| Nakagawa, A | 1 |
| Hirono, N | 2 |
| Ehret, MJ | 1 |
| Chamberlin, KW | 1 |
| Vaitkevičius, A | 1 |
| Kaubrys, G | 3 |
| Audronytė, E | 1 |
| Konishi, K | 1 |
| Hori, K | 2 |
| Tani, M | 1 |
| Tomioka, H | 2 |
| Kitajima, Y | 1 |
| Akashi, N | 1 |
| Inamoto, A | 1 |
| Kurosawa, K | 1 |
| Yuda, H | 1 |
| Hanashi, T | 1 |
| Ouchi, H | 1 |
| Hosoi, M | 1 |
| Hachisu, M | 1 |
| Kato, Y | 1 |
| Yin, Y | 1 |
| Zhuang, J | 1 |
| Pan, X | 1 |
| Li, P | 2 |
| Li, YP | 1 |
| Huang, LQ | 1 |
| Zhao, ZX | 1 |
| Kröger, E | 1 |
| Mouls, M | 1 |
| Wilchesky, M | 1 |
| Berkers, M | 1 |
| Carmichael, PH | 1 |
| van Marum, R | 1 |
| Souverein, P | 1 |
| Egberts, T | 1 |
| Laroche, ML | 1 |
| Kuzmickienė, J | 2 |
| Groppa, F | 2 |
| De Rosa, G | 2 |
| Granziera, S | 2 |
| Alexopoulos, C | 2 |
| Padrini, R | 2 |
| Manzo, V | 2 |
| Gauthier, S | 23 |
| Rountree, S | 1 |
| Finn, B | 1 |
| LaPlante, B | 1 |
| Weber, E | 1 |
| Oltersdorf, T | 1 |
| Kono, S | 2 |
| Waring, JF | 1 |
| Tang, Q | 3 |
| Robieson, WZ | 3 |
| King, DP | 1 |
| Das, U | 1 |
| Dubow, J | 1 |
| Dutta, S | 1 |
| Ota, H | 1 |
| Ogawa, S | 1 |
| Akishita, M | 1 |
| Manzo, C | 1 |
| Kok, KS | 1 |
| Loke, Y | 1 |
| Southgate, J | 1 |
| Russo, P | 1 |
| Kisialiou, A | 1 |
| Moroni, R | 1 |
| Prinzi, G | 1 |
| Fini, M | 1 |
| Kitt, J | 1 |
| Irons, R | 1 |
| Al-Obaidi, M | 1 |
| Missouris, C | 1 |
| Torjesen, I | 1 |
| Howard, R | 8 |
| McShane, R | 4 |
| Lindesay, J | 7 |
| Ritchie, C | 4 |
| Baldwin, A | 5 |
| Barber, R | 4 |
| Burns, A | 15 |
| Dening, T | 6 |
| Findlay, D | 5 |
| Holmes, C | 10 |
| Jones, R | 14 |
| McKeith, I | 5 |
| Macharouthu, A | 5 |
| O'Brien, J | 6 |
| Sheehan, B | 5 |
| Juszczak, E | 5 |
| Katona, C | 4 |
| Hills, R | 3 |
| Knapp, M | 6 |
| Brown, RG | 4 |
| Banerjee, S | 5 |
| Adams, J | 5 |
| Johnson, T | 7 |
| Bentham, P | 8 |
| Phillips, PP | 1 |
| Shanmuganathan, B | 1 |
| Sheeja Malar, D | 1 |
| Sathya, S | 1 |
| Pandima Devi, K | 1 |
| Ala, T | 1 |
| Yu, Q | 1 |
| Chen, P | 2 |
| Pai, MC | 1 |
| Aref, H | 1 |
| Bassil, N | 1 |
| Srinivasan, AV | 1 |
| diTommaso, S | 1 |
| Yuksel, O | 1 |
| Ali, TB | 1 |
| Schleret, TR | 1 |
| Reilly, BM | 1 |
| Chen, WY | 1 |
| Abagyan, R | 1 |
| Szeto, JY | 1 |
| Lewis, SJ | 1 |
| Kobayashi, H | 2 |
| Ohnishi, T | 1 |
| Nakagawa, R | 1 |
| Yoshizawa, K | 1 |
| Kracmarova, A | 1 |
| Kassa, J | 1 |
| Lai, TJ | 1 |
| Mohandas, E | 1 |
| Yun Kim, S | 1 |
| Nair, G | 1 |
| Brindisi, M | 1 |
| Gemma, S | 1 |
| Campiani, G | 1 |
| Filipic, S | 1 |
| Butini, S | 1 |
| Ruela, AL | 1 |
| Confaloni, A | 2 |
| Tosto, G | 2 |
| Tata, AM | 1 |
| Teipel, SJ | 3 |
| Galluzzi, S | 2 |
| Bakardjian, H | 1 |
| Prati, F | 1 |
| Wallin, ÅK | 7 |
| Kubota, N | 2 |
| Florian, H | 1 |
| Lipschitz, S | 1 |
| Homma, A | 7 |
| Atarashi, H | 1 |
| Nakai, K | 1 |
| Kearney, MC | 1 |
| Caffarel-Salvador, E | 1 |
| Fallows, SJ | 1 |
| McCarthy, HO | 1 |
| Donnelly, RF | 1 |
| Voříšek, V | 1 |
| Palička, V | 1 |
| Simoni, E | 1 |
| Caporaso, R | 1 |
| Jayant, S | 1 |
| Sharma, BM | 1 |
| Sharma, B | 2 |
| Moon, CM | 1 |
| Matsuda, T | 1 |
| Nagasawa, S | 1 |
| Katagiri, N | 1 |
| Nara, A | 1 |
| Chiba, F | 1 |
| Kubo, Y | 1 |
| Torimitsu, S | 1 |
| Yajima, D | 1 |
| Akutsu, M | 1 |
| Iwase, H | 1 |
| Iizuka, T | 1 |
| Kameyama, M | 1 |
| Wen, C | 1 |
| Jakki, SL | 1 |
| Ramesh, YV | 1 |
| Gowthamarajan, K | 1 |
| Senthil, V | 1 |
| Jain, K | 1 |
| Sood, S | 1 |
| Pathak, D | 1 |
| Owen, RT | 1 |
| Balasubramaniam, SC | 1 |
| Chen, JJ | 1 |
| Xiao, T | 1 |
| Jiao, B | 1 |
| Tang, B | 1 |
| Shen, L | 1 |
| Kim, JY | 1 |
| Han, MR | 1 |
| Shin, SW | 1 |
| Nam, SY | 1 |
| Luzny, J | 1 |
| Ivanova, K | 1 |
| Conti, E | 1 |
| Tremolizzo, L | 1 |
| Santarone, ME | 1 |
| Tironi, M | 1 |
| Radice, I | 1 |
| Zoia, CP | 1 |
| Aliprandi, A | 1 |
| Salmaggi, A | 1 |
| Dominici, R | 1 |
| Casati, M | 1 |
| Appollonio, I | 1 |
| Ferrarese, C | 1 |
| Kumai, K | 1 |
| Nakamura, K | 1 |
| Deardorff, WJ | 2 |
| Zhong, G | 1 |
| Fu, S | 1 |
| Chi, T | 1 |
| Rao, X | 1 |
| Zeng, S | 1 |
| Xu, D | 1 |
| Sheng, G | 1 |
| Ji, X | 2 |
| Zou, L | 1 |
| Tortorella, M | 1 |
| Zhang, K | 1 |
| Hu, W | 1 |
| De Beaumont, L | 1 |
| Pelleieux, S | 1 |
| Lamarre-Théroux, L | 1 |
| Dea, D | 1 |
| Poirier, J | 1 |
| Zhang, ZX | 2 |
| Zhao, RP | 1 |
| Wang, DS | 1 |
| Wang, AN | 1 |
| Serrano, MP | 1 |
| Herrero-Labrador, R | 1 |
| Futch, HS | 1 |
| Serrano, J | 1 |
| Fernandez, AP | 1 |
| Martínez-Murillo, R | 1 |
| Amat-Foraster, M | 1 |
| Leiser, SC | 1 |
| Herrik, KF | 1 |
| Richard, N | 1 |
| Agerskov, C | 1 |
| de Jong, IEM | 1 |
| Hroudová, J | 1 |
| Fišar, Z | 1 |
| Masopust, J | 1 |
| Vysata, O | 1 |
| Tomek, J | 1 |
| King, D | 1 |
| Romeo, R | 1 |
| O'Brien, JT | 2 |
| Phillips, PPJ | 1 |
| Ritchie, CW | 1 |
| Berry, S | 1 |
| Tisserand, GL | 1 |
| Lampela, P | 1 |
| Lavikainen, P | 1 |
| Kim, HY | 1 |
| Kim, HV | 1 |
| Lee, DK | 1 |
| Yang, SH | 1 |
| Sarno, TA | 1 |
| Bram, JM | 1 |
| Khosravan, A | 1 |
| Marani, S | 1 |
| Sadeghi Googheri, MS | 1 |
| Emon, MA | 1 |
| Kodamullil, AT | 1 |
| Karki, R | 1 |
| Younesi, E | 1 |
| Hofmann-Apitius, M | 1 |
| Ricci, G | 1 |
| Darwish, M | 1 |
| Takemoto, M | 1 |
| Wang, CN | 1 |
| Song, L | 1 |
| Wang, JL | 1 |
| Ye, Y | 1 |
| Jiang, B | 1 |
| Chase, TN | 1 |
| Farlow, MR | 13 |
| Clarence-Smith, K | 1 |
| Fisher, A | 1 |
| Carney, G | 1 |
| Bassett, K | 1 |
| Dormuth, CR | 1 |
| Feng, R | 1 |
| Gong, Y | 1 |
| Cai, J | 1 |
| Feng, N | 1 |
| Shi, L | 1 |
| Doody, RS | 18 |
| Caramillo, EM | 1 |
| Echevarria, DJ | 1 |
| Fukui, Y | 1 |
| Ichinose, J | 1 |
| Morihara, R | 1 |
| Campbell, NL | 1 |
| Perkins, AJ | 1 |
| Gao, S | 1 |
| Skaar, TC | 1 |
| Hendrie, HC | 1 |
| Fowler, N | 1 |
| Callahan, CM | 1 |
| Boustani, MA | 1 |
| Kaneko, N | 2 |
| Sawamoto, K | 2 |
| FitzGerald, DB | 1 |
| Crucian, GP | 1 |
| Mielke, JB | 1 |
| Shenal, BV | 1 |
| Burks, D | 1 |
| Womack, KB | 1 |
| Ghacibeh, G | 1 |
| Drago, V | 1 |
| Foster, PS | 1 |
| Valenstein, E | 1 |
| Heilman, KM | 2 |
| Sugimoto, H | 6 |
| Zivin, M | 1 |
| Mucha, L | 1 |
| Shaohung, S | 1 |
| Cuffel, B | 1 |
| McRae, T | 9 |
| Mark, TL | 1 |
| Del Valle, M | 2 |
| Jones, RW | 5 |
| Kivipelto, M | 2 |
| Feldman, H | 8 |
| Sparks, L | 1 |
| Waters, DD | 1 |
| Hey-Hadavi, J | 1 |
| Breazna, A | 1 |
| Schindler, RJ | 2 |
| Ramos, H | 1 |
| Sabbagh, MN | 4 |
| Richardson, S | 8 |
| Relkin, N | 1 |
| Gilstad, JR | 1 |
| Finucane, TE | 6 |
| Sochocka, M | 1 |
| Zaczyńska, E | 1 |
| Leszek, J | 1 |
| Siemieniec, I | 1 |
| Błach-Olszewska, Z | 1 |
| Yeates, A | 1 |
| Akintade, L | 1 |
| Zhang, RY | 1 |
| Schwam, EM | 7 |
| Perdomo, CA | 7 |
| Hansen, RA | 1 |
| Gartlehner, G | 1 |
| Webb, AP | 1 |
| Morgan, LC | 1 |
| Moore, CG | 1 |
| Jonas, DE | 1 |
| Hansson, O | 1 |
| Moretto, G | 1 |
| Ruis, J | 1 |
| Jacobson, SA | 1 |
| Yeh, HH | 1 |
| Ko, JY | 1 |
| Hsiung, GY | 1 |
| Feldman, HH | 3 |
| Talarico, G | 1 |
| Lenzi, GL | 2 |
| Bruno, G | 2 |
| van Straaten, EC | 1 |
| Harvey, D | 1 |
| Scheltens, P | 1 |
| Barkhof, F | 1 |
| Thal, LJ | 3 |
| Jack, CR | 1 |
| DeCarli, C | 1 |
| Nikisch, G | 2 |
| Wiedemann, G | 2 |
| Kiessling, B | 2 |
| Hertel, A | 2 |
| Laks, J | 2 |
| Engelhardt, E | 2 |
| Mittelman, MS | 1 |
| Brodaty, H | 5 |
| Wallen, AS | 1 |
| Jelic, V | 2 |
| Haglund, A | 5 |
| Kowalski, J | 1 |
| Langworth, S | 1 |
| Winblad, B | 11 |
| Huvent-Grelle, D | 1 |
| Roche, J | 1 |
| Gaxatte, C | 1 |
| Dewailly, P | 1 |
| Puisieux, F | 1 |
| Lopez, OL | 6 |
| Mackell, JA | 1 |
| Kassalow, LM | 1 |
| Hongo, J | 1 |
| Shinagawa, Y | 1 |
| Sato, J | 1 |
| Tatsumi, H | 1 |
| Tohyama, J | 1 |
| Soma, T | 1 |
| Iidaka, T | 1 |
| Fukui, T | 3 |
| Irizarry, MC | 1 |
| Raman, R | 2 |
| Schwarzschild, MA | 1 |
| Becerra, LM | 1 |
| Peterson, RC | 1 |
| Ascherio, A | 1 |
| Wagner, T | 1 |
| Krasz, D | 1 |
| Hofmann, E | 1 |
| Ignatov, I | 1 |
| Belden, C | 1 |
| Jacobson, S | 1 |
| Connor, D | 1 |
| Mohan, M | 1 |
| Carpenter, PK | 1 |
| Bennett, C | 1 |
| Russell, WJ | 1 |
| Knopman, DS | 2 |
| Salloway, S | 6 |
| Goldman, R | 3 |
| Watkins, WE | 1 |
| Murthy, AK | 1 |
| Rozzini, L | 2 |
| Chilovi, BV | 1 |
| Bertoletti, E | 1 |
| Ghianda, D | 1 |
| Conti, M | 1 |
| Trabucchi, M | 4 |
| Peskind, E | 1 |
| Soininen, H | 6 |
| Mousavi, M | 1 |
| Eagle, G | 1 |
| Lane, R | 7 |
| Blais, L | 1 |
| Kettani, FZ | 1 |
| Perreault, S | 1 |
| Leroux, JC | 1 |
| Forget, A | 1 |
| Kergoat, MJ | 2 |
| Persson, CM | 1 |
| Levander, S | 1 |
| López-Bastida, J | 1 |
| Hart, W | 1 |
| García-Pérez, L | 1 |
| Linertová, R | 1 |
| Rothi, LJ | 1 |
| Fuller, R | 1 |
| Leon, SA | 1 |
| Kendall, D | 1 |
| Moore, A | 1 |
| Wu, SS | 1 |
| Crosson, B | 1 |
| Nadeau, SE | 1 |
| Imai, Y | 2 |
| Tago, H | 2 |
| Shigeta, M | 3 |
| Iwamoto, T | 7 |
| Takita, M | 2 |
| Arimoto, I | 2 |
| Koma, H | 2 |
| Ohbayashi, T | 2 |
| Pietrzak, RH | 1 |
| Maruff, P | 1 |
| Snyder, PJ | 2 |
| Abernethy, AP | 1 |
| Farrell, TW | 1 |
| Takahashi, T | 1 |
| Crutchfield, D | 1 |
| Yancheva, S | 1 |
| Ihl, R | 1 |
| Nikolova, G | 1 |
| Panayotov, P | 1 |
| Schlaefke, S | 1 |
| Hoerr, R | 1 |
| Tian, J | 1 |
| Yin, J | 1 |
| Hu, Q | 1 |
| Sheng, S | 1 |
| Wang, P | 1 |
| Ren, Y | 1 |
| Sato, N | 1 |
| Ueki, A | 2 |
| Ueno, H | 1 |
| Shinjo, H | 2 |
| Morita, Y | 2 |
| Tsuno, N | 1 |
| Davis, ML | 1 |
| Barrett, AM | 1 |
| Smith, DA | 1 |
| Venneri, A | 4 |
| Hatoum, HT | 1 |
| Thomas, SK | 4 |
| Lin, SJ | 3 |
| Bullock, R | 12 |
| Lu, PH | 1 |
| Teng, E | 1 |
| Tingus, K | 1 |
| Rodda, J | 1 |
| Morgan, S | 1 |
| Walker, Z | 1 |
| Binder, C | 1 |
| Dalziel, W | 1 |
| Smyth, S | 1 |
| Camacho, F | 1 |
| Peng, XW | 1 |
| Dong, KL | 1 |
| Lisi, D | 1 |
| Leyhe, T | 2 |
| Hoffmann, N | 1 |
| Stransky, E | 2 |
| Laske, C | 2 |
| Velayudhan, L | 1 |
| Lovestone, S | 1 |
| Nozawa, M | 1 |
| Ichimiya, Y | 1 |
| Nozawa, E | 1 |
| Utumi, Y | 1 |
| Sugiyama, H | 1 |
| Murayama, N | 1 |
| Iseki, E | 1 |
| Róman, G | 1 |
| Hecker, J | 8 |
| Boundy, K | 1 |
| Posner, H | 1 |
| Phillips, P | 3 |
| Barber, B | 1 |
| Brown, R | 4 |
| Gray, R | 5 |
| Griffin, M | 3 |
| Hughes, A | 4 |
| Jacoby, R | 5 |
| Onions, C | 2 |
| Raftery, J | 2 |
| Fossey, J | 1 |
| Douglas, S | 1 |
| Bradley, P | 1 |
| Hancock, J | 1 |
| James, IA | 1 |
| Mittelman, M | 1 |
| Gibson, L | 2 |
| Seeher, K | 1 |
| Black, SE | 3 |
| Moline, M | 4 |
| Albert, K | 1 |
| Suh, GH | 1 |
| Wimo, A | 7 |
| O'Connor, D | 1 |
| Dominguez, J | 1 |
| Yang, BM | 1 |
| Franceschi, M | 3 |
| Bizzarro, A | 4 |
| Mangialasche, F | 1 |
| Paris, F | 3 |
| Matera, MG | 1 |
| Daniele, A | 1 |
| Mecocci, P | 4 |
| Masullo, C | 4 |
| Dallapiccola, B | 1 |
| Sevilla, C | 2 |
| Jiménez Caballero, PE | 1 |
| Alfonso, V | 1 |
| González-Adalid, M | 1 |
| Stix, G | 1 |
| Schwam, E | 6 |
| Waldemar, G | 10 |
| Hernandez, RK | 1 |
| Farwell, W | 1 |
| Cantor, MD | 1 |
| Lawler, EV | 1 |
| Dong, H | 2 |
| Yuede, CM | 1 |
| Coughlan, CA | 1 |
| Murphy, KM | 1 |
| Csernansky, JG | 4 |
| Akhondzadeh, S | 1 |
| Shafiee Sabet, M | 1 |
| Harirchian, MH | 1 |
| Togha, M | 1 |
| Cheraghmakani, H | 1 |
| Razeghi, S | 1 |
| Hejazi, SS | 1 |
| Yousefi, MH | 1 |
| Alimardani, R | 1 |
| Jamshidi, A | 1 |
| Rezazadeh, SA | 1 |
| Yousefi, A | 1 |
| Zare, F | 1 |
| Vossoughi, A | 1 |
| Modrego, PJ | 1 |
| Fayed, N | 1 |
| Errea, JM | 1 |
| Rios, C | 1 |
| Pina, MA | 1 |
| Sarasa, M | 1 |
| Handa, T | 3 |
| Katare, RG | 2 |
| Kakinuma, Y | 3 |
| Arikawa, M | 3 |
| Ando, M | 1 |
| Sasaguri, S | 1 |
| Yamasaki, F | 3 |
| Crane, PK | 1 |
| Lockhart, IA | 1 |
| Mitchell, SA | 1 |
| Kelly, S | 1 |
| Alva, G | 1 |
| Meng, X | 2 |
| Olin, JT | 4 |
| Hanyu, H | 7 |
| Hirao, K | 2 |
| Kanetaka, H | 2 |
| Koizumi, K | 5 |
| Takaya, T | 1 |
| Okamoto, M | 1 |
| Yodoi, K | 1 |
| Hata, K | 1 |
| Kijima, Y | 1 |
| Nakajima, H | 1 |
| Nishikawa, Y | 1 |
| Kita, T | 3 |
| Ito, M | 1 |
| Seo, T | 1 |
| Kawashima, S | 2 |
| Furihata, M | 1 |
| Akiyama, T | 1 |
| Carøe, TK | 1 |
| Moe, C | 1 |
| Reeves, S | 1 |
| Matthews, D | 1 |
| Grasby, P | 1 |
| Chonpathompikunlert, P | 1 |
| Wattanathorn, J | 1 |
| Muchimapura, S | 1 |
| Harms, MP | 1 |
| Staggs, JM | 1 |
| Xiong, C | 1 |
| Morris, JC | 4 |
| Galvin, JE | 2 |
| Truter, I | 1 |
| Sadowsky, C | 1 |
| Perez, JA | 1 |
| Bouchard, RW | 1 |
| Goodman, I | 1 |
| Tekin, S | 1 |
| Hasegawa, T | 1 |
| Santoro, A | 1 |
| Siviero, P | 1 |
| Minicuci, N | 1 |
| Bellavista, E | 1 |
| Mishto, M | 1 |
| Olivieri, F | 1 |
| Marchegiani, F | 1 |
| Chiamenti, AM | 1 |
| Benussi, L | 2 |
| Ghidoni, R | 2 |
| Nacmias, B | 1 |
| Bagnoli, S | 1 |
| Ginestroni, A | 1 |
| Scarpino, O | 1 |
| Feraco, E | 1 |
| Gianni, W | 1 |
| Cruciani, G | 1 |
| Paganelli, R | 1 |
| Di Iorio, A | 1 |
| Scognamiglio, M | 1 |
| Grimaldi, LM | 1 |
| Gabelli, C | 1 |
| Sorbi, S | 1 |
| Binetti, G | 2 |
| Crepaldi, G | 1 |
| Franceschi, C | 1 |
| Sadowsky, CH | 1 |
| Kanaya, K | 2 |
| Abe, S | 2 |
| Sakai, M | 2 |
| Fujii, H | 2 |
| Formosa, X | 1 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 1 |
| Badia, A | 1 |
| Clos, MV | 1 |
| Mancini, F | 1 |
| Dafni, T | 1 |
| Hayashi, Y | 1 |
| Ishida, Y | 1 |
| Inoue, T | 1 |
| Udagawa, M | 1 |
| Takeuchi, K | 1 |
| Yoshimuta, H | 1 |
| Kiue, K | 1 |
| Ninomiya, Y | 1 |
| Kawano, J | 1 |
| Sameshima, T | 1 |
| Kawahara, T | 1 |
| Goto, I | 1 |
| Shudo, K | 1 |
| Kurayama, S | 1 |
| Nakamura, J | 1 |
| Okahara, K | 1 |
| Mitsuyama, Y | 1 |
| Calciano, MA | 1 |
| Einstein, R | 1 |
| Cornelli, U | 1 |
| Formiga, F | 1 |
| Fort, I | 1 |
| Robles, MJ | 1 |
| Rodriguez, D | 1 |
| Regalado, P | 1 |
| Panza, F | 1 |
| Frisardi, V | 1 |
| Capurso, C | 1 |
| D'Introno, A | 1 |
| Colacicco, AM | 1 |
| Chiloiro, R | 1 |
| Dellegrazie, F | 1 |
| Di Palo, A | 1 |
| Capurso, A | 1 |
| Solfrizzi, V | 1 |
| Gadzhanova, S | 1 |
| Roughead, L | 1 |
| Mackson, J | 1 |
| Getsios, D | 3 |
| Blume, S | 3 |
| Ishak, KJ | 2 |
| Maclaine, GD | 1 |
| Yamagata, B | 1 |
| Watanabe, T | 2 |
| McGeown, WJ | 1 |
| Shanks, MF | 2 |
| Forbes-McKay, KE | 1 |
| Waiter, GD | 1 |
| Elrick, I | 1 |
| Venneri, MG | 1 |
| Shioda, N | 1 |
| Han, F | 1 |
| Moriguchi, S | 2 |
| Fukunaga, K | 1 |
| Bitner, RS | 1 |
| Bunnelle, WH | 1 |
| Decker, MW | 1 |
| Drescher, KU | 1 |
| Kohlhaas, KL | 1 |
| Markosyan, S | 1 |
| Marsh, KC | 1 |
| Nikkel, AL | 1 |
| Browman, K | 1 |
| Radek, R | 1 |
| Anderson, DJ | 1 |
| Buccafusco, J | 1 |
| Gopalakrishnan, M | 1 |
| Perryman, M | 1 |
| Lewis, M | 1 |
| Rivers, PA | 1 |
| Rosenblatt, A | 2 |
| Mimica, N | 1 |
| Presecki, P | 1 |
| Borah, B | 1 |
| Sacco, P | 1 |
| Zarotsky, V | 1 |
| Suda, S | 1 |
| Sugihara, G | 1 |
| Suyama, R | 1 |
| Mori, N | 1 |
| Takei, N | 1 |
| Lopez, O | 2 |
| Knox, S | 1 |
| Criado-Alvarez, JJ | 1 |
| Romo Barrientos, C | 1 |
| Urbano, R | 1 |
| Yu, C | 1 |
| Jordan, J | 1 |
| Robertson, D | 1 |
| Diedrich, A | 1 |
| Canan, F | 1 |
| Ataoglu, A | 1 |
| Hollingworth, SA | 1 |
| Byrne, GJ | 1 |
| Yardley, J | 4 |
| Moline, ML | 1 |
| Brand-Schieber, E | 2 |
| Zou, H | 2 |
| Hsu, T | 2 |
| Satlin, A | 2 |
| Schwalbe, O | 1 |
| Scheerans, C | 1 |
| Freiberg, I | 1 |
| Schmidt-Pokrzywniak, A | 1 |
| Stang, A | 1 |
| Kloft, C | 1 |
| Niu, YX | 1 |
| Tan, JP | 1 |
| Guan, JQ | 1 |
| Zhang, ZQ | 1 |
| Wang, LN | 1 |
| Inanaga, K | 1 |
| Ichiki, T | 1 |
| Miyazaki, R | 1 |
| Takeda, K | 1 |
| Hashimoto, T | 1 |
| Matsuura, H | 1 |
| Sunagawa, K | 1 |
| Gold, M | 3 |
| Alderton, C | 1 |
| Zvartau-Hind, M | 2 |
| Egginton, S | 1 |
| Saunders, AM | 2 |
| Irizarry, M | 2 |
| Craft, S | 1 |
| Landreth, G | 1 |
| Linnamägi, U | 1 |
| Sawchak, S | 2 |
| Kharbanda, M | 1 |
| Mathela, CS | 1 |
| Bae, HJ | 1 |
| Shim, YS | 1 |
| Kim, BK | 2 |
| Kwon, JC | 2 |
| Yoo, BG | 1 |
| Lee, JS | 1 |
| Ghorbani, A | 1 |
| Chitsaz, A | 1 |
| Shishegar, M | 1 |
| Akbari, M | 1 |
| Vecchione, G | 1 |
| Gallo, AP | 2 |
| Grandone, E | 1 |
| Santini, SA | 2 |
| Maher-Edwards, G | 1 |
| Dixon, R | 1 |
| Hunter, J | 2 |
| Hopton, G | 1 |
| Jacobs, G | 1 |
| Williams, P | 1 |
| Galluzzi, KE | 1 |
| Appelt, DM | 1 |
| Balin, BJ | 1 |
| Magliulo, L | 1 |
| Dahl, ML | 2 |
| Lombardi, G | 2 |
| Fallarini, S | 1 |
| Villa, LM | 2 |
| Biolcati, A | 2 |
| Scordo, MG | 2 |
| Scharre, DW | 1 |
| Vekeman, F | 1 |
| Lefebvre, P | 1 |
| Mody-Patel, N | 1 |
| Kahler, KH | 1 |
| Duh, MS | 1 |
| Massoud, F | 2 |
| Desmarais, JE | 1 |
| López-Pousa, S | 4 |
| Bermejo-Pareja, F | 1 |
| Frank, A | 2 |
| Hernández, F | 1 |
| León, T | 1 |
| Rejas-Gutiérrez, J | 1 |
| Wu, SL | 1 |
| Lai, CL | 1 |
| Kapai, NA | 1 |
| Solntseva, EI | 1 |
| Skrebitskii, VG | 1 |
| Oguro, H | 1 |
| Onoda, K | 1 |
| Kobayashi, S | 2 |
| McCarthy, AD | 1 |
| Owens, IJ | 1 |
| Bansal, AT | 1 |
| McTighe, SM | 1 |
| Bussey, TJ | 2 |
| Saksida, LM | 2 |
| Matsuda, O | 2 |
| Shido, E | 1 |
| Hashikai, A | 1 |
| Shibuya, H | 1 |
| Kouno, M | 1 |
| Hara, C | 1 |
| Saito, M | 1 |
| Komatsu, S | 1 |
| Andrieu, S | 2 |
| Sampaio, C | 1 |
| Carrillo, M | 1 |
| Khachaturian, ZS | 1 |
| Hendrix, SB | 1 |
| Grundman, M | 2 |
| Schneider, LS | 8 |
| Salmon, E | 2 |
| Potter, WZ | 1 |
| Salmon, D | 1 |
| Donohue, M | 1 |
| Bednar, MM | 1 |
| Vellas, B | 11 |
| Ahmed, HH | 1 |
| Van Puyvelde, K | 1 |
| Mets, T | 1 |
| Ashwood, T | 1 |
| Nilsson, J | 1 |
| Eckerwall, G | 1 |
| Ferreri, F | 2 |
| Pasqualetti, P | 1 |
| Määttä, S | 1 |
| Ponzo, D | 1 |
| Guerra, A | 1 |
| Bressi, F | 1 |
| Chiovenda, P | 1 |
| Del Duca, M | 1 |
| Giambattistelli, F | 1 |
| Ursini, F | 1 |
| Tombini, M | 1 |
| Vernieri, F | 1 |
| Rossini, PM | 2 |
| Kinnair, D | 1 |
| Machili, C | 1 |
| Prettyman, R | 1 |
| Van Diepen, E | 1 |
| Piau, A | 1 |
| Caillaud, C | 1 |
| Voisin, T | 1 |
| Perry, E | 1 |
| Francis, P | 1 |
| Morris, J | 1 |
| Howes, MJ | 1 |
| Chazot, P | 1 |
| Lees, G | 1 |
| Riordan, KC | 1 |
| Hoffman Snyder, CR | 1 |
| Wellik, KE | 1 |
| Caselli, RJ | 1 |
| Wingerchuk, DM | 1 |
| Demaerschalk, BM | 1 |
| Romberg, C | 1 |
| Mattson, MP | 1 |
| Mughal, MR | 1 |
| Cai, LL | 1 |
| Guan, J | 1 |
| Liu, MF | 1 |
| Maclaine, G | 2 |
| Hernández, L | 1 |
| Selke, GW | 1 |
| van den Bussche, H | 4 |
| Voigt-Radloff, S | 1 |
| Hüll, M | 1 |
| Hayashida, M | 1 |
| Shibahara, N | 1 |
| Tanaka, K | 1 |
| Miyata, T | 1 |
| Matsumoto, K | 2 |
| Harrington, C | 1 |
| Chiang, C | 1 |
| Davies, J | 1 |
| Donovan, C | 1 |
| Jeter, B | 1 |
| van Dyck, CH | 4 |
| Veloso, F | 1 |
| Bibbiani, F | 1 |
| Lenzer, J | 1 |
| Chianella, C | 1 |
| Gragnaniello, D | 1 |
| Maisano Delser, P | 1 |
| Visentini, MF | 1 |
| Sette, E | 1 |
| Tola, MR | 1 |
| Barbujani, G | 1 |
| Fuselli, S | 1 |
| Henigsberg, N | 1 |
| Kalember, P | 1 |
| Hrabać, P | 1 |
| Rados, M | 2 |
| Bajs, M | 1 |
| Kovavić, Z | 1 |
| Loncar, M | 1 |
| Madzar, T | 1 |
| Peter, F | 1 |
| Susanne, J | 1 |
| Margareta, H | 1 |
| Silvia, W | 1 |
| Wolfgang, K | 1 |
| Thomas, L | 1 |
| Heinz, TK | 1 |
| Cacabelos, R | 1 |
| Sampedro, C | 1 |
| Couceiro, V | 1 |
| Vargas, M | 1 |
| Granizo, E | 1 |
| Baurecht, W | 1 |
| Doppler, E | 1 |
| Kimura, N | 1 |
| Kumamoto, T | 1 |
| Masuda, T | 1 |
| Hanaoka, T | 1 |
| Okazaki, T | 1 |
| Arakawa, R | 1 |
| Jeon, S | 1 |
| Bose, S | 1 |
| Hur, J | 1 |
| Jun, K | 1 |
| Kim, YK | 1 |
| Cho, KS | 1 |
| Goveas, JS | 2 |
| Xie, C | 2 |
| Ward, BD | 2 |
| Wu, Z | 1 |
| Franczak, M | 1 |
| Jones, JL | 2 |
| Antuono, PG | 2 |
| Li, SJ | 2 |
| Mancuso, C | 1 |
| Siciliano, R | 1 |
| Barone, E | 1 |
| Butterfield, DA | 1 |
| Preziosi, P | 1 |
| Gustavsson, A | 1 |
| Jönsson, L | 2 |
| Parmler, J | 1 |
| Andreasen, N | 7 |
| Klimkowicz-Mrowiec, A | 1 |
| Marona, M | 1 |
| Spisak, K | 1 |
| Jagiella, J | 1 |
| Wolkow, P | 1 |
| Szczudlik, A | 1 |
| Slowik, A | 1 |
| Wang, CZ | 1 |
| Du, GJ | 1 |
| Zhen, Z | 1 |
| Calway, T | 1 |
| Yuan, CS | 1 |
| Takeda, M | 2 |
| Tanaka, T | 3 |
| Okochi, M | 1 |
| Iliffe, S | 1 |
| McGrath, T | 1 |
| Mitchell, D | 1 |
| Lo, D | 1 |
| Engedal, K | 4 |
| Davis, B | 2 |
| Richarz, U | 1 |
| Schäuble, B | 1 |
| Léger, GC | 1 |
| Salomone, S | 1 |
| Caraci, F | 1 |
| Leggio, GM | 1 |
| Fedotova, J | 1 |
| Drago, F | 1 |
| Kiriike, N | 2 |
| Ashraf Ali, M | 1 |
| Arumugam, N | 1 |
| Almansour, AI | 1 |
| Elumalai, K | 1 |
| Stefanacci, RG | 1 |
| Amanzio, M | 1 |
| Benedetti, F | 1 |
| Vase, L | 1 |
| Savino, M | 1 |
| Garrubba, M | 1 |
| Chen, G | 1 |
| Franczak, MB | 1 |
| Bidzan, L | 1 |
| Bidzan, M | 1 |
| Hartz, S | 1 |
| Tao, S | 1 |
| Dong, GS | 1 |
| Jiang, QH | 1 |
| Yang, HQ | 1 |
| Neumeister, KL | 1 |
| Riepe, MW | 4 |
| Fazekas, CO | 1 |
| Schwartz, LM | 1 |
| Woloshin, S | 1 |
| Wolff, ML | 1 |
| Yildiz, GB | 1 |
| Bozoglu, E | 2 |
| Yay, A | 2 |
| Aydemir, E | 1 |
| Naughton, DP | 1 |
| Shah, I | 1 |
| Petroczi, A | 1 |
| McLaren, DG | 1 |
| Sreenivasan, A | 1 |
| Diamond, EL | 1 |
| Mitchell, MB | 1 |
| Van Dijk, KR | 1 |
| Deluca, AN | 1 |
| O'Brien, JL | 1 |
| Rentz, DM | 1 |
| Sperling, RA | 2 |
| Martinelli Boneschi, F | 1 |
| Biella, G | 1 |
| Giacalone, G | 1 |
| Lupoli, S | 1 |
| Clerici, F | 1 |
| Galimberti, D | 1 |
| Squitti, R | 1 |
| Mariani, S | 1 |
| Mariani, C | 1 |
| Scarpini, E | 1 |
| Magnani, G | 1 |
| Tamimi, I | 1 |
| Ojea, T | 1 |
| Sanchez-Siles, JM | 1 |
| Rojas, F | 1 |
| Martin, I | 1 |
| Gormaz, I | 1 |
| Perez, A | 1 |
| Dawid-Milner, MS | 1 |
| Mendez, L | 1 |
| Tamimi, F | 1 |
| Pouryamout, L | 1 |
| Dams, J | 1 |
| Wasem, J | 1 |
| Dodel, R | 1 |
| Neumann, A | 1 |
| Miao, YC | 1 |
| Tian, JZ | 1 |
| Mao, M | 1 |
| Bottini, G | 1 |
| Berlingeri, M | 1 |
| Basilico, S | 1 |
| Passoni, S | 1 |
| Danelli, L | 1 |
| Colombo, N | 1 |
| Sberna, M | 1 |
| Sterzi, R | 1 |
| Paulesu, E | 1 |
| Bond, M | 1 |
| Rogers, G | 1 |
| Peters, J | 1 |
| Miners, A | 1 |
| Moxham, T | 1 |
| Davis, S | 1 |
| Thokala, P | 1 |
| Wailoo, A | 1 |
| Jeffreys, M | 1 |
| Hwang, SH | 1 |
| Shin, EJ | 1 |
| Shin, TJ | 1 |
| Lee, BH | 1 |
| Kang, J | 1 |
| Kwon, SH | 1 |
| Jang, CG | 1 |
| Kim, HC | 1 |
| Nah, SY | 1 |
| Geldmacher, DS | 5 |
| Soysal, P | 1 |
| Ateskan, U | 1 |
| Li, DQ | 1 |
| Zhou, YP | 1 |
| Tariot, P | 1 |
| Xue, G | 1 |
| Shi, C | 1 |
| Xie, X | 1 |
| Odawara, T | 1 |
| Pautola, L | 1 |
| Reinikainen, M | 1 |
| Toba, K | 1 |
| Yamada, Y | 2 |
| Machida, A | 1 |
| Kozaki, K | 1 |
| Bland, P | 1 |
| Lin, SM | 1 |
| Zhou, RQ | 1 |
| Tang, WJ | 1 |
| Huang, PX | 1 |
| Dong, Y | 1 |
| Yu, ZH | 1 |
| Chen, JL | 1 |
| Wei, L | 1 |
| Xing, SL | 1 |
| Cao, HJ | 1 |
| Zhao, HB | 1 |
| Andersen, F | 1 |
| Viitanen, M | 1 |
| Halvorsen, DS | 1 |
| Straume, B | 1 |
| Wilsgaard, T | 1 |
| Engstad, TA | 1 |
| Luger, P | 1 |
| Weber, M | 1 |
| Dittrich, B | 1 |
| Zaidel, L | 1 |
| Allen, G | 1 |
| Cullum, CM | 2 |
| Briggs, RW | 1 |
| Hynan, LS | 2 |
| Weiner, MF | 4 |
| McColl, R | 1 |
| Gopinath, KS | 1 |
| McDonald, E | 1 |
| Rubin, CD | 1 |
| Mintzer, J | 3 |
| Klinkenberg, I | 1 |
| Sambeth, A | 1 |
| Blokland, A | 1 |
| Yan, H | 1 |
| Chen, M | 1 |
| Yang, L | 1 |
| Ioannidis, P | 1 |
| Maiovis, P | 1 |
| Balamoutsos, G | 1 |
| Karacostas, D | 1 |
| Yagi, Y | 1 |
| Watanabe, Y | 1 |
| Yokote, H | 1 |
| Amino, T | 1 |
| Kamata, T | 1 |
| Rountree, SD | 1 |
| Hayashi, H | 1 |
| Kawakatsu, S | 1 |
| Suzuki, A | 1 |
| Shibuya, Y | 1 |
| Kobayashi, R | 1 |
| Sato, C | 1 |
| Otani, K | 1 |
| Nagakura, A | 1 |
| Shitaka, Y | 1 |
| Yarimizu, J | 1 |
| Matsuoka, N | 1 |
| Warren, JE | 1 |
| Patel, MC | 1 |
| Seki, T | 2 |
| Kamiya, T | 1 |
| Furukawa, K | 2 |
| Azumi, M | 1 |
| Ishizuka, S | 1 |
| Takayama, S | 1 |
| Nagase, S | 1 |
| Yamakuni, T | 1 |
| Yaegashi, N | 1 |
| Cheewakriengkrai, L | 1 |
| Christensen, DD | 1 |
| Wang, YR | 1 |
| Lu, CY | 1 |
| Liu, HC | 1 |
| Lin, SK | 1 |
| Sung, SM | 1 |
| Wolfson, C | 1 |
| Oremus, M | 1 |
| Shukla, V | 1 |
| Momoli, F | 1 |
| Demers, L | 1 |
| Perrault, A | 1 |
| Moride, Y | 1 |
| Lott, IT | 1 |
| Osann, K | 1 |
| Doran, E | 1 |
| Nelson, L | 1 |
| Byrne, EJ | 1 |
| Maurer, K | 1 |
| Nobili, F | 5 |
| Vitali, P | 4 |
| Canfora, M | 2 |
| Girtler, N | 3 |
| De Leo, C | 3 |
| Mariani, G | 2 |
| Pupi, A | 2 |
| Rodriguez, G | 5 |
| Rigaud, AS | 2 |
| Traykov, L | 2 |
| Latour, F | 1 |
| Couderc, R | 1 |
| Moulin, F | 1 |
| Forette, F | 3 |
| Jann, MW | 1 |
| Shirley, KL | 1 |
| Small, GW | 2 |
| Koulibaly, M | 1 |
| Migneco, O | 1 |
| Ebmeier, K | 1 |
| Robert, PH | 2 |
| Darcourt, J | 1 |
| Ott, BR | 4 |
| Ito, T | 1 |
| Yamadera, H | 1 |
| De Carli, F | 1 |
| Saine, K | 2 |
| Martin-Cook, K | 2 |
| Hynan, L | 1 |
| Svetlik, DA | 2 |
| Kim, JM | 1 |
| Yoon, JS | 1 |
| Sauer, J | 1 |
| Castro, A | 1 |
| Clegg, A | 4 |
| Bryant, J | 2 |
| Nicholson, T | 2 |
| McIntyre, L | 2 |
| De Broe, S | 2 |
| Gerard, K | 2 |
| Waugh, N | 2 |
| Graham, JE | 2 |
| Fay, S | 3 |
| Grossi, E | 1 |
| Buscema, M | 1 |
| Intraligi, M | 1 |
| Savarè, R | 1 |
| Rinaldi, P | 1 |
| Cherubini, A | 1 |
| Senin, U | 1 |
| Klinger, T | 2 |
| Berger, FM | 3 |
| Falk, WE | 1 |
| Daly, EJ | 1 |
| Tsai, GE | 1 |
| Gunther, J | 1 |
| Brown, P | 1 |
| Emir, B | 4 |
| Subbiah, P | 7 |
| McRae, TD | 1 |
| Kaasinen, V | 1 |
| Någren, K | 1 |
| Järvenpää, T | 1 |
| Roivainen, A | 1 |
| Oikonen, V | 1 |
| Kurki, T | 1 |
| Rinne, JO | 1 |
| Verhey, F | 3 |
| Wetterholm, AL | 4 |
| Mastey, V | 6 |
| Miceli, R | 1 |
| Chin, W | 2 |
| Pratt, RD | 6 |
| Surick, IW | 1 |
| Ieni, JR | 6 |
| Mori, S | 2 |
| Nabeshima, T | 3 |
| Noda, Y | 2 |
| Kamei, H | 1 |
| Hopper, P | 1 |
| Trotter, C | 1 |
| Allain, H | 3 |
| Bentue-Ferrer, D | 3 |
| Belliard, S | 1 |
| Reymann, JM | 2 |
| Djemaï, M | 1 |
| Merienne, M | 1 |
| Parnetti, L | 2 |
| Amici, S | 2 |
| Lanari, A | 2 |
| Romani, C | 1 |
| Antognelli, C | 2 |
| Davidsson, P | 2 |
| Pottel, H | 1 |
| Blennow, K | 4 |
| Gallai, V | 2 |
| Brown, D | 1 |
| Chisholm, JA | 1 |
| Owens, J | 1 |
| Pimlott, S | 2 |
| Patterson, J | 2 |
| Wyper, D | 2 |
| Bowler, JV | 1 |
| Kohler, J | 2 |
| Jendroska, K | 2 |
| Pilartz, H | 1 |
| Adler, G | 2 |
| Calabrese, P | 2 |
| Gertz, HJ | 2 |
| Haupt, M | 1 |
| Mielke, R | 2 |
| Paulus, HJ | 1 |
| Zedlick, D | 1 |
| Shimizu, T | 1 |
| Tanaka, Y | 4 |
| Takasaki, M | 5 |
| Hager, K | 4 |
| Göbel, C | 1 |
| Hegerl, U | 1 |
| Mergl, R | 1 |
| Henkel, V | 1 |
| Gallinat, J | 1 |
| Kotter, G | 1 |
| Müller-Siecheneder, F | 1 |
| Pogarell, O | 1 |
| Juckel, G | 1 |
| Schröter, A | 1 |
| Bahra, R | 3 |
| Laux, G | 1 |
| Möller, HJ | 3 |
| Katada, E | 1 |
| Sawaki, A | 1 |
| Dohi, Y | 1 |
| Ueda, R | 1 |
| Ojika, K | 2 |
| Ohkoshi, N | 1 |
| Satoh, D | 1 |
| Nishi, M | 1 |
| Shoji, S | 1 |
| Gold, PE | 1 |
| Cahill, L | 1 |
| Wenk, GL | 1 |
| Oda, T | 1 |
| Tominaga, I | 1 |
| Inada, T | 1 |
| Ames, D | 2 |
| Whalen, E | 3 |
| Masuda, Y | 1 |
| Kawamura, A | 1 |
| Payne, K | 1 |
| Davies, LM | 1 |
| Noyce, PR | 1 |
| Weiss, MC | 1 |
| Sánchez Morillo, J | 1 |
| Demartini Ferrari, A | 1 |
| Roca de Togores López, A | 1 |
| Relkin, NR | 1 |
| Reichman, WE | 1 |
| Orazem, J | 1 |
| Stahl, SM | 3 |
| Markowitz, JS | 1 |
| Gutterman, EM | 3 |
| Papadopoulos, G | 1 |
| Tanaka, M | 2 |
| Yokode, M | 1 |
| Matsubayashi, K | 1 |
| Borroni, B | 5 |
| Pettenati, C | 2 |
| Bordonali, T | 1 |
| Akkawi, N | 1 |
| Di Luca, M | 5 |
| Prasher, VP | 3 |
| Adams, C | 1 |
| Holder, R | 1 |
| Coulter, F | 1 |
| Gillespie, R | 1 |
| Livingston, H | 1 |
| Quinn, E | 1 |
| Rimmer, E | 1 |
| Smith, M | 2 |
| Walker, A | 1 |
| Sakurai, H | 3 |
| Bianchetti, A | 2 |
| Cipriani, G | 1 |
| Provenzano, G | 1 |
| Rozzini, R | 1 |
| Wilcock, G | 3 |
| Howe, I | 2 |
| Coles, H | 1 |
| Lilienfeld, S | 1 |
| Truyen, L | 2 |
| Kershaw, P | 1 |
| Harvey, R | 1 |
| Warner, J | 4 |
| Butler, R | 4 |
| Prabhakaran, P | 1 |
| Smith Doody, R | 1 |
| Fagnani, F | 1 |
| Lafuma, A | 1 |
| Pechevis, M | 1 |
| Seux, ML | 1 |
| Fuchsberger, T | 1 |
| Baezner, H | 1 |
| Daffertshofer, M | 1 |
| Krishnan, KR | 3 |
| Charles, HC | 1 |
| Weisler, R | 1 |
| Perdomo, C | 3 |
| Rogers, S | 1 |
| Kemp, PM | 1 |
| Hoffmann, S | 1 |
| Wilkinson, S | 1 |
| Zivanovic, M | 1 |
| Thom, J | 1 |
| Bolt, L | 1 |
| Fleming, J | 1 |
| Wilkinson, DG | 5 |
| Santens, P | 1 |
| Ventura, M | 2 |
| Balkan, S | 1 |
| Yaraş, N | 1 |
| Mihçi, E | 1 |
| Dora, B | 1 |
| Ağar, A | 1 |
| Yargiçoğlu, P | 1 |
| Alhainen, K | 1 |
| Goldlist, B | 1 |
| Gordon, M | 1 |
| Naglie, G | 1 |
| Yano, H | 1 |
| Fukuhara, Y | 1 |
| Wada, K | 1 |
| Kowa, H | 1 |
| Nakashima, K | 2 |
| Brassen, S | 1 |
| Kaufer, DI | 2 |
| Román, GC | 1 |
| Rogers, SJ | 1 |
| Adelman, EE | 1 |
| Karlawish, JH | 2 |
| Emre, M | 2 |
| Potkin, SG | 1 |
| Auriacombe, S | 2 |
| Pere, JJ | 2 |
| Calvini, P | 1 |
| Piccardo, A | 1 |
| Urakami, K | 2 |
| Boada-Rovira, M | 1 |
| Cras, P | 1 |
| Baloyannis, S | 1 |
| Finkel, SI | 1 |
| Mintzer, JE | 2 |
| Dysken, M | 1 |
| Burt, T | 2 |
| Murthy, A | 1 |
| Graham, SM | 2 |
| McDonald, S | 1 |
| Gergel, I | 1 |
| Boles Ponto, LL | 1 |
| Schultz, SK | 2 |
| Leonard Watkins, G | 1 |
| Hichwa, RD | 1 |
| Liston, DR | 1 |
| Nielsen, JA | 1 |
| Villalobos, A | 1 |
| Chapin, D | 1 |
| Jones, SB | 1 |
| Hubbard, ST | 1 |
| Shalaby, IA | 1 |
| Ramirez, A | 1 |
| Nason, D | 1 |
| White, WF | 1 |
| Bordier, P | 3 |
| Garrigue, S | 3 |
| Barold, SS | 1 |
| Bressolles, N | 1 |
| Lanusse, S | 3 |
| Clémenty, J | 1 |
| Ibach, B | 3 |
| Haen, E | 1 |
| Alisky, JM | 1 |
| Corey-Bloom, J | 3 |
| Nagura, H | 1 |
| Kitamura, S | 1 |
| Maltz, JS | 1 |
| Eberling, JL | 1 |
| Jagust, WJ | 1 |
| Budinger, TF | 1 |
| Shimode, H | 1 |
| Nakajima, T | 1 |
| Froelich, L | 1 |
| Heun, R | 1 |
| Heuser, I | 2 |
| Kornhuber, J | 2 |
| Kurz, A | 2 |
| Mueller-Thomsen, T | 1 |
| Ries, F | 1 |
| Waechtler, C | 1 |
| Metz, M | 1 |
| Goebel, C | 1 |
| López Ibor, MI | 1 |
| Maestú, F | 1 |
| Campo, P | 1 |
| López Ibor, JJ | 1 |
| Ortiz, T | 1 |
| Royall, DR | 1 |
| Yasui-Furukori, N | 1 |
| Furukori, H | 1 |
| Kaneda, A | 1 |
| Kaneko, S | 1 |
| Tateishi, T | 1 |
| Gambi, F | 4 |
| Reale, M | 4 |
| Iarlori, C | 4 |
| Salone, A | 1 |
| Toma, L | 1 |
| Paladini, C | 1 |
| De Luca, G | 1 |
| Feliciani, C | 3 |
| Salvatore, M | 3 |
| Salerno, RM | 1 |
| Theoharides, TC | 1 |
| Conti, P | 1 |
| Exton, M | 1 |
| Gambi, D | 4 |
| Bohnen, N | 1 |
| Kaufer, D | 1 |
| Hendrickson, R | 2 |
| Ivanco, L | 1 |
| Moore, R | 1 |
| DeKosky, S | 1 |
| Pedone, C | 1 |
| Lapane, KL | 3 |
| Mor, V | 1 |
| Bernabei, R | 2 |
| Francis, PT | 1 |
| Payne-Parrish, J | 2 |
| Liang, YQ | 1 |
| Saykin, AJ | 1 |
| Wishart, HA | 1 |
| Rabin, LA | 1 |
| Flashman, LA | 1 |
| McHugh, TL | 1 |
| Mamourian, AC | 1 |
| Santulli, RB | 1 |
| Kudo, T | 2 |
| Sternon, J | 2 |
| Bier, JC | 1 |
| Qizilbash, N | 1 |
| Mossello, E | 1 |
| Tonon, E | 1 |
| Caleri, V | 1 |
| Tilli, S | 1 |
| Cantini, C | 1 |
| Cavallini, MC | 1 |
| Bencini, F | 1 |
| Mecacci, R | 1 |
| Marini, M | 2 |
| Bardelli, F | 1 |
| Sarcone, E | 1 |
| Razzi, E | 1 |
| Biagini, CA | 1 |
| Masotti, G | 1 |
| Courtney, C | 1 |
| Farrell, D | 1 |
| Lynch, L | 1 |
| Sellwood, E | 1 |
| Edwards, S | 1 |
| Hardyman, W | 1 |
| Crome, P | 1 |
| Lendon, C | 1 |
| Shaw, H | 1 |
| Evans, JG | 2 |
| Birks, J | 6 |
| Van Baelen, B | 1 |
| Whitehead, A | 1 |
| Wilcock, GK | 1 |
| Knopman, D | 1 |
| Dean, C | 1 |
| Vethanayagam, S | 1 |
| Olivieri, S | 1 |
| Langley, A | 1 |
| Pandita-Gunawardena, ND | 1 |
| Hogg, F | 1 |
| Clare, C | 1 |
| Damms, J | 1 |
| Blasko, I | 1 |
| Bodner, T | 1 |
| Knaus, G | 1 |
| Walch, T | 1 |
| Monsch, A | 1 |
| Hinterhuber, H | 1 |
| Marksteiner, J | 1 |
| Zhou, FM | 1 |
| Dani, JA | 1 |
| Shah, SN | 2 |
| Shao, D | 1 |
| Zou, C | 1 |
| Luo, C | 1 |
| Hux, M | 2 |
| Shah, S | 1 |
| Thompson, S | 1 |
| Lanctôt, KL | 1 |
| Burton, A | 1 |
| Robillard, A | 2 |
| Lussier, I | 2 |
| Namiki, C | 1 |
| Thuy, DH | 1 |
| Yoshida, H | 1 |
| Kawasaki, K | 1 |
| Hashikawa, K | 1 |
| Fukuyama, H | 1 |
| Wallesch, CW | 1 |
| Ebert, AD | 1 |
| Kaduszkiewicz, H | 3 |
| Beck-Bornholdt, HP | 2 |
| Zimmermann, T | 3 |
| Akwa, Y | 1 |
| Jackson, S | 1 |
| Ham, RJ | 1 |
| Jane Newby, V | 1 |
| Anne Kenny, R | 1 |
| McKeith, IG | 1 |
| Edwards, K | 1 |
| Therriault O'connor, J | 1 |
| Gorman, C | 1 |
| Narahashi, T | 1 |
| Marszalec, W | 1 |
| Yeh, JZ | 1 |
| Aguglia, E | 1 |
| Onor, ML | 1 |
| Saina, M | 1 |
| Maso, E | 1 |
| Beusterien, KM | 1 |
| Gause, D | 1 |
| Kimel, M | 1 |
| Arcona, S | 3 |
| Mirski, D | 1 |
| Seltzer, B | 3 |
| Zolnouni, P | 1 |
| Nunez, M | 1 |
| Ieni, J | 2 |
| Mizuno, S | 1 |
| Kameda, A | 1 |
| Inagaki, T | 2 |
| Chapman, SB | 1 |
| Rackley, A | 1 |
| Zientz, J | 1 |
| Gill, SS | 1 |
| Bronskill, SE | 1 |
| Mamdani, M | 1 |
| Sykora, K | 1 |
| Shulman, KI | 1 |
| Anderson, GM | 1 |
| Hillmer, MP | 1 |
| Wodchis, WP | 1 |
| Rochon, PA | 1 |
| Sakakibara, R | 1 |
| Uchiyama, T | 1 |
| Yoshiyama, M | 1 |
| Yamanishi, T | 1 |
| Hattori, T | 1 |
| Kazui, H | 3 |
| Mori, E | 3 |
| Jagust, W | 1 |
| Stern, RA | 1 |
| Davis, JD | 1 |
| Rogers, BL | 1 |
| Smith, KE | 1 |
| Harrington, CJ | 1 |
| Jackson, IM | 1 |
| Prange, AJ | 1 |
| Muñiz, R | 1 |
| Reisberg, B | 1 |
| Peña-Casanova, J | 1 |
| del Ser, T | 1 |
| Cruz-Jentoft, AJ | 1 |
| Serrano, P | 1 |
| Navarro, E | 1 |
| García de la Rocha, ML | 1 |
| Galiano, M | 1 |
| Fernández-Bullido, Y | 1 |
| Serra, JA | 1 |
| González-Salvador, MT | 1 |
| Singer, M | 1 |
| Romero, B | 1 |
| Koenig, E | 1 |
| Förstl, H | 2 |
| Brunner, H | 1 |
| Arya, P | 2 |
| Van Dam, D | 1 |
| Abramowski, D | 1 |
| Staufenbiel, M | 1 |
| De Deyn, PP | 1 |
| Turon-Estrada, A | 2 |
| Garre-Olmo, J | 2 |
| Pericot-Nierga, I | 1 |
| Lozano-Gallego, M | 2 |
| Vilalta-Franch, M | 1 |
| Hernández-Ferràndiz, M | 2 |
| Morante-Muñoz, V | 1 |
| Isern-Vila, A | 1 |
| Gelada-Batlle, E | 2 |
| Majó-Llopart, J | 1 |
| Harry, RD | 1 |
| Zakzanis, KK | 1 |
| Bohnen, NI | 1 |
| Ivanco, LS | 1 |
| Lopresti, BJ | 1 |
| Koeppe, RA | 3 |
| Meltzer, CC | 1 |
| Constantine, G | 1 |
| Davis, JG | 1 |
| Mathis, CA | 1 |
| Dekosky, ST | 1 |
| Moore, RY | 1 |
| Kmietowicz, Z | 1 |
| Passmore, AP | 1 |
| Bayer, AJ | 1 |
| Steinhagen-Thiessen, E | 1 |
| Agosti, C | 1 |
| Martini, G | 1 |
| Volpi, R | 1 |
| Brambilla, C | 1 |
| Caimi, L | 2 |
| Obermayr, RP | 1 |
| Mayerhofer, L | 1 |
| Knechtelsdorfer, M | 1 |
| Mersich, N | 1 |
| Huber, ER | 1 |
| Geyer, G | 1 |
| Tragl, KH | 1 |
| Lucci, I | 2 |
| Csernansky, CA | 1 |
| Martin, MV | 1 |
| Bertchume, A | 1 |
| Vallera, D | 1 |
| Thomas, DA | 1 |
| Libon, DJ | 1 |
| Ledakis, GE | 1 |
| Yasuda, M | 1 |
| Mauskopf, JA | 1 |
| Paramore, C | 1 |
| Lee, WC | 1 |
| Snyder, EH | 1 |
| van Hout, HP | 1 |
| Bosmans, JE | 1 |
| Stalman, WA | 1 |
| Bennett, D | 1 |
| Ferris, S | 1 |
| Jin, S | 1 |
| Kaye, J | 1 |
| Levey, A | 1 |
| Pfeiffer, E | 1 |
| Blacker, D | 2 |
| Taguchi, S | 1 |
| White, RE | 1 |
| Schaefer, LA | 1 |
| Cai, DY | 1 |
| Chen, JX | 1 |
| Sun, LP | 1 |
| Zhang, JJ | 1 |
| Huang, QF | 1 |
| Ellis, JM | 1 |
| Kimura, M | 1 |
| Akasofu, S | 1 |
| Ogura, H | 6 |
| Sawada, K | 1 |
| Raschetti, R | 1 |
| Maggini, M | 1 |
| Sorrentino, GC | 1 |
| Martini, N | 1 |
| Caffari, B | 1 |
| Vanacore, N | 1 |
| Dengiz, A | 1 |
| Kaiser, T | 1 |
| Florack, C | 1 |
| Franz, H | 1 |
| Sawicki, PT | 1 |
| Schoenknecht, P | 1 |
| Kamleiter, M | 1 |
| Silver, G | 1 |
| Schroeder, J | 1 |
| Maeda, K | 1 |
| Borkowska, A | 1 |
| Ziolkowska-Kochan, M | 1 |
| Rybakowski, JK | 1 |
| Asai, Y | 1 |
| Koeda, T | 1 |
| Reynard, C | 1 |
| Robert, F | 2 |
| Gencel, L | 2 |
| Lafitte, A | 2 |
| Suh, DC | 1 |
| Valiyeva, E | 1 |
| Vo, L | 1 |
| Bergman, H | 5 |
| Rapatz, G | 3 |
| Nagel, J | 4 |
| Gasper, MC | 1 |
| Rosengarten, B | 1 |
| Paulsen, S | 1 |
| Molnar, S | 1 |
| Kaschel, R | 1 |
| Gallhofer, B | 1 |
| Kaps, M | 1 |
| Marra, C | 1 |
| Acciarri, A | 1 |
| Valenza, A | 1 |
| Tiziano, FD | 1 |
| Brahe, C | 1 |
| Lingala, V | 1 |
| Mithal, A | 1 |
| Enzenauer, RW | 1 |
| Bowers, PJ | 1 |
| Hill, J | 1 |
| Fillit, H | 4 |
| Barnes, DE | 1 |
| Cheng, HY | 1 |
| Gauthier, SG | 1 |
| O'Neill, MF | 1 |
| Olsen, CE | 1 |
| Poulsen, HD | 1 |
| Lublin, HK | 1 |
| Onder, G | 1 |
| Zanetti, O | 2 |
| Giacobini, E | 2 |
| Frisoni, GB | 1 |
| Bartorelli, L | 1 |
| Carbone, G | 1 |
| Lambertucci, P | 1 |
| Silveri, MC | 1 |
| Kirshner, HS | 1 |
| Kuhl, DE | 2 |
| Snyder, SE | 1 |
| Minoshima, S | 2 |
| Frey, KA | 2 |
| Kilbourn, MR | 2 |
| Kircher, TT | 1 |
| Erb, M | 1 |
| Grodd, W | 1 |
| Leube, DT | 1 |
| Miller, JP | 1 |
| Takeda, A | 2 |
| Loveman, E | 2 |
| Kirby, J | 2 |
| Picot, J | 2 |
| Payne, E | 2 |
| Green, C | 3 |
| Vollmar, HC | 1 |
| Butzlaff, M | 1 |
| Sadik, K | 1 |
| da Silva, CH | 1 |
| Campo, VL | 1 |
| Taft, CA | 1 |
| Isabella, L | 1 |
| Crowell, TA | 1 |
| Paramadevan, J | 1 |
| Abdullah, L | 1 |
| Mullan, M | 1 |
| Kitabayashi, Y | 1 |
| Ueda, H | 1 |
| Tsuchida, H | 1 |
| Narumoto, J | 1 |
| Fukui, K | 1 |
| Mazeh, D | 1 |
| Zemishlani, H | 1 |
| Barak, Y | 1 |
| Mirecki, I | 1 |
| Paleacu, D | 1 |
| Moraes, Wdos S | 1 |
| Poyares, DR | 1 |
| Guilleminault, C | 2 |
| Ramos, LR | 1 |
| Bertolucci, PH | 1 |
| Tufik, S | 2 |
| Joray, S | 1 |
| Ghika, J | 1 |
| von Gunten, A | 1 |
| Büla, C | 1 |
| Gold, G | 1 |
| Assal, F | 1 |
| Estermann, S | 1 |
| Daepp, GC | 1 |
| Cattapan-Ludewig, K | 1 |
| Berkhoff, M | 1 |
| Frueh, BE | 1 |
| Goldblum, D | 1 |
| Kuo, SC | 1 |
| Ownby, RL | 1 |
| Hogan, DB | 1 |
| Kilander, L | 2 |
| Eriksson, S | 2 |
| Båtsman, S | 2 |
| Jansson-Blixt, C | 1 |
| Johannsen, P | 2 |
| Qvitzau, S | 1 |
| Babiloni, C | 1 |
| Cassetta, E | 1 |
| Dal Forno, G | 1 |
| Del Percio, C | 1 |
| Ferri, R | 1 |
| Lanuzza, B | 1 |
| Miniussi, C | 1 |
| Moretti, DV | 1 |
| Pascual-Marqui, RD | 1 |
| Luca Romani, G | 1 |
| Salinari, S | 1 |
| Wuntakal, B | 1 |
| Aupperle, PM | 2 |
| Stiles, MM | 1 |
| Martin, S | 1 |
| Persons, RK | 1 |
| Asp, E | 1 |
| Cloutier, F | 1 |
| Cook, C | 1 |
| Robertson, ML | 1 |
| Fisk, J | 1 |
| Dei, DW | 1 |
| Ohkura, T | 1 |
| McCaffrey, P | 1 |
| Margaine, J | 1 |
| Maruyama, M | 2 |
| Tomita, N | 1 |
| Iwasaki, K | 1 |
| Ootsuki, M | 1 |
| Matsui, T | 1 |
| Nemoto, M | 1 |
| Okamura, N | 2 |
| Higuchi, M | 1 |
| Tsutsui, M | 1 |
| Kaneta, T | 1 |
| Drzezga, A | 1 |
| Bartenstein, P | 1 |
| Schwaiger, M | 1 |
| Hu, HT | 1 |
| Yao, JL | 1 |
| Yu, HZ | 1 |
| Wang, YH | 1 |
| Tang, HC | 1 |
| Ji, CJ | 1 |
| Xu, T | 1 |
| Nourhashémi, F | 2 |
| Olmo, JG | 1 |
| Franch, JV | 1 |
| Estrada, AT | 1 |
| Cors, OS | 1 |
| Nierga, IP | 1 |
| Vantelon, C | 1 |
| Gilbert, S | 1 |
| Kerneis, S | 1 |
| Wolmark, Y | 1 |
| Legrain, S | 1 |
| Edwards, KR | 1 |
| Kuloor, CB | 1 |
| Puranik, A | 1 |
| Schneider, E | 1 |
| Varsaldi, F | 1 |
| Miglio, G | 1 |
| Suleyman, T | 1 |
| Tevfik, P | 1 |
| Abdulkadir, G | 1 |
| Ozlem, S | 1 |
| Dybicz, SB | 1 |
| Keohane, DJ | 1 |
| Erwin, WG | 1 |
| Meurling, L | 1 |
| Pettersson, T | 1 |
| Hugosson, K | 1 |
| Hellström-Lindahl, E | 1 |
| Cooke, JR | 1 |
| Loredo, JS | 1 |
| Marler, M | 1 |
| Fiorentino, L | 1 |
| Harrison, T | 1 |
| Ancoli-Israel, S | 1 |
| Opie, LH | 1 |
| Martin, FL | 1 |
| Moore, S | 1 |
| Fullwood, NJ | 1 |
| Kida, Y | 1 |
| de Leon, MJ | 1 |
| Zetterberg, H | 1 |
| Takatori, Y | 1 |
| Ushuijima, Y | 1 |
| Okuyama, C | 1 |
| Kubota, T | 1 |
| Nakai, T | 1 |
| Nishimura, T | 1 |
| Marder, K | 1 |
| Mazza, M | 1 |
| Capuano, A | 1 |
| Bria, P | 1 |
| Mazza, S | 1 |
| Nardone, R | 1 |
| Marth, R | 1 |
| Ausserer, H | 1 |
| Bratti, A | 1 |
| Tezzon, F | 1 |
| Verhey, FR | 1 |
| Hieda, S | 1 |
| Bocti, C | 1 |
| Black, S | 1 |
| Bedard, MA | 1 |
| Tran, T | 1 |
| Cancelli, I | 1 |
| Cadore, IP | 1 |
| Merlino, G | 1 |
| Valentinis, L | 1 |
| Moratti, U | 1 |
| Bergonzi, P | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Blesa, R | 1 |
| Meyer, J | 1 |
| Petersen, R | 1 |
| Griffith, P | 1 |
| Lichtenberg, P | 1 |
| Marinho, V | 1 |
| Conn, D | 1 |
| Ravikumar, K | 1 |
| Sridhar, B | 1 |
| Sathe, DG | 1 |
| Naidu, AV | 1 |
| Sawant, KD | 1 |
| Duysen, EG | 1 |
| Li, B | 1 |
| Darvesh, S | 1 |
| Lockridge, O | 1 |
| Gu, W | 1 |
| Yoo, JH | 1 |
| Valdovinos, MG | 1 |
| Williams, DC | 1 |
| Capellà, D | 1 |
| Vidal, X | 1 |
| Fleisher, AS | 1 |
| Sowell, BB | 1 |
| Taylor, C | 1 |
| Gamst, AC | 1 |
| Kondro, W | 1 |
| Nasman, B | 1 |
| Ekdahl, A | 1 |
| Grut, M | 2 |
| Rydén, M | 1 |
| Wallin, A | 1 |
| Jonsson, M | 1 |
| Olofsson, H | 1 |
| Eriksdotter Jonhagen, M | 1 |
| Beier, MT | 1 |
| Campanozzi, MD | 1 |
| Casali, E | 1 |
| Neviani, F | 1 |
| Martini, E | 1 |
| Neri, M | 1 |
| García-Ayllón, MS | 1 |
| Silveyra, MX | 1 |
| Brimijoin, S | 1 |
| Sáez-Valero, J | 1 |
| Akiyama, H | 1 |
| Kawamura, E | 1 |
| Torii, K | 1 |
| Inoue, Y | 1 |
| Zhou, ZL | 1 |
| Liang, LZ | 1 |
| Yan, YX | 1 |
| Zarowitz, BJ | 1 |
| Stefanacci, R | 1 |
| Hollenack, K | 1 |
| O'Shea, T | 1 |
| Gruber, J | 1 |
| Tangalos, EG | 1 |
| Ginestet, L | 1 |
| Ferrario, JE | 1 |
| Raisman-Vozari, R | 1 |
| Hirsch, EC | 1 |
| Debeir, T | 1 |
| Dyer, C | 1 |
| Ewers, M | 1 |
| Reisig, V | 1 |
| Schweikert, B | 1 |
| Happich, M | 1 |
| Small, BJ | 1 |
| Gagnon, E | 1 |
| Robinson, B | 1 |
| Derouesné, C | 1 |
| Lacomblez, L | 2 |
| Faison, WE | 1 |
| Aerssens, J | 1 |
| Alvidrez, J | 1 |
| Anand, R | 1 |
| Farrer, LA | 1 |
| Jarvik, L | 1 |
| Manly, J | 1 |
| Murphy, GM | 1 |
| Regier, D | 1 |
| Kurlan, R | 1 |
| Thal, L | 1 |
| Saumier, D | 1 |
| Murtha, S | 1 |
| Phillips, N | 1 |
| Whitehead, V | 1 |
| Chertkow, H | 1 |
| Weycker, D | 1 |
| Taneja, C | 1 |
| Edelsberg, J | 1 |
| Erder, MH | 1 |
| Setyawan, J | 1 |
| Oster, G | 1 |
| Egert, S | 1 |
| Wagenpfeil, S | 1 |
| Fuh, JL | 1 |
| Wang, SJ | 1 |
| Anderson, KE | 1 |
| Brickman, AM | 1 |
| Flynn, J | 1 |
| Scarmeas, N | 1 |
| Van Heertum, R | 1 |
| Sackeim, H | 1 |
| Marder, KS | 1 |
| Bell, K | 1 |
| Moeller, JR | 1 |
| Stern, Y | 1 |
| Freund-Levi, Y | 1 |
| Basun, H | 1 |
| Cederholm, T | 1 |
| Faxén-Irving, G | 1 |
| Garlind, A | 1 |
| Vedin, I | 1 |
| Palmblad, J | 1 |
| Wahlund, LO | 1 |
| Eriksdotter-Jönhagen, M | 1 |
| Gillette-Guyonnet, S | 1 |
| Reynish, E | 1 |
| Correia, S | 1 |
| Horn, R | 1 |
| Connelly, PJ | 1 |
| Prentice, NP | 1 |
| Cousland, G | 1 |
| Bonham, J | 1 |
| Belmin, J | 1 |
| Péquignot, R | 1 |
| Konrat, C | 1 |
| Pariel-Madjlessi, S | 1 |
| Sachdev, P | 1 |
| Berman, K | 1 |
| Kemp, NM | 1 |
| Cullen, B | 1 |
| Winstein, CJ | 1 |
| Bentzen, KR | 1 |
| Boyd, L | 1 |
| Papageorgiou, SG | 1 |
| Kontaxis, T | 1 |
| Antelli, A | 1 |
| Kalfakis, N | 1 |
| Ha-Kawa, S | 1 |
| Yoshimura, M | 1 |
| Nobuhara, K | 1 |
| Kinoshita, T | 1 |
| Sawada, S | 1 |
| Jambor, KM | 1 |
| Semla, TP | 1 |
| Samus, QM | 1 |
| Onyike, CU | 1 |
| Baker, AS | 1 |
| McNabney, M | 1 |
| Mayer, LS | 1 |
| Brandt, J | 1 |
| Lyketsos, CG | 1 |
| Caffarra, P | 1 |
| Vezzadini, G | 1 |
| Copelli, S | 1 |
| Dieci, F | 1 |
| Messa, G | 1 |
| Nonis, E | 1 |
| Tei, E | 1 |
| Yamamoto, H | 1 |
| Miyazaki, A | 1 |
| Nakadate, T | 1 |
| Kato, N | 1 |
| Albert, MS | 1 |
| Corrao, S | 1 |
| Scaglione, R | 1 |
| Calvo, L | 1 |
| Licata, G | 1 |
| Korczyn, AD | 2 |
| Anghelescu, I | 1 |
| Gorman, M | 1 |
| Carver, D | 1 |
| Neno, R | 1 |
| Howard, RJ | 1 |
| Ballard, CG | 1 |
| Burns, AS | 1 |
| DeCesare, J | 1 |
| Rodger, M | 1 |
| Benjamin, B | 1 |
| Lang, CJ | 1 |
| Terrière, E | 1 |
| Sharman, M | 1 |
| Donaghey, C | 1 |
| Herrmann, L | 1 |
| Lonie, J | 2 |
| Strachan, M | 1 |
| Dougall, N | 1 |
| Best, J | 1 |
| Ebmeier, KP | 1 |
| Papadopoulos, R | 1 |
| Bachariou, A | 1 |
| Ross, L | 1 |
| Sheikh, J | 1 |
| Musiał, A | 1 |
| Kenklies, M | 1 |
| McAfoose, J | 1 |
| Engel, J | 1 |
| Münch, G | 1 |
| Sakka, P | 1 |
| López Pousa, S | 1 |
| Eschweiler, GW | 1 |
| Buchkremer, G | 1 |
| Nozaki, I | 1 |
| Inao, G | 1 |
| Brucki, S | 1 |
| Nitrini, R | 1 |
| Lu, CJ | 1 |
| Chien, KL | 1 |
| Chen, ST | 1 |
| Chen, RC | 1 |
| Funaki, Y | 1 |
| Tashiro, M | 1 |
| Kato, M | 1 |
| Ishikawa, Y | 1 |
| Ishikawa, H | 1 |
| Iwata, R | 1 |
| Yanai, K | 1 |
| Arai, T | 1 |
| Rocca, P | 2 |
| Marino, F | 1 |
| Montemagni, C | 1 |
| Perrone, D | 1 |
| Bogetto, F | 2 |
| Moraes, W | 1 |
| Poyares, D | 1 |
| Sukys-Claudino, L | 1 |
| Hyvärinen, M | 1 |
| Josiassen, MK | 1 |
| Kørner, A | 1 |
| Lehto, H | 1 |
| Wetterberg, P | 1 |
| Lyle, S | 1 |
| Grizzell, M | 1 |
| Willmott, S | 1 |
| Benbow, S | 2 |
| Clark, M | 1 |
| Jolley, D | 2 |
| Ashby, D | 1 |
| Bartha, R | 1 |
| Rupsingh, R | 1 |
| Rylett, J | 1 |
| Wells, JL | 1 |
| Borrie, MJ | 1 |
| Landmark, K | 1 |
| Reikvam, A | 1 |
| Valerio, S | 1 |
| Desmedt, A | 1 |
| Philippin, JN | 1 |
| Trocmé-Thibierge, C | 1 |
| Morain, P | 1 |
| Downey, D | 1 |
| Umegaki, H | 1 |
| Itoh, A | 1 |
| Suzuki, Y | 1 |
| Gongadze, N | 1 |
| Antelava, N | 1 |
| Kezeli, T | 1 |
| Okudjava, M | 1 |
| Pachkoria, K | 1 |
| Tsunekawa, H | 1 |
| Mouri, A | 1 |
| Yoneda, F | 1 |
| Akai, T | 1 |
| Tateno, M | 1 |
| Morii, H | 1 |
| Fujii, K | 1 |
| Pang, YP | 1 |
| Kozikowski, AP | 1 |
| Ohnishi, A | 2 |
| Mihara, M | 2 |
| Kamakura, H | 1 |
| Tomono, Y | 2 |
| Hasegawa, J | 2 |
| Yamazaki, K | 2 |
| Morishita, N | 2 |
| Shimamura, Y | 1 |
| Palacios, JM | 1 |
| Nightingale, SL | 1 |
| Fricker, J | 1 |
| Bailey, C | 1 |
| Bryson, HM | 1 |
| Benfield, P | 1 |
| Nichols, ME | 1 |
| Kelly, CA | 1 |
| Cayton, H | 1 |
| Gray, S | 1 |
| Wagner, N | 1 |
| Kojima, J | 1 |
| Nakajima, K | 1 |
| Ochiai, M | 1 |
| Nakayama, K | 1 |
| Henry, RG | 1 |
| Wekstein, DR | 1 |
| Heath, ML | 1 |
| Roscoe, T | 1 |
| Robertson, M | 1 |
| Hastie, I | 1 |
| Shintani, EY | 1 |
| Uchida, KM | 1 |
| Ross, JS | 1 |
| Shua-Haim, JR | 1 |
| Rogers, SL | 6 |
| Mohs, R | 1 |
| Friedhoff, LT | 3 |
| Eisner, E | 1 |
| Barner, EL | 1 |
| Taverni, JP | 1 |
| Seliger, G | 1 |
| Lichtman, SW | 1 |
| Royston, MC | 1 |
| Honma, A | 1 |
| Melzer, D | 2 |
| Misson, J | 1 |
| Kendall, MJ | 1 |
| Collier, J | 1 |
| Elie, LM | 1 |
| Cole, MG | 1 |
| Tom, T | 1 |
| Larson, EB | 2 |
| Mohs, RC | 2 |
| Sparano, N | 1 |
| Post, SG | 2 |
| Whitehouse, PJ | 2 |
| Stewart, A | 1 |
| Phillips, R | 1 |
| Dempsey, G | 1 |
| Lake, JT | 1 |
| Peskind, ER | 1 |
| Lawton, C | 1 |
| Hodges, J | 1 |
| Magnuson, TM | 1 |
| Keller, BK | 1 |
| Burke, WJ | 3 |
| Tune, LE | 1 |
| Sunderland, T | 1 |
| Warren, S | 1 |
| Hier, DB | 1 |
| Pavel, D | 1 |
| Bouman, WP | 1 |
| Pinner, G | 1 |
| Wengel, SP | 2 |
| Roccaforte, WH | 2 |
| Bayer, BL | 1 |
| McNeilly, DP | 1 |
| Knop, D | 1 |
| Levy, R | 1 |
| Evans, M | 2 |
| Baxter, T | 1 |
| Black, D | 1 |
| Prempeh, H | 1 |
| Zamar, AC | 1 |
| Wise, ME | 1 |
| Watson, JP | 1 |
| Shostak, D | 1 |
| Bhattacharjya, A | 1 |
| Brod, M | 1 |
| Dor, A | 1 |
| Hay, J | 1 |
| Henke, C | 1 |
| Hill, S | 1 |
| Neumann, P | 1 |
| O'Brien, B | 1 |
| Pugner, K | 1 |
| Sawada, T | 1 |
| Stone, R | 1 |
| Derquesné, C | 1 |
| van Gool, WA | 1 |
| Shadlen, MF | 1 |
| Terpstra, T | 2 |
| Yamanishi, Y | 7 |
| Iimura, Y | 2 |
| Yamatsu, K | 1 |
| Babic, T | 2 |
| Zurak, N | 1 |
| Mushlin, AI | 1 |
| Neumann, PJ | 3 |
| Hermann, RC | 1 |
| Kuntz, KM | 1 |
| Araki, SS | 2 |
| Duff, SB | 1 |
| Leon, J | 1 |
| Berenbaum, PA | 1 |
| Goldman, PA | 1 |
| Williams, LW | 1 |
| Weinstein, MC | 2 |
| Steele, LS | 1 |
| Glazier, RH | 1 |
| O'Brien, BJ | 1 |
| Goeree, R | 1 |
| Iskedjian, M | 1 |
| Blackhouse, G | 1 |
| Gagnon, M | 1 |
| Tiseo, P | 1 |
| Kryger, G | 1 |
| Sussman, JL | 1 |
| Pryse-Phillips, W | 1 |
| Whitlock, JA | 1 |
| Lemière, J | 1 |
| Van Gool, D | 1 |
| Dom, R | 1 |
| McLendon, BM | 1 |
| Garcia, A | 1 |
| Lindgren, P | 1 |
| Jönsson, B | 1 |
| Hemingway-Eltomey, JM | 1 |
| Lerner, AJ | 1 |
| Warner, JP | 1 |
| Reeves, RR | 2 |
| Struve, FA | 2 |
| Patrick, G | 2 |
| Booker, JG | 1 |
| Nave, DW | 1 |
| Foster, RH | 1 |
| Plosker, GL | 1 |
| Mega, MS | 1 |
| Masterman, DM | 1 |
| O'Connor, SM | 1 |
| Barclay, TR | 1 |
| Burke, JR | 1 |
| Morgenlander, JC | 1 |
| Benazzi, F | 1 |
| Gokalsing, E | 1 |
| Bertogliati, C | 1 |
| Russell, E | 1 |
| Page, S | 1 |
| Greenberg, SM | 1 |
| Tennis, MK | 1 |
| Brown, LB | 1 |
| Gomez-Isla, T | 1 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 1 |
| Walsh, KL | 1 |
| Corwin, C | 1 |
| Daffner, KR | 1 |
| Friedman, P | 1 |
| Meadows, ME | 1 |
| Growdon, JH | 1 |
| Kaur, J | 1 |
| Zhang, MQ | 1 |
| Kawakami, Y | 1 |
| Ellis, A | 1 |
| Watson, D | 1 |
| Chowdhury, T | 1 |
| Lewis, B | 1 |
| Kosasa, T | 4 |
| Kuriya, Y | 2 |
| Matsui, K | 1 |
| Mumenthaler, MS | 1 |
| Dallocchio, C | 1 |
| Buffa, C | 1 |
| Mazzarello, P | 1 |
| Staff, RT | 1 |
| Gemmell, HG | 1 |
| Murray, AD | 1 |
| Emilien, G | 1 |
| Beyreuther, K | 1 |
| Masters, CL | 1 |
| Maloteaux, JM | 1 |
| Watts-Tobin, MA | 1 |
| Horn, N | 1 |
| Birks J, S | 1 |
| Alagiakrishnan, K | 1 |
| Wong, W | 1 |
| Blanchette, PL | 1 |
| Dooley, M | 1 |
| Lamb, HM | 1 |
| Donohue, JA | 1 |
| Brooks, RL | 2 |
| Coyne, AC | 1 |
| Fotiou, F | 1 |
| Fountoulakis, KN | 1 |
| Goulas, A | 1 |
| Palikaras, A | 1 |
| Carcenac, D | 1 |
| Martin-Hunyadi, C | 1 |
| Kiesmann, M | 1 |
| Demuynck-Roegel, C | 1 |
| Alt, M | 1 |
| Kuntzmann, F | 1 |
| Araki, S | 2 |
| Kwak, YT | 1 |
| Han, IW | 1 |
| Baik, J | 1 |
| Koo, MS | 1 |
| Foster, BM | 1 |
| Fontaine, CS | 1 |
| Imamura, T | 1 |
| Matthews, HP | 1 |
| Korbey, J | 1 |
| Rowden, J | 1 |
| Foster, NL | 1 |
| Samuel, W | 1 |
| Caligiuri, M | 1 |
| Lacro, J | 1 |
| McClure, FS | 1 |
| Warren, K | 1 |
| Jeste, DV | 1 |
| Deleu, D | 2 |
| Hanssens, Y | 1 |
| McMahon, PM | 1 |
| Harris, GJ | 1 |
| Gazelle, GS | 1 |
| Cameron, I | 1 |
| Curran, S | 1 |
| Newton, P | 1 |
| Petty, D | 1 |
| Wattis, J | 1 |
| Kasa, P | 2 |
| Papp, H | 1 |
| Torok, I | 1 |
| Fillit, HM | 2 |
| Amouyal-Barkate, K | 1 |
| Bagheri-Charabiani, H | 1 |
| Montastruc, JL | 1 |
| Moulias, S | 1 |
| Yorston, GA | 1 |
| Verrico, MM | 1 |
| Nace, DA | 1 |
| Towers, AL | 1 |
| Kishnani, PS | 1 |
| Spiridigliozzi, GA | 1 |
| Heller, JH | 1 |
| Sullivan, JA | 1 |
| Shinotoh, H | 1 |
| Aotsuka, A | 1 |
| Fukushi, K | 1 |
| Nagatsuka, S | 1 |
| Tanaka, N | 1 |
| Ota, T | 1 |
| Tanada, S | 1 |
| Irie, T | 1 |
| Allington, M | 1 |
| Salib, E | 1 |
| Earl-Slater, A | 1 |
| Walley, T | 1 |
| Shinosaki, K | 1 |
| Nishikawa, T | 1 |
| Kashiwagi, Y | 1 |
| Dunn, NR | 1 |
| Pearce, GL | 1 |
| Shakir, SA | 1 |
| Nakamura, S | 1 |
| Grutzendler, J | 1 |
| Eriksson, B | 1 |
| Hesse, C | 1 |
| Gordon, B | 1 |
| Colciaghi, F | 3 |
| Pastorino, L | 3 |
| Cottini, E | 2 |
| Monastero, R | 1 |
| Cattabeni, F | 3 |
| Hirai, S | 1 |
| Claxton, K | 1 |
| Sippl, W | 1 |
| Contreras, JM | 1 |
| Parrot, I | 1 |
| Rival, YM | 1 |
| Wermuth, CG | 1 |
| Rasmusen, L | 1 |
| Yan, B | 1 |
| Dunbar, F | 1 |
| Maelicke, A | 1 |
| Hake, AM | 1 |
| Doyle, Y | 1 |
| Seno, H | 1 |
| Yamamori, C | 1 |
| Itoga, M | 1 |
| Tsubouchi, K | 1 |
| Lampley-Dallas, VT | 1 |
| Rice, DP | 1 |
| Max, W | 1 |
| Lloyd, JR | 1 |
| Duttagupta, S | 1 |
| Zharikov, GA | 1 |
| Slagle, MA | 1 |
| Nakano, S | 1 |
| Matsuda, H | 1 |
| Uno, M | 1 |
| Archetti, S | 2 |
| Romani, R | 1 |
| Kogan, EA | 1 |
| Virchovsky, RG | 1 |
| Treves, TA | 1 |
| Neufeld, MY | 1 |
| Ikeda, S | 1 |
| Ikegami, N | 1 |
| Vilalta-Franch, J | 1 |
| Fajardo-Tibau, C | 1 |
| Cruz-Reina, MM | 1 |
| Schreiter Gasser, U | 1 |
| Gasser, T | 2 |
| Cocuzza, E | 1 |
| Marchiaro, L | 1 |
| Gasser, US | 1 |
| Katz, IR | 1 |
| Yamaguchi, Y | 1 |
| Higashi, M | 1 |
| Matsuno, T | 1 |
| Huxley, A | 1 |
| Haque, MS | 1 |
| Connolly, C | 1 |
| Hill, JW | 1 |
| Futterman, R | 1 |
| Kawashima, T | 1 |
| Yamada, S | 1 |
| Tribut, O | 1 |
| Polard, E | 1 |
| Lecavorzin, P | 1 |
| Lam, W | 1 |
| Werber, AE | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| Corsini, P | 1 |
| González Moneo, MJ | 1 |
| Garrido Barral, A | 1 |
| Suwata, J | 1 |
| Kamata, K | 1 |
| Nishijima, T | 1 |
| Yoshikawa, T | 1 |
| Higgins, GA | 1 |
| Enderlin, M | 1 |
| Fimbel, R | 1 |
| Haman, M | 1 |
| Grottick, AJ | 1 |
| Soriano, M | 1 |
| Richards, JG | 1 |
| Kemp, JA | 1 |
| Gill, R | 1 |
| Arai, Y | 1 |
| Limura, Y | 1 |
| Frank, JC | 1 |
| Cherry, D | 1 |
| Kohatsu, ND | 1 |
| Kemp, B | 1 |
| Hewett, L | 1 |
| Mittman, B | 1 |
| Loria-Kanza, Y | 1 |
| Robert, P | 1 |
| Blount, PJ | 1 |
| McDeavitt, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg[NCT02550665] | Phase 3 | 176 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease: Multicenter Randomized Controlled Trial[NCT03810794] | 180 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | |||
| Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease: A Multi-center Single-arm Study in China[NCT02787746] | Phase 4 | 241 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients[NCT03184467] | Phase 2 | 96 participants (Actual) | Interventional | 2017-09-05 | Completed | ||
| The Effect of Electroacupuncture Combined With Donepezil on Cognitive Function in Alzheimer's Disease Patients: Study Protocol for a Randomized Controlled Trial[NCT02305836] | Phase 2 | 334 participants (Anticipated) | Interventional | 2017-06-30 | Recruiting | ||
| Multidomain Alzheimers Risk Reduction Study (MARRS) Pilot[NCT03683394] | 172 participants (Actual) | Interventional | 2018-08-30 | Completed | |||
| Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil[NCT02006641] | Phase 3 | 858 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor[NCT02006654] | Phase 3 | 734 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil[NCT01955161] | Phase 3 | 933 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Dementia Clinical Trials: A Study on the Clinical Trial Participation of Dementia Patients[NCT05850000] | 500 participants (Anticipated) | Observational | 2024-05-31 | Not yet recruiting | |||
| A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donep[NCT01712074] | Phase 2 | 186 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria were met. The termination was not due to safety concerns.) | ||
| Detecting an Early Response to Donepezil With Measures of Visual Attention[NCT03073876] | Phase 4 | 25 participants (Actual) | Interventional | 2005-12-01 | Completed | ||
| Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-[NCT01129596] | 10,238 participants (Actual) | Observational | 2010-06-10 | Completed | |||
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer's Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Tra[NCT01024660] | Early Phase 1 | 155 participants (Anticipated) | Interventional | 2009-12-31 | Completed | ||
| Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease[NCT00478205] | Phase 3 | 1,467 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression[NCT01658228] | Phase 4 | 86 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease[NCT01137526] | Phase 2 | 267 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance[NCT03011476] | Phase 4 | 20 participants (Anticipated) | Interventional | 2017-04-11 | Recruiting | ||
| Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil[NCT01019421] | Phase 2 | 278 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study: an Ambispective, Multicentre, Open Cohort Study[NCT03401619] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2017-09-21 | Active, not recruiting | |||
| "Efficacy of Chinese Traditional Medicine Smart Soup in Cognition and Behavior Regulation in Alzheimer's Disease"[NCT05538507] | Phase 2 | 180 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477] | Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | ||
| Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders[NCT00403520] | Phase 4 | 240 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors[NCT01549834] | Phase 2 | 434 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793[NCT01690195] | Phase 2 | 343 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.) | ||
| Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985[NCT01676935] | Phase 2 | 349 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.) | ||
| A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease[NCT01527916] | Phase 2 | 438 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs[NCT01362686] | 200 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Low study accrual caused the study to be ended early.) | |||
| Can Early Counseling and Support for Alzheimer's Disease Caregivers Improve Burden? A Multi-centre Active Randomized Clinical Trial in Local Health Services[NCT02685787] | 230 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | |||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Can Cognitive Enhancers Reduce the Risk of Falls in Older People With Mild Cognitive Impairment? A Randomized Controled Trial[NCT00934531] | 60 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Enhanced Care Home Outcomes (ECHO): An Evaluation of the Experiences of Staff and Stakeholders Working With an Integrated Care Home Support Service (CHSS)[NCT02703792] | 19 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.[NCT00505167] | Phase 4 | 64 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patient[NCT00428389] | Phase 3 | 262 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's[NCT02987842] | 30 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | |||
| Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial[NCT02409238] | Phase 4 | 105 participants (Actual) | Interventional | 2015-03-11 | Terminated (stopped due to "Limits of grant funding reached~A/Prof Ng Tze Pin (P.I. & holder of NMRC Grant (CIRG12may033) funding this study) retired in Aug 2022.~Resignations of staff and collaborators especially over the 1st 2 years of the COVID-19 pandemic") | ||
| A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects[NCT00428090] | Phase 3 | 862 participants (Actual) | Interventional | 2007-02-27 | Completed | ||
| An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.[NCT00550420] | Phase 3 | 331 participants (Actual) | Interventional | 2007-10-01 | Terminated (stopped due to Based on preliminary parent study results) | ||
| A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease[NCT00348192] | Phase 2 | 200 participants | Interventional | 2006-05-31 | Completed | ||
| A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.[NCT01772095] | 389 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.[NCT00490568] | Phase 3 | 1,461 participants (Actual) | Interventional | 2007-08-08 | Terminated (stopped due to Based on preliminary parent study results) | ||
| A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjec[NCT00348309] | 1,496 participants (Actual) | Interventional | 2006-07-06 | Completed | |||
| A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APO[NCT00348140] | Phase 3 | 1,468 participants (Actual) | Interventional | 2006-07-12 | Completed | ||
| A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)[NCT00911807] | Phase 2 | 217 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Brain Polypeptide Solution in Improving Cognitive Function in Mild Alzheimer's Disease[NCT03978338] | 200 participants (Anticipated) | Interventional | 2019-07-31 | Not yet recruiting | |||
| Differences of Functional Changes in Brain by Rivastigmine According to Butyrylcholinesterase Alleles in Alzheimer's Disease Patients(Rivastigmine, Imaging, and BuChE in AD: RIBA)[NCT02063269] | 70 participants (Anticipated) | Interventional | 2014-02-28 | Active, not recruiting | |||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Efficacy Study of Yi-Zhi-An-Shen Granules For Older Adults With Amnestic Mild Cognitive Impairment: a Randomized, Double-blind, Placebo-controlled Study[NCT03601000] | Phase 1/Phase 2 | 80 participants (Actual) | Interventional | 2018-04-21 | Completed | ||
| Phase 4 Study of Cognitive Therapy and Donepezil in Alzheimers Disease.[NCT00443014] | Phase 4 | 187 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia[NCT00545974] | Phase 4 | 81 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial[NCT01653457] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | ||
| Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease[NCT02521558] | 30 participants (Actual) | Interventional | 2015-09-30 | Terminated (stopped due to Enrollment was halted early because of low adherence to the intervention.) | |||
| A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)[NCT00567060] | 676 participants (Actual) | Interventional | 2000-05-31 | Completed | |||
| A Home-based Personalized Multidomain RCT From the Canadian Therapeutic Platform for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP)[NCT05375513] | 275 participants (Anticipated) | Interventional | 2023-06-05 | Recruiting | |||
| The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients[NCT00480870] | Phase 4 | 65 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Cognitive Benefits of Treating Apnea in Dementia[NCT00477828] | 61 participants (Actual) | Interventional | 2000-04-30 | Completed | |||
| Ageing Gut Brain Interactions[NCT03593941] | 60 participants (Actual) | Observational | 2018-08-02 | Completed | |||
| Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery[NCT01186289] | 0 participants (Actual) | Interventional | 2010-10-31 | Withdrawn (stopped due to Principal Investigator decided not to pursue enrollment due to changes in standard of care.) | |||
| Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial[NCT00211159] | 204 participants | Interventional | 2000-12-31 | Completed | |||
| The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study[NCT04249869] | Phase 1/Phase 2 | 28 participants (Anticipated) | Interventional | 2020-02-01 | Not yet recruiting | ||
| Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial[NCT02781220] | 69 participants (Actual) | Observational | 2016-07-31 | Active, not recruiting | |||
| Implications for Management of PET Amyloid Classification Technology[NCT02778971] | 41 participants (Actual) | Observational | 2016-06-30 | Completed | |||
| A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention[NCT00142324] | Phase 4 | 190 participants | Interventional | 2003-11-30 | Active, not recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)[NCT00000173] | Phase 3 | 0 participants | Interventional | 1999-03-31 | Completed | ||
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| Pilot Examination of Galantamine in the Management of Tic Disorders[NCT00226824] | Phase 4 | 1 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to Unable to recruit subjects into the trial.) | ||
| Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease[NCT00408525] | Phase 1 | 41 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A composite Z-score for risk factors based on the following: the Rapid Assessment of Physical Activity for Older Adult (RAPA), steps per day averaged over 7 days; blood pressure measures averaged for each six-month period for participants with hypertension; the Pittsburgh Sleep Quality Index (PSQI); use of potentially harmful prescription medications; the Center for Epidemiologic Studies - Depression Scale (CES-D); hemoglobin A1c (HbA1c) values averaged over a 12-month time period; the Patient-Reported Outcomes Measurement Information System (PROMIS) Satisfaction with Social Activities, Short Form; and self-reported smoking. Higher score indicates greater risk factor burden. A z-score of 0 represents the population mean.~Treatment effects were estimated using LMMs for the changes from baseline to each follow-up assessment (6, 12, 18, and 24 months), with ATEs estimated by the average of the four visit-specific between-group differences in adjusted mean change from baseline." (NCT03683394)
Timeframe: 2 Years
| Intervention | z-score (Mean) |
|---|---|
| SMARRT Intervention | 0.06 |
| Health Education Control | -0.05 |
"Cognitive function will be measured by the modified Neuropsychological Test Battery (mNTB) global score, which is a composite z-score, an average of z-scores from tests of several cognitive domains. The total score is reported. Higher values signify higher cognitive performance. A z-score of 0 represents the population mean.~Treatment effects were estimated using linear mixed models (LMMs) for the changes from baseline to each follow-up assessment (6, 12, 18, and 24 months), with average treatment effects (ATEs) estimated by the average of the four visit-specific between-group differences in adjusted mean change from baseline.~Changes made to the protocol due to Covid-19, i.e., switching to telephone data collection, will likely limit our ability to examine cognitive change effectively, as several of the most important cognitive tests cannot be administered via telephone." (NCT03683394)
Timeframe: 2 Years
| Intervention | z-score (Mean) |
|---|---|
| SMARRT Intervention | 0.34 |
| Health Education Control | 0.19 |
Number of participants at follow up visits with Mild Cognitive Impairment, Alzheimer's Disease, and/or Dementia or with a low score on the Cognitive Abilities Screening Instrument (CASI) (<27 consistent with cognitive impairment). Lower score indicates poorer cognition; range is 0-33. (NCT03683394)
Timeframe: 2 Years
| Intervention | Participants (Count of Participants) |
|---|---|
| SMARRT Intervention | 5 |
| Health Education Control | 8 |
Measured with Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health. Higher score indicates better global health and quality of life; range = 0 to 20. (NCT03683394)
Timeframe: 2 Years
| Intervention | score on a scale (Mean) |
|---|---|
| SMARRT Intervention | 12.69 |
| Health Education Control | 11.58 |
"Change from baseline to Week 24 in Neuropsychiatric Inventory (NPI) total score.~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome)." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.31 |
| Idalopirdine 10 mg | -0.94 |
| Idalopirdine 30 mg | -0.54 |
"Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score.~The Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog) is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment)." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.64 |
| Idalopirdine 10 mg | 0.55 |
| Idalopirdine 30 mg | 1.27 |
Change from baseline to Week 24 in Mini Mental State Examination (MMSE). The Mini Mental State Examination (MMSE) is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit). (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.24 |
| Idalopirdine 10 mg | -0.45 |
| Idalopirdine 30 mg | -0.34 |
"Change from baseline to Week 24 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score.~The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability)." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.39 |
| Idalopirdine 10 mg | -1.22 |
| Idalopirdine 30 mg | -1.36 |
"Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 24.~The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening)." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.30 |
| Idalopirdine 10 mg | 4.24 |
| Idalopirdine 30 mg | 4.35 |
"Change from baseline to Week 24 in EQ-5D Visual Analogue Scale (EQ-5D VAS).~The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state)." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.35 |
| Idalopirdine 10 mg | 1.87 |
| Idalopirdine 30 mg | 1.00 |
"Change from baseline to Week 24 in EuroQol 5-dimensional (EQ-5D) utility score~The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). Each descriptive item is rated on a 3-point index ranging from 1 (no problems) to 3 (extreme problems) that is used for calculating a single summary index (from 0 to 1). A higher EQ-5D score indicates a worse outcome." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.03 |
| Idalopirdine 10 mg | 0.02 |
| Idalopirdine 30 mg | 0.01 |
"Change from baseline to Week 24 in NPI anxiety item score in patients with an NPI anxiety item score of at least 2 at baseline~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total score for the NPI anxiety item ranges from 0-12 (frequency multiplied by severity), where a higher score represents a worse outcome." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.48 |
| Idalopirdine 10 mg | -1.82 |
| Idalopirdine 30 mg | -1.69 |
Clinical response at Week 24 (based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog below or equal to -4, change in ADCS-ADL23 at least 0, and ADCS-CGIC below or equal to 4]) (NCT02006641)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 20 |
| Idalopirdine 10 mg | 33 |
| Idalopirdine 30 mg | 22 |
Clinical worsening at Week 24 (Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog above or equal to 4, change in ADCS-ADL23 below 0, and ADCS-CGIC above 4]) (NCT02006641)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 27 |
| Idalopirdine 10 mg | 28 |
| Idalopirdine 30 mg | 27 |
"Change in single NPI item scores at Week 24.~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). Total score for each single NPI item ranges from 0-12 (frequency multiplied by severity), where higher scores represent worse outcome." (NCT02006641)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delusions | Hallucinations | Agitation/aggression | Depression/dysphoria | Anxiety | Elation/euphoria | Apathy/indifference | Disinhibition | Irritability/lability | Aberrant motor behaviour | Sleep | Appetite/eating disorder | |
| Idalopirdine 10 mg | -0.18 | -0.06 | -0.06 | -0.08 | -0.06 | -0.05 | -0.19 | -0.04 | -0.05 | 0.06 | -0.07 | -0.30 |
| Idalopirdine 30 mg | 0.00 | -0.03 | -0.06 | -0.14 | -0.02 | -0.02 | -0.24 | 0.02 | -0.17 | 0.12 | 0.12 | -0.07 |
| Placebo | 0.01 | 0.00 | 0.02 | -0.20 | -0.05 | 0.01 | 0.00 | 0.08 | 0.03 | -0.03 | -0.04 | -0.14 |
"Change from baseline to Week 24 in Neuropsychiatric Inventory (NPI) total score~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome)." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.46 |
| Idalopirdine 60 mg (or 30 mg) | -0.74 |
"Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score.~The Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog) is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment)." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.68 |
| Idalopirdine 60 mg (or 30 mg) | 0.13 |
"Change from baseline to Week 24 in Mini Mental State Examination (MMSE).~The Mini Mental State Examination (MMSE) is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit)." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.64 |
| Idalopirdine 60 mg (or 30 mg) | -0.35 |
"Change from baseline to Week 24 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score.~The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability)." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.72 |
| Idalopirdine 60 mg (or 30 mg) | -1.05 |
"Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 24.~The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening)." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Idalopirdine 60 mg (or 30 mg) | 4.39 |
"Change from baseline to Week 24 in EQ-5D Visual Analogue Scale (EQ-5D VAS).~The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state)." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.40 |
| Idalopirdine 60 mg (or 30 mg) | 0.51 |
"Change from baseline to Week 24 in EuroQol 5-dimensional (EQ-5D) utility score~The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). Each descriptive item is rated on a 3-point index ranging from 1 (no problems) to 3 (extreme problems) that is used for calculating a single summary index (from 0 to 1). A higher EQ-5D score indicates a worse outcome." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.01 |
| Idalopirdine 60 mg (or 30 mg) | -0.00 |
"Change from baseline to Week 24 in NPI anxiety item score in patients with an NPI anxiety item score of at least 2 at baseline~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total score for the NPI anxiety item ranges from 0-12 (frequency multiplied by severity), where a higher score represents a worse outcome." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.93 |
| Idalopirdine 60 mg (or 30 mg) | -1.52 |
Clinical response at Week 24 (based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog below or equal to -4, change in ADCS-ADL23 at least 0, and ADCS-CGIC below or equal to 4]) (NCT02006654)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 32 |
| Idalopirdine 60 mg (or 30 mg) | 35 |
Clinical worsening at Week 24 (Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog above or equal to 4, change in ADCS-ADL23 below 0, and ADCS-CGIC above 4]) (NCT02006654)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 37 |
| Idalopirdine 60 mg (or 30 mg) | 40 |
"Change in single NPI item scores at Week 24.~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). Total score for each single NPI item ranges from 0-12 (frequency multiplied by severity), where higher scores represent worse outcome." (NCT02006654)
Timeframe: Baseline and Week 24
| Intervention | units on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delusions | Hallucinations | Agitation/aggression | Depression/dysphoria | Anxiety | Elation/euphoria | Apathy/indifference | Disinhibition | Irritability/lability | Aberrant motor behaviour | Sleep | Appetite/eating disorder | |
| Idalopirdine 60 mg (or 30 mg) | 0.03 | 0.08 | 0.03 | -0.18 | -0.07 | 0.03 | -0.19 | -0.00 | -0.04 | 0.11 | -0.12 | -0.21 |
| Placebo | -0.00 | 0.05 | 0.15 | -0.28 | -0.16 | 0.02 | -0.06 | 0.12 | 0.10 | 0.08 | -0.13 | -0.25 |
"Change from baseline to Week 24 in Neuropsychiatric Inventory (NPI) total score.~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome)." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.21 |
| Idalopirdine 30 mg | -0.21 |
| Idalopirdine 60 mg | -0.39 |
"Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score.~The Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog) is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment)." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.13 |
| Idalopirdine 30 mg | 0.47 |
| Idalopirdine 60 mg | 0.18 |
Change from baseline to Week 24 in Mini Mental State Examination (MMSE). The Mini Mental State Examination (MMSE) is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit). (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.06 |
| Idalopirdine 30 mg | -0.27 |
| Idalopirdine 60 mg | 0.27 |
"Change from baseline to Week 24 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score.~The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability)." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.03 |
| Idalopirdine 30 mg | -2.12 |
| Idalopirdine 60 mg | -2.02 |
"Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 24.~The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening)." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.29 |
| Idalopirdine 30 mg | 4.32 |
| Idalopirdine 60 mg | 4.13 |
"Change from baseline to Week 24 in EQ-5D Visual Analogue Scale (EQ-5D VAS).~The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state)." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.40 |
| Idalopirdine 30 mg | -0.12 |
| Idalopirdine 60 mg | 0.34 |
"Change from baseline to Week 24 in EuroQol 5-dimensional (EQ-5D) utility score~The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). Each descriptive item is rated on a 3-point index ranging from 1 (no problems) to 3 (extreme problems) that is used for calculating a single summary index (from 0 to 1). A higher EQ-5D score indicates a worse outcome." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.01 |
| Idalopirdine 30 mg | 0.00 |
| Idalopirdine 60 mg | 0.00 |
"Change from baseline to Week 24 in NPI anxiety item score in patients with an NPI anxiety item score of at least 2 at baseline~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total score for the NPI anxiety item ranges from 0-12 (frequency multiplied by severity), where a higher score represents a worse outcome." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.12 |
| Idalopirdine 30 mg | -1.56 |
| Idalopirdine 60 mg | -1.64 |
Clinical response at Week 24 (based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog below or equal to -4, change in ADCS-ADL23 at least 0, and ADCS-CGIC below or equal to 4]) (NCT01955161)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 34 |
| Idalopirdine 30 mg | 37 |
| Idalopirdine 60 mg | 27 |
Clinical worsening at Week 24 (Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog above or equal to 4, change in ADCS-ADL23 below 0, and ADCS-CGIC above 4]) (NCT01955161)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 40 |
| Idalopirdine 30 mg | 42 |
| Idalopirdine 60 mg | 33 |
"Change in single NPI item scores at Week 24.~The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). Total score for each single NPI item ranges from 0-12 (frequency multiplied by severity), where higher scores represent worse outcome." (NCT01955161)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delusions | Hallucinations | Agitation/aggression | Depression/dysphoria | Anxiety | Elation/euphoria | Apathy/indifference | Disinhibition | Irritability/lability | Aberrant motor behaviour | Sleep | Appetite/eating disorder | |
| Idalopirdine 30 mg | -0.04 | 0.03 | 0.04 | -0.06 | -0.13 | 0.03 | -0.23 | -0.06 | 0.02 | 0.33 | 0.01 | -0.14 |
| Idalopirdine 60 mg | -0.01 | -0.03 | 0.10 | -0.08 | -0.13 | 0.03 | -0.27 | -0.01 | 0.00 | -0.13 | 0.03 | -0.04 |
| Placebo | -0.11 | 0.13 | 0.01 | 0.02 | -0.02 | 0.09 | -0.18 | 0.05 | -0.14 | 0.03 | 0.03 | -0.08 |
ADAS-cog13 (13-item ADAS cog) is a psychometric instrument that evaluates word recall, ability to follow commands, constructional praxis, naming, ideational praxis, orientation, word recognition, memory, comprehension of spoken language, word-finding, and language ability, with a measure of delayed word recall and concentration/ distractibility. The total score of the 13-item scale ranges from 0 to 85, with an increase in score indicating cognitive worsening. (NCT01712074)
Timeframe: Baseline and Week 16
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| PF-05212377 30 mg | 0.111 |
| Placebo | -0.584 |
The NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, as well as appetite/eating. The NPI total score (for 12 behavioral domains) is calculated as the product of frequency and severity for each domain, and ranges from 0 to 144. An increase in score indicates a worsening of symptoms. (NCT01712074)
Timeframe: Baseline and Week 16
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| PF-05212377 30 mg | -3.990 |
| Placebo | -6.184 |
Proportion of participants with TEAEs leading to discontinuation over the 12-week double blind treatment period and washout. Adverse events (AEs) occurring following start of treatment or increasing in severity were counted as treatment emergent (NCT01712074)
Timeframe: Week 4 to Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| PF-05212377 30 mg | 3.3 |
| Placebo | 0 |
"Proportion (%) of participants with laboratory abnormalities (without regard to baseline abnormalities) of potential clinical concern over the 12-week double blind treatment period.~The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, uric acid, albumin, and total protein; urinalysis (pH, glucose, protein/albumin, hemoglobin/blood, ketones/acetone, nitrites, leukocyte esterase, microscopy [if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase]); others (only at screening or needed: urine drug screen, thyroid panel, Vitamin B12, methylmalonic acid, folate and Hemoglobin A1)." (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) |
|---|---|
| PF-05212377 30 mg | 36.0 |
| Placebo | 52.0 |
The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.1 |
| Placebo | -1.3 |
The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -2.5 |
| Placebo | -1.6 |
The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | milliseconds (msec) (Mean) |
|---|---|
| PF-05212377 30 mg | -2.8 |
| Placebo | -3.6 |
The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.1 |
| Placebo | 0.1 |
The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | 0.1 |
| Placebo | -0.3 |
The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.3 |
| Placebo | -0.8 |
The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.2 |
| Placebo | -5.5 |
The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | 0.8 |
| Placebo | -2.2 |
The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -3.0 |
| Placebo | -4.9 |
The BP changes from baseline at Week 6 (Visit 3) including supine systolic BP, standing systolic BP, standing systolic BP, supine diastolic BP, standing diastolic BP. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | millimeters of mercury (mm Hg) (Mean) | |||
|---|---|---|---|---|
| Supine Systolic BP | Standing Systolic BP | Supine Diastolic BP | Standing Diastolic BP | |
| PF-05212377 30 mg | -3.6 | -4.1 | -2.2 | -1.1 |
| Placebo | -3.9 | -3.0 | -1.8 | -1.0 |
The BP changes from baseline at Week 10 (Visit 4) including supine systolic BP, standing systolic BP, standing systolic BP, supine diastolic BP, standing diastolic BP. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Supine Systolic BP | Standing Systolic BP | Supine Diastolic BP | Standing Diastolic BP | |
| PF-05212377 30 mg | -3.4 | -3.8 | -2.4 | -1.2 |
| Placebo | -0.3 | 0.8 | -0.7 | 0.3 |
The BP changes from baseline at Week 16/Early Termination (Visit 5) including supine systolic BP, standing systolic BP, standing systolic BP, supine diastolic BP, standing diastolic BP. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Supine Systolic BP | Standing Systolic BP | Supine Diastolic BP | Standing Diastolic BP | |
| PF-05212377 30 mg | -1.4 | -1.0 | -2.1 | -0.8 |
| Placebo | -1.1 | -1.1 | -0.3 | 0.0 |
"Participants in each category of the Columbia Classification Algorithm of Suicide Assessment (C-CASA) mapped from the Columbia-Suicide Severity Rating Scale (C-SSRS) responses were reported.~C-CASA Event Code: <1> Completed suicide; <2> Suicide attempt; <3> Preparatory acts towards imminent suicidal behavior; <4> Suicidal Ideation; <7> Self-injurious behavior, no suicidal intent.~The suicidality assessments were performed at Screening, Week 0 (Visit 1), Week 4 (Visit 2), Week 6, (Visit 3), Week 10 (Visit 4), Week 16 (Visit 5), and Week 18 (Visit 6).~Only participants falling any category of C-CASA events were listed below." (NCT01712074)
Timeframe: From Screening to Week 18/Early Termination
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 4 (Visit 2): <4> | Week 6 (Visit 3): <4> | Week 10 (Visit 4): : <4> | Week 16/Early Termination (Visit 5): <4> | Week 4 (Visit 2): <7> | Week 6 (Visit 3): <7> | |
| PF-05212377 30 mg | 2 | 0 | 2 | 1 | 0 | 1 |
| Placebo | 1 | 1 | 0 | 0 | 1 | 0 |
| Placebo Run-in | 1 | 0 | 0 | 0 | 0 | 0 |
Proportion (%) of participants with PR Interval abnormalities meeting categorical criteria over the 12 week double blind treatment period. The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). Participants with post-baseline PR absolute value>=300 msec , a PR increase of >=25% (for participants with a baseline value>=200 msec), or with an increase >=50% (for participants with a baseline value<200 msec) were counted. (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Post-Baseline Maximum Absolute Value >=300 msec | Post-Baseline Maximum Increase >=25/50% | |
| PF-05212377 30 mg | 0 | 0 |
| Placebo | 4.4 | 0 |
Proportion (%) of participants with vital signs abnormalities (absolute and change from baseline) meeting categorical criteria over the 12-week double blind treatment period were counted. Vital signs data included blood pressure (BP) and pulse rate. (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absolute Supine Systolic BP<90 mmHg | Absolute Standing Systolic BP<90 mmHg | Absolute Supine Diastolic BP<50 mmHg | Absolute Standing Diastolic BP <50 mmHg | Absolute Supine Pulse Rate <40 bpm | Absolute Supine Pulse Rate >120 bpm | Absolute Standing Pulse Rate <40 bpm | Absolute Standing Pulse Rate >140 bpm | Increase in Supine Systolic BP>=30 mmHg | Increase in Standing Systolic BP>=30 mmHg | Increase in Supine Diastolic BP >=20 mmHg | Increase in Standing Diastolic BP >=20 mmHg | Decrease in Supine Systolic BP>=30 mmHg | Decrease in Standing Systolic BP>=30 mmHg | Decrease in Supine Diastolic BP >=20 mmHg | Decrease in Standing Diastolic BP >=20 mmHg | |
| PF-05212377 30 mg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.2 | 4.4 | 3.3 | 5.5 | 5.5 | 8.8 | 4.4 |
| Placebo | 1.1 | 1.1 | 2.1 | 0 | 0 | 0 | 0 | 0 | 5.3 | 3.2 | 4.3 | 5.3 | 5.3 | 5.3 | 5.3 | 6.4 |
Proportion (%) of participants with QRS Complex abnormalities meeting categorical criteria over the 12 week double blind treatment period. The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization). Participants with post-baseline QRS complex absolute value>=100 msec , a QRS complex increase of >=25% (for participants with a baseline value>=100 msec), or with an increase >=50% (for participants with a baseline value<100 msec) were counted. (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Post-Baseline Maximum Absolute Value >=200 msec | Post-Baseline Maximum Increase >=25/50% | |
| PF-05212377 30 mg | 0 | 0 |
| Placebo | 0 | 0 |
"Proportion (%) of participants with QTcF Interval abnormalities meeting categorical criteria over the 12-week double blind treatment period. The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula.~Participants with a post-baseline QTcF absolute value of 450 - <480, 480 - <500, or >=500 mec, or with a post-baseline QTcF increase of 30 - <60 or >=60 msec were counted." (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Post-Baseline Absolute Value of 450-<480 msec | Post-Baseline Absolute Value of 480-<500 msec | Change from Baseline of 30 -<60 msec | Change from Baseline >=60 msec | |
| PF-05212377 30 mg | 15.4 | 4.4 | 6.6 | 0 |
| Placebo | 14.0 | 1.1 | 3.2 | 0 |
The pulse rate changes from baseline at Week 10 (Visit 4) including supine pulse rate, and standing pulse rate. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | bpm (Mean) | |
|---|---|---|
| Supine Pulse Rate | Standing Pulse Rate | |
| PF-05212377 30 mg | -0.4 | -0.7 |
| Placebo | 0.5 | 1.8 |
The pulse rate changes from baseline at Week 16/Early Termination (Visit 5) including supine pulse rate, and standing pulse rate. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | bpm (Mean) | |
|---|---|---|
| Supine Pulse Rate | Standing Pulse Rate | |
| PF-05212377 30 mg | -0.8 | -1.9 |
| Placebo | 0.6 | 0.8 |
The pulse rate changes from baseline at Week 6 (Visit 3) including supine pulse rate, and standing pulse rate. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | beats per minute (bpm) (Mean) | |
|---|---|---|
| Supine Pulse Rate | Standing Pulse Rate | |
| PF-05212377 30 mg | -1.4 | -0.3 |
| Placebo | 1.4 | 1.3 |
Change of Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog); primary outcome measure of drug efficacy. Minimum value = 0, maximum value = 70. Higher scores represent worse cognitive functioning. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Drug | -1.90 |
| Placebo | .99 |
Computerized attention task measures the accuracy of reporting stimuli presented within 399 ms interval. Higher accuracy represents better performance. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | milliseconds (Mean) |
|---|---|
| Drug Treatment | -.022 |
Computerized attention task measures the accuracy of reporting stimuli presented at time intervals, varying load. Faster reaction time and accuracy represents better performance. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | milliseconds (Mean) |
|---|---|
| Drug Treatment | -.06 |
Measure of language / semantic function. This task requires participants to generate words belonging to specific categories within 1 minute. There are three trials. Total scores is computed by obtaining the mean number of words generated across the three trials (fruits/vegetables/animals). Higher score represents better outcome. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Drug | .17 |
| Placebo | -2.8 |
Computerized attention task measuring response time to detect a target after a spatial orienting cues of either valid (cue on same side in space as target) or Invalid Cue (cue on opposite side of space as target). Longer response time (msec) indicates worse performance. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | milliseconds (Median) |
|---|---|
| Drug | 496.5 |
| Placebo | 452.5 |
Dementia Rating Scale (DRS) change score (performance at 6 weeks minus performance at baseline). This is a global measure of cognitive function. Scores range from 0 - 144; higher scores represent better cognitive functioning. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Drug | 1.67 |
| Placebo | -.54 |
This measure represents the change in the variable longest Digit Span Backwards (LDSB) from baseline to 6 weeks. Score represents the maximum length of number repeated in the backward condition. Score ranges from 0 to 8. Higher scores represent better outcome. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Drug | 0.5 |
| Placebo | 0.1 |
This measure represents the change in the variable longest Digit Span Forward (LDSF) from baseline to 6 weeks. Score represents the maximum length of number repeated in the forward condition. Score ranges from 0 to 9. Higher scores represent better outcome. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Drug | -0.6 |
| Placebo | -0.4 |
Hopkins Verbal Learning Test- Revised (HVLT-R) (Brandt, 1991) is a list-learning task. Recall variable is computed by adding the number of words repeated in each of the three learning trials. Raw scores of each measure were used in the analyses. Total Recall ranges from 0-30. Higher scores represent better outcome. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Drug | .17 |
| Placebo | .40 |
Letter fluency (FAS) (Benton, 1967) was selected to assess speed of verbal generativity. Participants are required to generate words that start with a particular letter (excluding n; three trials (words starting with 'F', 'A', 'S' each for 1 minute minutes) are administered. Higher performance is better with range from 0 to unlimited. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Drug | .003 |
| Placebo | .17 |
Measure of visuospatial function requiring matching designs from the Benton Visual Form Discrimination test. Total scores is calculated by adding the number of items correct. Total score ranges from 0-32, higher score is better. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Drug | .92 |
| Placebo | .33 |
Change of Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog); primary outcome measure of drug efficacy. Minimum value = 0, maximum value = 70. Higher scores represent worse cognitive functioning. (NCT03073876)
Timeframe: Baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Drug Treatment | -.29 |
The Delis-Kaplan Executive Function (D-KEFS Trail) Subtest 4: Number-Letter Switching Scaled Score was used to assess executive functioning. Scaled scores range from 1-19. Higher scores represent less impairment (below 8 = low; 8-12 = average; > 12 = above average). Scores represent seconds to complete the task. Faster performance is better. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Drug | -1.67 |
| Placebo | -2.3 |
Scale of instrumental activities of daily living (IADLs), adapted from Lawton Brody scale. Caregiver rates 8 functional items from 0-2 severity. Total score is the sum of ratings for each item. Total score ranges from 0 (minimum) to 16 (maximum) with higher scores representing worse functional outcomes. (NCT03073876)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Drug Treatment | 6.54 |
Mini Mental Status Examination (MMSE) is a commonly used cognitive screener. Scores range from 0-30; higher scores mean better cognitive functioning. (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Drug | -.17 |
| Placebo | -1.09 |
Neuropsychiatric Inventory (NPI) is a scale that measures neuropsychiatric symptoms. We reported a score that captures the frequency of each symptom multiplied by the severity rating score. Scores range from 0 - 144; Higher scores represent worse outcomes. (NCT03073876)
Timeframe: 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| Drug Treatment | 14.09 |
Computerized attention task measures response time to detect a target presented at varied interstimulus intervals (350ms and 500ms). Participants respond to centrally presented asterisk on computer screen. Time elapsed from prior stimulus (= interstimulus interval) indicates when prior stimulus was presented. xx (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | response time in msec (Median) | |
|---|---|---|
| 350 | 500 | |
| Drug | 42 | 33 |
| Placebo | 13 | 13 |
Computerized attention task measures the variability (SD) in response time to detect a target presented at varied interstimulus intervals (350ms and 500ms) (NCT03073876)
Timeframe: Baseline to 6 weeks
| Intervention | msec (Mean) | |
|---|---|---|
| 350ms | 500ms | |
| Drug | -26.7 | 28.46 |
| Placebo | -4.5 | 8.37 |
Computerized attention task measures response time to detect a target across blocks of stimuli. Data shown for performance at Block1 and Block5 (NCT03073876)
Timeframe: 6 weeks
| Intervention | msec (Median) | |
|---|---|---|
| Block 1 | Block 5 | |
| Drug | 415 | 451 |
| Placebo | 402 | 487 |
Computerized attention task measures reaction time (RT) to detect a target presented at varied interstimulus interval comparing Block 1 (presented at beginning of session) and Block 2 (presented at end of session) (NCT03073876)
Timeframe: 6 weeks
| Intervention | msec (Median) | |
|---|---|---|
| Block 1 | Block 2 | |
| Drug | 400 | 395 |
| Placebo | 331 | 385 |
The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | -1.2 |
| Donepezil IR 10 mg | -1.2 |
The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 0.6 |
| Donepezil IR 10 mg | 0.4 |
The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Donepezil SR 23 mg | 2.6 |
| Donepezil IR 10 mg | 0.4 |
The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 4.23 |
| Donepezil IR 10 mg | 4.29 |
The modified ADAS-Cog is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation. Subjects' scores represent the total number of errors made throughout the various tasks. The total number of possible errors is between 0-85. (NCT01658228)
Timeframe: Week 16
| Intervention | number of errors on a scale from 0-85 (Mean) |
|---|---|
| Donepezil Treatment Group | 13.2 |
| Placebo Treatment Group | 13.9 |
The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained. (NCT01658228)
Timeframe: Week 16
| Intervention | Words (Mean) |
|---|---|
| Donepezil Treatment Group | 7.4 |
| Placebo Treatment Group | 7.4 |
The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) was obtained. (NCT01658228)
Timeframe: Week 16
| Intervention | Words (Mean) |
|---|---|
| Donepezil Treatment Group | 45.6 |
| Placebo Treatment Group | 46.6 |
We are not seeking to establish efficacy of these three medications for the indication of Alzheimer's disease. Each of these medications already has FDA-approval for Alzheimer's. The primary outcome measure is the discontinuation rate among the three medications. Based on previous systematic reviews, these rates are reportedly in the range of 30% by 12 weeks compared with placebo. We will determine the approximate date of discontinuation by self-reports from the caregiver through the telephone-based interview at 6, 12, and 18 weeks. (NCT01362686)
Timeframe: 6, 12, and 18 week interviews from enrollment
| Intervention | participants (Number) |
|---|---|
| Donepezil | 26 |
| Galantamine | 35 |
| Rivastigmine | 37 |
The current HABC-Monitor includes 30 items covering four clinically relevant domains of dementia, ie, cognitive, functional, behavioral, and psychological symptoms, and caregiver quality of life. For brevity and practical use in the clinical setting, each item on the four scales was designed to have the same item response options consisting of four categories that use the frequency of the target problem in the past 2 weeks. The HABC- Monitor took approximately 6 minutes to complete. The scores of the four scales are summed to create the total scores which were used in this analysis.The higher the total score, the higher the level of self reported caregiver burden. The minimum score is 0 and the maximum score is 90. (NCT01362686)
Timeframe: baseline, 6, 12, and 18 week interviews
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline HABC | 6 Week HABC | 12 Week HABC | 18 Week HABC | |
| Donepezil | 18.76 | 18.61 | 16.04 | 16.90 |
| Galantamine | 18.34 | 19.16 | 18.00 | 19.92 |
| Rivastigmine | 16.61 | 16.43 | 13.63 | 15.80 |
The NPI is based on a structured interview administered to an informal caregiver and has been adopted by the Alzheimer's Disease Cooperative Studies Group to obtain information on the presence of psychopathology in behavioral areas including delusions, apathy, hallucinations, disinhibition, agitation, depression, aberrant motor behavior, anxiety, night-time behavior, and euphoria.9 For each of 12 symptoms, if the caregiver reports the presence of psychopathology, a frequency and severity score are multiplied to yield a possible item score range of 0-12, and a possible total score range of 0-144. The NPI can be used to assess changes in the patient's behavior over the past month. The NPI also assesses the level of caregiver distress attributable to each of the 12 patient behaviors, with a possible total caregiver distress score range of 0-60. Higher scores indicate higher severity of psychopathology and caregiver disress. The NPI has excellent reliability and validity. (NCT01362686)
Timeframe: Baseline, 6, 12, 18 week interviews from enrollment
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| 6 WeekNPI Patient | 6 Week NPI Caregiver | 12 Week NPI Patient | 12 Week NPI Caregiver | 18 Week NPI Patient | 18 Week NPI Caregiver | |
| Donepezil | 12.71 | 5.94 | 9.62 | 5.66 | 9.06 | 5.56 |
| Galantamine | 9.42 | 4.40 | 8.40 | 4.33 | 10.67 | 6.22 |
| Rivastigmine | 8.63 | 3.91 | 5.24 | 2.22 | 7.26 | 2.89 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
A secondary assessment of the safety and tolerability of 2 paradigms for switching from donepezil to rivastigmine patch in patients with Alzheimer's disease (AD) was the number of participants who discontinued from the study due to any reason during extension phases of the study. (NCT00428389)
Timeframe: From week 5 through the end of extension phase (25 weeks)
| Intervention | Participants (Number) |
|---|---|
| Immediate Switch | 32 |
| Delayed Switch | 26 |
A secondary assessment of the safety and tolerability of 2 paradigms for switching from donepezil to rivastigmine patch in patients with Alzheimer's disease (AD) was the number of participants who discontinued from the study due to an AE during the combined core and extension phases of the study. (NCT00428389)
Timeframe: Baseline through the end of study (25 weeks)
| Intervention | Participants (Number) |
|---|---|
| Immediate Switch | 23 |
| Delayed Switch | 15 |
The primary objective of the study was to evaluate the safety and tolerability of 2 paradigms for switching from donepezil to rivastigmine patch in patients with Alzheimer's disease (AD). The primary variable to assess tolerability of switching was the number of participants who discontinued from the study due to any reason during the core phase. (NCT00428389)
Timeframe: Baseline through the end of the core phase of the study (Week 5)
| Intervention | Participants (Number) |
|---|---|
| Immediate Switch | 11 |
| Delayed Switch | 10 |
The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement. (NCT00428389)
Timeframe: Baseline and Week 25 (end of the extension phase) and at the end of study
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At Week 25 (n= 96, 106) | At the End of Study (n= 115, 118) | |
| Delayed Switch | -0.4 | -0.3 |
| Immediate Switch | -0.7 | -0.5 |
The NPI-10 assesses a wide range of behavior problems encountered in dementia patients. The 10 behavioral domains comprising the NPI-10 are evaluated through an interview of the caregiver by a mental health professional. The scale includes both frequency and severity ratings of each domain as well as a composite domain score (frequency x severity). The sum of the composite scores for the 10 domains yields the NPI total score, which ranges from 0 to 120, the lower the score the less severe the symptoms. A negative change score from baseline indicates improvement. (NCT00428389)
Timeframe: Baseline, Week 25 (end of the extension phase) and at End of Study
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At week 25 (n= 95, 107) | At the End of Study (n= 114, 118) | |
| Delayed Switch | 0.4 | 0.5 |
| Immediate Switch | -0.1 | -0.8 |
The ADCS-ADL scale is composed of 23 items to assess the basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, making judgments and decisions. Responses for each item are obtained through a caregiver interview. The total score is the sum of all items and sub-questions. The range for the total ADCS-ADL score is 0 to 78; a higher score indicates a more self-sufficient individual. A positive change from baseline indicates improvement. (NCT00428389)
Timeframe: Baseline, Week 25 (end of the extension phase) and at the end of Study
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At Week 25 (n= 95, 107) | At the End of Study (n= 113, 117) | |
| Delayed Switch | -4.2 | -4.2 |
| Immediate Switch | -3.9 | -3.1 |
"The CGIC is an assessment tool used by a skilled clinician to make a judgment of the severity or a change of a patient's condition. The clinician relies solely on information obtained from the patient at the Baseline visit as well as clinical information obtained throughout the study period. The clinician does not have access to any post-baseline cognitive testing data. The CGIC is rated on a seven-point scale, ranging from (1) very much improved to (4) no change to (7) very much worse." (NCT00428389)
Timeframe: Baseline, Week 5 (end of the core phase) and Week 25 (end of the extension phase)
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| At Week 5 (n= 116, 114) | At Week 25 (n= 105, 109) | |
| Delayed Switch | 4.0 | 4.3 |
| Immediate Switch | 3.9 | 4.1 |
The blood sample was collected for assessments of HbA1c levels at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Percentage (%) (Least Squares Mean) |
|---|---|
| Placebo | 0.1 |
| RSG XR 2 mg | 0.2 |
| RSG XR 8 mg | 0.1 |
| Donepezil 10 mg | 0.1 |
Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the par. had rested in the supine position in a quiet room (no TV, minimal talking) for at least 10 minutes. Conduction intervals from the 12-lead ECGs were manually read and confirmed by an external cardiologist/vendor. The ECG HR of Central Cardiologist reported. The assessments was performed at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Screening/Visit 1/W-6. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Beats per minute (Mean) |
|---|---|
| Placebo | 2.1 |
| RSG XR 2 mg | -2.8 |
| RSG XR 8 mg | -0.3 |
| Donepezil 10 mg | -4.7 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Items were evaluated by tests and clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicates more dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.5 |
| RSG XR 2 mg | 0.3 |
| RSG XR 8 mg | 0.7 |
| Donepezil 10 mg | -0.1 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Items were evaluated by tests and clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicates more dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.6 |
| RSG XR 2 mg | -0.2 |
| RSG XR 8 mg | 0.6 |
| Donepezil 10 mg | 0.9 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Items were evaluated by tests and clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicates more dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.0 |
| RSG XR 2 mg | 1.2 |
| RSG XR 8 mg | 1.2 |
| Donepezil 10 mg | 0.6 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means greater dysfunction. It was based on interviews with the par. and caregiver by an independent rater. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.3 |
| RSG XR 2 mg | 4.3 |
| RSG XR 8 mg | 4.1 |
| Donepezil 10 mg | 3.8 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means greater dysfunction. It was based on interviews with the par. and caregiver by an independent rater. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.2 |
| RSG XR 2 mg | 4.2 |
| RSG XR 8 mg | 4.1 |
| Donepezil 10 mg | 3.9 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means greater dysfunction. It was based on interviews with the par. and caregiver by an independent rater. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.3 |
| RSG XR 2 mg | 4.3 |
| RSG XR 8 mg | 4.2 |
| Donepezil 10 mg | 3.8 |
The MMSE consists of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The scale is completed by the investigator, based on the performance of the par. and takes approximately 5 to 10 minutes to administer. The assessments was performed at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived (NCT00428090)
Timeframe: Baseline (W0) and W24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.5 |
| RSG XR 2 mg | -0.6 |
| RSG XR 8 mg | -0.7 |
| Donepezil 10 mg | 0.4 |
Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the par. had rested in the supine position in a quiet room (no TV, minimal talking) for at least 10 minutes. Conduction intervals from the 12-lead ECGs were manually read and confirmed by an external cardiologist/vendor. The ECG parameters includes PR interval, QRS duration, QT - uncorrected interval, QTc Bazett (QTcB), QTc Fridericia (QTcF) and RR interval of Central Cardiologist are reported. The assessments was performed at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Screening/Visit 1/W-6. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | milliseconds (MSEC) (Mean) | |||||
|---|---|---|---|---|---|---|
| PR Interval, n=16,11, 14, 4 | QRS Duration, n=17, 11, 14, 5 | QT Interval, n=17, 11, 14, 5 | QTcB, n=17, 11, 14, 5 | QTcF, n=17, 11, 14, 5 | RR Interval | |
| Donepezil 10 mg | -5.5 | 0.9 | 15.9 | -0.2 | 4.9 | 76.5 |
| Placebo | 2.2 | 1.1 | 5.3 | 10.2 | 8.1 | -12.3 |
| RSG XR 2 mg | 6.9 | 0.7 | 15.6 | 7.1 | 10.0 | 43.8 |
| RSG XR 8 mg | 6.0 | 3.6 | 19.8 | 20.0 | 20.1 | -0.5 |
The ACQLI was an assessment of caregiver quality of life. This instrument consists of 30 questions exploring various aspects of carer's quality of life. Each of the questions had a two point response and the 30 questions were summed to provide a total score. Items are assumed to be unidimensional (i.e., represent a single variable) and are scored 0/1 (false/true) before summation into a total score with a 0-30 range. To ease comparisons between scales, ACQLI scores were transformed to range between 0-100 (100: worse). The assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | |
|---|---|---|
| ACQLI, W12, n=141, 148, 137, 60 | ACQLI, W24, n=128, 132, 126, 54 | |
| Donepezil 10 mg | 0.5 | -0.0 |
| Placebo | 0.5 | 0.6 |
| RSG XR 2 mg | -0.6 | -0.2 |
| RSG XR 8 mg | -0.1 | 0.0 |
Body weight will be measured at all visits, without shoes and wearing light clothing. The assessments was performed at Baseline, W4, W8, W12, W16, and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Kilogram (Kg) (Mean) | ||||
|---|---|---|---|---|---|
| Week 4, n=160, 161, 153, 79 | Week 8, n=150, 157, 147, 66 | Week 12, n=143, 149, 136, 61 | Week 16, n=143, 146, 132, 61 | Week 24, 133, 132, 125, 55 | |
| Donepezil 10 mg | -0.1 | -0.4 | -0.9 | -1.0 | -0.8 |
| Placebo | 0.1 | -0.0 | 0.0 | -0.0 | -0.3 |
| RSG XR 2 mg | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 |
| RSG XR 8 mg | 0.3 | 0.8 | 0.9 | 1.1 | 0.8 |
Hematology parameters were assessed at Baseline, W4, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and Up to W24
| Intervention | Percentage of red blood cells in blood (Mean) | ||
|---|---|---|---|
| Week 4, n=152, 152, 138, 76 | Week 12, n=132, 142, 132, 60 | Week 24, n=128, 124, 115, 54 | |
| Donepezil 10 mg | -0.0024 | -0.0055 | -0.0001 |
| Placebo | -0.0011 | -0.0007 | -0.0010 |
| RSG XR 2 mg | -0.0088 | -0.0152 | -0.0123 |
| RSG XR 8 mg | -0.0125 | -0.0316 | -0.0326 |
Hematology parameters were assessed at Baseline, W4, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Grams per liter (G/L) (Mean) | ||
|---|---|---|---|
| Week 4, n=152, 152, 138, 76 | Week 12, n=132, 142, 132, 60 | Week 24, n=128, 124, 115, 54 | |
| Donepezil 10 mg | -0.4 | -0.6 | 0.2 |
| Placebo | 0.1 | -0.2 | -1.3 |
| RSG XR 2 mg | -2.8 | -4.5 | -4.2 |
| RSG XR 8 mg | -3.9 | -10.5 | -11.9 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Endpoint treatment differences were adjusted to take account of missing data. It was evaluated at Baseline, W8, W16 and W24. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| ADAS-Cog, W8, n=153, 155,147,67 | ADAS-Cog, W16, n=143,145,132,62 | ADAS-Cog, W24, n=131, 130,125,156 | |
| Donepezil 10 mg | -0.3 | -1.1 | 0.6 |
| Placebo | 0.4 | 0.5 | 2.0 |
| RSG XR 2 mg | -0.5 | 0.6 | 1.2 |
| RSG XR 8 mg | 0.5 | 1.3 | 1.2 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means more dysfunction. The scale was based on interviews with the par. and caregiver and was completed by an independent rater. It required separate structured 15-20 minute interviews with the par. and caregiver. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. It was evaluated at Baseline, W8, W16 and W24. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| CIBIC+, W8, n=150, 156,147,67 | CIBIC+, W16, n=144,145,127,61 | CIBIC+, W24, n=131,133, 127, 56 | |
| Donepezil 10 mg | 3.9 | 3.8 | 3.8 |
| Placebo | 4.1 | 4.2 | 4.3 |
| RSG XR 2 mg | 3.9 | 4.0 | 4.3 |
| RSG XR 8 mg | 4.1 | 4.1 | 4.2 |
The DAD, assessed the ability of a par. to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. The percentage score was calculated as (DAD total score/total number of applicable items) multiplied by 100. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| DAD, W8, n=147,152, 144, 65 | DAD, W16, n=141,143,131,59 | DAD, W24, n=129,133,127,55 | |
| Donepezil 10 mg | 0.5 | 1.1 | -0.2 |
| Placebo | -0.8 | -2.6 | -3.7 |
| RSG XR 2 mg | -0.6 | -1.7 | -2.4 |
| RSG XR 8 mg | -0.3 | -1.7 | -3.8 |
The EQ-5D Proxy is a 2 part scale used to assess the quality of life and utility benefit. The data for Part 2 is presented. It is a the visual analogue scale Thermometer which assessed caregiver's impression of par. overall health. The Thermometer has endpoints of 100 (best imaginable health state) and 0 (worst imaginable health state). EQ-5D Proxy assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | |
|---|---|---|
| EQ-5D Proxy Thermometer, W12, n=141, 146, 135, 62 | EQ-5D Proxy Thermometer, W24, n=128, 130, 126, 55 | |
| Donepezil 10 mg | -2.6 | 1.5 |
| Placebo | 1.4 | 1.9 |
| RSG XR 2 mg | 0.3 | -0.7 |
| RSG XR 8 mg | 1.7 | 0.2 |
The EQ-5D Proxy was a 2 part scale used to assess the quality of life and utility benefit. The data for Part 1 is presented. It is a 5 dimensional Health State Classification. Caregivers were asked to respond as they feel the par. would on dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Answers to each question were recorded on a 3-point scale which indicates the level of impairment (level 1= no problem; level 2=some or moderate problem(s) and level 3=unable, or extreme problem with higher scores indicating greater dysfunction. EQ-5D Proxy assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | |
|---|---|---|
| EQ-5D Proxy Utility, W12, n=141,146, 135, 62 | EQ-5D Proxy Utility, W24, n=128, 130, 125, 55 | |
| Donepezil 10 mg | 0.01 | 0.00 |
| Placebo | -0.02 | -0.02 |
| RSG XR 2 mg | 0.00 | 0.02 |
| RSG XR 8 mg | 0.01 | -0.02 |
"The NPI assessed behavioral disturbances comprises 10 dimensions: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressiveness and agitation, irritability, anxiety and aberrant motor activity. The par. caregiver asked about behavior in the par. If Yes, the informant then rates both the severity on a 3-point scale, 1: mild to 3: severe (total range: 0-36) and the frequency using a 4-point scale, 1: occasionally to 4: very frequently. The total domain score was frequency × severity. The distress was scored on 5-point scale, 0: no distress to 5 - very severe or extreme. A total NPI score can be calculated by adding all domain scores together; NPI total score: from 0-144 and NPI distress score: from 0-60, all with higher scores indicating more severe behavioral disturbance. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0." (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| NPI, W8, n=146,151,144,65 | NPI, W16, n=139,142,131,59 | NPI, W24, n=129,133,127,55 | |
| Donepezil 10 mg | -0.1 | 0.5 | -0.6 |
| Placebo | 0.2 | -0.1 | 1.2 |
| RSG XR 2 mg | 0.1 | -0.0 | 1.6 |
| RSG XR 8 mg | 0.5 | -0.1 | 1.1 |
Change from Baseline in short term memory assessment score was assessed from a combined analysis of items 1 (word recall task) and 7 (word recognition task) of ADAS-Cog scale. Word recall task consist of the participants score was the mean number of words not recalled on three trials (maximum score 10) and word recognition task, to score this item the number of incorrect responses was counted (maximum error score was 12). Higher score indicating greater dysfunction. Total score is sum of individual score. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| ADAS-Cog Q1 plus Q7, W8, n=152,155,146,67 | ADAS-Cog Q1 plus Q7, W16, n=143,143,130,62 | ADAS-Cog Q1 plus Q7, W24, n=131,128,123,56 | |
| Donepezil 10 mg | -0.4 | -0.6 | 0.2 |
| Placebo | 0.1 | 0.1 | 0.7 |
| RSG XR 2 mg | -0.1 | 0.6 | 0.3 |
| RSG XR 8 mg | 0.5 | 0.8 | 0.6 |
HbA1c assessment was performed par. with type 2 diabetes mellitus or HbA1c >=6.5% at Screening only. HbA1c levels were assessed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Percentage (Mean) | |
|---|---|---|
| Week 12, n=48, 46, 38, 22 | Week 24, n=123, 120, 117, 52 | |
| Donepezil 10 mg | -0.2 | 0.0 |
| Placebo | -0.1 | 0.1 |
| RSG XR 2 mg | 0.2 | 0.2 |
| RSG XR 8 mg | 0.1 | 0.1 |
Clinical chemistry parameters were identified as of PCC (H, L), if values were out of RR: Alanine aminotransferase (ALT, none-120 [250% upper limit of RR, ULRR]), Albumin (0.75-2), Aspartate aminotransferase (AST,none-105 (3-64y), 137.5 (65+y), >250%ULRR), Alkaline phosphatase (ALP,none-312.5 (20+y), >250%ULRR), blood urea nitrogen (BUN)/Creatinine ratio (none-1.25), BUN (none-11), Chloride (80-115), Calcium (0.75-1.25), Carbon dioxide (CO2, 15-40) content, Creatinine (22, <50% lower limit of RR [LLRR]-155, >125%ULRR), Creatine phosphokinase (CPK, none-1.25), Gamma glutamyl transferase (GGT,none-2.5), Glucose (3.6-7.8), High density lipoprotein (HDL,0.65-none), Lactate dehydrogenase (LDH,none-1.25), Low density lipoprotein (LDL,none-2), Magnesium (0.5-2), Potassium (3-5.5), Phosphorus inorganic (0.5-1.5), Sodium (130-150), Total protein (0.8-1.5), Total cholesterol (none-1.25), Total bilirubin (none-1.95), Triglycerides (none-9). Data for Creatinine clearance not reported. (NCT00428090)
Timeframe: Up to W24
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT H, n=156, 162, 151, 77 | AST H, n=156, 162, 151, 77 | BUN/Creatinine ratio H, n=156, 162, 151, 77 | Cholesterol H, n=141, 148, 137, 62 | Creatinine H, n=156, 162, 151, 77 | CPK H, n=156, 162, 151, 77 | GGT H, n=156, 162, 151, 77 | Glucose H, n=156, 162, 151, 77 | Glucose L, n=156, 162, 151, 77 | LDL H, n=141, 147, 136, 62 | Phosphorus L, n=156, 162, 151, 77 | Potassium H, n=156, 162, 150, 77 | Sodium H, n=156, 162, 151, 77 | Sodium L, n=156, 162, 151, 77 | BUN H, n=156, 162, 151, 77 | Total Bilirubin H, n=156, 162, 151, 77 | |
| Donepezil 10 mg | 0 | 0 | 9 | 1 | 3 | 5 | 1 | 8 | 1 | 10 | 0 | 2 | 1 | 2 | 5 | 0 |
| Placebo | 2 | 2 | 8 | 7 | 5 | 5 | 2 | 12 | 3 | 36 | 0 | 4 | 0 | 0 | 7 | 0 |
| RSG XR 2 mg | 0 | 0 | 8 | 17 | 1 | 13 | 1 | 19 | 5 | 51 | 0 | 2 | 0 | 0 | 5 | 1 |
| RSG XR 8 mg | 0 | 0 | 19 | 29 | 4 | 11 | 0 | 9 | 4 | 55 | 1 | 2 | 0 | 1 | 12 | 0 |
Haematology parameters were identified as of PCC (high [H], low [L]), if the values were out of the reference range (RR). The range for parameters was: platelet (100AV-500AV), red blood cell (RBC, 0.8-1.2), hemoglobin (L: female [F]:10, male [M]:11; H: F:16.5-AV, M:18), hematocrit (0.8-1.2), white blood cell (WBC, 3-15), neutrophils (0.75-1.5), lymphocytes (0.75-1.5), monocytes (0.75-2), eosinophils (none-2), basophils (none-2), mean corpuscle volume (MCV, 0.8-1.2), mean corpuscular hemoglobin (MCH, 0.8-1.2), mean corpuscular hemoglobin concentration (MCHC, 0.8-1.2), red cell distribution width (RDW, 0.8-1.2). Data for mean platelet volume (reference range not established) not reported (NCT00428090)
Timeframe: Up to W24
| Intervention | Participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eosinophils H, n=156, 161, 151, 72 | Hematocrit H, n=157, 161,151, 76 | Hematocrit L, n=157, 161,151, 76 | Hemoglobin H, n=157, 161,151, 76 | Hemoglobin L, n=157, 161,151, 76 | Lymphocytes L, n=156, 161,151, 76 | MCH H, n=157, 161,151, 76 | MCH L, n=157, 161,151, 76 | MCV L, n=156, 161,151, 76 | Monocytes H, n=156, 161,151, 76 | Monocytes L, n=156, 161,151, 76 | Platelet H, n=157, 160,150, 76 | Platelet L, n=157, 160,150, 76 | RDW H, n=157, 161,151, 76 | RBC L, n=157, 161,151, 76 | Total neutrophil H, n=156, 161, 151, 76 | Total neutrophil L, n=156, 161, 151, 76 | WBC H, n=157, 161,151, 76 | WBC L, n=157, 161,151, 76 | |
| Donepezil 10 mg | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | 0 | 0 | 1 | 1 | 1 | 3 | 1 | 0 |
| Placebo | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 9 | 1 | 2 | 4 | 0 | 0 | 2 | 0 | 4 |
| RSG XR 2 mg | 0 | 1 | 0 | 2 | 3 | 2 | 0 | 1 | 0 | 0 | 10 | 0 | 1 | 6 | 1 | 0 | 5 | 0 | 4 |
| RSG XR 8 mg | 1 | 0 | 1 | 0 | 8 | 2 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 10 | 1 | 1 | 7 | 1 | 7 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE included significant or unexpected worsening or exacerbation of the condition/indication under study, exacerbation of a chronic or intermittent pre-existing condition, new conditions detected or diagnosed, signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational product or a concurrent medication. Number of participants with any AE and as per severity were reported. Refer to the general AE/SAE module for a list of AEs and SAEs. (NCT00428090)
Timeframe: Up to W24
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Any AE | Mild AE | Moderate AE | Severe AE | |
| Donepezil 10 mg | 42 | 22 | 15 | 5 |
| Placebo | 62 | 32 | 25 | 5 |
| RSG XR 2 mg | 60 | 35 | 22 | 3 |
| RSG XR 8 mg | 69 | 37 | 30 | 2 |
SBP, DBP and HR of par. were recorded in sitting posture as vital signs, while body weight was measured without shoes and wearing light clothing at each visit. The blood pressure (BP) and HR values were identified as of PCC if the vales were out of the reference range (for SBP, 90 to 140 millimeters of mercury (mmHg), DBP, 50 to 90 mmHg, and HR >100 or <50 beats per minute [bpm]) or meet a change from Baseline criterion. For SBP it was increase from Baseline (high) if increased by more than or equal to (>=) 40 mmHg; decrease from Baseline (low) if decreased by >=30 mmHg. For DBP, increase from Baseline (high) if increased by >=30 mmHg; decrease from Baseline (low) if decreased by >=20 mmHg. For HR, increase from Baseline (high) if increased by >=30 bpm; decrease from Baseline (low) if decreased by >=30 bpm. For weight, increase from Baseline (high) if increased by >=7%; decrease from Baseline (low) if decreased by >=7%. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Up to W24
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP, >140 or <90 | SBP, Increase from Baseline >=40 | SBP, Decrease from Baseline >=30 | DBP, >90 or <50 | DBP, Increase from Baseline >=30 | DBP, Decrease from Baseline >=20 | HR, >100 or <50 | HR, Increase from Baseline >=30 | HR, Decrease from Baseline >=30 | Weight, Increase from Baseline >=7% | Weight, Decrease from Baseline >=7% | |
| Donepezil 10 mg | 24 | 3 | 6 | 8 | 1 | 8 | 2 | 1 | 1 | 1 | 5 |
| Placebo | 52 | 1 | 7 | 17 | 4 | 8 | 2 | 1 | 3 | 9 | 7 |
| RSG XR 2 mg | 61 | 3 | 9 | 16 | 1 | 12 | 4 | 3 | 0 | 21 | 4 |
| RSG XR 8 mg | 41 | 3 | 15 | 13 | 1 | 25 | 4 | 3 | 0 | 25 | 3 |
The RUD instrument was developed as a comprehensive tool to assess the amount of resource use among demented par. RUD assess both formal and informal resource use of the par. and the primary caregiver, making it possible to calculate costs from a societal perspective. Q1 relates to assisting par. with basic activities of daily living and Q2 relates to instrumental activities of daily living. The assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
| Intervention | Hours (Mean) | |||
|---|---|---|---|---|
| RUD Q1, W12, n=141, 149, 137, 69 | RUD Q1, W24, n=128, 133, 127, 55 | RUD Q2, W12, n=141, 149, 137, 62 | RUD Q2, W24, n=128, 133, 127, 55 | |
| Donepezil 10 mg | -5.7 | 3.7 | -5.3 | 1.1 |
| Placebo | 2.3 | 19.4 | 13.7 | 17.1 |
| RSG XR 2 mg | 4.5 | -0.6 | 9.0 | 9.7 |
| RSG XR 8 mg | -9.8 | -2.7 | 4.9 | 11.6 |
Edema was considered as adverse event of special interest (AESI). The process for AESI selection was based on RSG's pharmacologic class and relevant AEs potentially associated with RSG. Percentage of participants reported with edema as AESI were reported. (NCT00550420)
Timeframe: Up to 82 Weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| RSG XR 8 mg | 13 |
The 11-item ADAS-cog was used to assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores ranged from 0 to 70 with higher scores indicating greater dysfunction. Baseline was referred to Visit 1 (W0)assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W24 and W52
| Intervention | Score on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| All subject population, W24 | All subject population, W52 | APOE4, Neg, W24 | APOE4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
| RSG XR 8 mg | 1.9 | 2.5 | 2.1 | 3.0 | 1.8 | 1.8 |
BW of participants were recorded as vital sign at each visit. The BW were identified as of potential clinical concern if the vales were increased or decreased from Baseline by >=7%. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline was measured as the BW at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W8, W12, W16, W24, W36, W52, W64 and Follow-up (W82)
| Intervention | Kilograms (kg) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| BW, W4 | BW, W8 | BW, W12 | BW, W16 | BW, W24 | BW, W36 | BW, W52 | BW, Year 2 W12 | BW, Follow-up | |
| RSG XR 8 mg | 0.2 | 0.4 | 0.5 | 0.5 | 0.6 | 0.5 | -0.0 | 0.5 | 0.5 |
The DAD, assessed the ability of a participant to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assesses a participant's ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. The percentage score was calculated as (DAD total score/total number of applicable items) multiplied by 100. The DAD was conducted as an interview with the caregiver and took approximately 20 minutes. Baseline was referred to Visit 1 (W0) assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W24 and W52
| Intervention | Score on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
| RSG XR 8 mg | -3.2 | -5.2 | -4.5 | -6.2 | -2.2 | -3.8 |
HbA1c was evaluated as safety parameter in this study. The values of change from Baseline was presented. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline was measured as the BW at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Vsit 1 W0), W12, W24, W36, W52, W76 and Follow-up (W82)
| Intervention | Percent HbA1c (Mean) | |||||
|---|---|---|---|---|---|---|
| W12 | W24 | W36 | W52 | W76 | Follow-up | |
| RSG XR 8 mg | -0.02 | 0.08 | 0.03 | 0.09 | 0.08 | 0.07 |
HR of participants was recorded as vital sign at each visit. The HR values were identified as of potential clinical concern if the vales were out of the reference range 50 to 100 beats per minute (BPM) or meet a change from Baseline criterion. The change from Baseline criterion was as, increase in HR (high) from Baseline if HR was increased by >= 30 bpm or decrease in HR (Low) from Baseline if HR was decreased by >= 30 bpm from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the HR at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W8, W12, W16, W24, W36, W52, W64 and Follow-up (W82)
| Intervention | BPM (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HR, W4 | HR, W8 | HR, W12 | HR, W16 | HR, W24 | HR, W36 | HR, W52 | HR, Year 2 W12 | HR, Follow-up | |
| RSG XR 8mg | 1.1 | 1.8 | 2.2 | 1.2 | 1.0 | 1.7 | -0.8 | 2.9 | 1.6 |
The MMSE consisted of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The scale was completed by the investigator, based on the performance of the participant, and took approximately 5 to 10 minutes to administer. Change from parent Baseline in MMSE was analyzed using a mixed model for repeated measures (MMRM). Baseline was referred to Visit 1 (W0)assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W 24 and W52
| Intervention | Score on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
| RSG XR 8 mg | -0.7 | -1.6 | -0.7 | -1.2 | -0.7 | -2.1 |
"The NPI assessed behavioural disturbances comprises 10 dimensions: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressiveness and agitation, irritability, anxiety and aberrant motor activity. The participant caregiver asked about behaviour in the participant. If Yes, the informant then rates both the severity on a 3-point scale, 1: mild to 3: severe (total range: 0-36) and the frequency using a 4-point scale, 1: occasionally to 4: very frequently. The total domain score was frequency × severity. The distress was scored on 5-point scale, 0: no distress to 5 - very severe or extreme. A total NPI score was calculated by adding all domain scores together: NPI total score (from 0-144) and NPI distress score (from 0-60), with higher scores indicating more severe behavioral disturbance. Baseline was referred to Visit 1 (W0) assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value." (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W24 and W52
| Intervention | Score on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
| RSG XR 8 mg | 1.1 | 2.1 | 1.9 | 1.5 | 0.4 | 2.8 |
Non-fasting measures of lipid metabolism including cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG) were measured at Baseline (W0), W4, W16, W36, W52, Year 2 W24 and Follow-up. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline was calculated as the value at the indicated visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W16, W36, W52, W76, and W82
| Intervention | Millimoles per litre (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TC, W4 | TC, W16 | TC, W36 | TC, W52 | TC, Year 2 W24 | TC, Follow-up | HDL, W4 | HDL, W16 | HDL, W36 | HDL, W52 | HDL, Year 2 W24 | HDL, Follow-up | LDL, W4 | LDL, W16 | LDL, W36 | LDL, W52 | LDL, Year 2 W24 | LDL, Follow-up | TG, W4 | TG, W16 | TG, W36 | TG, W52 | TG, Year 2 W24 | TG, Follow-up | |
| RSG XR 8 mg | 0.106 | 0.200 | 0.140 | 0.333 | 1.163 | 0.069 | -0.035 | -0.030 | -0.069 | -0.020 | -0.150 | -0.057 | 0.088 | 0.211 | 0.163 | 0.385 | 1.051 | 0.133 | 0.084 | 0.027 | 0.050 | -0.179 | 0.573 | -0.062 |
SBP and DBP of participant were recorded in sitting posture as vital sign at each visit. The blood pressure (BP) values were identified as of potential clinical concern if the vales were out of the reference range (for SBP, 90 to 140 mmHg and DBP, 50 to 90 mmHg) or meet a change from Baseline criterion. The change from Baseline criterion for SBP, was increase from Baseline (high) if increased by more than or equal to (>=) 40 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 30 mmHg from Baseline. For DBP, increase form Baseline (high) if increased by >= 30 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 20 mmHg from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the blood pressure value recorded at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W8, W12, W16, W24, W36, W52, W64 and Follow-up (W82)
| Intervention | millimeter of mercury (mmHg) (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP, W4 | SBP, W8 | SBP, W12 | SBP, W16 | SBP, W24 | SBP, W36 | SBP, W52 | SBP, Year 2 W12 | SBP, Follow-up | DBP, W4 | DBP, W8 | DBP, W12 | DBP, W16 | DBP, W24 | DBP, W36 | DBP, W52 | DBP, Year 2 W12 | DBP, Follow-up | |
| RSG XR 8 mg | -0.2 | -1.1 | -0.7 | -1.3 | -1.2 | -3.0 | 0.3 | -0.1 | -0.5 | -0.8 | -2.1 | -2.0 | -2.2 | -2.1 | -3.0 | -1.4 | 2.8 | -0.9 |
The CIBIC+ score used for global functioning assessment. The CIBIC+ assessment comprised of a 7-point rating of severity. It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; The lower score indicated betterment in functioning and higher score means greater dysfunction. The scale was based on interviews with the participant and the caregiver and was completed by an independent rater. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W 24 and W 52
| Intervention | Score on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
| RSG XR 8 mg | 4.3 | 4.5 | 4.3 | 4.7 | 4.3 | 4.3 |
BW of participants were recorded as vital sign at each visit. The BW were identified as of potential clinical concern if the vales were increased or decreased from Baseline by >=7%. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline in BW was measured as the BW value at specified visit minus the Baseline BW value. Number of participants with abnormal BW at any time during treatment period were reported. (NCT00550420)
Timeframe: Baseline (Visit 1, W0) to W 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Increase from Baseline >=7% | Decrease from Baseline >=7% | |
| RSG XR 8 mg | 30 | 16 |
HR of participants was recorded as vital sign at each visit. The HR values were identified as of potential clinical concern if the vales were out of the reference range 50 to 100 beats per minute (BPM) or meet a change from Baseline criterion. The change from Baseline criterion was as, increase in HR (high) from Baseline if HR was increased by >= 30 bpm or decrease in HR (Low) from Baseline if HR was decreased by >= 30 bpm from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the HR at specified visit minus the Baseline value. Number of participants with abnormal HR at any time during treatment period were reported. (NCT00550420)
Timeframe: Up to 82 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| HR, >100 or <50 | HR, Increase from baseline >=30 | |
| RSG XR 8 mg | 3 | 2 |
SBP and DBP of participant were recorded in sitting posture as vital sign at each visit. The blood pressure (BP) values were identified as of potential clinical concern if the vales were out of the reference range (for SBP, 90 to 140 mmHg and DBP, 50 to 90 mmHg) or meet a change from Baseline criterion. The change from Baseline criterion for SBP, was increase from Baseline (high) if increased by more than or equal to (>=) 40 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 30 mmHg from Baseline. For DBP, increase form Baseline (high) if increased by >= 30 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 20 mmHg from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the blood pressure value recorded at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Up to 82 weeks
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| SBP, >140 or <90, | SBP, Increase from Baseline >=40, | SBP, Decrease from Baseline >=30, | DBP, >90 or <50, | DBP, Increase from Baseline >=30, | DBP, Decrease from Baseline >=20, | |
| RSG XR 8 mg | 84 | 8 | 22 | 23 | 2 | 31 |
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The drug related-AEs of special interest (AESI) was reported. The severity of the AESI was categorized as mild, moderate and severe. Number of participants with AEs were reported for treatment duration of the study. (NCT00550420)
Timeframe: Up to Week 82
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Any AEs | Total Drug-Related AESI | Mild AESI | Moderate AESI | Severe AESI | |
| RSG XR 8mg | 125 | 46 | 31 | 13 | 2 |
The clinical chemistry parameters including alanine amino transferase (ALT), aldolase, aspartate amino transferase (AST), blood urea nitrogen /creatinine (BUN/Creat) ratio, cholesterol (Chol), creatine kinase, creatinine, direct bilirubin, gamma glutamyl transferase (GGT), glucose, high density lipid (HDL), low density lipid (LDL), potassium, troponin 1, and urea were assessed as safety parameters. The number of participants with values outside the reference range (potential clinical concern ) at any time on treatment (ATOT) and follow-up period were reported. The treatment period was till W104 followed by 6 weeks of follow-up period till W110 of study. (NCT00550420)
Timeframe: Up to 82 weeks
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, ATOT, High | ALT, Follow-up, High | Aldolase, ATOT, High | Aldolase, ATOT, Low | Aldolase, Follow-up, Low | AST, ATOT, High | AST, Follow-up, High | BUN/Creat ratio, ATOT, High | BUN/Creat ratio, Follow-up, High | Chol, ATOT, High | Chol, Follow-up, High | Creatine Kinase, ATOT, High | Creatine Kinase, Follow-up, High | Creatinin, ATOT, High | Creatinin, Follow-up, High | Direct Bilirubin, ATOT, High | GGT, ATOT, High | GGT, Follow-up, High | Glucose, ATOT, High | Glucose, ATOT, Low | Glucose, Follow-up, High | HDL, ATOT, Low | LDL, ATOT, High | LDL, Follow-up, High | Potassium, ATOT, High | Potassium, ATOT, Low | Troponin I, ATOT, High | Urea, ATOT, High | Urea, Follow-up, High | |
| RSG XR 8 mg | 1 | 1 | 3 | 7 | 3 | 2 | 1 | 18 | 1 | 52 | 13 | 32 | 7 | 4 | 5 | 1 | 308 | 142 | 19 | 5 | 8 | 1 | 135 | 45 | 4 | 1 | 2 | 19 | 7 |
The hematological parameters including eosinophils, lymphocytes, monocytes, platelet count, Segmented Neutrophils, total neutrophils, white blood cell (WBC), red blood cell (RBC) counts, hemoglobin, hematocrit count, mean corpuscle hemoglobin (MCH) and mean corpuscle volume (MCV) were analyzed as safety parameters. The number of participants with values outside the reference range (potential clinical concern ) at any time on treatment (ATOT) and follow-up period were reported. The treatment period was till W104 followed by 6 weeks of follow-up period till W110 of study. (NCT00550420)
Timeframe: Up to 82 weeks
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eosinophils, ATOT, High | Hematocrit, ATOT, Low | Hematocrit, Follow-up, Low | Hemoglobin, ATOT, High | Hemoglobin, ATOT, Low | Hemoglobin, Follow-Up, Low | Lymphocytes, ATOT, Low | Lymphocytes, Follow-Up, Low | MCH, ATOT, High | MCH, Follow-Up, High | MCV, ATOT, High | MCV, Follow-Up, High | Monocytes, ATOT, Low | Monocytes, ATOT, High | Platelet count, ATOT, High | Platelet count, ATOT, Low | Red Cell Distribution Width, ATOT, High | Red Cell Distribution Width,Follow-up, High | Red Blood Cell count, ATOT, Low | Red Blood Cell count, Follow-up, Low | Segmented Neutrophils, ATOT, High | Segmented Neutrophils, ATOT, Low | Segmented Neutrophils, Follow-up, Low | Total Neutrophils, ATOT, High | Total Neutrophils, ATOT, Low | Total Neutrophils, Follow-Up, Low | WBC, ATOT, Low | |
| RSG XR 8 mg | 1 | 2 | 1 | 1 | 20 | 8 | 5 | 3 | 1 | 1 | 1 | 1 | 17 | 5 | 1 | 2 | 30 | 8 | 4 | 4 | 1 | 14 | 2 | 1 | 14 | 2 | 9 |
A serious adverse event is defined as any untoward medical occurrence that, at any dose results in death, life-threatening condition, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or a congenital anomaly or birth defect. The SAEs and deaths are reported from Visit 1 (W0) till end of the follow-up period (W110) (NCT00550420)
Timeframe: Up to Week 82
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any SAE | Death | |
| RSG XR 8 mg | 8 | 3 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores ranged from 0 to 70 with higher scores indicating greater dysfunction. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point. (NCT00490568)
Timeframe: Baseline (Week 0) and Week 24, 52
| Intervention | Scores on scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 24 (Full population) | Week 52 (Full population) | Week 24 (APOE4 negatives) | Week 52 (APOE4 negatives) | Week 24 (APOE4 positives) | Week 52(APOE4 positives) | Week 24 (APOE4 E4 homozygotes) | Week 52 (APOE4 E4 homozygotes) | Week 24 (APOE4 E4 heterozygotes) | Week 52 (APOE4 E4 heterozygotes) | |
| RSG XR | 2.5 | 5.1 | 2.3 | 4.8 | 2.6 | 5.4 | 2.7 | 5.2 | 2.6 | 5.4 |
The CDR-SB is a validated clinical assessment of global function in par. with Alzheimer's disease (AD). Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or box scores, were added together to give the CDR-Sum of Boxes which ranged from 0 to 18 (severe impairment). Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point. (NCT00490568)
Timeframe: Baseline (Week 0) and Week 24, 52
| Intervention | Scores on scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 24 (Full population) | Week 52 (Full population) | Week 24 (APOE4 negatives) | Week 52 (APOE4 negatives) | Week 24 (APOE4 positives) | Week 52 (APOE4 positives) | Week 24 (APOE4 E4 homozygotes) | Week 52 (APOE4 E4 homozygotes) | Week 24 (APOE4 E4 heterozygotes) | Week 52 (APOE4 E4 heterozygotes) | |
| RSG XR | 0.7 | 1.6 | 0.6 | 1.3 | 0.7 | 1.9 | 0.9 | 1.9 | 0.7 | 1.9 |
DAD, assessed the ability of a participant to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assesses a participant's ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. The percentage score was calculated as (DAD total score/total number of applicable items) * 100. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point. (NCT00490568)
Timeframe: Baseline (Week 0) and Week 24, 52
| Intervention | Scores on scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 24 (Full population) | Week 52 (Full population) | Week 24 (APOE4 negatives) | Week 52 (APOE4 negatives) | Week 24 (APOE4 positives) | Week 52 (APOE4 positives) | Week 24 (APOE4 E4 homozygotes) | Week 52 (APOE4 E4 homozygotes) | Week 24 (APOE4 E4 heterozygotes) | Week 52 (APOE4 E4 heterozygotes) | |
| RSG XR | -5.6 | -10.8 | -4.6 | -10.9 | -6.2 | -10.7 | -5.6 | -12.6 | -6.4 | -10.1 |
The MMSE consisted of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores ranged from 0 to 30, with lower scores indicating greater cognitive impairment. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point. (NCT00490568)
Timeframe: Baseline (Week 0) and Week 24, 52
| Intervention | Scores on scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 24 (Full population) | Week 52 (Full population) | Week 24 (APOE4 negatives) | Week 52 (APOE4 negatives) | Week 24 (APOE4 positives) | Week 52 (APOE4 positives) | Week 24 (APOE4 E4 homozygotes) | Week 52 (APOE4 E4 homozygotes) | Week 24 (APOE4 E4 heterozygotes) | Week 52 (APOE4 E4 heterozygotes) | |
| RSG XR | -1.2 | -2.3 | -0.7 | -1.5 | -1.5 | -2.8 | -1.5 | -2.5 | -1.5 | -2.9 |
12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, motor disturbance, appetite, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions=participant has problems with a particular sub-domain of behavior, the caregiver asked all the questions about that domain, rating the frequency (1=occasionally to 4=very frequently) on a 4-point scale, their severity (1=Mild to 3=Severe) on a 3-point scale, and the distress on a 5-point scale. Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point. (NCT00490568)
Timeframe: Baseline (Week 0) and Week 24, 52
| Intervention | Score on scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 24 (Full population) | Week 52 (Full population) | Week 24 (APOE4 negatives) | Week 52 (APOE4 negatives) | Week 24 (APOE4 positives) | Week 52 (APOE4 positives) | Week 24 (APOE4 E4 homozygotes) | Week 52 (APOE4 E4 homozygotes) | Week 24 (APOE4 E4 heterozygotes) | Week 52 (APOE4 E4 heterozygotes) | |
| RSG XR | 1.4 | 3.2 | 1.0 | 2.4 | 1.7 | 3.8 | 1.8 | 4.2 | 1.6 | 3.7 |
The clinical chemistry data included non-fasting measures of lipid metabolism (TC,HDL,LDL,triglycerides). Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the lipids (TC,HDL,LDL,triglycerides) value recorded at specified visit minus the Baseline value. (NCT00490568)
Timeframe: Up to 82 Weeks (including follow up)
| Intervention | millimole per litre (mmol/l) (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TC at Week 4 | TC at Week 16 | TC at Week 36 | TC at Week 52 | TC at Week 76 | TC at follow up | HDL at Week 4 | HDL at Week 16 | HDL at Week 36 | HDL at Week 52 | HDL at Week 76 | HDL at follow up | LDL at Week 4 | LDL at Week 16 | LDL at Week 36 | LDL at Week 52 | LDL at Week 76 | LDL at follow up | Triglycerides at Week 4 | Triglycerides at Week 16 | Triglycerides at Week 36 | Triglycerides at Week 52 | Triglycerides at Week 76 | Triglycerides at follow up | |
| RSG XR | 0.076 | 0.201 | 0.246 | 0.174 | -0.715 | 0.093 | 0.007 | -0.014 | -0.026 | -0.035 | 0.050 | -0.058 | 0.062 | 0.210 | 0.281 | 0.228 | -0.200 | 0.148 | 0.004 | -0.025 | -0.062 | -0.092 | -0.150 | -0.035 |
BW was measured at all visits, without shoes and wearing light clothing. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the body weight at specified visit minus the Baseline value. (NCT00490568)
Timeframe: Up to 70 Weeks (including follow up)
| Intervention | kg (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| BW at Week 4 | BW at Week 8 | BW at Week 12 | BW at Week 16 | BW at Week 24 | BW at Week 36 | BW at Week 52 | BW at Week 64 | BW at Follow-up | |
| RSG XR | 0.3 | 0.6 | 0.6 | 0.7 | 0.6 | 1.0 | 1.2 | 1.4 | 0.5 |
Vital sign HR was measured at each visit. HR was measured once, after the participant sat quietly for at least 5 minutes. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the HR at specified visit minus the Baseline value. (NCT00490568)
Timeframe: Up to 70 Weeks (including follow up)
| Intervention | beats per minute (bpm) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HR at Week 4 | HR at Week 8 | HR at Week 12 | HR at Week 16 | HR at Week 24 | HR at Week 36 | HR at Week 52 | HR at Week 64 | HR at Follow-up | |
| RSG XR | 1.0 | 1.8 | 1.6 | 1.6 | 0.9 | 1.3 | 0.7 | 1.0 | 0.9 |
Vital signs SBP and DBP were measured at each visit. All measurements were made on the participant non-dominant arm supported at heart level, using the same cuff size and same equipment. Blood pressure was measured once, after the participant sat quietly for at least 5 minutes. DBP was measured at the disappearance of Korotkoff sounds (Phase V). If the participant was a smoker or used tobacco products, a period of 30 minutes without tobacco was allowed before taking these measurements. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the blood pressure value recorded at specified visit minus the Baseline value. (NCT00490568)
Timeframe: Up to 70 Weeks (including follow up)
| Intervention | millimeters of mercury (mmHg) (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP at Week 4 | SBP at Week 8 | SBP at Week 12 | SBP at Week 16 | SBP at Week 24 | SBP at Week 36 | SBP at Week 52 | SBP at Week 64 | SBP at Follow-up | DBP at Week 4 | DBP at Week 8 | DBP at Week 12 | DBP at Week 16 | DBP at Week 24 | DBP at Week 36 | DBP at Week 52 | DBP at Week 64 | DBP at Follow-up | |
| RSG XR | -1.4 | -2.4 | -2.7 | -3.7 | -2.1 | -1.4 | -1.7 | -2.2 | -1.8 | -1.4 | -2.0 | -2.1 | -2.4 | -2.4 | -2.0 | -3.6 | -6.3 | -0.9 |
Oedema was considered as adverse event of special interest (AESI). The process for AESI selection was based on RSG's pharmacologic class and relevant AEs potentially associated with RSG. The number of participants and their percentage for the adverse event of the various types of oedema were reported. (NCT00490568)
Timeframe: Up to 76 Weeks
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Oedema peripheral | Face oedema | Pitting oedema | Oedema | Pulmonary oedema | Eyelid oedema | |
| RSG XR | 130 | 8 | 5 | 3 | 1 | 1 |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The severity of the AE'S was categorized as mild, moderate and severe. Number of participants reporting AEs during the on treatment phase of the study. (NCT00490568)
Timeframe: Up to 76 Weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Any AE | Mild AE | Moderate AE | Severe AE | |
| RSG XR | 724 | 345 | 289 | 88 |
The frequency of participant vital sign weight was obtained to check if the values have CFB of PCC IFB >=7 percent. With the exception of Week 4, when participants were first titrated to the 8mg RSG XR dose, at every time point in the study where weight was measured the percentage of participants experienced an increase in BW of PCC was approximately 2 times greater than the percentage of participants experiencing an decrease in BW of PCC DFB >=7 percent. The number of participants with values of PCC including follow up were reported. (NCT00490568)
Timeframe: Up to 70 Weeks (including follow up)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ATOT, BW(IFB)>=7 percent | ATOT, BW(DFB)>= 7 percent | Follow up, BW(IFB)>=7 percent | Follow up, BW(DFB)>= 7 percent | |
| RSG XR | 188 | 83 | 90 | 51 |
The clinical chemistry data included alanine amino transferase (ALT), albumin, aldolase, asparatate amino transferase (AST), BUN/creatinine ratio, carbon dioxide(CO2) content, chloride, cholesterol, creatinine kinase (CK), creatinine, direct bilirubin (DB), gamma glutamyl transferase (GGT), glucose, glycosylated Hemoglobin (HbA1C), HDL, LDL, lactate dehydrogenase (LD), magnesium, potassium, sodium, total bilirubin (TB), triglycerides, troponin I, urea. The number of participants with values of PCC (defined as high and low) ATOT were reported. (NCT00490568)
Timeframe: Up to Week 82 (including follow up)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow up, ALT (high) | Follow up, Albumin (low) | ATOT, Aldolase (high) | ATOT, Aldolase (low) | Follow up, Aldolase (high) | Follow up, Aldolase (low) | ATOT, AST (high) | Follow up, AST (high) | ATOT, BUN/creatinine ratio (high) | Follow up, BUN/creatinine ratio (high) | ATOT, CO2 content (low) | Follow up, CO2 content (low) | ATOT, chloride (high) | ATOT, cholesterol (high) | Follow up, cholesterol (high) | ATOT, CK (high) | Follow up, CK (high) | ATOT, Creatinine (high) | Follow up, creatinine (high) | ATOT, DB (high) | ATOT, GGT (high) | Follow up, GGT (high) | ATOT, Glucose (high) | ATOT, Glucose (low) | Follow up, glucose (high) | Follow up, glucose (low) | ATOT, HbA1c (high) | ATOT, HDL (low) | Follow up, HDL (low) | ATOT, LDL (low) | Follow up, LDL (low) | ATOT, LD (high) | Follow up, LD (high) | ATOT, Magnesium (low) | Follow up, Magnesium (low) | ATOT, Potassium (high) | ATOT, Potassium (low) | Follow up, Potassium (high) | Follow up, Potassium (low) | ATOT, Sodium (high) | ATOT, Sodium (low) | Follow up, Sodium (low) | ATOT, TB (high) | Follow up, TB (high) | ATOT, Triglycerides (high) | ATOT, Troponin I (high) | Follow up, Troponin I (high) | ATOT, Urea (high) | Follow up, Urea (high) | |
| RSG XR | 2 | 1 | 16 | 78 | 3 | 14 | 2 | 3 | 87 | 37 | 2 | 3 | 1 | 175 | 50 | 131 | 40 | 27 | 10 | 4 | 7 | 2 | 100 | 40 | 31 | 13 | 2 | 11 | 7 | 469 | 211 | 1 | 1 | 1 | 1 | 17 | 1 | 2 | 1 | 2 | 4 | 1 | 1 | 1 | 1 | 13 | 2 | 97 | 42 |
The hematology data included eosinophils, haematocrit, haemoglobin, lymphocytes, mean corpuscular haemoglobin (MCH), mean corpuscular volume (MCV), monocytes, platelet count, red cell distribution width (RDW), red blood cell (RBC) count, segmented neutrophils (SN), total neutrophils (TN), white blood cell (WBC) count. The number of participants with values of PCC (defined as high and low) ATOT were reported. (NCT00490568)
Timeframe: Up to Week 82 (including follow up)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATOT, Eosinophils (high) | ATOT, Haematocrit (low) | Follow up, Haematocrit (low) | ATOT, Haemoglobin (high) | ATOT, Haemoglobin (low) | Follow up, Hemoglobin (high) | Follow up, Hemoglobin (low) | ATOT, Lymphocytes (high) | ATOT, Lymphocytes (low) | Follow up, Lymphocytes (high) | Follow up, Lymphocytes (low) | ATOT, MCH (low) | Follow up, MCH (low) | ATOT, MCV (low) | ATOT, monocytes (high) | ATOT, monocytes (low) | Follow up, monocytes (low) | ATOT, platelet count (high) | ATOT, platelet count (low) | ATOT, RDW (high) | Follow up, RDW (high) | ATOT, RBC (low) | Follow up, RBC (low) | ATOT, SN (high) | ATOT, SN (low) | Follow up, SN (high) | Follow up, SN (low) | ATOT, TN (high) | ATOT, TN (low) | Follow up, TN (high) | Follow up, TN (low) | ATOT, WBC (high) | ATOT, WBC (low) | Follow up, WBC (high) | Follow up, WBC (low) | |
| RSG XR | 2 | 8 | 6 | 2 | 74 | 2 | 25 | 3 | 21 | 3 | 9 | 5 | 1 | 1 | 1 | 61 | 23 | 7 | 5 | 158 | 45 | 12 | 4 | 6 | 15 | 3 | 3 | 3 | 15 | 2 | 3 | 5 | 22 | 3 | 11 |
HR was measured once, after the participant sat quietly for at least 5 minutes. The frequency of participant vital sign heart rate was obtained to check if the values lie outside of a pre-determined reference range (RR) 50-100 bpm or have a change from Baseline of PCC IFB >=30 and DFB >=30. The number of participants with values of PCC including follow up were reported. (NCT00490568)
Timeframe: Up to 70 Weeks (including follow up)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| ATOT,HR (RR)>100 or <50 | ATOT,HR (IFB)>=30 | ATOT,HR (DFB)>=30 | Follow up,HR (RR)>100 or <50 | Follow up,HR (IFB)>=30 | Follow up,HR (DFB)>=30 | |
| RSG XR | 55 | 25 | 14 | 18 | 11 | 6 |
The frequency of participant vital sign sitting blood pressure was obtained to check if the values lie outside of a pre-determined reference range (RR) for SBP 90-140 mmHg, DBP 50-90 mmHg or have a change from Baseline of PCC for SBP increase from Baseline (IFB) >=40, decrease from Baseline (DFB) >= 30 for and for DBP (IFB) >= 30 ,DFB >= 20. The number of participants with values of PCC at any time on treatment (ATOT) and follow up were reported. (NCT00490568)
Timeframe: Up to 70 Weeks (including follow up)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATOT,SBP(RR)>140 or <90 | ATOT,SBP(IFB)>=40 | ATOT,SBP(DFB)>=30 | Follow up,SBP(RR)>140 or <90 | Follow up,SBP(IFB)>=40 | Follow up,SBP(DFB)>=30 | ATOT,DBP(RR)>90 or<50 | ATOT,DBP(IFB)>=30 | ATOT,DBP(DFB)>= 20 | Follow up,DBP(RR)>90 or<50 | Follow up,DBP(IFB)>=30 | Follow up, DBP(DFB)>= 20 | |
| RSG XR | 520 | 33 | 179 | 240 | 13 | 63 | 141 | 20 | 211 | 54 | 5 | 67 |
A SAE is defined as any untoward medical occurrence that, at any dose results in death, is a life-threatening condition, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or a congenital anomaly or birth defect. Number of participants with SAEs and deaths were reported for treatment duration of the study. (NCT00490568)
Timeframe: Up to 76 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any SAE | Deaths | |
| RSG XR | 126 | 20 |
Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Change from Baseline in HbA1c was calculated as the value at Week 48 minus the value at Baseline. (NCT00348309)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Percentage of total hemoglobin (Least Squares Mean) |
|---|---|
| Placebo | 0.14 |
| 2mg Rosiglitazone Extended Release | 0.21 |
| 8mg Rosiglitazone Extended Release | 0.18 |
The MMSE consists of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. The scale was completed by the investigator, based on the performance of the participant, and took approximately 5 to 10 minutes to administer. The scores from 11 tests were combined to obtain the total score. The total scores range from 0 to 30, with lower scores indicating greater cognitive impairment and higher score indicating better outcome; a positive change from screening indicated an improvement. The total MMSE score for participants at screening was between 10 and 26, inclusive, in order to be eligible to participate in the trial. Change from screening is calculated as endpoint value minus the screening value. (NCT00348309)
Timeframe: Screening (Week -4) and Week 48
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.6 |
| 2mg Rosiglitazone Extended Release | -1.6 |
| 8mg Rosiglitazone Extended Release | -1.7 |
ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in patients with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change was calculated as endpoint value (Week 54) minus Week 48 value. (NCT00348309)
Timeframe: Week 48 and 54
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.7 |
| 2mg Rosiglitazone Extended Release | 1.1 |
| 8mg Rosiglitazone Extended Release | 1.1 |
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change was calculated as endpoint value (Week 54) minus Week 48 value. (NCT00348309)
Timeframe: Week 48 and 54
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.2 |
| 2mg Rosiglitazone Extended Release | 0.2 |
| 8mg Rosiglitazone Extended Release | 0.1 |
ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in patients with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change from baseline is calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 8, 16, 24, 36 and 48
| Intervention | Score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 36 | Week 48 | |
| 2mg Rosiglitazone Extended Release | -0.6 | -0.5 | -0.2 | 1.3 | 2.1 |
| 8mg Rosiglitazone Extended Release | -0.2 | 0.1 | 0.8 | 2.2 | 2.6 |
| Placebo | -0.2 | -0.1 | 1.0 | 1.8 | 2.9 |
The ACQLI was an assessment of caregiver quality of life. This instrument consists of 30 questions exploring various aspects of carer's quality of life. Each of the questions had a two point response and the 30 questions were summed to provide a total score. Items are assumed to be unidimensional (i.e., represent a single variable) and are scored 0/1 (false/true) before summation into a total score with a 0-30 range. The total score ranged from 0 to 30, where 0 indicated absence of symptoms and higher score indicated worse outcomes; a negative change from baseline indicated improvement. Change from baseline was calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 12, 36 and 48
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 12 | Week 36 | Week 48 | |
| 2mg Rosiglitazone Extended Release | -0.2 | 0.6 | 0.3 |
| 8mg Rosiglitazone Extended Release | -0.0 | 0.6 | 1.1 |
| Placebo | 0.5 | 1.0 | 1.2 |
ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in participants with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change from baseline is calculated as Week 48 value minus the baseline value. APOE4 negative, All except E4/E4's: comprised of APOE4 negative and E4 heterozygote and full population was analyzed for this outcome measure. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the genetic subgroups. Least square mean is entered for adjusted mean. (NCT00348309)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| APOE4 negatives | All except E4/E4s | Full populations | |
| 2mg Rosiglitazone Extended Release | 1.6 | 2.1 | 2.4 |
| 8mg Rosiglitazone Extended Release | 2.7 | 3.1 | 3.2 |
| Placebo | 2.9 | 3.1 | 3.4 |
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change from baseline is calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 12, 24, 36 and 48
| Intervention | Score on a scale (Mean) | |||
|---|---|---|---|---|
| Week 12 | Week 24 | Week 36 | Week 48 | |
| 2mg Rosiglitazone Extended Release | 0.3 | 0.5 | 0.7 | 1.0 |
| 8mg Rosiglitazone Extended Release | 0.3 | 0.8 | 1.2 | 1.6 |
| Placebo | 0.4 | 0.7 | 1.0 | 1.5 |
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change from baseline is calculated as Week 48 value minus the baseline value. APOE4 negative, All except E4/E4's: comprised of APOE4 negative and E4 heterozygote and full population was analyzed for this outcome measure. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the genetic subgroups. (NCT00348309)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| APOE4 negatives | All except E4/E4s | Full population | |
| 2mg Rosiglitazone Extended Release | 0.8 | 1.0 | 1.0 |
| 8mg Rosiglitazone Extended Release | 1.5 | 1.7 | 1.7 |
| Placebo | 1.3 | 1.5 | 1.6 |
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. The scale includes 23 items relating to instrumental activities of daily living and 17 items relating to basic self-care. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. Total score was obtained by adding the rating for each question and converting this total score out of 100. The total score ranged from 0 to 100, where higher score indicated better function and lower score indicated greater severity of symptoms; a positive change from baseline indicated an improvement. Change from baseline is calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 8, 16, 24 and 48
| Intervention | Scores on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| At Week 8 | At Week 16 | At Week 24 | At Week 48 | |
| 2mg Rosiglitazone Extended Release | -0.5 | -1.6 | -2.2 | -5.7 |
| 8mg Rosiglitazone Extended Release | -1.1 | -2.1 | -3.3 | -8.4 |
| Placebo | 0.1 | -1.6 | -3.5 | -7.8 |
"The EQ-5D Proxy is a two part scale that evaluated the participant's health status via Thermometer and Utility scores. The Thermometer score was the caregiver's rating of the participant's overall health status on a VAS (0 [worst possible status] to 100 [best imaginable status]). The Utility score was a caregiver rating of health status on dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression] where '1' indicated better health state (no problems); '3' indicated worst health state (confined to bed). Total possible score was the sum of individual items, ranged from 5 to 15; lower score indicated a better health state and higher score indicated greater severity of symptoms. A positive change from baseline indicated improvement in the Thermometer score and a negative change from baseline indicated improvement in the Utility score. Change from baseline is calculated as endpoint value minus the baseline value." (NCT00348309)
Timeframe: Baseline (Week 0), Week 12, 36 and 48
| Intervention | Score on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Thermometer: Week 12 | Thermometer: Week 36 | Thermometer: Week 48 | Utility: Week 12 | Utility: Week 36 | Utility: Week 48 | |
| 2mg Rosiglitazone Extended Release | 0.3 | -1.6 | -0.3 | 0.02 | -0.01 | -0.02 |
| 8mg Rosiglitazone Extended Release | -0.5 | -2.1 | -2.4 | -0.01 | -0.04 | -0.05 |
| Placebo | 0.5 | 0.8 | -1.5 | 0.01 | -0.02 | -0.04 |
Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Change from Baseline in HbA1c was calculated as the value at time point minus the value at Baseline. (NCT00348309)
Timeframe: Baseline (Week 0) and Week 12, 24 and 36
| Intervention | Percent of total hemoglobin (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 36 | |
| 2mg Rosiglitazone Extended Release | 0.14 | 0.12 | 0.19 |
| 8mg Rosiglitazone Extended Release | 0.16 | 0.06 | 0.15 |
| Placebo | 0.01 | 0.07 | 0.20 |
Blood samples of participants were collected for Hematocrit . Change from baseline in Hematocrit was calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 4, 8, 12, 16, 36 and 48
| Intervention | litre (Mean) | |||
|---|---|---|---|---|
| Week 4 | Week 16 | Week 36 | Week 48 | |
| 2mg Rosiglitazone Extended Release | -0.0068 | -0.0174 | -0.0167 | -0.0177 |
| 8mg Rosiglitazone Extended Release | -0.0115 | -0.0339 | -0.0352 | -0.0346 |
| Placebo | -0.0007 | -0.0003 | -0.0037 | -0.0029 |
Blood samples of participants were collected for Hemoglobin. Change from baseline in Hemoglobin was calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 4, 16, 36 and 48
| Intervention | grams per litre (g/L) (Mean) | |||
|---|---|---|---|---|
| Week 4 | Week 16 | Week 36 | Week 48 | |
| 2mg Rosiglitazone Extended Release | -2.5 | -6.2 | -6.4 | -6.5 |
| 8mg Rosiglitazone Extended Release | -3.7 | -11.9 | -12.5 | -12.2 |
| Placebo | -0.4 | -0.6 | -2.0 | -1.9 |
The NPI is a questionnaire that quantifies behavioral changes in dementia. For each of 12 behavioral domains there are 4 scores: Frequency (scale:1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale: 0=not at all distressing to 5=extremely distressing).The NPI Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual Item Scores, to yield a possible total score of 0 to 24. Lower score=less severity. Change from baseline is calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 8, 16, 24 and 48
| Intervention | Score on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| At Week 8 | At Week 16 | At Week 24 | At Week 48 | |
| 2mg Rosiglitazone Extended Release | -0.7 | -0.6 | -0.2 | 0.1 |
| 8mg Rosiglitazone Extended Release | -0.3 | 0.1 | 0.2 | 1.8 |
| Placebo | -0.3 | -0.3 | 0.4 | 1.6 |
The RUD instrument was developed as a comprehensive tool to assess the amount of resource use among demented patients. RUD assessd both formal and informal resource use of the patient and the primary caregiver, making it possible to calculate costs from a societal perspective. Q1 corresponds to the number of hours during the last month the caregiver spent assisting the patient with toilet visits, eating, dressing, grooming, walking and bathing and Q2 corresponds to the number of hours during the last month the caregiver spent assisting the patient with shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. (NCT00348309)
Timeframe: Baseline (Week 0), Week 12, 24, 36 and 48
| Intervention | hours (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Q1: Week 12 | Q1: Week 24 | Q1: Week 36 | Q1: Week 48 | Q2: Week 12 | Q2: Week 24 | Q2: Week 36 | Q2: Week 48 | |
| 2mg Rosiglitazone Extended Release | 2.4 | 3.4 | 10.0 | 17.0 | 2.4 | 1.6 | 4.6 | 8.4 |
| 8mg Rosiglitazone Extended Release | -0.1 | 7.0 | 15.2 | 18.1 | 1.5 | 6.5 | 13.3 | 27.0 |
| Placebo | 1.6 | 10.7 | 16.3 | 21.7 | -6.4 | 0.3 | 5.0 | 10.8 |
Mean Change From Baseline in heart rate was calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
| Intervention | beats per min (bpm) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | Week 36 | Week 48 | Week 54 | |
| 2mg Rosiglitazone Extended Release | 1.1 | 1.3 | 1.8 | 1.3 | 1.3 | 1.8 | 1.4 | 1.4 |
| 8mg Rosiglitazone Extended Release | 0.6 | 1.0 | 0.7 | 0.8 | 0.8 | 1.1 | 0.7 | 0.0 |
| Placebo | 0.8 | 1.5 | 1.6 | 1.0 | 0.9 | 0.9 | 1.2 | 0.5 |
Short term memory assessment score was based on ADAS-Cog questionnaire (Question 1 and 7). ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in participants with AD. Question 1 (Word Recall) and Question 7 (Word Recognition) of the ADAS-Cog questionnaire were summed to get a short term memory assessment score. Word recall task consist of the participants score was the mean number of words not recalled on three trials (maximum score 10) and word recognition task, to score this item the number of incorrect responses was counted (maximum error score was 12). The total score ranged from 0 to 22 with 0 indicating absence of symptoms and higher scores indicating greater dysfunction; a negative change from baseline indicated improvement. Change from Baseline in short term memory assessment was calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 8, 16, 24, 36, 48 and 56
| Intervention | Score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 36 | Week 48 | Week 54 | |
| 2mg Rosiglitazone Extended Release | -0.4 | -0.7 | -0.4 | 0.3 | 0.3 | 0.8 |
| 8mg Rosiglitazone Extended Release | -0.3 | -0.4 | -0.1 | 0.7 | 0.4 | 0.9 |
| Placebo | -0.3 | -0.4 | 0.1 | 0.4 | 0.6 | 1.1 |
The plethysmographic method was used to measure BP throughout the study. Change in Systolic and Diastolic BP was calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
| Intervention | Millimeter of mercury (mmHg) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic BP Week 4 | Systolic BP Week 8 | Systolic BP Week 12 | Systolic BP Week 16 | Systolic BP Week 24 | Systolic BP Week 36 | Systolic BP Week 48 | Systolic BP Week 54 | Diastolic BP Week 4 | Diastolic BP Week 8 | Diastolic BP Week 12 | Diastolic BP Week 16 | Diastolic BP Week 24 | Diastolic BP Week 36 | Diastolic BP Week 48 | Diastolic BP Week 54 | |
| 2mg Rosiglitazone Extended Release | -1.0 | -0.7 | -2.5 | -1.7 | -1.0 | -0.3 | -0.6 | -1.1 | -0.7 | -0.9 | -1.3 | -1.3 | -1.2 | -0.6 | -0.5 | -0.4 |
| 8mg Rosiglitazone Extended Release | -2.3 | -2.9 | -4.2 | -3.7 | -3.5 | -2.7 | -2.5 | -2.3 | -1.2 | -2.1 | -2.5 | -3.0 | -2.6 | -3.3 | -1.9 | -1.8 |
| Placebo | -0.7 | -0.3 | -0.5 | -0.8 | -1.2 | -1.6 | -1.0 | 0.0 | -0.4 | -0.0 | 0.0 | -0.7 | -1.1 | -1.2 | -0.8 | -0.9 |
Body weight was measured at all visits, without shoes and wearing light clothing. Mean Change From Baseline in Weight was calculated as endpoint value minus the baseline value. (NCT00348309)
Timeframe: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
| Intervention | kilogram (kg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | Week 36 | Week 48 | Week 54 | |
| 2mg Rosiglitazone Extended Release | 0.2 | 0.3 | 0.3 | 0.3 | 0.6 | 0.7 | 0.8 | 0.7 |
| 8mg Rosiglitazone Extended Release | 0.3 | 0.7 | 0.9 | 1.0 | 0.9 | 1.3 | 1.3 | 0.8 |
| Placebo | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.4 | 0.3 |
Only those parameters for which at least one value of clinical concern (CC) was reported are summarized. Pre-defined limits of potential clinical concern (CC Low [relative to the lower limit of normal], CC High [relative to the upper limit of normal]) are: Hematocrit 0.8, 1.2; hemoglobin 10-11, 16.5-18; Red blood corpuscles(RBC) 0.8, 1.2; mean corpuscular volume (MCV) 0.8, 1.2; mean corpuscular hemoglobin (MCH) 0.8, 1.2; White blood corpuscles (WBC) 3- absolute value, 15-absolute value, Red Cell Distribution Width (RDW) 0.8, 1.2; Lymphocytes 0.75, 1.5; Monocytes NA, 2; Eosinophil NA, 2; platelet count 100-absolute, 500-absoulte; segmented neutrophil (SN) 0.75, 1.5 and Total Neutrophil (TN) 0.75, 1.5. (NCT00348309)
Timeframe: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eosinophils high | Hematocrit low | Hemoglobin high | Hemoglobin low | Lymphocytes high | Lymphocytes low | Mean CH high | Mean CH low | Mean CV high | Mean CV low | Monocytes low | Platelet count high | Platelet count low | RDW high | RBC high | RBC low | SN high | SN low | TN high | TN low | WBC high | WBC low | |
| 2mg Rosiglitazone Extended Release | 3 | 2 | 0 | 11 | 1 | 10 | 0 | 2 | 0 | 1 | 55 | 2 | 2 | 31 | 1 | 1 | 2 | 6 | 1 | 6 | 1 | 5 |
| 8mg Rosiglitazone Extended Release | 0 | 5 | 0 | 31 | 2 | 13 | 1 | 0 | 1 | 0 | 65 | 7 | 4 | 86 | 0 | 8 | 4 | 13 | 2 | 13 | 3 | 12 |
| Placebo | 0 | 2 | 2 | 8 | 0 | 8 | 0 | 2 | 0 | 2 | 81 | 4 | 1 | 18 | 0 | 0 | 8 | 2 | 4 | 2 | 4 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. The data was reported for prospective period. (NCT00348309)
Timeframe: Up to Week 54
| Intervention | Participants (Number) | |
|---|---|---|
| Any TEAEs | Any SAEs | |
| 2mg Rosiglitazone Extended Release | 273 | 45 |
| 8mg Rosiglitazone Extended Release | 327 | 50 |
| Placebo | 304 | 62 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 3.8 |
| RSG XR 2mg | 3.6 |
| RSG XR 8mg | 3.8 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 3.9 |
| RSG XR 2mg | 3.8 |
| RSG XR 8mg | 3.8 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 3.2 |
| RSG XR 2mg | 3.5 |
| RSG XR 8mg | 4.0 |
"The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or box scores, can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Primary inference will be based on the week 48 treatment differences obtained from the MMRM model. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups." (NCT00348140)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.8 |
| RSG XR 2mg | 1.8 |
| RSG XR 8mg | 1.7 |
"The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or box scores, can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Primary inference will be based on the week 48 treatment differences obtained from the MMRM model. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups." (NCT00348140)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.9 |
| RSG XR 2mg | 1.8 |
| RSG XR 8mg | 1.8 |
"The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or box scores, can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Primary inference will be based on the week 48 treatment differences obtained from the MMRM model. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups." (NCT00348140)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.8 |
| RSG XR 2mg | 1.7 |
| RSG XR 8mg | 1.7 |
Blood samples were collected for assessments of HbA1c levels at Baseline and up to Week 48. Change from Baseline was calculated as value at scheduled time point minus Baseline value . Baseline was defined as value at Week 0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 48
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| Placebo | 0.13 |
| RSG XR 2mg | 0.18 |
| RSG XR 8mg | 0.26 |
The MMSE consists of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The scale is completed by the investigator, based on the performance of the participant. Change from screening was calculated as value at scheduled time point minus screening value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented. (NCT00348140)
Timeframe: Screening (Week -4) and Week 48
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| RSG XR 2mg | -2.3 |
| RSG XR 8mg | -2.0 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. It was of interest to compare the single blind phase data between the treatment groups defined based on the double blind treatment group. This analysis only included participants who received at least one dose of single-blind medication. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Week 48 and Week 54
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.0 |
| RSG XR 2mg | 0.4 |
| RSG XR 8mg | 0.5 |
"The CDR-SB was a validated clinical assessment of global function in participants with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or box scores, can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). It was of interest to compare the single blind phase data between the treatment groups defined based on the double blind treatment group. This analysis only included participants who received at least one dose of single-blind medication. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented." (NCT00348140)
Timeframe: Week 48 and Week 54
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| RSG XR 2mg | 0.2 |
| RSG XR 8mg | 0.3 |
Clinical chemistry parameters were identified as of PCC (High, Low), if values were out of RR: Alanine amino transferase (ALT,none-120 [250percent upper limit of RR, ULRR ]),Album in (0.75-2),Aldolase(1.1-1.1),Aspartate amino transferase (AST,none-105 (3-64y),137.5(65+y),>250 percent ULRR), Alkaline phosphatase(ALP,none-312.5 (20+y),>250percent ULRR),blood urea nitrogen(BUN)/Creatinine ratio(none-1.25),BUN(none-11),Chloride(80-115),Calcium (0.75-1.25),Carbon dioxide(CO2,15-40) content,Creatinine (22,<50percent lower limit of RR [LLRR ]-155, >125percent ULRR),Creatine phosphokinase(CPK,none-1.25),Gamma glutamyl transferase(GGT,none-2.5),Glucose (3.6-7.8),HbA1C, High density lipoprotein (HDL,0.65-none),Lactate dehydrogenase (LDH,none -2), Low density lipoprotein(LDL,none-1.25),Magnesium (0.5-2),Potassium (3-5.5),Phosphorus inorganic(0.5-1.5), Sodium (130-150), Total protein (0.8-1.5),Total cholesterol(none -1.5),Direct Billirubin. (NCT00348140)
Timeframe: Upto Week 48
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT- High | Aldolase- High | Aldolase- Low | Alkaline Phosphatase- High | AST- High | BUN/Creatinine ratio- High | Calcium- Low | Carbondioxide content/BicarbonateLow | Cholesterol- High | Creatine Kinase- High | Creatinine- High | Direct Bilirubin- High | GGT- High | Glucose- High | Glucose- Low | Glycosylated Hemoglobin A1C | HDL Cholesterol, direct- Low | LDL Cholesterol calculation- High | Lactate Dehydrogenase- High | Magnesium- Low | Phosphorus, inorganic- High | Potassium- High | Potassium- Low | Sodium- High | Sodium- Low | Total Bilirubin- High | Troponin I- High | Urea/BUN- High | |
| Placebo | 2 | 2 | 2 | 2 | 1 | 17 | 1 | 0 | 21 | 33 | 10 | 1 | 6 | 81 | 14 | 1 | 0 | 65 | 0 | 1 | 2 | 11 | 3 | 2 | 4 | 5 | 1 | 27 |
| RSG XR 2mg | 1 | 2 | 1 | 0 | 1 | 25 | 0 | 0 | 32 | 63 | 12 | 0 | 2 | 60 | 22 | 1 | 0 | 106 | 0 | 0 | 0 | 12 | 1 | 0 | 6 | 1 | 1 | 40 |
| RSG XR 8mg | 1 | 0 | 0 | 0 | 2 | 40 | 0 | 3 | 61 | 69 | 15 | 1 | 5 | 55 | 22 | 0 | 3 | 162 | 1 | 1 | 0 | 12 | 0 | 2 | 2 | 1 | 1 | 48 |
Haematology parameters were identified as of PCC (high [H], low [L]), if the values were out of the reference range (RR). The range for parameters was: platelet (100AV-500AV), red blood cell (RBC , 0.8-1.2), hemoglobin (L: female [F]:10, male [M]:11; H: F:16.5-AV, M:18), hematocrit (0.8-1.2), white blood cell (WBC, 3-15), Total neutrophils (ANC- absolute Neutrophil count) (0.75-1.5), lymphocytes (0.75-1.5), monocyte s (0.75-2), eosinophils (none -2), basophils (none -2), mean corpuscle volume (MCV, 0.8-1.2), mean corpuscular hemoglobin (MCH, 0.8-1.2), mean corpuscular hemoglobin concentration (MCHC , 0.8-1.2), red cell distribution width (RDW, 0.8-1.2), Neutrophil bands (none-1) and segmented neutrophils (0.75-1.3). Full population data was presented. (NCT00348140)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eosinophils- High | Hematocrit- Low | Hemoglobin- High | Hemoglobin- Low | Lymphocytes- High | Lymphocytes- Low | MCH- High | MCH- Low | MCV- High | MCV- Low | Monocytes- Low | Platelet count- High | Platelet count- Low | RDW- High | RDW- Low | Red Blood Cell count- High | Red Blood Cell count- Low | Total Neutrophils (ANC)- High | Total Neutrophils (ANC)- Low | White Blood Cell count- High | White Blood Cell count- Low | |
| Placebo | 3 | 3 | 1 | 9 | 3 | 11 | 0 | 1 | 0 | 0 | 44 | 3 | 3 | 11 | 1 | 0 | 3 | 4 | 4 | 5 | 4 |
| RSG XR 2mg | 1 | 3 | 3 | 14 | 1 | 3 | 0 | 3 | 0 | 1 | 21 | 2 | 0 | 18 | 0 | 0 | 3 | 0 | 2 | 2 | 3 |
| RSG XR 8mg | 1 | 6 | 1 | 36 | 1 | 7 | 1 | 3 | 1 | 1 | 44 | 4 | 2 | 50 | 0 | 1 | 11 | 0 | 10 | 0 | 12 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. It was calculated at Weeks 8, 16, 24 and 36. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 8, 16, 24, 36
| Intervention | Scores on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 36 | |
| Placebo | 0.1 | 0.2 | 1.1 | 2.6 |
| RSG XR 2mg | 0.2 | 0.3 | 1.5 | 2.8 |
| RSG XR 8mg | 0.3 | 0.2 | 1.1 | 2.6 |
The ACQLI is an assessment of caregiver quality of life. This instrument consisted of 30 questions exploring various aspects of carer's quality of life. Each of the questions had two point response, and the 30 questions were summed to provide a total score. Items were assumed to be unidimensional (i.e., represent a single variable) and were scored 0/1 (false/true) before summation into a total score with a 0-30 range. To ease comparisons between scales, ACQLI scores were transformed to range between 0-100 (100: worse). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 12, 36, 48
| Intervention | Scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 12 | Week 36 | Week 48 | |
| Placebo | 0.3 | 1.2 | 1.1 |
| RSG XR 2mg | 0.1 | 0.8 | 1.3 |
| RSG XR 8mg | 0.2 | 1.4 | 1.2 |
"The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or box scores, can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. It was calculated at Weeks 12, 24 and 36. Full population data was presented." (NCT00348140)
Timeframe: Baseline (Week 0) and Week 12, 24, 36
| Intervention | Scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 36 | |
| Placebo | 0.3 | 0.9 | 1.4 |
| RSG XR 2mg | 0.4 | 0.8 | 1.3 |
| RSG XR 8mg | 0.3 | 0.9 | 1.3 |
The DAD assessed the ability of a participant to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assessed a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. The percentage score was calculated as (DAD Total score /Total number of applicable items) multiplied by 100. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 8, 16, 24, 48
| Intervention | Scores on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 48 | |
| Placebo | -2.3 | -3.0 | -4.6 | -9.5 |
| RSG XR 2mg | -1.2 | -2.3 | -2.8 | -9.4 |
| RSG XR 8mg | -2.3 | -3.9 | -4.7 | -10.4 |
The RUD instrument was developed as a comprehensive tool to assess the amount of resource use among demented patients. RUD assessd both formal and informal resource use of the patient and the primary caregiver, making it possible to calculate costs from a societal perspective. Q1 corresponds to the number of hours during the last month the caregiver spent assisting the patient with toilet visits, eating, dressing, grooming, walking and bathing and Q2 corresponds to the number of hours during the last month the caregiver spent assisting the patient with shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 12, 24, 36, 48
| Intervention | Caregiver hours (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Q1 Week 12 | Q1 Week 24 | Q1 Week 36 | Q1 Week 48 | Q2 Week 12 | Q2 Week 24 | Q2 Week 36 | Q2 Week 48 | |
| Placebo | -2.4 | 7.4 | 11.2 | 15.7 | -1.1 | 5.6 | 16.4 | 21.8 |
| RSG XR 2mg | 1.8 | 9.0 | 12.7 | 19.7 | 5.8 | 15.6 | 23.4 | 26.0 |
| RSG XR 8mg | 3.5 | 10.9 | 13.4 | 19.2 | 6.4 | 12.3 | 15.2 | 21.6 |
The EQ-5D Proxy is an assessment of quality of life and utility benefit. The EQ-5D Proxy is composed of two parts: part one is the five dimensional Health State Classification. The Utility score is a caregiver rating of health status on dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Answers to each question were responded to on a 3-point scale which indicates the level of impairment (level 1= no problem; level 2=some or moderate problem(s) and level 3=unable, or extreme problem with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 12, 36, 48
| Intervention | Scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Ultility score Week 12 | Utility score Week 36 | Utility score Week 48 | |
| Placebo | -0.02 | -0.03 | -0.03 |
| RSG XR 2mg | -0.01 | -0.03 | -0.05 |
| RSG XR 8mg | -0.03 | -0.06 | -0.04 |
The EQ-5D Proxy is an assessment of quality of life and utility benefit. The EQ-5D Proxy is composed of two parts: part two is the visual analogue scale 'Thermometer'. Caregivers are asked to respond as they feel the participant would on dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 'Thermometer' has endpoints of 100 (best imaginable health state) and 0 (worst imaginable health state). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Week 12, 36, 48
| Intervention | Scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Thermometer score Week 12 | Thermometer score Week 36 | Thermometer score Week 48 | |
| Placebo | 2.4 | 1.7 | 2.1 |
| RSG XR 2mg | -0.0 | 1.3 | -0.5 |
| RSG XR 8mg | 0.1 | -0.4 | -1.4 |
Blood samples were collected for assessments of HbA1c levels at Baseline, Weeks 12, 24, 36, 48, 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. (NCT00348140)
Timeframe: Baseline (Week 0) and Weeks 12, 24, 36, 48, 54
| Intervention | Percentage of HbA1c (Mean) | ||||
|---|---|---|---|---|---|
| Week 12 | Week 24 | Week 36 | Week 48 | Week 54 | |
| Placebo | 0.02 | 0.09 | 0.15 | 0.16 | 0.09 |
| RSG XR 2mg | 0.13 | 0.17 | 0.19 | 0.19 | 0.03 |
| RSG XR 8mg | 0.15 | 0.17 | 0.25 | 0.27 | 0.03 |
Hematology parameters were assessed at Baseline and up to Week 48. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. (NCT00348140)
Timeframe: Baseline (Week 0) and Weeks 4, 16, 36, 48
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Week 4 | Week 16 | Week 36 | Week 48 | |
| Placebo | -0.0020 | -0.0018 | -0.0017 | -0.0026 |
| RSG XR 2mg | -0.0088 | -0.0166 | -0.0174 | -0.0167 |
| RSG XR 8mg | -0.0121 | -0.0320 | -0.0300 | -0.0303 |
Hematology parameters were assessed at Baseline, Weeks 4, 16, 36, 48. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Weeks 4, 16, 36, 48
| Intervention | GramLiter (GL) (Mean) | |||
|---|---|---|---|---|
| Week 4 | Week 16 | Week 36 | Week 48 | |
| Placebo | -0.5 | -0.6 | -0.7 | -0.7 |
| RSG XR 2mg | -2.9 | -6.1 | -6.2 | -5.8 |
| RSG XR 8mg | -3.9 | -11.2 | -10.6 | -10.7 |
"NPI is an assessment of frequency and severity of behavioral disturbances in dementia that comprised of 10 dimensions: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressiveness and agitation, irritability, anxiety, aberrant motor activity. Participant's caregiver asked about behavior in participant. If Yes, informant then rated both severity on a 3-point scale, 1-mild to 3-severe (total range: 0-36) and frequency using a 4-point scale, 1-occasionally to 4-very frequently. Total score was frequency × severity. Distress was scored on 5-point scale, 0-no distress to 5-very severe or extreme. Total NPI score was calculated by adding all domain scores; NPI total score: 0-144 and NPI distress score: 0-60, higher scores indicated more severe behavioral disturbance. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Adjusted means were presented. Full population data was presented." (NCT00348140)
Timeframe: Baseline (Week 0) and Week 8, 16, 24, 48
| Intervention | Scores on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 48 | |
| Placebo | -0.0 | 0.1 | 1.3 | 2.6 |
| RSG XR 2mg | -0.3 | 0.2 | 0.3 | 1.5 |
| RSG XR 8mg | -0.2 | 0.1 | 0.2 | 1.9 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Questions 1 (word recall) and 7 (word recognition) of ADAS-Cog questionnaire was summed to get a short term memory assessment. The score for Question 1 was calculated as the mean number of words not recalled over the trials for which data was available. If data for all three trials was missing, or if the score for Question 7 was missing then the short term memory score will also be set to missing. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. (NCT00348140)
Timeframe: Baseline (Week 0) and upto Week 48
| Intervention | Scores on an scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 36 | Week 48 | |
| Placebo | -0.2 | -0.3 | -0.0 | 0.6 | 0.6 |
| RSG XR 2mg | -0.2 | -0.4 | -0.0 | 0.7 | 0.6 |
| RSG XR 8mg | -0.1 | -0.5 | 0.2 | 0.7 | 0.9 |
Body weight was measured at all visits, without shoes and wearing light clothing. The assessment was performed at Baseline, Weeks 4, 8, 12, 16, 24, 36, 48, 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Weeks 4, 8, 12, 16, 24, 36, 48, 54
| Intervention | Kilograms (Kg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | Week 36 | Week 48 | Week 54 | |
| Placebo | -0.1 | 0.1 | 0.0 | 0.0 | 0.1 | -0.0 | 0.1 | 0.1 |
| RSG XR 2mg | 0.1 | 0.2 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 |
| RSG XR 8mg | 0.5 | 0.9 | 1.2 | 1.3 | 1.2 | 1.5 | 1.9 | 1.2 |
Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the participant had rested in the supine position in a quiet room (no TV, minimal talking) for atleast 10 minutes. The ECG parameters includes PR interval, QRS duration, QT - uncorrected interval, QTc Bazett (QTcB), QTc Fridericia (QTcF) and RR interval. The assessments were performed at Baseline and up to Week 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Weeks 4, 8, 16, 24, 36, 48, 54
| Intervention | MSEC (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR Interval, Week 0, +1hr | RR Interval, Week 0, +2hr | RR Interval, Week 0, +3hr | RR Interval, Week 0, +4hr | RR Interval, Week 4, Pre-Dose | RR Interval, Week 4, +1hr | RR Interval, Week 4, +2hr | RR Interval, Week 4, +3hr | RR Interval, Week 4, +4hr | RR Interval, Week 8 | RR Interval, Week 16 | RR Interval, Week 24 | RR Interval, Week 36 | RR Interval, Week 48 | RR Interval, Week 54 | QT interval, Week 0, +1hr | QT Interval, Week 0, +2hr | QT Interval, Week 0, +3hr | QT Interval, Week 0, +4hr | QT Interval, Week 4, Pre-Dose | QT Interval, Week 4, +1hr | QT Interval, Week 4, +2hr | QT Interval, Week 4, +3hr | QT Interval, Week 4, +4hr | QT Interval, Week 8 | QT Interval, Week 16 | QT Interval, Week 24 | QT Interval, Week 36 | QT Interval, Week 48 | QT Interval, Week 54 | QTcB interval, Week 0, +1hr | QTcB Interval, Week 0, +2hr | QTcB Interval, Week 0, +3hr | QTcB Interval, Week 0, +4hr | QTcB Interval, Week 4, Pre-Dose | QTcB Interval, Week 4, +1hr | QTcB Interval, Week 4, +2hr | QTcB Interval, Week 4, +3hr | QTcB Interval, Week 4, +4hr | QTcB Interval, Week 8 | QTcB Interval, Week 16 | QTcB Interval, Week 24 | QTcB Interval, Week 36 | QTcB Interval, Week 48 | QTcB Interval, Week 54 | QTcF interval, Week 0, +1hr | QTcF Interval, Week 0, +2hr | QTcF Interval, Week 0, +3hr | QTcF Interval, Week 0, +4hr | QTcF Interval, Week 4, Pre-Dose | QTcF Interval, Week 4, +1hr | QTcF Interval, Week 4, +2hr | QTcF Interval, Week 4, +3hr | QTcF Interval, Week 4, +4hr | QTcF Interval, Week 8 | QTcF Interval, Week 16 | QTcF Interval, Week 24 | QTcF Interval, Week 36 | QTcF Interval, Week 48 | QTcF Interval, Week 54 | PR Interval, Week 0, +1hr | PR Interval, Week 0, +2hr | PR Interval, Week 0, +3hr | PR Interval, Week 0, +4hr | PR Interval, Week 1, Pre-dose | PR Interval, Week 1, +1hr | PR Interval, Week 1, +2hr | PR Interval, Week 1, +3hr | PR Interval, Week 1, +4hr | PR Interval, Week 8 | PR Interval, Week 16 | PR Interval, Week 24 | PR Interval, Week 36 | PR Interval, Week 48 | PR Interval, Week 54 | QRS Interval, Week 0, +1hr | QRS Interval, Week 0, +2hr | QRS Interval, Week 0, +3hr | QRS Interval, Week 0, +4hr | QRS Interval, Week 4, Pre-Dose | QRS Interval, Week 4, +1hr | QRS Interval, Week 4, +2hr | QRS Interval, Week 4, +3hr | QRS Interval, Week 4, +4hr | QRS Interval, Week 8 | QRS Interval, Week 16 | QRS Interval, Week 24 | QRS Interval, Week 36 | QRS Interval, Week 48 | QRS Interval, Week 54 | |
| Placebo | 26.7 | 23.8 | 3.5 | -8.8 | -0.2 | 23.2 | 24.0 | 7.4 | -2.1 | 0.6 | 9.0 | -1.3 | -8.0 | -8.2 | 10.9 | 5.2 | 6.4 | 2.2 | -0.3 | -0.8 | 3.6 | 5.2 | 3.8 | 1.9 | -1.4 | 2.4 | 1.6 | 0.5 | 2.0 | 2.1 | -0.4 | 1.6 | 1.9 | 1.7 | -0.5 | -0.9 | 0.4 | 2.4 | 2.8 | -1.3 | 1.1 | 2.2 | 2.5 | 4.5 | 0.2 | 1.5 | 3.2 | 1.9 | 1.0 | -0.6 | 0.6 | 2.0 | 2.9 | 2.5 | -1.4 | 1.4 | 2.0 | 1.8 | 3.5 | 0.8 | 0.6 | 0.0 | 0.2 | 1.8 | -0.2 | 0.3 | 0.7 | 0.7 | 0.9 | -1.3 | -0.7 | -1.9 | -1.2 | -0.6 | -0.5 | 0.2 | 0.2 | -0.1 | 0.1 | 0.6 | 1.1 | 1.0 | 1.3 | 0.1 | 0.2 | 0.8 | 0.9 | 1.7 | 1.5 | 0.8 |
| RSG XR 2mg | 17.9 | 11.0 | 4.6 | -12.1 | -9.6 | 8.7 | 6.8 | 8.5 | -4.7 | 0.5 | -1.5 | 2.8 | -3.7 | -17.0 | 5.4 | 4.5 | 3.8 | 3.2 | -1.6 | -0.7 | 2.7 | 4.2 | 3.6 | 0.8 | 0.5 | -0.3 | 2.4 | 0.0 | -0.7 | 2.4 | 0.7 | 1.6 | 2.4 | 1.2 | 1.3 | 0.9 | 2.8 | 2.1 | 2.3 | 0.7 | 0.3 | 1.5 | 0.9 | 3.1 | 1.4 | 2.0 | 2.3 | 2.6 | 0.2 | 0.6 | 1.5 | 3.3 | 2.6 | 1.7 | 0.6 | 0.1 | 1.9 | 0.6 | 1.8 | 1.7 | 0.0 | 0.2 | -0.1 | 1.5 | 0.4 | 1.6 | 0.9 | 1.4 | 1.1 | 0.7 | 0.6 | 0.1 | -2.3 | -2.5 | -0.6 | 0.6 | 0.8 | 0.8 | 0.5 | 0.2 | 0.4 | 0.7 | 0.7 | 0.8 | 0.8 | -0.5 | 1.3 | 1.7 | 1.3 | 0.9 |
| RSG XR 8mg | 30.4 | 17.7 | 0.6 | -5.7 | -14.0 | 4.3 | 2.5 | -3.0 | -20.6 | -32.6 | -20.8 | -31.3 | -43.4 | -32.7 | -26.0 | 5.4 | 5.0 | 1.9 | 1.8 | -1.7 | 1.4 | 3.2 | 0.6 | -1.4 | -4.1 | -1.3 | -2.2 | -4.7 | -2.7 | -1.2 | -0.7 | 1.5 | 2.0 | 3.2 | 1.5 | 1.0 | 2.9 | 1.6 | 3.6 | 3.2 | 3.6 | 5.2 | 4.3 | 5.0 | 4.5 | 1.3 | 2.6 | 1.9 | 2.8 | 0.4 | 1.1 | 2.9 | 1.3 | 1.9 | 0.7 | 1.9 | 2.6 | 1.3 | 2.4 | 2.6 | 0.4 | -0.8 | -0.8 | 0.0 | 0.7 | 1.3 | 1.5 | 2.6 | 0.8 | 0.8 | 0.1 | -0.5 | -0.9 | -0.8 | 0.0 | 0.4 | 0.4 | 0.5 | -0.2 | 0.8 | 1.0 | 1.5 | 1.5 | 1.4 | 0.5 | 0.1 | 1.1 | 0.4 | 1.0 | 1.1 |
Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the participant had rested in the supine position in a quiet room (no TV, minimal talking) for atleast 10 minutes. The ECG parameters includes HR. The assessments were performed at Baseline and up to Week 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value . Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Baseline (Week 0) and Weeks 4, 8, 16, 24, 36, 48, 54
| Intervention | Beats per minute (BPM) (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 0, +1hr | Week 0, +2hr | Week 0, +3hr | Week 0, +4hr | Week 4, Pre-dose | Week 4, +1hr | Week 4, +2hr | Week 4, +3hr | Week 4, +4hr | Week 8 | Week 16 | Week 24 | Week 36 | Week 48 | Week 54 | |
| Placebo | -1.6 | -1.4 | 0.0 | 0.6 | 0.2 | -1.4 | -1.4 | -0.4 | 0.2 | 0.2 | -0.1 | 0.2 | 0.7 | 0.9 | -0.5 |
| RSG XR 2mg | -1.1 | -0.5 | -0.1 | 1.0 | 0.7 | -0.4 | -0.3 | -0.2 | 0.7 | 0.2 | 0.3 | -0.3 | 0.5 | 1.2 | -0.2 |
| RSG XR 8mg | -1.8 | -1.0 | 0.1 | 0.4 | 1.0 | -0.1 | -0.2 | 0.2 | 1.4 | 2.4 | 1.5 | 2.3 | 2.9 | 2.4 | 1.7 |
HR of participants were recorded in sitting posture as vital sign at each visit. The HR values were identified as of potential clinical concern if the values were out of the reference range (50 to 100 beats per minute) or meet a change from baseline criterion. The change from baseline criterion for HR, was increase from Baseline (high) if increased by more than or equal to (>=) 30 from Baseline; decrease from Baseline (low) if decreased by >= 30 from Baseline. Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Upto Week 54
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| >100 or <50 | Increase from Baseline >=30 | Decrease from Baseline >=30 | |
| Placebo | 12 | 0 | 2 |
| RSG XR 2mg | 5 | 0 | 0 |
| RSG XR 8mg | 5 | 4 | 1 |
SBP and DBP of participants were recorded in sitting posture as vital sign at each visit. The blood pressure (BP) values were identified as of potential clinical concern if the values were out of the reference range (for SBP, 90 to 140 mmHg and DBP, 50 to 90 mmHg) or meet a change from baseline criterion. The change from baseline criterion for SBP, was increase from Baseline (high) if increased by more than or equal to (>=) 40 mm Hg from Baseline; decrease from Baseline (low) if decreased by >= 30 mmHg from Baseline. For DBP, increase from baseline (high) if increased by >=30 mmHg from baseline; decrease from Baseline (low) if decreased by >= 20 mmHg from Baseline. Baseline was defined as value at Week 0. (NCT00348140)
Timeframe: Upto Week 54
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| SBP >140 or <90 | SBP Increase from Baseline>=40 | SBP Decrease from Baseline>=30 | DBP >90 or <50 | DBP Increase from Baseline>=30 | DBP Decrease from Baseline >=20 | |
| Placebo | 67 | 1 | 19 | 8 | 0 | 12 |
| RSG XR 2mg | 72 | 3 | 19 | 15 | 0 | 18 |
| RSG XR 8mg | 86 | 3 | 14 | 12 | 1 | 13 |
Body weight was measured at all visits, without shoes and wearing light clothing. The assessment was performed a t Baseline and up to Week 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented. (NCT00348140)
Timeframe: Upto Week 54
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Increase from Baseline >=7% | Decrease from Baseline >=7% | |
| Placebo | 33 | 28 |
| RSG XR 2mg | 31 | 32 |
| RSG XR 8mg | 47 | 23 |
AE was defined as any untoward medical occurrence in a participant temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was any untoward medical occurrence that, at any dose results in death, was life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect or was considered as medically significant. (NCT00348140)
Timeframe: Upto Week 48
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| On treatment AEs | On treatment SAEs | Mild AEs | Moderate AEs | Severe AEs | |
| Placebo | 275 | 60 | 109 | 111 | 55 |
| RSG XR 2mg | 298 | 58 | 119 | 128 | 50 |
| RSG XR 8mg | 319 | 66 | 112 | 158 | 48 |
The ADAS-cog+ is a validated, widely used, 14 item psychometric instrument for testing cognitive functions with increased sensitivity in detecting changes in milder patients compared to the original ADAS-cog. It has a maximum score of 85 with a higher score indicating impairment and was assessed by a qualified neuropsychologist. (NCT00911807)
Timeframe: baseline and week 28
| Intervention | points on a scale (Mean) |
|---|---|
| Cerebrolysin + Donepezil | -2.348 |
| Cerebrolysin | -1.711 |
| Donepezil | -1.246 |
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions indicate that the patient has problems with a particular sub-domain of behavior, the caregiver is only then asked all the questions about that domain, rating the frequency of the symptoms on a 4-point scale, their severity on a 3-point scale, and the distress the symptom causes them on a 5-point scale. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement. (NCT00545974)
Timeframe: Baseline, 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | -1.9 |
| Placebo | 0.3 |
The scale is rated on a 7-point scale, using a range of responses from 1 (very much improved) through 7 (very much worse). The clinician compares the participant's current condition to the condition at admission to the project. (NCT00545974)
Timeframe: 26 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | 4.4 |
| Placebo | 4.8 |
(NCT00545974)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Memantine | 1 |
| Placebo | 2 |
"Clinical dementia rating sum of boxes CDR-SB (0-18) high scores indicate high impairment.~Functional activities questionnaire FAQ (0-30) high scores indicate high impairment.~Texas functional living scale TFLS (0 to 52) high scores suggest better instrumental activities of daily living functioning.~Mini-Mental State Examination MMSE (0-30) low scores indicate low cognition. The executive interview EXIT25 (0 to 50) high scores indicate more executive impairment.~A modified unified Parkinson's disease rating scale UPDRS (0-199) high scores indicate worse disability.~Boston naming test (0-15) low scores indicate more retrieval difficulties." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| CDR-SB | FAQ | TFLS | MMSE | EXIT25 | UPDRS | Boston naming test | |
| Memantine | 1.5 | 4.3 | -3.7 | -1.2 | 1.9 | 1.7 | -1.4 |
| Placebo | 1.5 | 2.9 | -2.8 | -0.9 | 0.7 | 1.4 | 0.7 |
"Letter fluency, score is number of words recalled starting with a specified letter for 60 seconds. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials for the score. Low scores indicate high impairment~Category fluency, score is number of items generated belonging to a specific category (such as animals) in 60 seconds, low scores indicate high impairment.~Digit symbol, score is number of symbols that correctly corresponded to the random numerals entered in the form in 90 seconds. Participants are given a table of numerals with matching symbols, and a form with random numerals with open spaces. Low scores indicate high impairment.~Digits backwards, score is number of digits backwards recalled (range: 0-14), The participant hears a list of digits and is asked to repeat the digits backwards. Low scores indicate high impairment." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | number of items recalled (Mean) | |||
|---|---|---|---|---|
| Letter fluency | Category fluency | Digit symbol | Digits backwards | |
| Memantine | -0.1 | -0.5 | -3.9 | 0.1 |
| Placebo | -0.3 | -0.7 | 4.2 | -0.2 |
301 reviews available for donepezil and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Ligands | 2019 |
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Resp | 2019 |
Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Cholinesterases; Humans; L | 2020 |
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Line, Tumor; Coumaric Acids; H | 2021 |
Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Indans; | 2022 |
A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Exercise; Humans; Ra | 2021 |
Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Rivastigmine | 2022 |
The Hybrid Compounds as Multi-target Ligands for the Treatment of Alzheimer's Disease: Considerations on Donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Ligands | 2022 |
The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.
Topics: Activities of Daily Living; Alzheimer Disease; Amino Acids; Cholinesterase Inhibitors; Cognition; Do | 2022 |
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; | 2022 |
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Pip | 2022 |
Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal, Humanized; Donepezil; Indans; Memantine; Patents | 2022 |
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Topics: Adult; Alzheimer Disease; Donepezil; Galantamine; Humans; Memantine; Network Meta-Analysis; Nootropi | 2022 |
Pharmacogenetic studies in Alzheimer disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Biomarkers; Donepezil; Humans; Pharmacogenomic Testin | 2022 |
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Human | 2021 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2022 |
A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia.
Topics: Alzheimer Disease; Dementia, Vascular; Donepezil; Humans; Mental Status and Dementia Tests; Nimodipi | 2022 |
Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials.
Topics: Alzheimer Disease; Antipsychotic Agents; Bayes Theorem; Cholinesterase Inhibitors; Donepezil; Humans | 2022 |
Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Donepezil; Humans; Memantine; Patient-Centered Ca | 2022 |
Development of new Alzheimer's disease drug candidates using donepezil as a key model.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Don | 2023 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Drugs, Chinese Herbal | 2022 |
Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Don | 2023 |
Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Don | 2023 |
Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Don | 2023 |
Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Don | 2023 |
[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Memantine; Receptors, | 2023 |
Fatigue in Alzheimer's disease: biological basis and clinical management-a narrative review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cognition Disorders; Cross-Sectional Studies; Donep | 2023 |
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Topics: Acetylcholinesterase; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Donepezil; Galantamine | 2023 |
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chemistry Techniques, Synthetic; Donepezil; Dopamine Agents; Drug Design | 2019 |
Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors | 2019 |
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Repositioning; Galantamine; Humans; Ri | 2019 |
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Rivastigmine | 2020 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Female; | 2020 |
Effects of saffron (Crocus sativus L.) on cognitive function. A systematic review of RCTs.
Topics: Alzheimer Disease; Cognition; Cognitive Dysfunction; Crocus; Donepezil; Humans | 2020 |
Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Delivery Systems; Humans; Memantine; R | 2020 |
Current Strategies and Novel Drug Approaches for Alzheimer Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholinesterase Inhibitors; Donepezil; Gala | 2020 |
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.
Topics: Alzheimer Disease; Animals; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Dementia; Donepezil; Ga | 2020 |
Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.
Topics: Alzheimer Disease; China; Donepezil; Humans; Memantine; Network Meta-Analysis | 2020 |
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Ex | 2021 |
Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy: A Comprehensive Review.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 2021 |
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Crocus; Donepezil; Humans; Memantine | 2021 |
Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Dietary Supplements; Donepezil; Galantamine; Humans | 2022 |
[Pharmacokinetics/Pharmacodynamic Analysis to Link Pharmacokinetics to Efficacy and Drug Interaction of Alzheimer's Disease Drugs].
Topics: Acetylcholine; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cilostazol; Donepezil; Drug Co | 2021 |
[Donepezil Reduces Amyloid Precursor Protein Endocytosis by Resulting from Increase in the Expression of Sorting Nexin Protein 33].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biological Transport; Cholinergic Neuron | 2021 |
An Update on the Routes for the Delivery of Donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Administration Routes; Drug Delivery S | 2021 |
Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donep
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Data Analysis; Donepezil; Female; Humans; In | 2021 |
Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?
Topics: Alzheimer Disease; Donepezil; Drug Synergism; Humans; Indans; Neuroprotective Agents; Parkinson Dise | 2021 |
Alzheimer Disease: Monotherapy vs. Combination Therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; | 2017 |
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interac | 2017 |
Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.
Topics: Alzheimer Disease; Donepezil; Drug Therapy, Combination; Humans; Indans; Memantine; Nootropic Agents | 2017 |
Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Progression; Donepezil; Early Diagnos | 2017 |
Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Don | 2017 |
Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Comorbidity; Donepezil; Galan | 2018 |
Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes.
Topics: Alzheimer Disease; Asia, Eastern; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Huma | 2018 |
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognitive Dysfunction; Combined Modality Therapy; Compl | 2018 |
Profiling donepezil template into multipotent hybrids with antioxidant properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Donepezil; Humans; | 2018 |
A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2019 |
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier | 2018 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Humans; Ind | 2018 |
A review of clinical treatment considerations of donepezil in severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; PubMed | 2018 |
The efficacy and safety of memantine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Therapy, Combination; Excit | 2018 |
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Cholinesterases; Donep | 2018 |
An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combina | 2018 |
Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.
Topics: Alzheimer Disease; China; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Meman | 2018 |
Classics in Chemical Neuroscience: Donepezil.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Humans; Nerv | 2019 |
Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
Topics: Alzheimer Disease; Antiparkinson Agents; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepe | 2018 |
Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2019 |
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; G | 2013 |
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statis | 2013 |
High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Humans; I | 2013 |
[Nitrergic cerebrovascular regulation as affected by donepezil].
Topics: Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Donepezil; Humans; Indans | 2013 |
Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Communication Disorders; Donepezil; Galantamine; Human | 2013 |
Atypical aging in Down syndrome.
Topics: Adult; Aging; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Dementia; Donepez | 2013 |
[Donepezil in Alzheimer's disease and vascular dementia].
Topics: Alzheimer Disease; Dementia, Vascular; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Tre | 2013 |
Drugs for cognitive loss and dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cogniti | 2013 |
Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; | 2014 |
Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Memantine; Pipe | 2013 |
[Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinergic Neurons; Cholinesterase Inhibitors; Donepezil; | 2013 |
Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepezil; Galan | 2014 |
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Noo | 2014 |
The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis.
Topics: Alzheimer Disease; Cognition; Donepezil; Humans; Indans; Neuropsychological Tests; Nootropic Agents; | 2014 |
Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biological Availability; Cholinesterase Inhibitors; Donepezil; Half-Life | 2014 |
Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dystonia; Female; Humans | 2014 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfuncti | 2014 |
Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Gait; Galantamine | 2014 |
[Progress of dementia medicine: Special reference to Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cholinesterase Inhibitors; Donepezil; D | 2014 |
Improving the predictive value of interventional animal models data.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Data Mining; Databases, Factual; Disease Mode | 2015 |
Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Rel | 2015 |
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Galant | 2015 |
Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinergic Antagonists; Cholinesterase Inhibitors; D | 2015 |
Namzaric--a combination of 2 old drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Com | 2015 |
Upper gastrointestinal bleed associated with cholinesterase inhibitor use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Duodenal Ulcer; Endoscop | 2015 |
Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Fe | 2017 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Th | 2016 |
The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Topics: Aged; Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Gal | 2016 |
Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Lewy Body Disease; Piperidi | 2016 |
Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Ligands; Piperidin | 2017 |
Promising Therapies for Alzheimer's Disease.
Topics: Allosteric Regulation; Alzheimer Disease; Animals; Donepezil; Humans; Indans; Ligands; Neuroprotecti | 2016 |
Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Gala | 2016 |
Psychopharmacological Studies in Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; | 2016 |
Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.
Topics: Alzheimer Disease; Donepezil; Drug Therapy, Combination; Humans; Indans; Memantine; Piperidines; Pra | 2016 |
Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Topics: Alzheimer Disease; Animals; Apolipoproteins E; Cytochrome P-450 CYP2D6; Donepezil; Humans; Indans; N | 2016 |
Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Memantine; Piper | 2016 |
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
Topics: Adolescent; Adult; Alzheimer Disease; Biological Availability; Cholinesterase Inhibitors; Cognition; | 2016 |
Alzheimer's disease in the zebrafish: where can we take it?
Topics: Alzheimer Disease; Animals; Dementia; Disease Models, Animal; Donepezil; Humans; Indans; Memantine; | 2017 |
[Neuronal migration in the adult brain].
Topics: Adult Stem Cells; Alzheimer Disease; Animals; Cell Differentiation; Cell Division; Cell Movement; Ce | 2008 |
Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy.
Topics: Alzheimer Disease; Biomarkers; Brain; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil | 2008 |
Results, rhetoric, and randomized trials: the case of donepezil.
Topics: Advertising; Aged; Alzheimer Disease; Conflict of Interest; Donepezil; Drug Industry; Drug Utilizati | 2008 |
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamat | 2008 |
Donepezil: potential neuroprotective and disease-modifying effects.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Eva | 2008 |
Pharmacological treatment in moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Memantine; Phenylcarbamates; Pipe | 2008 |
Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy; Evidence-Base | 2008 |
[Diagnosis of and therapy for Alzheimer-type dementia].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antipsychotic Agents; Brain; Cholinesterase Inhibitors; Di | 2008 |
Integrating symptomatic- and disease-modifying treatments.
Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Neuropsycholog | 2008 |
[Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients].
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Dystonia | 2009 |
Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature.
Topics: Age of Onset; Alzheimer Disease; Cholinesterase Inhibitors; Codon; Donepezil; Electrophysiology; Exc | 2008 |
Donepezil for dementia in people with Down syndrome.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Humans; Indans; Piperidines; | 2009 |
Pain and palliative care pharmacotherapy literature summaries and analyses.
Topics: Alzheimer Disease; Amphetamines; Anesthetics, Local; Anticoagulants; Antidepressive Agents; Depressi | 2009 |
Discontinuing Alzheimer's disease drug therapy: why, when, and how.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Approval; Drug Monitoring; Excitatory | 2008 |
Donepezil in the treatment of patients with Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Randomized Controlled T | 2009 |
Treatment of Alzheimer's disease in the long-term-care setting.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Humans; Indan | 2009 |
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; | 2009 |
[Final IQWiG to Ginkgo biloba].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Clinical Trials as Topic; Cognition; Donepezil; | 2009 |
Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Middle Aged; Mu | 2009 |
Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; | 2009 |
Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Choline | 2010 |
[Care continuity for patients with Down syndrome during transition from childhood to adulthood].
Topics: Adolescent; Adult; Aged; Alzheimer Disease; Child; Comprehensive Health Care; Continuity of Patient | 2010 |
Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease; Blood Pressure; Capsules; | 2010 |
[Donepezil-induced neuroprotection of acetylcholinergic neurons in olfactory bulbectomized mice].
Topics: Alzheimer Disease; Animals; Choline O-Acetyltransferase; Cholinergic Fibers; Cholinesterase Inhibito | 2010 |
Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Assisted Li | 2010 |
Modern care for patients with Alzheimer disease: rationale for early intervention.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognition; Donepezil; Excitator | 2010 |
Switching cholinesterase inhibitors in older adults with dementia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylca | 2011 |
Predicting cognitive decline in Alzheimer's disease: an integrated analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2010 |
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.
Topics: Acetylcholine; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Clinical Trials as Topic; Delaye | 2011 |
Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Continuity of Patient Care; Donep | 2011 |
[Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Careg | 2011 |
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Ga | 2011 |
New drugs for Alzheimer's disease in Japan.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Excitatory Amino Acid Antag | 2011 |
Use of memantine for the treatment of dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Humans; Indans; | 2011 |
Pharmacological treatment of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; I | 2011 |
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Drug Discovery; Excitatory Amino Acid Antago | 2012 |
Reviewing the role of donepezil in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Nootropic Agents; | 2012 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; G | 2011 |
The costs of Alzheimer's disease and the value of effective therapies.
Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Ga | 2011 |
A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment.
Topics: Aged; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Humans; Indans; Nootropic Agents; Piperid | 2012 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; | 2012 |
Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Drug Costs; Economics, Pharmac | 2012 |
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; | 2012 |
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Evidence-B | 2013 |
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combin | 2013 |
A 10-year perspective on donepezil.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Drug | 2013 |
Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 2012 |
Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Topics: Aged; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donep | 2002 |
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Topics: Aging; Alzheimer Disease; Biological Availability; Carbamates; Cholinesterase Inhibitors; Donepezil; | 2002 |
Medical treatment of Alzheimer's disease: past, present, and future.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials a | 2002 |
Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Binding Sites; Carbamates; Cholinesterase Inhibitors; | 2001 |
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost of Illness; Cost-Benefit Analys | 2002 |
Donepezil: tolerability and safety in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase II as | 2002 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Done | 2002 |
[Mild Cognitive Impairment: potential therapeutics].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Dopamine Agonist | 2002 |
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; | 2002 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Nootro | 2003 |
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as To | 2003 |
Dementia.
Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo | 2003 |
Update on Alzheimer drugs (donepezil).
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
[Subcortical vascular encephalopathy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Brain; Carbamates; Clinical Trials as Topic; | 2003 |
[Mechanisms of action of Alzheimer medications].
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory | 2003 |
Donepezil: a clinical review of current and emerging indications.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2004 |
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Femal | 2003 |
Acetylcholinesterase inhibition in Alzheimer's Disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galan | 2004 |
[Drugs for the treatment of Alzheimer's disease].
Topics: Acetylcholine; Alzheimer Disease; Antidepressive Agents; Cerebral Cortex; Cholinesterase Inhibitors; | 2004 |
[Prognosis in Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, C | 2004 |
[Differential diagnosis of and therapy for senile dementia].
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Cholinesterase Inhibitors; Diagnosis, Differential; Diagno | 2004 |
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Animals; Behavioral Symptoms; Brain; Butyrylcholinest | 2004 |
[Drug therapy for aged patients with Alzheimer disease].
Topics: Aged; Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secret | 2004 |
[Memantine (Ebixa), glutaminergic modulator].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Glutamic | 2004 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Hum | 2004 |
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Excitatory Amino Acid | 2004 |
Evidence-based pharmacotherapy of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cost-Benefit Ana | 2004 |
Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Ginkgo biloba; Humans; I | 2004 |
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; | 2004 |
[Scope and limitations of acetylcholinesterase inhibitors].
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Clinical Trials as Topi | 2004 |
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseas | 2004 |
[Doubtful evidence for the use of the cholinesterase inhibitor donepezil in patients with dementia--a systematic review].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Fem | 2004 |
Mild cognitive impairment: a treatment at last?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepez | 2004 |
The safety and tolerability of donepezil in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Donepezil; Drug Interactions; | 2004 |
Mechanisms of action of cognitive enhancers on neuroreceptors.
Topics: Alzheimer Disease; Animals; Donepezil; Galantamine; Humans; Indans; Nicotinic Agonists; Nootropic Ag | 2004 |
Representation of patients with dementia in clinical trials of donepezil.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; | 2004 |
Dementia: finding the signals in the noise.
Topics: Alzheimer Disease; Dementia; Donepezil; Estrogen Replacement Therapy; Humans; Indans; Magnetic Reson | 2005 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamin | 2004 |
A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Hum | 2005 |
Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
Topics: Aged; Alzheimer Disease; Cognition; Dementia, Vascular; Donepezil; Female; Humans; Indans; Male; Mul | 2005 |
Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
Topics: Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorder | 2004 |
Cholinesterase inhibitors in the treatment of dementia.
Topics: Acetylcholine; Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost of Ill | 2005 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootr | 2004 |
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Lon | 2005 |
[Community strategies for rehabilitation in senile dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Community Mental Health Services; Diagnosis, Differentia | 2005 |
Refining treatment guidelines in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2005 |
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Manag | 2005 |
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamat | 2005 |
Cholinergic treatment: what are the early neuropathological targets?
Topics: Aged; Alzheimer Disease; Brain; Cholinergic Agents; Cholinesterase Inhibitors; Dementia; Donepezil; | 2005 |
Alzheimer's disease: the benefits of early treatment.
Topics: Aged; Alzheimer Disease; Cerebral Infarction; Cholinesterase Inhibitors; Donepezil; Humans; Indans; | 2005 |
Drug therapy of dementia in elderly patients. A review.
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotectiv | 2005 |
Clinical trials in mild cognitive impairment: lessons for the future.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Top | 2006 |
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Phe | 2006 |
Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Circadian Rhythm; Donepezil; Galantamine; Humans | 2006 |
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Evide | 2006 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Nootro | 2006 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Nootropic Agen | 2006 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; | 2005 |
Navigating patients and caregivers through the course of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Doub | 2006 |
Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepez | 2006 |
[Cognitive impairment].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Therapy, Com | 2006 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Human | 2006 |
Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Synergism; D | 2006 |
Donepezil: a review.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; | 2005 |
Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; | 2006 |
[Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease].
Topics: Alzheimer Disease; Animals; Cell Death; Cells, Cultured; Cerebral Cortex; Cholinesterase Inhibitors; | 2006 |
[Pharmacotherapy for Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Neu | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.
Topics: Alzheimer Disease; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Autistic Disor | 2007 |
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Men | 2007 |
The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Med | 2007 |
Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment.
Topics: Adult; Alzheimer Disease; Cognition Disorders; Disease Progression; Donepezil; Humans; Indans; Neuro | 2007 |
[Delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Confusion; Delirium; | 2007 |
Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Donepezil; Ethnicity; Galantamine; Humans; Indan | 2007 |
Donepezil: an update.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; N | 2007 |
[Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Human | 2007 |
[Management of Alzheimer disease].
Topics: Aged; Alzheimer Disease; Animals; Antipsychotic Agents; Caregivers; Case Management; Cholinesterase | 2007 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
[Acetylcholinesterase inhibitors for dementia--an update].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galanta | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indan | 2007 |
Donepezil for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; | 2007 |
[Are anti-dementia drugs worthwhile?].
Topics: Activities of Daily Living; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Cost | 2007 |
Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Topics: Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Galantamine; Huma | 2007 |
Practical clinical use of therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition D | 2007 |
[Neuronal migration in the adult brain].
Topics: Adult; Alzheimer Disease; Animals; Brain; Cell Differentiation; Cell Movement; Cell Survival; Cerebr | 2007 |
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Donepezil; Evidence-Base | 2008 |
Pharmacologic management of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Hum | 2008 |
The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Humans; Ind | 2008 |
[Treatment of Alzheimer's disease: status quo and future considerations].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Behavioral Symptoms; Choline; Cholinesteras | 2008 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognitio | 1996 |
Donepezil.
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; | 1997 |
Dementia in the elderly.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Female; | 1997 |
Providing dental care for patients diagnosed with Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Caregivers; Cholinesterase | 1997 |
Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Diarrhea; Donepezil; Drug Administrati | 1997 |
Preparing yourself. Visiting loved ones with Alzheimer's disease.
Topics: Adaptation, Psychological; Adult; Aged; Alzheimer Disease; Child; Cholinesterase Inhibitors; Donepez | 1997 |
Donepezil use in Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Inte | 1998 |
Donezepil for dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Drug Monitoring; Hum | 1997 |
Donepezil for Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Middle Aged; Patient | 1997 |
[Therapeutic agents for Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Human | 1998 |
New drug treatment for Alzheimer's disease: lessons for healthcare policy.
Topics: Advertising; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Decision | 1998 |
Therapeutic advances: donepezil for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Contraindi | 1997 |
The fear of forgetfulness: a grassroots approach to an ethics of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Ethics, Medical; Female; Humans; Inda | 1998 |
Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Cost-Benefit Analysis; Disease Progression; Donepezil; | 1998 |
The role of the psychiatrist in Alzheimer's disease.
Topics: Alzheimer Disease; Attitude to Health; Caregivers; Donepezil; Drug Therapy, Combination; Family Heal | 1998 |
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Diso | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
New cholinergic therapies: treatment tools for the psychiatrist.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinergic Agents; Cholin | 1998 |
Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Ph | 1998 |
Clinical profile of donepezil in the treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Cognition; | 1999 |
Donepezil update.
Topics: Aged; Alzheimer Disease; Donepezil; Follow-Up Studies; Humans; Indans; Middle Aged; Nootropic Agents | 1998 |
What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Piperidines; | 1999 |
Alzheimer's disease: the advent of effective therapy.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Diagnostic Imaging; Donepezil; Female; Humans; I | 1998 |
[Discovery and development of donepezil hydrochloride for the treatment of Alzheimer's disease].
Topics: Acetylcholine; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Done | 1999 |
Clinical benefits of a new piperidine-class AChE inhibitor.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Ind | 1999 |
Rational design of anti-dementia therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Drug De | 1999 |
Do we have drugs for dementia? No.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Ginkgo biloba; Humans; Indans; Ne | 1999 |
Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Chemical and Drug Induced Liver Injury; Choli | 1999 |
An economic perspective on Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Combi | 1999 |
Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepe | 1999 |
Donepezil. Pharmacoeconomic implications of therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Costs and Cost Analysis; Donepezil; Drug Evaluation; E | 1999 |
Update on Alzheimer's disease. Promising advances in detection and treatment.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Donepez | 1999 |
Therapeutic standards in Alzheimer disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Huma | 1999 |
Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Crystallography, X-Ray; Donepezil; Drug Des | 2000 |
Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Crystallography, X-Ray; Donepezil; Hum | 2000 |
Prospects for pharmacological intervention in Alzheimer disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Anti-Inflammatory Agents, Non-Steroidal; An | 2000 |
[Development of donepezil hydrochloride (Aricept) for the treatment of Alzheimer's disease].
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Des | 2000 |
Donepezil for mild and moderate Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Piperi | 2000 |
Donepezil: a review of its use in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Donepezil; Humans; Indans; Piperidines | 2000 |
[Pharmacological properties of donepezil hydrochloride (Aricept), a drug for Alzheimer's disease].
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Clinical Trials as Topi | 2000 |
Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents.
Topics: Affect; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Mental Disord | 2000 |
Cholinesterase inhibitors stabilize Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition | 2000 |
[Current status of the treatment of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 2000 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Ana | 2001 |
The pharmacology of donepezil: a new treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Int | 1999 |
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Topics: Alzheimer Disease; Carbamates; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Neurop | 2001 |
[Recent development of anti-dementia drugs].
Topics: Acetylcholinesterase; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inh | 2001 |
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Ph | 2001 |
Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Cost of Illness; Donepezil; Female; Humans; Indans; Ma | 2001 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinic | 2001 |
Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Biomarkers; Blood Platelets; Cholinesterase Inhib | 2001 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase | 2001 |
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Double | 2001 |
Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezi | 2001 |
Donepezil hydrochloride: a treatment drug for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; N | 2001 |
[Perspectives for drug treatment in Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Gala | 2001 |
[Latest therapies for treating dementia].
Topics: Adult; Aged; Alzheimer Disease; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepress | 2002 |
Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Design; Huma | 2002 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; D | 2002 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therap | 2002 |
Clinical use of cholinomimetic agents: a review.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Brain Injuries; Carbamates; Clinical Trials as | 2002 |
297 trials available for donepezil and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial.
Topics: Alzheimer Disease; Body Weight; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Dr | 2021 |
[Abdominal acupoint thread embedding therapy based on "brain-intestinal connection" for mild-to-moderate Alzheimer's disease and its effects on serum levels of APP and Aβ
Topics: Acupuncture Points; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Brain; | 2021 |
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amino Acid Sequence; Animals; Blood Pressure; CHO | 2021 |
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.
Topics: Alzheimer Disease; Behavioral Symptoms; Donepezil; Humans; Indans; Memantine; Piperidines; Prospecti | 2021 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Humans; Treatment Outc | 2022 |
Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.
Topics: Alzheimer Disease; Cognition; Donepezil; Humans; Indans; Piperidines; Resveratrol | 2022 |
Efficacy and safety of sodium oligomannate in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Humans; Ions; Nausea; Sodium | 2022 |
Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer's disease: a study protocol for a multicenter randomized controlled trial.
Topics: Acupuncture Therapy; Alzheimer Disease; China; Cognition; Donepezil; Humans; Multicenter Studies as | 2022 |
Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.
Topics: Adolescent; Adult; Alzheimer Disease; Cross-Over Studies; Donepezil; Humans; Middle Aged; Young Adul | 2022 |
Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Donepezil; Extracellula | 2022 |
A single-center, randomized, parallel design study to evaluate the efficacy of donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker: the COG-EYE study protocol for a phase II trial.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase II | 2022 |
Clinical efficacy of acupuncture combined with Western medicine in the treatment of mild to moderate Alzheimer disease: A protocol of a randomized controlled trial.
Topics: Activities of Daily Living; Acupuncture Therapy; Alzheimer Disease; Donepezil; Double-Blind Method; | 2022 |
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piper | 2023 |
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Double-Blind Method; Female; Humans; Male | 2023 |
Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Humans; Indans; Piperi | 2023 |
Comment on "Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel-group, non-inferiority study".
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Piperidines | 2023 |
Efficacy and Safety of a Transdermal Donepezil Patch in Patients with Mild to Moderate Alzheimer's Disease: Open-Label, Extension Study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Humans; Indans; Piperi | 2023 |
Differential response to donepezil in MRI subtypes of mild cognitive impairment.
Topics: Alzheimer Disease; Atrophy; Cognitive Dysfunction; Donepezil; Humans; Magnetic Resonance Imaging | 2023 |
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Teprenone in Patients with Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anti-Ulcer Agents; Atrophy; Cognition; Diterpenes; Donepezil; Double-Blind | 2019 |
Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Asian People; Chol | 2020 |
Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula () and Routine Western Medicine.
Topics: Aged; Aged, 80 and over; Alpinia; Alzheimer Disease; Attention; Biomarkers; Cholinesterase Inhibitor | 2020 |
[Effect of electroacupuncture at governor vessel on learning-memory ability and serum level of APP, Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Cognition; Donepezil; Elec | 2020 |
Volume Analysis of Brain Cognitive Areas in Alzheimer's Disease: Interim 3-Year Results from the ASCOMALVA Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cognition; Donepezil; Double-Blind Method; Female | 2020 |
Early-start
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Double-Blind Method; | 2021 |
Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil.
Topics: Alzheimer Disease; Cognition; Cognition Disorders; Donepezil; Humans; Neuropsychological Tests | 2021 |
Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil.
Topics: Alzheimer Disease; Cognition; Donepezil; Double-Blind Method; Humans; Latent Class Analysis; Nootrop | 2021 |
Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Me | 2021 |
Safety and Pharmacokinetics of HTL0018318, a Novel M
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Humans; Indans; | 2021 |
Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings, randomized and controlled clinical trial.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Double-Blind Method; Drugs, Chin | 2021 |
Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cognition; Donepezil; Enzyme-Link | 2017 |
Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Body Mass Index; Body Weight; Chol | 2017 |
The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer's disease patients: study protocol for a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; China; Clinical Protocols; C | 2017 |
Changes in brain amyloid-β accumulation after donepezil administration.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Brain; Donepez | 2017 |
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Basal Forebrain; Cholinergic Neurons; Disease Progression; Donepez | 2017 |
Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.
Topics: Acupuncture Therapy; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; | 2017 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitor | 2018 |
A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Cognition Diso | 2018 |
Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Donepezil; Double- | 2019 |
Effectiveness of Anti-Dementia Drugs in Extremely Severe Alzheimer's Disease: A 12-Week, Multicenter, Randomized, Single-Blind Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Follow-Up Studies; Humans; Male; Mema | 2018 |
A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study.
Topics: Aged; Alzheimer Disease; Atrophy; Cerebral Cortex; Cholinesterase Inhibitors; Cross-Over Studies; Do | 2018 |
Effect and Safety of Huannao Yicong Formula () in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cognition; Donepezil; Double-Blind M | 2019 |
Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Donepezil; Dopamine Agents; Double-Blind M | 2019 |
Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Rela | 2019 |
Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Female; Fol | 2013 |
Concentration of donepezil to the cognitive response in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Female; Follow-Up Studies; Humans; | 2013 |
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2013 |
Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.
Topics: Activities of Daily Living; Alzheimer Disease; Analysis of Variance; Cognition Disorders; Donepezil; | 2013 |
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia | 2014 |
Effect of donepezil in Alzheimer disease can be measured by a computerized human analog of the Morris water maze.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Computers; Donepezil; Female; Humans; Indans; Ma | 2014 |
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Blotting, Western; B | 2014 |
Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Choli | 2014 |
Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease.
Topics: Adamantane; Aged; Alzheimer Disease; Donepezil; Double-Blind Method; Female; Humans; Indans; Male; N | 2014 |
The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brief Psychiatric Rating Scale; Ce | 2014 |
Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cogniti | 2014 |
Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer's disease patients.
Topics: Adult; Alzheimer Disease; Donepezil; Double-Blind Method; Drug Compounding; Drug Costs; Drug Deliver | 2015 |
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2014 |
The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Donepezil; D | 2014 |
A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Donepezil; Dose-Response Relations | 2014 |
Donepezil improves gait performance in older adults with mild Alzheimer's disease: a phase II clinical trial.
Topics: Aged; Alzheimer Disease; Anti-Dyskinesia Agents; Attention; Cholinesterase Inhibitors; Donepezil; Ex | 2015 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Biomarkers; Blood Chemical Analys | 2015 |
Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Disease Management; Donepezil; Doub | 2014 |
The effectiveness of reality orientation in the treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Combined Modality Therapy; Do | 2015 |
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Disease Progression; Donepezil; Double-Blind Method; Female; Franc | 2015 |
[Nourishing Xin and Shen method improved mild cognitive impairment due to subcortical small vessel disease: a clinical study].
Topics: Alzheimer Disease; Biomedical Research; Cognition; Cognitive Dysfunction; Dementia; Donepezil; Drugs | 2015 |
Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition | 2016 |
A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers.
Topics: Adult; Alzheimer Disease; Biological Availability; Cross-Over Studies; Donepezil; Drug Therapy, Comb | 2015 |
The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Topics: Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; E | 2015 |
Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; China; Cognition; Donepezil; Doub | 2015 |
Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Caregivers; Donepezil; Female; Hum | 2015 |
Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cognition; Cognition Disorders; Do | 2015 |
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
Topics: Aged; Alzheimer Disease; Apathy; Caregivers; Cholinergic Agents; Donepezil; Double-Blind Method; Dru | 2015 |
Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.
Topics: Alzheimer Disease; Cholinergic Agents; Cognition; Donepezil; Double-Blind Method; Drug Therapy, Comb | 2015 |
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Cholinesterase Inhibitors; Cognition; | 2015 |
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Double-Blind Method; Female; Homes | 2015 |
Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Female; Humans; Indans; Male; Neur | 2015 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cholinesterase Inhibitors; Donepezil; Dose | 2017 |
Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Delayed-Action Preparations; Donepezil; Double-B | 2016 |
Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
Topics: Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; | 2016 |
Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood-Brain Barrier; Capillary Permeability; Cholinester | 2017 |
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2017 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Cerebral Cortex; Cognitive Dysfunction; Disease | 2016 |
The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
Topics: Aged; Alzheimer Disease; Anxiety; Apathy; Caregivers; Depression; Donepezil; Double-Blind Method; Fe | 2017 |
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Comb | 2017 |
Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial.
Topics: Aged; Alzheimer Disease; China; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; H | 2017 |
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Costs; Drug-R | 2017 |
Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer's disease: the Osaki-Tajiri Project.
Topics: Aged; Alzheimer Disease; Art; Cognition Disorders; Combined Modality Therapy; Donepezil; Humans; Ind | 2008 |
Effects of donepezil on verbal memory after semantic processing in healthy older adults.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Comprehension; Don | 2008 |
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholinesterase I | 2008 |
Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Donepezil; Female; Humans; Indans; | 2008 |
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Atrophy; Brain; Cerebral Ventricl | 2008 |
A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Caregivers; Cholinesterase Inhibitors; Counse | 2008 |
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2009 |
Serum albumin level interferes with the effect of donepezil in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Mo | 2008 |
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Butyrylcholinesterase; Chol | 2009 |
Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil.
Topics: Aged; Algorithms; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cognition; Donepezil; | 2009 |
Errorless practice as a possible adjuvant to donepezil in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Done | 2009 |
Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2009 |
Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Cross-Over Studi | 2009 |
A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cilostazol; Donepezil; Drug Therapy, Combination | 2009 |
Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bulgaria; Donepezil; Double-Blind Method; Drug Therapy, | 2009 |
Selective benefit of donepezil on oral naming in Alzheimer's disease in men compared to women.
Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Female; Humans; Indans; Male; Nootropic Agents; P | 2009 |
Donepezil delays progression to AD in MCI subjects with depressive symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Brain; Cholinesterase Inhibitors; Cognitio | 2009 |
[Clinical observation on acupuncture combined with Yizhi Jiannao granules for treatment of Alzheimer's disease].
Topics: Acupuncture Points; Acupuncture Therapy; Administration, Oral; Aged; Alpinia; Alzheimer Disease; Com | 2009 |
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Monitoring; F | 2009 |
Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinesterase Inhibitors; Cognition; Disease Progressio | 2009 |
The long-term efficacy and tolerability of donepezil in patients with vascular dementia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Donepezil; Double | 2010 |
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
Topics: Alzheimer Disease; Donepezil; Dopamine Agents; Evidence-Based Medicine; Humans; Indans; Memantine; N | 2009 |
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Homes for | 2009 |
The effects of counseling spouse caregivers of people with Alzheimer disease taking donepezil and of country of residence on rates of admission to nursing homes and mortality.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Caregivers; Cholinesterase Inhibitors; Counse | 2009 |
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Donepezil; Double-Blind Method; Fem | 2009 |
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Crocus; Donepezil; Double-Blind Method; Female; | 2010 |
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Cholinesterase Inhibitors; Donepez | 2010 |
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Antiparkinson Age | 2010 |
The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Mapping; Cerebral Arteries; Cerebral Cortex; Cereb | 2010 |
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Donepez | 2010 |
Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Bisphenol A-Glycidyl Methacrylate; Choline | 2010 |
Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cognition; Disability Evaluation; Donepezil; Double-B | 2010 |
Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Assisted Living Facilities; Cognition; Donepezil; Female | 2010 |
Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apathy; Brief Psychiatric Rating Scale; Cholinesterase I | 2011 |
Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cognition Disorders; Donepezil; Double-Blind | 2010 |
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Dose-Re | 2010 |
Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; China; Cholinesterase Inhibitors; C | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Disorders; Cholinesterase Inhibit | 2011 |
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Cogniti | 2011 |
[The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer's disease treated in routine clinical practice in Spain].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cost of Illness; Donepezil; Female; Humans; I | 2010 |
Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Combined Modality Therapy; Do | 2010 |
Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition; Delayed-Action Preparatio | 2011 |
Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2011 |
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aromatherapy; Cholinesterase Inhibitors; Data Interpreta | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donep | 2011 |
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Body Weight; Cholinesterase Inhibitors; Don | 2011 |
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Amino Acids; Donepezil; Double-Blind Method; Fe | 2011 |
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Amino Acids; Donepezil; Double-Blind Method; Fe | 2011 |
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Amino Acids; Donepezil; Double-Blind Method; Fe | 2011 |
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Amino Acids; Donepezil; Double-Blind Method; Fe | 2011 |
Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer's disease using 3DSRT.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Flow Velocity; Cerebrovascular Circulation; Donepe | 2012 |
Two galantamine titration regimens in patients switched from donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Rela | 2012 |
[Effects of donepezil treatment on platelets α and β secretase activities in Alzheimer's disease patients].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid Precursor Protein Secretases; Blood Platelets; C | 2011 |
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2012 |
[Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer's disease: friend or foe?].
Topics: Adipokines; Adiponectin; Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Appetite; Bi | 2012 |
Cardiac safety of donepezil in elderly patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Blood Pressure; Cholinesterase Inh | 2012 |
Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain Mapping; Cognition; Donepezil; Dopamine Agents; Female; Humans; Indan | 2012 |
Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: a randomized, double-blind and parallel-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Double-Blind Me | 2012 |
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dose-Response Rel | 2012 |
Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Hirudins; | 2012 |
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Biomarkers, Pharmacological; Cognition; | 2012 |
[Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial].
Topics: Alzheimer Disease; Cognition; Donepezil; Drugs, Chinese Herbal; Humans; Indans; Nootropic Agents; Pi | 2012 |
The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Combined | 2012 |
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Donepezil; Dopamine Agents; Dose-R | 2012 |
The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Donepezil; Double-Blind Metho | 2012 |
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cognition; Cytochrome P-450 | 2013 |
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase | 2012 |
Auditory cortical function during verbal episodic memory encoding in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Auditory Cortex; Auditory Perceptual D | 2013 |
Effect of polymer, plasticizer and filler on orally disintegrating film.
Topics: Administration, Oral; Alzheimer Disease; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Donep | 2014 |
Down syndrome and Alzheimer disease: response to donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Drug Administration Schedule | 2002 |
Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients.
Topics: Aged; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Donepezil; Female; Humans; | 2002 |
Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Donepezil | 2002 |
Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; M | 2002 |
Goal setting and attainment in Alzheimer's disease patients treated with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Goals; H | 2002 |
Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Donepezil; Female; Ger | 2002 |
Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Cognition; Donepez | 2002 |
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinesterase Inhibitor | 2002 |
An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cost of Illness; Donepezil; Double-B | 2003 |
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Butyrylcholinesterase; C | 2002 |
Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cholinesterase Inhib | 2003 |
Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cerebrovascular Circulation; Choli | 2003 |
Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia.
Topics: Alzheimer Disease; Biomechanical Phenomena; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2003 |
Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anxiety; Arousal; Depression; Donepezil; Double-Blind Method; Female; Human | 2002 |
A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antidepr | 2003 |
Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cost of I | 2003 |
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Carbamates; Cholesterol; Cholinesterase Inhibitors; Dise | 2003 |
Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Humans; Indans; Lo | 2003 |
Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Double-Blind Met | 2003 |
Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug The | 2003 |
A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition; Donepezil; Drug Administration Schedule; Female; Galantamine; Hu | 2003 |
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Chemistry; Cholinesterase Inhibitors; Done | 2003 |
A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2003 |
Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Electr | 2003 |
Quantitative EEG and perfusional single photon emission computed tomography correlation during long-term donepezil therapy in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Circulation; Donepezil; Electroencephalo | 2004 |
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.
Topics: Aged; Alzheimer Disease; Ambulatory Care; Antidepressive Agents; Behavioral Symptoms; Cholinesterase | 2004 |
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Attitude of Health Personnel | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Double-Blind Method; | 2004 |
Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Done | 2004 |
Effects of cholinergic drugs and cognitive training on dementia.
Topics: Aged; Aging; Alzheimer Disease; Cholinergic Agents; Cognition; Cognitive Behavioral Therapy; Combine | 2004 |
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cells, Cultured; Cholinesterase Inhibitors; Donepezil; F | 2004 |
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Fema | 2004 |
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2004 |
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Double-Blind Method; Female; Humans; Indans; | 2004 |
Impact of donepezil treatment for Alzheimer's disease on caregiver time.
Topics: Activities of Daily Living; Alzheimer Disease; Caregivers; Donepezil; Home Nursing; Humans; Indans; | 2004 |
Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Ambulatory Care; Australia; Canada; Caregivers; | 2004 |
Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Mapping; Caregivers; Cerebral Cortex; Cholinestera | 2004 |
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; G | 2004 |
Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Donepezil; Double-Blind Method; | 2004 |
Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; | 2004 |
Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Cholinesterase Inh | 2004 |
Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Electromyography; Female; Humans; Indans; Mal | 2005 |
Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer dementia.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Cognition Disorders; Cross-Sectional Studies; Donepezil | 2004 |
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorde | 2004 |
Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Administratio | 2005 |
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cerebral Cortex; Cholin | 2005 |
The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Analysis of Variance; Area Under Curve; Cholinesterase Inhibitors; D | 2005 |
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Atrophy; Cholinesterase Inhibitors; Cohort Studies; Dise | 2005 |
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Cognition Disord | 2005 |
Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Brain; Brain Ischemia; Cholinesterase Inhibitors; Cognition Disorders; Demo | 2005 |
Switching from donepezil to galantamine: a double-blind study of two wash-out periods.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Drug Administrat | 2005 |
Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Cognition; Decision Making; Discrimin | 2005 |
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort S | 2005 |
Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disability Evaluation; Donepe | 2005 |
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2005 |
Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Blood Flow Velocity; Cerebrovascular Circulation; Cho | 2006 |
Treatment persistency with rivastigmine and donepezil in a large state medicaid program.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Patient | 2005 |
Patient populations in clinical studies of donepezil in vascular dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Dementia, Vascular; Donepezil; Double-Blind Metho | 2003 |
Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition; | 2005 |
Neuroanatomical predictors of response to donepezil therapy in patients with dementia.
Topics: Alzheimer Disease; Brain Mapping; Cholinesterase Inhibitors; Donepezil; Hippocampus; Humans; Indans; | 2005 |
The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cell Differentiation; Chemokine CC | 2006 |
Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2006 |
Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Comorbidity; Cr | 2006 |
The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Electroencephalo | 2006 |
3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2006 |
Donepezil and vitamin E for mild cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Donepezil; Humans; Indans; Long-Term Care; Piperidines; Trea | 2006 |
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Donepezil; Female; Hu | 2006 |
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Doub | 2006 |
Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cognition; Disease Progression; Do | 2006 |
Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders.
Topics: Aged; Alzheimer Disease; Brain Mapping; Cerebral Cortex; Data Interpretation, Statistical; Donepezil | 2006 |
A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine | 2006 |
Verbal repetition in patients with Alzheimer's disease who receive donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2006 |
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Cardiovascular System; Cholinesterase In | 2006 |
Benefits of combining donepezil plus traditional Japanese herbal medicine on cognition and brain perfusion in Alzheimer's disease: a 12-week observer-blind, donepezil monotherapy controlled trial.
Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Donepezi | 2006 |
Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cholinesterase Inhibitors; Cross-Over S | 2006 |
[Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Fe | 2006 |
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Behavi | 2006 |
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Press | 2006 |
Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamin | 2006 |
Regional cerebral blood flow in Alzheimer's disease: comparison between short and long-term donepezil therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Circulation; Donepezil; Dose-Resp | 2006 |
Donepezil in patients with severe Alzheimer's disease: double-blind parallel-group, placebo controlled study.
Topics: Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Confidence In | 2006 |
Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Dementi | 2006 |
Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Caregivers; Cost | 2007 |
Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease.
Topics: Acoustic Stimulation; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cerebral Cor | 2006 |
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Female; Geneti | 2006 |
Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Black or African American; Cholinesterase Inhibitors; Donepezil; Female; Fo | 2006 |
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dose-Response Relationship, Drug; Female; Fol | 2007 |
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Apolipoprotein | 2007 |
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Disease Progression; Donepezil; Female; Human | 2007 |
[Clinical study of Reinhartdt and sea cucumber capsule combined with donepezil in treating Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Capsules; Donepezil; Drug Therapy, Combination; | 2007 |
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Antips | 2007 |
Cognitive predictors of donepezil therapy response in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Femal | 2007 |
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholin | 2008 |
Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; | 2008 |
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Cholinesterase Inhibitors; D | 2008 |
Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease?
Topics: Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Donepezil; Do | 2007 |
Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase I | 2007 |
Donepezil for the treatment of agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2007 |
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.
Topics: Aged; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Cognition Disorders; Disease Progr | 2007 |
Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Donepez | 2007 |
Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain-Derived Neurotrophic Factor; Case-Control Studies; | 2008 |
Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients.
Topics: Aged; Alzheimer Disease; Asian People; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Dr | 2007 |
Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Double-Blind Method; Female; Follow-Up Studie | 2008 |
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; D | 2008 |
Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort S | 2008 |
High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cholinesterase | 2008 |
Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Rela | 2008 |
Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dose-Response Relationship, Drug; Female; Hum | 2008 |
Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Donepezil; Drug Resistance; Female; Follow-Up Studies; G | 2008 |
Prediction of response to donepezil in Alzheimer's disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion.
Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Donepezil; Female; Humans; Indans; Male | 2008 |
Quantitative analysis of the effects of donepezil on regional cerebral blood flow in Alzheimer's disease by using an automated program, 3DSRT.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; | 2008 |
Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects.
Topics: Administration, Oral; Adult; Aged; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Chromatograp | 1993 |
Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.
Topics: Adult; Alzheimer Disease; Blood Proteins; Cholinesterase Inhibitors; Chromatography, High Pressure L | 1993 |
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Double-Blind Method; Femal | 1998 |
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
Topics: Adult; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; H | 1998 |
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Double- | 1998 |
Clinical experience with Donepezil (Aricept) in the UK.
Topics: Alzheimer Disease; Clinical Protocols; Donepezil; Double-Blind Method; Humans; Indans; Licensure, Ph | 1998 |
First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Humans; Indans; Middle Aged; Models, Economic | 1998 |
Is donepezil effective for treating Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Double-Blind Method; Femal | 1999 |
Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepe | 1999 |
The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Event-Related Pote | 1999 |
Donepezil therapy in clinical practice: a randomized crossover study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cross-Over Studies; Donepezil; Double-Blind M | 2000 |
Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Circulation; Donepezil; Female; Humans; | 2000 |
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Double-Blind Method; Female; Humans; Indans; | 2000 |
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Admini | 2000 |
Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Donepezil; Dose-Response Relationship | 2000 |
Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Electromyography | 2000 |
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Biomarkers; | 2001 |
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Humans; | 2001 |
Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.
Topics: Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Blood Platelets; Blotting, Western; Choline | 2001 |
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Humans; | 2001 |
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2001 |
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholin | 2001 |
Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; | 2001 |
Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease.
Topics: Acetylcholine; Aged; Alzheimer Disease; Atrophy; Cholinergic Fibers; Cholinesterase Inhibitors; Done | 2002 |
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Double- | 2001 |
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
Topics: Adult; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Double-Blind Meth | 2002 |
The effects of donepezil on quantitative EEG in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Electroencephalography; Female; Human | 2002 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female | 2002 |
976 other studies available for donepezil and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Synthesis and activity studies of N-[omega-N'-(adamant-1'-yl)aminoalkyl]- 2-(4'-dimethylaminophenyl)acetamides: in the search of selective inhibitors for the different molecular forms of acetylcholinesterase.
Topics: Acetamides; Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Catalytic Domain; Cattle; Choli | 1998 |
3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.
Topics: Acetylcholinesterase; Acetylthiocholine; Alzheimer Disease; Amyloid beta-Peptides; Benzopyrans; Benz | 2003 |
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholi | 2005 |
Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cell Line; Ce | 2007 |
Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Butyryl | 2007 |
Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Histamine H3 Antagonists | 2008 |
Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Cell Line; C | 2009 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Design, synthesis and evaluation of novel 5,6-dimethoxy-1-oxo-2,3-dihydro-1H-2-indenyl-3,4-substituted phenyl methanone analogues.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Drug Design; Humans; Indenes; Ne | 2009 |
Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Combined Chemotherapy | 2010 |
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Calc | 2010 |
Substituted spiro [2.3'] oxindolespiro [3.2″]-5,6-dimethoxy-indane-1″-one-pyrrolidine analogue as inhibitors of acetylcholinesterase.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Inhibitory Concentration 50; Molecular Structu | 2010 |
(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.
Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer Simulation; Inhibitory Concent | 2011 |
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cattle; Cholinesterase Inhi | 2011 |
Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopep | 2011 |
Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's di
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholi | 2011 |
Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chem | 2012 |
Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Chelating Agents; Cholinesterase Inhibitors; Drug Design; H | 2012 |
Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Diamines; Humans; Models, | 2012 |
Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminopyridines; Binding Sites; Blood-Brain Barrier; Butyryl | 2012 |
Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Chol | 2013 |
Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2013 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Azoles; Butyrylcholinestera | 2013 |
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cannabinoid Receptor Agonists; Cholinesterase Inh | 2014 |
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Azoles; Biocompatible Materials; Butyrylcholi | 2014 |
Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Elec | 2014 |
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cotinine; Humans; | 2014 |
Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Drug Design; Genistein | 2014 |
Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Binding Sites; Catalytic Domain; Cholinestera | 2014 |
Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Chelating Agents; Cholinesterase Inhibitors; Donep | 2014 |
Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Curcumin; | 2014 |
Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Chloroceb | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2014 |
Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein.
Topics: Alzheimer Disease; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; | 2015 |
Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Drug Evaluation, P | 2015 |
Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Benzylamines; Cholinesterase Inhibitors; Chromones; Drug Design; Hu | 2015 |
Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Delivery Systems; Drug | 2015 |
Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Apige | 2015 |
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
Topics: Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Computer Simulation; Cryst | 2015 |
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrie | 2015 |
Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Desi | 2015 |
Discovery of isoalloxazine derivatives as a new class of potential anti-Alzheimer agents and their synthesis.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cell Line, Tumor; Cel | 2015 |
Multifunctional novel Diallyl disulfide (DADS) derivatives with β-amyloid-reducing, cholinergic, antioxidant and metal chelating properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Allyl Compounds; Alzheimer Disease; Amyloid beta-Peptides; Anhydrides; Antioxi | 2015 |
New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Dose- | 2015 |
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Clioquinol; Cognition; | 2015 |
Synthesis of donepezil-based multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Catalytic Domain; Cholinesterase Inhibitors; Donep | 2015 |
Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Binding Sites; Butyrylcholinesterase | 2016 |
One-pot synthesis of tetrazole-1,2,5,6-tetrahydronicotinonitriles and cholinesterase inhibition: Probing the plausible reaction mechanism via computational studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinergic Agents; Cholinesterase I | 2016 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Chol | 2016 |
Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Butyrylcholinesterase; Choline | 2016 |
Biological evaluation of synthetic α,β-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell | 2016 |
Development of cyanopyridine-triazine hybrids as lead multitarget anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; | 2016 |
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholin | 2016 |
Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Butyrylcholinesterase; Cell Survival | 2016 |
New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
Topics: Alzheimer Disease; Amines; Animals; Antioxidants; Cell Line, Tumor; Cholinesterases; Drug Design; Hu | 2016 |
Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Binding Sites; Butyrylcholin | 2016 |
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cel | 2016 |
Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line; Cholinesterase Inhibitors; Drug D | 2016 |
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Dru | 2016 |
Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carb | 2016 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain B | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell S | 2016 |
Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Line; Ch | 2016 |
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cataly | 2016 |
Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Cell Line; Donepezil; Drug Delivery Systems; Drug Design; Humans; | 2017 |
Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cholinesterase Inhibitors; Coumaric Acids; D | 2017 |
Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzyl Compounds; Binding Sites; Cholinesterase I | 2017 |
Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2016 |
Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line, Tumor; Cholinesterase Inhibitors; Donep | 2017 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
3,4-Dihydroquinazoline derivatives inhibit the activities of cholinesterase enzymes.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Quinazolines | 2017 |
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT
Topics: Administration, Oral; Alzheimer Disease; Animals; Drug Discovery; Humans; Indoles; Male; Piperazines | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Chelating Agents; Cholinesterase Inh | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease.
Topics: Acrylates; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Line; Cells, Cul | 2017 |
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell S | 2017 |
Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinestera | 2017 |
Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chol | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Animals; Cholinesterase Inhibitors; Donepezil; Dru | 2017 |
Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivates.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopep | 2017 |
Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; | 2017 |
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2017 |
Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzylamines; Blood-Retinal Barrier; | 2017 |
New racemic annulated pyrazolo[1,2-b]phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell | 2017 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; G | 2017 |
A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response Relation | 2017 |
From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease.
Topics: Acetylcholinesterase; Allosteric Regulation; Alzheimer Disease; Binding Sites; Cell Proliferation; C | 2017 |
Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biological Products; Butyrylcholines | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Exploration of multi-target potential of chromen-4-one based compounds in Alzheimer's disease: Design, synthesis and biological evaluations.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Chromans; Dose-Response | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell L | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Des | 2018 |
Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.
Topics: Acetylcholinesterase; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inh | 2018 |
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Rel | 2018 |
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I | 2018 |
Design, synthesis and evaluation of novel multi-target-directed ligands for treatment of Alzheimer's disease based on coumarin and lipoic acid scaffolds.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cholinesterase Inhibitors; Choline | 2018 |
Design, synthesis and evaluation of novel bivalent β-carboline derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Butyrylcholinesterase | 2018 |
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterases; Histamine Antagonists; Indoles; | 2018 |
Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Donepezil; E | 2018 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Li | 2018 |
Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butylated Hyd | 2018 |
Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Carbazoles; Cholinesterase | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug | 2018 |
Novel multitarget-directed ligands targeting acetylcholinesterase and σ
Topics: Acetylcholinesterase; Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Crys | 2019 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Click Chemistry; Drug Design; D | 2019 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 In | 2019 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Bloo | 2019 |
Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cell L | 2019 |
Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chol | 2019 |
A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Carboxylic Ester Hydro | 2019 |
Design, synthesis, and biological evaluation of novel 4-oxobenzo[d]1,2,3-triazin-benzylpyridinum derivatives as potent anti-Alzheimer agents.
Topics: Alzheimer Disease; Humans; Neuroprotective Agents; Pyridines | 2019 |
Design, synthesis, and biological evaluation of rutacecarpine derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Line, Tumor; Chelatin | 2019 |
Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
Topics: Acetylcholinesterase; Alkynes; Alzheimer Disease; Catalytic Domain; Cell Line, Tumor; Cholinesterase | 2019 |
Naphthalene-triazolopyrimidine hybrid compounds as potential multifunctional anti-Alzheimer's agents.
Topics: Alzheimer Disease; Anti-Anxiety Agents; Drug Design; Humans; Naphthalenes | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cell Surv | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stres | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Molecular | 2019 |
Novel multi target-directed ligands targeting 5-HT
Topics: Alzheimer Disease; Animals; Antioxidants; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; | 2019 |
Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amnesia; Amyloid beta-Peptides; Animals; Butyrylcho | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antioxidants | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Search for new multi-target compounds against Alzheimer's disease among histamine H
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzopyrans; Butyrylcholinesterase; Cholinesterase | 2020 |
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H
Topics: Alzheimer Disease; Animals; Calcium Channel Blockers; Cholinesterase Inhibitors; Humans; Memory Diso | 2019 |
1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzothiazole | 2020 |
Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apigenin; Butyrylcholineste | 2020 |
Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibi | 2020 |
The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylc | 2020 |
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Butyrylcholinestera | 2020 |
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Antagonists; Cognitive Dysfunction; Cyclic Nucleotide Phosph | 2020 |
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, | 2020 |
Design, synthesis and biological evaluation of novel naturally-inspired multifunctional molecules for the management of Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Antioxidants; Biological Pro | 2020 |
Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Cell | 2020 |
Synthesis and biological evaluation of novel quinazoline-triazole hybrid compounds with potential use in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amino Acid Sequence; Catalytic Domain; Cholinesterase Inhib | 2020 |
New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cholinesterase Inh | 2020 |
MicroRNA-Based Multitarget Approach for Alzheimer's Disease: Discovery of the First-In-Class Dual Inhibitor of Acetylcholinesterase and MicroRNA-15b Biogenesis.
Topics: Acetylcholinesterase; Alzheimer Disease; Caco-2 Cells; Cholinesterase Inhibitors; Drug Discovery; Hu | 2020 |
Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Butyrylcholinester | 2020 |
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Carbolines; Cell Line; Ch | 2020 |
Design, synthesis, and biological activity of novel semicarbazones as potent Ryanodine receptor1 inhibitors of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Calcium Channel Blockers; Calcium Signaling; Dantrolene; Disease Models, | 2021 |
Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relation | 2021 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2021 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2021 |
Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Crystallography, X-Ray; | 2021 |
Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Blood-Brain Barrier; Butyrylcholinesterase; Cell Line, Tumo | 2021 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; | 2021 |
Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Bindi | 2021 |
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Anacardium; Binding Sites; Butyrylcholinesterase; Catalytic | 2021 |
Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Dru | 2021 |
Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as Aβ antiaggregant.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Cholinesterase Inhibito | 2021 |
The structural simplification of lysergic acid as a natural lead for synthesizing novel anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Biological Products; Cell Survival; Cholinesterase | 2021 |
Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in th
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Blood-Brain Barrier; | 2021 |
Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors | 2021 |
Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholine | 2021 |
Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitor | 2021 |
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
Topics: Alzheimer Disease; Aminoquinolines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Asp | 2021 |
Further SAR studies on natural template based neuroprotective molecules for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Biological Products; Biphenyl Compou | 2021 |
Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Survival; Cholinester | 2021 |
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Biphenyl Compounds; Butyrylcholi | 2022 |
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli | 2022 |
Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain | 2022 |
Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antineoplastic Agents; Apoptosis; Carbolines; Cell Line, Tu | 2022 |
Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cholinesteras | 2022 |
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholin | 2022 |
Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer's agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Donepezil | 2022 |
Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line; Cell Survival; Cholineste | 2022 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites | 2022 |
Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2022 |
Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil | 2022 |
Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; | 2022 |
Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cholinesterase Inhibit | 2022 |
Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Donepezil; Garcinia mangostana; Mice; Wat | 2021 |
Blood-Brain Barrier Permeable and NO-Releasing Multifunctional Nanoparticles for Alzheimer's Disease Treatment: Targeting NO/cGMP/CREB Signaling Pathways.
Topics: Alzheimer Disease; Animals; Apoptosis; Cell Line, Tumor; Donepezil; Drug Carriers; Drug Liberation; | 2021 |
Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cells, Cultured; Cholinesterase Inhib | 2021 |
Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle.
Topics: Aged; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Humans; Mitochondria; Muscle, Skeletal | 2021 |
Donepezil improves vascular function in a mouse model of Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cardiovascular Diseases; Cholinesterase Inhibitors; Cogni | 2021 |
Association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against Alzheimer's disease.
Topics: Alzheimer Disease; Aryldialkylphosphatase; Cholinesterase Inhibitors; Donepezil; Humans; Mutation; P | 2021 |
Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Carbolines; Cognitive Dysfunction; Donepezil; Human | 2022 |
Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Cognitive Dysfunction; | 2022 |
Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Double-Blind Method; Humans; Ind | 2022 |
Effects of electroacupuncture on DNA methylation of the TREM2 gene in senescence-accelerated mouse prone 8 mice.
Topics: 5-Methylcytosine; Alzheimer Disease; Animals; Disease Models, Animal; DNA Methylation; Donepezil; El | 2022 |
Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Phe | 2022 |
Design, Synthesis, and Evaluation of Novel 2
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Donepezil | 2022 |
Co-Treatment with the Herbal Medicine SIP3 and Donepezil Improves Memory and Depression in the Mouse Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Depression; Diseas | 2022 |
A single-molecule with multiple investigations: Synthesis, characterization, computational methods, inhibitory activity against Alzheimer's disease, toxicity, and ADME studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Donepezil; Galantamine; Humans; Molecular Docking Simulatio | 2022 |
Targeting the Beta-2-Adrenergic Receptor and the Risk of Developing Alzheimer's Disease: A Retrospective Inception Cohort Study.
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Humans; Retr | 2022 |
First Donepezil Transdermal Patch Approved for Alzheimer Disease.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; | 2022 |
Synthesis, Characterisation and Docking Studies of Thioxoquinoline Derivatives as Potential Anti-Alzheimer Agents.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Ligands; Molecular Docking Si | 2022 |
Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Galantamine; | 2022 |
[Galangin alleviates learning and memory impairments in APP/PS1 double- transgenic mice by regulating Akt/MEF2D/Beclin-1 signaling pathway].
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyl | 2022 |
Design, synthesis, and biological evaluation of thienopyrimidine and thienotriazine derivatives as multitarget anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; | 2022 |
Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2022 |
Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer's agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Chalcone; Chalcones; Chalon | 2022 |
Donepezil ameliorates Aβ pathology but not tau pathology in 5xFAD mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Donepezil; Mice; Mice, Tr | 2022 |
A Coumarin-Donepezil Hybrid as a Blood-Brain Barrier Permeable Dual Cholinesterase Inhibitor: Isolation, Synthetic Modifications, and Biological Evaluation of Natural Coumarins.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Bloo | 2022 |
Corpus callosum anatomical changes in Alzheimer patients and the effect of acetylcholinesterase inhibitors on corpus callosum morphometry.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Corpus Callosum; Donepezil; Fema | 2022 |
A novel multi-target strategy for Alzheimer's disease treatment via sublingual route: Donepezil/memantine/curcumin-loaded nanofibers.
Topics: Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor; Curcumin; Donepezil; Glycogen Synthas | 2022 |
A donepezil patch (Adlarity) for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans | 2022 |
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine | 2022 |
Aaptamine - a dual acetyl - and butyrylcholinesterase inhibitor as potential anti-Alzheimer's disease agent.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2022 |
Phytochemicals-based Therapeutics against Alzheimer's Disease: An Update.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Donepezil; Humans; Phytochemicals; Quality of Life; Rivast | 2022 |
Recent Modifications of Anti-dementia Agents Focusing on Tacrine and/or Donepezil Analogs.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Nootropic Age | 2023 |
Combination of NSAIDs with donepezil as multi-target directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inh | 2022 |
Insights of Valacyclovir in Treatment of Alzheimer's Disease: Computational Docking Studies and Scopolamine Rat Model.
Topics: Acetylcholinesterase; Acyclovir; Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiviral | 2022 |
Effect of tricyclic 1,2-thiazine derivatives in neuroinflammation induced by preincubation with lipopolysaccharide or coculturing with microglia-like cells.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Coculture Techniques; Donepezil; Humans; Inflammation; | 2022 |
Multipotent Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease: Synthesis, Biological Analysis and Molecular Docking Study of Benzimidazole-Based Thiazole Derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amino Acids; Benzimidazoles; Butyrylcholinesterase; Choline | 2022 |
A Recent Appraisal of Small-Organic Molecules as Anti-Alzheimer's Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesteras | 2023 |
Research status, hotspots and trends of acupuncture and moxibustion in the treatment of Alzheimer's disease: A bibliometric analysis.
Topics: Acupuncture; Acupuncture Therapy; Alzheimer Disease; Animals; Donepezil; Mice; Moxibustion | 2022 |
Neuroprotective effects of combined therapy with memantine, donepezil, and vitamin D in ovariectomized female mice subjected to dementia model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Donepezil; Female; Hippocampus; Interleukin-4; Me | 2023 |
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cognitive Dysfunction; Donepezil; Humans; Indans; | 2022 |
Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer's Disease Patients in Japan: LIFE Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2022 |
Effects of Donepezil Treatment on Brain Metabolites, Gut Microbiota, and Gut Metabolites in an Amyloid Beta-Induced Cognitive Impairment Mouse Pilot Model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognitive Dysfunction; Disease Models, Ani | 2022 |
Roles of hybrid donepezil scaffolds as potent human acetylcholinesterase inhibitors using in silico interaction analysis, drug-likeness, and pharmacokinetics prediction.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Molecular Doc | 2022 |
In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2022 |
Neuroprotective effects of nerolidol against Alzheimer's disease in Wistar rats.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derived Neurotrophic Factor; Disease | 2022 |
Combination of Donepezil and Memantine Attenuated Cognitive Impairment Induced by Mixed Endocrine-Disrupting Chemicals: an In Silico Study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Indans; Mema | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
[Capabilities of combined therapy of Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Memantin | 2022 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Subcutaneous Implantable Microneedle System for the Treatment of Alzheimer's Disease by Delivering Donepezil.
Topics: Administration, Cutaneous; Alzheimer Disease; Donepezil; Drug Delivery Systems; Humans; Needles; Pol | 2022 |
Subcutaneous Implantable Microneedle System for the Treatment of Alzheimer's Disease by Delivering Donepezil.
Topics: Administration, Cutaneous; Alzheimer Disease; Donepezil; Drug Delivery Systems; Humans; Needles; Pol | 2022 |
Subcutaneous Implantable Microneedle System for the Treatment of Alzheimer's Disease by Delivering Donepezil.
Topics: Administration, Cutaneous; Alzheimer Disease; Donepezil; Drug Delivery Systems; Humans; Needles; Pol | 2022 |
Subcutaneous Implantable Microneedle System for the Treatment of Alzheimer's Disease by Delivering Donepezil.
Topics: Administration, Cutaneous; Alzheimer Disease; Donepezil; Drug Delivery Systems; Humans; Needles; Pol | 2022 |
Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway.
Topics: Aluminum; Aluminum Chloride; Alzheimer Disease; Animals; Bromelains; Cell Cycle Proteins; Disease Mo | 2023 |
Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway.
Topics: Aluminum; Aluminum Chloride; Alzheimer Disease; Animals; Bromelains; Cell Cycle Proteins; Disease Mo | 2023 |
Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway.
Topics: Aluminum; Aluminum Chloride; Alzheimer Disease; Animals; Bromelains; Cell Cycle Proteins; Disease Mo | 2023 |
Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway.
Topics: Aluminum; Aluminum Chloride; Alzheimer Disease; Animals; Bromelains; Cell Cycle Proteins; Disease Mo | 2023 |
Novel Dual AChE and ROCK2 Inhibitor Induces Neurogenesis via PTEN/AKT Pathway in Alzheimer's Disease Model.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Neuroblastoma | 2022 |
Novel Dual AChE and ROCK2 Inhibitor Induces Neurogenesis via PTEN/AKT Pathway in Alzheimer's Disease Model.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Neuroblastoma | 2022 |
Novel Dual AChE and ROCK2 Inhibitor Induces Neurogenesis via PTEN/AKT Pathway in Alzheimer's Disease Model.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Neuroblastoma | 2022 |
Novel Dual AChE and ROCK2 Inhibitor Induces Neurogenesis via PTEN/AKT Pathway in Alzheimer's Disease Model.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Neuroblastoma | 2022 |
Acetylcholinesterase inhibition of Alzheimer's disease: identification of potential phytochemicals and designing more effective derivatives to manage disease condition.
Topics: Acetylcholinesterase; Alzheimer Disease; Anthocyanins; Berberine; Cholinesterase Inhibitors; Diterpe | 2023 |
[Abnormal posture of the trunk related to donepezil hydrochloride: report of 2 cases].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2023 |
Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data.
Topics: Alzheimer Disease; Donepezil; Female; Humans; Italy; Male; Memantine; Retrospective Studies | 2023 |
Pharmacokinetic/Pharmacodynamic Models of an Alzheimer's Drug, Donepezil, in Rats.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Donepezil; Dose-Response Relationship, Drug; Model | 2023 |
[Mongolian medicine Heisuga-25 promotes the expression of neuroskeletal protein, increases the content of neurotransmitter and improves the symptoms of Alzheimer's disease in mice].
Topics: Acetylcholine; Alzheimer Disease; Animals; Donepezil; Dopamine; Medicine, Mongolian Traditional; Mic | 2023 |
Usmarapride (SUVN-D4010), a 5-HT
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Donepezil; Rats; Rivastigmine; Serotonin | 2023 |
Design, synthesis, and biological evaluation of thienopyrimidine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibit | 2023 |
Proposing novel natural compounds against Alzheimer's disease targeting acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; | 2023 |
Design, synthesis, in vitro, and in vivo evaluation of novel phthalazinone-based derivatives as promising acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; | 2023 |
Effects of donepezil treatment on plasma and urine metabolites in amyloid beta-induced Alzheimer's disease rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Donepezil; Fatty Acids; R | 2023 |
Development of an Induced Pluripotent Stem Cell-Based Liver-on-a-Chip Assessed with an Alzheimer's Disease Drug.
Topics: Alzheimer Disease; Donepezil; Endothelial Cells; Humans; Induced Pluripotent Stem Cells; Lab-On-A-Ch | 2023 |
Lobeline: A multifunctional alkaloid modulates cholinergic and glutamatergic activities.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Antineoplastic Agents; Cholinesterase I | 2023 |
Design, Synthesis, Molecular Docking, and Molecular Dynamics Simulation Studies of Novel 3-Hydroxypyridine-4-one Derivatives as Potential Acetylcholinesterase Inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Molecular Doc | 2023 |
Discovery of thiazole salt AChE inhibitors and development of thiamine disulfide prodrugs targeting the central nervous system.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Donepezil; Human | 2023 |
Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Neuropr | 2023 |
Mitochondria-Targeted Delivery Strategy of Dual-Loaded Liposomes for Alzheimer's Disease Therapy.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Donepezil; Liposomes; Mice; Mice, Transge | 2023 |
Design, Synthesis, and Biological Evaluation of Novel Indanone Derivatives as Cholinesterase Inhibitors for Potential Use in Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Butyrylcholinesterase; Cholinesterase Inhibitors; D | 2023 |
Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Donepezil; Edaravone; Inflammation | 2023 |
Lecanemab: Looking Before We Leap.
Topics: Aged; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Dementia; Donepezil; Humans; Medicare; U | 2023 |
Efficacy of donepezil plus hydrogen-oxygen mixture inhalation for treatment of patients with Alzheimer disease: A retrospective study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Piperidines; Ret | 2023 |
Design and development of benzyl piperazine linked 5-phenyl-1,2,4-triazole-3-thione conjugates as potential agents to combat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2023 |
Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer's Disease in Rat Model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Brain; Donepezil; Drug Carriers; Li | 2023 |
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; COVID-19; Donepezil; Female; Galantamine; Humans; Inda | 2023 |
Olax subscorpioidea prevented scopolamine-induced memory impairment through the prevention of oxido-inflammatory damage and modulation of cholinergic transmission.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinergic Agents; Donepezil; Hippocampus; Maze L | 2024 |
Efficacy evaluation and metabolomics analysis of Huanglian Jiedu decoction in combination with donepezil for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Animals; Donepezil; Drugs, Chinese Herbal; Inflammation; Interleukin-6; Metabolom | 2023 |
Discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis, biological evaluation, molecular docking and 3D-QSAR investigation.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzofurans; Cholinesterase Inhibitors; Donepezil; | 2023 |
Hydroxytyrosol-Donepezil Hybrids Play a Protective Role in an In Vitro Induced Alzheimer's Disease Model and in Neuronal Differentiated Human SH-SY5Y Neuroblastoma Cells.
Topics: Alzheimer Disease; Antioxidants; Donepezil; Humans; Neuroblastoma; tau Proteins | 2023 |
A causal inference study: The impact of the combined administration of Donepezil and Memantine on decreasing hospital and emergency department visits of Alzheimer's disease patients.
Topics: Alzheimer Disease; Donepezil; Emergency Service, Hospital; Hospitals; Humans; Memantine | 2023 |
Long-Term Safety, Tolerability, and Efficacy of a Transdermal Donepezil Patch in Patients with Severe Alzheimer's Disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Tablets; Treat | 2023 |
Biological Evaluation of Anti-Cholinesterase Activity, in Silico Molecular Docking Studies, and DFT Calculations of Green Synthesized Thiadiazolo[3,2-a]pyrimidine Derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Density Functional Theory; Donep | 2023 |
Piperazine-2-carboxylic acid derivatives as MTDLs anti-Alzheimer agents: Anticholinesterase activity, mechanistic aspect, and molecular modeling studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Carboxylic Acids; Cholinest | 2024 |
Effect of woohwangchungsimwon and donepezil co-treatment on cognitive function and serum metabolic profiles in a scopolamine-induced model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Donepezil; Humans; Metabolome; Methion | 2024 |
Ginsenoside RK1 improves cognitive impairments and pathological changes in Alzheimer's disease via stimulation of the AMPK/Nrf2 signaling pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Animals; Cognitive Dysfunction; Donepezil; NF-E2-R | 2024 |
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD).
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Piperidines; Quality of Life | 2023 |
Consumption of drugs for Alzheimer's disease on the Brazilian private market.
Topics: Alzheimer Disease; Brazil; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Memantine; Phenylca | 2023 |
Synthesis, biological evaluation, and computational studies of
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Curcumin; Donepezi | 2023 |
Donepezil modulates amyloid precursor protein endocytosis and reduction by up-regulation of SNX33 expression in primary cortical neurons.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Membrane; Cells, Cultured; Cerebral | 2019 |
Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biological Transport; Brain; Cholinesterase Inhibitors; Do | 2019 |
Early prediction of donepezil cognitive response in Alzheimer's disease by brain perfusion single photon emission tomography.
Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Humans; Mal | 2019 |
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamin | 2019 |
Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and anti-Alzheimer's agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholi | 2019 |
Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer's Disease Therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Chromones | 2019 |
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Develo | 2020 |
Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries.
Topics: Alkaloids; Alzheimer Disease; Animals; Basilar Artery; Brain Stem; Calcium; Cholinesterase Inhibitor | 2020 |
Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Catalytic Do | 2020 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progressio | 2020 |
Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer's disease and chronic obstructive pulmonary disease: a retrospective observational study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cholinesterase | 2020 |
Safflower Yellow Improves Synaptic Plasticity in APP/PS1 Mice by Regulating Microglia Activation Phenotypes and BDNF/TrkB/ERK Signaling Pathway.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Arginase; Brain-Derived Neurotrophic Fac | 2020 |
Acute cholinergic syndrome in a patient taking the prescribed dose of donepezil for Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationsh | 2020 |
Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Drug D | 2020 |
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Choliner | 2020 |
Donepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Humans | 2020 |
Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Chelating Agents; Chol | 2020 |
Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice.
Topics: Alzheimer Disease; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tran | 2020 |
Lepidine B from Lepidium sativum Seeds as Multi-Functional Anti- Alzheimer's Disease Agent: In Vitro and In Silico Studies.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic A | 2021 |
Alpinia oxyphylla-Schisandra chinensis Herb Pair Alleviates Amyloid-β Induced Cognitive Deficits via PI3K/Akt/Gsk-3β/CREB Pathway.
Topics: Alpinia; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognition Disorders; Cy | 2020 |
Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effect | 2020 |
Are cytochrome P4502D6 and apolipoprotein E genotypes associated with long-term cognitive and functional changes in patients treated with donepezil?
Topics: Activities of Daily Living; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cognition; Cyto | 2020 |
Treatment of Alzheimer's diseases using donepezil nanoemulsion: an intranasal approach.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Brain; Donepezil; Emulsions; Nanoparticles; | 2020 |
[Effect of electroacupuncture combined with Donepezil on learning-memory ability and expression of hippocampal β-amyloid clearance-related genes in SAMP8 mice].
Topics: Alzheimer Disease; Animals; Donepezil; Electroacupuncture; Hippocampus; Learning; Male; Memory; Mice | 2020 |
Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Middle Aged; T | 2020 |
Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Lycopene; Mema | 2020 |
Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China.
Topics: Aged; Alzheimer Disease; China; Donepezil; Dopamine Agents; Humans; Medication Adherence; Memantine; | 2020 |
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine | 2020 |
Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats.
Topics: Alzheimer Disease; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Donepezil; H | 2021 |
Long term use of donepezil and QTc prolongation.
Topics: Aged, 80 and over; Alzheimer Disease; Donepezil; Electrocardiography; Female; Heart Rate; Humans; Lo | 2021 |
A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebral Cortex; Cognitive Dysfunction; Disease P | 2020 |
Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Donepezil; Drug Therapy, Combination; Femal | 2020 |
Response of spike-wave discharges in aged APP/PS1 Alzheimer model mice to antiepileptic, metabolic and cholinergic drugs.
Topics: 3-Hydroxybutyric Acid; Action Potentials; Alzheimer Disease; Animals; Anticonvulsants; Atropine; Dis | 2020 |
Turning Donepezil into a Multi-Target-Directed Ligand through a Merging Strategy.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; C | 2021 |
Precision medicine in Alzheimer's disease: An origami paper-based electrochemical device for cholinesterase inhibitors.
Topics: Alzheimer Disease; Biosensing Techniques; Cholinesterase Inhibitors; Donepezil; Humans; Phenylcarbam | 2020 |
5-N-ethyl Carboxamidoadenosine Stimulates Adenosine-2b Receptor-Mediated Mitogen-Activated Protein Kinase Pathway to Improve Brain Mitochondrial Function in Amyloid Beta-Induced Cognitive Deficit Mice.
Topics: Adenosine A2 Receptor Agonists; Adenosine-5'-(N-ethylcarboxamide); Alzheimer Disease; Amyloid beta-P | 2020 |
Discovery of a New Donepezil-like Acetylcholinesterase Inhibitor for Targeting Alzheimer's Disease: Computational Studies with Biological Validation.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Humans | 2020 |
Donepezil provides neuroprotective effects against brain injury and Alzheimer's pathology under conditions of cardiac ischemia/reperfusion injury.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Brain Injuries; Disease Mode | 2021 |
Design, Synthesis, and Structure-Activity Relationships of Thiazole Analogs as Anticholinesterase Agents for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Biological Transport; Blood-Brain Barrier; Butyrylcholinest | 2020 |
Novel Hybrid Acetylcholinesterase Inhibitors Induce Differentiation and Neuritogenesis in Neuronal Cells in vitro Through Activation of the AKT Pathway.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Differentiation; Cell Line, Tum | 2020 |
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain Chemistry; Cholinesterase Inhibito | 2020 |
Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients With Alzheimer Disease.
Topics: Alzheimer Disease; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochrom | 2021 |
Dementia Diagnoses and Treatment in Geriatric Ward Patients: A Cross-Sectional Study in Poland.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studies; Dementia; | 2020 |
Understanding binding between donepezil and human ferritin: molecular docking and molecular dynamics simulation approach.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Ferritins; Humans; Ir | 2022 |
Donepezil induces ventricular arrhythmias by delayed repolarisation.
Topics: Alzheimer Disease; Animals; Arrhythmias, Cardiac; Atrioventricular Block; Cholinesterase Inhibitors; | 2021 |
The functional effects of piperine and piperine plus donepezil on hippocampal synaptic plasticity impairment in rat model of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Avoidance Learning; Benzodioxoles; Cytochrome P-450 Enzyme In | 2021 |
Biophysical, Biochemical, and Behavioral Implications of ApoE3 Conjugated Donepezil Nanomedicine in a Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoprotein E3; Donepezil; Nanomedicine; Pepti | 2020 |
Racial Differences in Alzheimer's Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2.
Topics: Academic Medical Centers; Aged; Alzheimer Disease; Black or African American; Cholinesterase Inhibit | 2021 |
Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Rivastigmine; Tacrine | 2021 |
Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option.
Topics: Age Factors; Aged; Alzheimer Disease; China; Cholinesterase Inhibitors; Cognition; Donepezil; Female | 2020 |
First Synthesis of Racemic
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Models, Molec | 2020 |
The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Autophagy; Autophagy-Related Protein-1 H | 2021 |
Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.
Topics: Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Galantamine; Global Health; Huma | 2021 |
Discovery of drug-like acetylcholinesterase inhibitors by rapid virtual screening of a 6.9 million compound database.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Catalytic Do | 2021 |
Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer's Disease Agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors | 2021 |
Discovery of new acetylcholinesterase inhibitors for Alzheimer's disease: virtual screening and
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Dose-Respons | 2021 |
Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Benzofurans; Cognitive Dysfu | 2021 |
Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Donepezil; Femal | 2021 |
The liquid crystalline phase behaviour of a nasal formulation modifies the brain disposition of donepezil in rats in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Donepezil; Liposomes; Rats; Rats, Wistar | 2021 |
Novel Donepezil-Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cholinesterase Inh | 2021 |
Disease-modifying treatment with I
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Donepezil; Female; Imidaz | 2021 |
Clinical study of donepezil combined with olanzapine in the treatment of senile dementia complicated with mental and behavioral disorders.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Olanzapine | 2022 |
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Fe | 2021 |
The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; | 2021 |
Effects of donepezil on the amplitude of low-frequency fluctuations in the brain of patients with Alzheimer's disease: evidence from resting-state functional magnetic resonance imaging.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibi | 2021 |
Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease.
Topics: Alzheimer Disease; Cytochrome P-450 CYP2D6; Donepezil; Humans; Nucleotides; Polymorphism, Single Nuc | 2022 |
Acetylcholine from the nucleus basalis magnocellularis facilitates the retrieval of well-established memory.
Topics: Acetylcholine; Alzheimer Disease; Animals; Antibodies, Monoclonal; Basal Nucleus of Meynert; Choline | 2021 |
The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Databas | 2021 |
Gelidiella acerosa protects against Aβ 25-35-induced toxicity and memory impairment in Swiss Albino mice: an in vivo report.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2017 |
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Canada; Cholinesterase Inhib | 2017 |
Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease.
Topics: Acetylcholine; Allosteric Site; Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Cholinestera | 2017 |
Statistical properties of continuous composite scales and implications for drug development.
Topics: Activities of Daily Living; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Clinical Trials, P | 2017 |
The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Antioxidants; Biomarkers; Case-Control Studies; Choli | 2017 |
Spatial recognition test: A novel cognition task for assessing topographical memory in mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Donepezil; Indans; Levetiracetam; Mal | 2017 |
Cholinergic symptoms and QTc prolongation following donepezil overdose.
Topics: Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Donepezil; Dr | 2017 |
Acetamide Derivatives of Chromen-2-ones as Potent Cholinesterase Inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Assessing the binding of cholinesterase inhibitors by docking and molecular dynamics studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; | 2017 |
Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anxiety; Autophagy; Brain-Derived Neurotrophic Fa | 2017 |
Utilization of Western medicine and traditional Chinese medicine among patients with Alzheimer's disease in Taiwan: a nationwide population-based study.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drugs | 2017 |
Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cen | 2017 |
Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study.
Topics: 3T3 Cells; Acetylcholinesterase; Alzheimer Disease; Animals; Cell Survival; Chemistry, Pharmaceutica | 2017 |
Location of white matter changes and response to donepezil in patients with Alzheimer's disease: A retrospective and observational study.
Topics: Aged; Alzheimer Disease; Donepezil; Female; Humans; Male; Retrospective Studies; Treatment Outcome; | 2018 |
Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholesterol; Cholinesterase Inhibitors; Donepezil; Femal | 2018 |
Effects of donepezil on liver and kidney functions for the treatment of Alzheimer's disease.
Topics: Aged; Alanine Transaminase; Alzheimer Disease; Aspartate Aminotransferases; Biomarkers; Blood Urea N | 2017 |
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).
Topics: Aging; Alzheimer Disease; Animals; Cheirogaleidae; Disease Models, Animal; Donepezil; Indans; Male; | 2017 |
Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Drug D | 2017 |
Modulatory effect of caffeic acid on cholinesterases inhibitory properties of donepezil.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Caffeic Acids; Cholinestera | 2017 |
Cognitive enhancing and antioxidant effects of tetrahydroxystilbene glucoside in Aβ1-42-induced neurodegeneration in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cerebral Cortex; Disease Models, An | 2018 |
Involvement of glucose related energy crisis and endoplasmic reticulum stress: Insinuation of streptozotocin induced Alzheimer's like pathology.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Animals; Biomarkers; Caspase 12; Cerebral Cortex; | 2018 |
A benzothiazole/piperazine derivative with acetylcholinesterase inhibitory activity: Improvement in streptozotocin-induced cognitive deficits in rats.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Avoidance Learning; Behavior, Animal; Benzothiazol | 2017 |
Could delirium and anti-dementia drugs effect the treatment of agitated nursing home residents with Alzheimer dementia?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Delirium; Don | 2018 |
A chiral enantioseparation generic strategy for anti-Alzheimer and antifungal drugs by short end injection capillary electrophoresis using an experimental design approach.
Topics: Alzheimer Disease; Antifungal Agents; Cyclodextrins; Donepezil; Electrophoresis, Capillary; Indans; | 2018 |
Synergistic enhancing-memory effect of donepezil and S 47445, an AMPA positive allosteric modulator, in middle-aged and aged mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Benzoxazines; | 2018 |
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Topics: Aged; Alzheimer Disease; Brain; Brain Mapping; Cerebrovascular Circulation; Cholinesterase Inhibitor | 2019 |
Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer's Disease: in vitro and ex vivo Characterization.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Drug L | 2018 |
Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer's dementia in very old age: A retrospective observational study.
Topics: Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Female; Ginkgo biloba; Humans; Indans; M | 2018 |
Amalaki Rasayana improved memory and neuronal metabolic activity in AbPP-PS1 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Carbon Isotopes; Cognition; Donep | 2017 |
Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-β load and related toxicity in a mouse model of Alzheimer's disease.
Topics: Acetylcholine; Aldehydes; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; | 2018 |
Acetyl Cholinesterase Inhibitors and Cell-Derived Peripheral Inflammatory Cytokines in Early Stages of Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cytokines; Donepezil; Female; Follow-Up Studies; | 2018 |
Characteristic deterioration of ADAS-Jcog subscale scores and correlations with regional cerebral blood flow reductions in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cognition; Cysteine; | 2018 |
Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Asian People; ATP Binding Cassette Transpor | 2018 |
Synthesis and biological evaluation of potential acetylcholinesterase inhibitors based on a benzoxazine core.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzoxazines; Cholinesterase Inhibitors; Donepezil; Drug De | 2018 |
Development of coumarin-benzofuran hybrids as versatile multitargeted compounds for the treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Binding Sites; Cholinesterase Inhibitors; Cou | 2018 |
Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Donepezil; Exanthema; Female; Huma | 2018 |
The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Longitudinal Studies; | 2018 |
Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer's Disease.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Blood Glucose; Cholester | 2018 |
In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro/in Vivo Correlations.
Topics: Administration, Cutaneous; Alzheimer Disease; Animals; Biological Availability; Donepezil; Drug Deli | 2018 |
Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cogniti | 2018 |
Acute inability to mobilise resulting from probable donepezil-induced myoclonus.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Mobility | 2018 |
Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopep | 2018 |
Possible mechanism of Vitis vinifera L. flavones on neurotransmitters, synaptic transmission and related learning and memory in Alzheimer model rats.
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derive | 2018 |
Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Japan-Great Outcome of Long-term trial with Donepezil (J-GOLD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorder | 2018 |
Access to Highly Enantioenriched Donepezil-like 1,4-Dihydropyridines as Promising Anti-Alzheimer Prodrug Candidates via Enantioselective Tsuji Allylation and Organocatalytic Aza-Ene-Type Domino Reactions.
Topics: Alzheimer Disease; Catalysis; Cyclization; Dihydropyridines; Donepezil; Prodrugs; Stereoisomerism | 2018 |
Drawing on the brain's resilience to fight Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Cognitive Remediation; Cognitive Reserve; Donepezil; Female; Humans; Male; | 2018 |
Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Brain; Calcineurin; Calcineurin Inhibitors; | 2018 |
Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's drug candidates.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Caco-2 Cells; Cell Lin | 2018 |
Ellagic acid: Insights into its neuroprotective and cognitive enhancement effects in sporadic Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line, Tumor; Cholinesterase Inhibitors; Cogni | 2018 |
Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesteras | 2018 |
Neurophysiological signals as predictive translational biomarkers for Alzheimer's disease treatment: effects of donepezil on neuronal network oscillations in TgF344-AD rats.
Topics: Alzheimer Disease; Animals; Biomarkers; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Do | 2018 |
Donepezil decreases heart rate in elderly patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Heart Rate; Humans | 2019 |
Development of bioanalytical HPLC method for simultaneous determination of the antialzhiemer, donepezil hydrochloride and the antidepressant, citalopram hydrobromide in raw materials, spiked human plasma and tablets dosage form.
Topics: Alzheimer Disease; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; C | 2019 |
Influence of Acetylcholinesterase Inhibitors Used in Alzheimer's Disease Treatment on the Activity of Antioxidant Enzymes and the Concentration of Glutathione in
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Donepezil; Fluorides; Glutathione; Human | 2018 |
Effect of donepezil hydrochloride & aerobic exercise training on learning and memory and its mechanism of action in an Alzheimer's disease rat model.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cerebral Cortex; Choline O-Acetyltransferase; Done | 2018 |
Reassembly of native components with donepezil to execute dual-missions in Alzheimer's disease therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoprotein A-I; Blood-Brain Barrier; Cell Lin | 2019 |
Lesson of the month 1: Prolonged QT syndrome due to donepezil: a reversible cause of falls?
Topics: Accidental Falls; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Long QT Syndrome; | 2019 |
Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Chromones | 2019 |
Novel Deoxyvasicinone-Donepezil Hybrids as Potential Multitarget Drug Candidates for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Cell Line; Ch | 2019 |
Metal based donepezil analogues designed to inhibit human acetylcholinesterase for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Design; GPI-Link | 2019 |
Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Databa | 2019 |
De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer Simulati | 2020 |
Effects of manual acupuncture combined with donepezil in a mouse model of Alzheimer's disease.
Topics: Acupuncture Therapy; Alzheimer Disease; Animals; Brain; Combined Modality Therapy; Disease Models, A | 2019 |
The acetylcholinesterase (AChE) inhibitor and anti-Alzheimer drug donepezil interacts with human erythrocytes.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dimyristoylphosphatidylcholine; | 2019 |
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cytochrome P-450 CYP2C9; Cyto | 2019 |
New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; CHO Cells; Cholinesterase Inhibitor | 2019 |
Revealing the mechanistic pathway of cholinergic inhibition of Alzheimer's disease by donepezil: a metadynamics simulation study.
Topics: Acetylcholinesterase; Alzheimer Disease; Catalysis; Catalytic Domain; Cholinesterase Inhibitors; Cry | 2019 |
Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Cholinesterase Inhi | 2019 |
Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017.
Topics: Aged; Alzheimer Disease; China; Cholinesterase Inhibitors; Donepezil; Female; Humans; Male; Memantin | 2019 |
One-Year Persistence with Donepezil, Memantine, and Rivastigmine in More than 66,000 Elderly Patients Followed in Poland.
Topics: Aged; Alzheimer Disease; Donepezil; Drug Utilization Review; Female; Humans; Male; Medication Adhere | 2019 |
[Anticholinesterases; peripheral and central effects].
Topics: Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Neostigmine; Neuromu | 2013 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galanta | 2013 |
Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Colorimetry; Donepezil; Indans; | 2013 |
Evolution of a cost-utility model of donepezil for Alzheimer's disease.
Topics: Alzheimer Disease; Costs and Cost Analysis; Decision Support Techniques; Donepezil; Humans; Indans; | 2013 |
Molecular recognition of rosmarinic acid from Salvia sclareoides extracts by acetylcholinesterase: a new binding site detected by NMR spectroscopy.
Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; C | 2013 |
Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibi | 2013 |
Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists.
Topics: Acetylcholinesterase; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Pepti | 2013 |
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Cho | 2013 |
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil | 2013 |
Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Area Under Curve; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans | 2013 |
Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Female; Humans; Indans; Male; Midd | 2014 |
Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cholineste | 2013 |
Steady-state plasma concentration of donepezil enantiomers and its stereoselective metabolism and transport in vitro.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure | 2013 |
Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition; Donepe | 2013 |
Serum adipokine levels modified by donepezil treatment in Alzheimer's disease.
Topics: Adipokines; Adiponectin; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cogn | 2014 |
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; C | 2014 |
Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brief Psychiatric Rating Scale; Ch | 2014 |
An over expression APP model for anti-Alzheimer disease drug screening created by zinc finger nuclease technology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosi | 2013 |
Increased levels of plasma p3-alcα35, a major fragment of Alcadeinα by γ-secretase cleavage, in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid Precursor Protein Secretases; Biomarkers; Calciu | 2014 |
Donepezil 23 mg: a brief insight on efficacy and safety concerns.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Piperidin | 2013 |
[A case report of early-onset Alzheimer's disease with multiple psychotic symptoms, finally diagnosed as APPV717I mutation by genetic testing].
Topics: Alzheimer Disease; Brain; Donepezil; Genetic Testing; Humans; Indans; Male; Middle Aged; Mutation; P | 2013 |
A brief report on the efficacy of donepezil in pain management in Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; | 2014 |
Donepezil-associated sick sinus syndrome.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Male; Piperidines; Si | 2014 |
Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Diagnostic an | 2014 |
Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Donepezil; | 2014 |
A novel PSEN1 mutation in a patient with sporadic early-onset Alzheimer's disease and prominent cerebellar ataxia.
Topics: Adult; Alzheimer Disease; Cerebellar Ataxia; Cholinesterase Inhibitors; DNA Mutational Analysis; Don | 2014 |
Donepezil and life expectancy in Alzheimer's disease: a retrospective analysis in the Tajiri Project.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2014 |
The potentially protective effect of donepezil in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Case-Control Studies; Donepezil; Female; Hippoc | 2014 |
Generating genius: how an Alzheimer's drug became considered a 'cognitive enhancer' for healthy individuals.
Topics: Adult; Aerospace Medicine; Aged; Alzheimer Disease; Aviation; Cholinesterase Inhibitors; Computer Si | 2014 |
Quantifying ligand-receptor interactions for gorge-spanning acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; GPI-Li | 2015 |
Frontoparietal cognitive control of verbal memory recall in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; | 2014 |
Reversal by aqueous extracts of Cistanche tubulosa from behavioral deficits in Alzheimer's disease-like rat model: relevance for amyloid deposition and central neurotransmitter function.
Topics: Alzheimer Disease; Amyloid; Animals; Brain; Brain Chemistry; Cistanche; Disease Models, Animal; Done | 2014 |
Motor cortex excitability changes in mild Alzheimer's disease are reversed by donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2014 |
Hippocampal P3-like auditory event-related potentials are disrupted in a rat model of cholinergic degeneration in Alzheimer's disease: reversal by donepezil treatment.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal; Auditory Perception; CA1 Region, Hippocampal; Ch | 2014 |
The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Berberine; Brain; Cell Survival; Cogniti | 2015 |
Donepezil-induced myoclonus in a patient with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Myoclonus; Pi | 2014 |
Measures to prevent Alzheimer's patients from discontinuing the use of cholinesterase inhibitors.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Medication Adherence; Piper | 2014 |
Biopolymer-based transdermal films of donepezil as an alternative delivery approach in Alzheimer's disease treatment.
Topics: Adhesiveness; Administration, Cutaneous; Alzheimer Disease; Animals; Biopolymers; Chemistry, Pharmac | 2015 |
Novel ionically crosslinked acrylamide-grafted poly(vinyl alcohol)/sodium alginate/sodium carboxymethyl cellulose pH-sensitive microspheres for delivery of Alzheimer's drug donepezil hydrochloride: Preparation and optimization of release conditions.
Topics: Acrylamide; Alginates; Alzheimer Disease; Carboxymethylcellulose Sodium; Chlorides; Donepezil; Drug | 2016 |
Donepezil-induced hepatotoxicity in an elderly adult taking fluoxetine.
Topics: Aged; Alanine Transaminase; Alzheimer Disease; Antidepressive Agents, Second-Generation; Aspartate A | 2014 |
FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Female; Forkhead Box Protein O | 2014 |
Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Humans; Indan | 2014 |
Clinical compliance of donepezil in treating Alzheimer's disease in taiwan.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2015 |
Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Dru | 2015 |
Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
Topics: Aged; Alzheimer Disease; Animals; Appetitive Behavior; Attention; Cognition; Defecation; Donepezil; | 2015 |
Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Disease Progress | 2014 |
Bone Marrow-Derived Endothelial Progenitor Cells Protect Against Scopolamine-Induced Alzheimer-Like Pathological Aberrations.
Topics: Adipose Tissue; Alzheimer Disease; Animals; Cell Movement; Cells, Cultured; Cognition Disorders; Cyt | 2016 |
Sulfonamides as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Butyrylcholinesterase | 2015 |
Donepezil-ferulic acid hybrids as anti-Alzheimer drugs.
Topics: Alzheimer Disease; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; D | 2015 |
Evaluation of Candidate Genes Related to Neuronal Apoptosis in Late-Onset Alzheimer’s Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Apoptosis; Chol | 2015 |
Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Do | 2015 |
Combination benefit of cognitive rehabilitation plus donepezil for Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Combined Modality | 2016 |
The combination of aricept with a traditional Chinese medicine formula, smart soup, may be a novel way to treat Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Brain; Disea | 2015 |
[Test scores as indicators of treatment efficacy in dementia caused by Alzheimer's disease in clinical practice].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2014 |
Increased libido associated with donepezil treatment: a case report.
Topics: Alzheimer Disease; Antidepressive Agents, Tricyclic; Cholinesterase Inhibitors; Donepezil; Dose-Resp | 2016 |
Donepezil attenuates Aβ-associated mitochondrial dysfunction and reduces mitochondrial Aβ accumulation in vivo and in vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cholineste | 2015 |
Donepezil treatment in ethnically diverse patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Donepezil; Ethnicity; Female; Humans; Indans; Male; Nootropic Agents; Piper | 2015 |
Multigram synthesis and in vivo efficacy studies of a novel multitarget anti-Alzheimer's compound.
Topics: Alzheimer Disease; Aminoquinolines; Amyloid beta-Protein Precursor; Animals; Animals, Genetically Mo | 2015 |
[ApoE gene polymorphism as a predictor of therapeutic response to treatment acetylcholinesterase inhibitor for elderly patients with Alzheimer's and vascular dementia types].
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil | 2014 |
The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model.
Topics: Aging; Alzheimer Disease; Animals; Cholinergic Agents; Cholinesterase Inhibitors; Disease Models, An | 2015 |
Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; | 2015 |
Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorder | 2016 |
Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Blood Platelets; Cholinesterase In | 2015 |
The Relationship Between Medial Temporal Lobe Atrophy and Cognitive Impairment in Patients With Dementia With Lewy Bodies.
Topics: Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Atrophy; Cognition Disorders; Do | 2015 |
Nootropic, neuroprotective and neurotrophic effects of phloretin in scopolamine induced amnesia in mice.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Animals; Antioxidants; Brain-Derived Neurotrophic | 2015 |
Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2016 |
Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apathy; Cholinesterase Inhibitors; Donepezil; Executive | 2016 |
Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Donepezil; Event-Related P | 2015 |
Normal Hearing Ability but Impaired Auditory Selective Attention Associated with Prediction of Response to Donepezil in Patients with Alzheimer's Disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Donepezil; | 2015 |
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase | 2015 |
Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chromatography, High Pressure Liquid; Cyclic N-Oxides; D | 2016 |
Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).
Topics: Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Mental Status Schedul | 2015 |
Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Donepezil; Female; Follow-Up Studi | 2015 |
Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil.
Topics: Aging; Alzheimer Disease; Animals; beta-Galactosidase; Cholinesterase Inhibitors; Cognition; Disease | 2015 |
Drug-induced lupus erythematosus associated with donepezil: a case report.
Topics: Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Hydrolases; Indans; Lupus Erythemat | 2015 |
A case of donepezil-related torsades de pointes.
Topics: Aged, 80 and over; Alzheimer Disease; Cardiopulmonary Resuscitation; Donepezil; Electrocardiography; | 2015 |
Continuing donepezil when Alzheimer symptoms worsen might delay nursing home admission, study indicates.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Nursing H | 2015 |
Antiaggregation Potential of Padina gymnospora against the Toxic Alzheimer's Beta-Amyloid Peptide 25-35 and Cholinesterase Inhibitory Property of Its Bioactive Compounds.
Topics: Acetone; Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Chol | 2015 |
Lifetime expectancy and quality-adjusted life-year in Alzheimer's disease with and without cerebrovascular disease: effects of nursing home replacement and donepezil administration--a retrospective analysis in the Tajiri Project.
Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Comorbidity; Donepezil; Hum | 2015 |
Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Cholinesterase Inhibitors; Donepezil; Female | 2016 |
Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Asian People; Cholinesterase Inhibitors; Cytoch | 2015 |
Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Asia; A | 2015 |
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Datab | 2015 |
Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?
Topics: Alzheimer Disease; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cognition Disorders; Done | 2016 |
The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E3; Asian People; Cytochrome P-450 CYP2D6 | 2016 |
Exploring the Phase Behavior of Monoolein/Oleic Acid/Water Systems for Enhanced Donezepil Administration for Alzheimer Disease Treatment.
Topics: Adhesiveness; Alzheimer Disease; Animals; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Dela | 2016 |
Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; | 2016 |
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2016 |
Microneedle-mediated delivery of donepezil: Potential for improved treatment options in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Area Under Curve; Cholinesterase Inhibitors; Donepezil; Indans; Male; Mi | 2016 |
An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepez | 2016 |
Protective effect of transient receptor potential vanilloid subtype 1 (TRPV1) modulator, against behavioral, biochemical and structural damage in experimental models of Alzheimer's disease.
Topics: Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Animals; Benzaldehydes; Brain; Chlorides; | 2016 |
Effects of donepezil on brain morphometric and metabolic changes in patients with Alzheimer's disease: A DARTEL-based VBM and (1)H-MRS.
Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Female; Follow-Up Studies; Hum | 2016 |
Postmortem redistribution mechanism of donepezil in the rat.
Topics: Alzheimer Disease; Animals; Autopsy; Blood Chemical Analysis; Cholinesterase Inhibitors; Donepezil; | 2016 |
Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; | 2017 |
Hepatotoxicity Associated with Donepezil in an Individual Taking Citalopram.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Chemical and Drug In | 2016 |
Novel anionic polymer as a carrier for CNS delivery of anti-Alzheimer drug.
Topics: Alzheimer Disease; Animals; Anions; Cell Line, Tumor; Central Nervous System; Central Nervous System | 2016 |
Unexplained Homonymous Hemianopia.
Topics: Alzheimer Disease; Atrophy; Cholinesterase Inhibitors; Donepezil; Female; Hemianopsia; Humans; Indan | 2016 |
Tip-loaded dissolving microneedles for transdermal delivery of donepezil hydrochloride for treatment of Alzheimer's disease.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; | 2016 |
DatSCAN In Differential Diagnostics of Lewy Body Disease.
Topics: Aged, 80 and over; Alzheimer Disease; Czech Republic; Diagnosis, Differential; Donepezil; Female; Hu | 2016 |
Donepezil modulates the endogenous immune response: implications for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Cells, Cultured | 2016 |
Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Survival; Cholinestera | 2016 |
Improved learning of sequential behaviour during cane gait training or stair climbing after femoral neck fracture: an implication for donepezil for very mild Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Canes; Cholinesterase Inhibitors; Donepezil; Executive Functio | 2017 |
Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepez | 2016 |
Fuzhisan ameliorates Aβ production and tau phosphorylation in hippocampal of 11month old APP/PS1 transgenic mice: A Western blot study.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Disease Models, Animal; Donepe | 2016 |
The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.
Topics: Alzheimer Disease; Animals; Cell Survival; Cerebral Cortex; Disease Models, Animal; Donepezil; Glios | 2017 |
The 5-HT
Topics: Alzheimer Disease; Animals; Benzylamines; Brain Stem; Cholinesterase Inhibitors; Donepezil; Electric | 2017 |
In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Ind | 2017 |
Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Finland; Galanta | 2017 |
Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cognition; Donepez | 2016 |
Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets.
Topics: ADAM10 Protein; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid | 2017 |
The effects of fluorine substitution on the chemical properties and inhibitory capacity of Donepezil anti-Alzheimer drug; density functional theory and molecular docking calculations.
Topics: Alzheimer Disease; Donepezil; Electrons; Fluorine; Humans; Hydrogen Bonding; Indans; Models, Molecul | 2017 |
Cholinesterase inhibitors are compatible with psychosocial intervention for Alzheimer disease patients suggested by neuroimaging findings.
Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cholinesterase Inhibitors; Donepezil; F | 2017 |
Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Computational Biology; Computer Simulation; Cyclos | 2017 |
Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Substituti | 2017 |
The Anti-dementia Effects of Donepezil Involve miR-206-3p in the Hippocampus and Cortex.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain-Derived Neurotrophic Factor; Cereb | 2017 |
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Tolerance; Fe | 2017 |
Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Antioxidants; Brain; Cholinesterase Inhibit | 2017 |
Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cell Line, Tumor; Cholinestera | 2017 |
Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Male; M | 2017 |
The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; | 2008 |
Prolonged treatment with donepezil increases acetylcholinesterase expression in the central nervous system.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Autoradiography; Cholinesterase Inhibitors; Densit | 2008 |
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil | 2008 |
Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".
Topics: Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholinesterase Inhibitors; Donepezil; Dru | 2008 |
Effect of donepezil on innate antiviral immunity of human leukocytes.
Topics: Adult; Aged; Alzheimer Disease; Analysis of Variance; Animals; Cell Line, Transformed; Cholinesteras | 2008 |
Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Piperidines; Psy | 2008 |
Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Case-Contro | 2009 |
[Alzheimer type dementia].
Topics: Alzheimer Disease; Apolipoprotein E4; Diagnosis, Differential; Disease Progression; Donepezil; Human | 2008 |
Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Middle Aged; Nootro | 2008 |
Randomized clinical trial results for donepezil in Alzheimer's disease: is the treatment glass half full or half empty?
Topics: Activities of Daily Living; Advertising; Aged; Alzheimer Disease; Conflict of Interest; Donepezil; D | 2008 |
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo | 2008 |
[Familial Alzheimer's disease with presenilin 2 N141I mutation. A case report].
Topics: Adult; Alzheimer Disease; Antidepressive Agents, Second-Generation; Brain; Citalopram; Codon; Donepe | 2008 |
Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Body Mass Index; C | 2008 |
Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Hispanic or Latino; Humans; Indans; M | 2008 |
SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cognition; Donepezil; Female; Humans; Image Proce | 2008 |
Plasma urate and progression of mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Boston; Cognition Disorders; Confounding Factors, Epidem | 2009 |
Possible Alzheimer's disease in an apolipoprotein E2 homozygote.
Topics: Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Donepezil; Female; Homozygote; Humans; Inda | 2009 |
The impact of Alzheimer's disease medication on muscle relaxants.
Topics: Alzheimer Disease; Androstanols; Cholinesterase Inhibitors; Donepezil; Drug Interactions; gamma-Cycl | 2009 |
Cracking the therapeutic nut in mild cognitive impairment: better nuts and better nutcrackers.
Topics: Alzheimer Disease; Biomarkers; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disord | 2009 |
Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls.
Topics: Accidental Falls; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Gait; Human | 2009 |
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; | 2009 |
Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Disease Progression; Donepezil; | 2009 |
GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2009 |
Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Behavioral Symptoms; Case-Control Stu | 2009 |
Top cited papers in international psychogeriatrics: 3. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cluster Analysis; Donepezil; Humans; Indans; Piperidin | 2009 |
[How long should drug therapy be continued for Alzheimer disease?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 2009 |
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinestera | 2009 |
Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2009 |
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Delayed-A | 2009 |
Response to "Results, rhetoric, and randomized trials: the case of donepezil".
Topics: Advertising; Aged; Alzheimer Disease; Conflict of Interest; Donepezil; Drug Industry; Drug Utilizati | 2009 |
Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Biomarkers; Brief Psychiatric Rating Scale; Donepezil; Female; Humans; Inda | 2009 |
International price comparisons of Alzheimer's drugs: a way to close the affordability gap.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Developing Countries; Donepezil; Drug Costs; Eco | 2009 |
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cohort Studies; Cytochrome P | 2009 |
Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Donepezil; | 2009 |
Turbocharging the brain.
Topics: Alzheimer Disease; Benzhydryl Compounds; Brain; Central Nervous System Agents; Central Nervous Syste | 2009 |
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Donepe | 2009 |
Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Biomarkers; Choli | 2009 |
Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Donepezil; Heart Failure; Indans; Male; Mice; Pi | 2009 |
Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Confounding Factors, Epidemiologi | 2009 |
Torsades de Pointes with QT prolongation related to donepezil use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Colitis; Donepezil; Electrocardiogr | 2009 |
Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model.
Topics: Acetylcholine; Alzheimer Disease; Animals; Caspase 3; Caspase 7; Cholinesterase Inhibitors; Donepezi | 2010 |
[Adverse events causing discontinuation of donepezil for Alzheimer's dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil | 2009 |
No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Dopamine; Female; Hu | 2010 |
Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Aziridines; Benzodioxoles; Choline; Cog | 2010 |
Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain Mapping; Cholinesterase Inhibitors; Cognition Disorders; Coh | 2010 |
Prescribing of drugs for Alzheimer's disease: a South African database analysis.
Topics: Aged; Alzheimer Disease; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Donepezil; | 2010 |
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; C | 2010 |
Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Brief Psychiatric Rating Scale; Cogni | 2010 |
Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.
Topics: Acetylcholinesterase; Alzheimer Disease; Amino Acid Motifs; Amyloid beta-Peptides; Amyloid Precursor | 2010 |
Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells.
Topics: Alzheimer Disease; Analysis of Variance; Blood Cells; Cholinesterase Inhibitors; Clinical Trials as | 2010 |
Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2010 |
Effect of donepezil on the continuum of depressive symptoms, mild cognitive impairment, and progression to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Depressive Disorder; Disease Progre | 2010 |
Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cost of Illness; Donepezil; Female; H | 2009 |
Anticholinesterase duration in the Australian veteran population.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Female; | 2010 |
Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Caregivers; Computer Simulation; Cost of Ill | 2010 |
Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Biomarkers; Donepezil; Dose-Response Relat | 2010 |
Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Donepezil; Female; Humans; Indans; Magnetic Reson | 2010 |
In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Protein Prec | 2010 |
Treatment disparities in medication prescribing for Alzheimer's: disease among ethnic groups.
Topics: Age Factors; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Healthcare Disparities | 2009 |
Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2011 |
How do we treat people with dementia in Croatia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Croatia; Cross-Cultural Comparison; Cross-Sectio | 2010 |
Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dopamine Agents; Female | 2010 |
Donepezil and concurrent sertraline treatment is associated with increased hippocampal volume in a patient with depression.
Topics: Adult; Alzheimer Disease; Atrophy; Cholinesterase Inhibitors; Cognition Disorders; Depressive Disord | 2010 |
[Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Ginkgo | 2010 |
The effect of donepezil treatment on cardiovascular mortality.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Coho | 2010 |
Memantine-related psychotic symptoms in a patient with bipolar disorder.
Topics: Alzheimer Disease; Antimanic Agents; Bipolar Disorder; Donepezil; Drug Interactions; Excitatory Amin | 2010 |
Prescribing trends in cognition enhancing drugs in Australia.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donep | 2011 |
Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Computer Simulation; Decision Making; D | 2010 |
Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice.
Topics: Alzheimer Disease; Animals; Apolipoproteins E; Atherosclerosis; Cardiovascular Diseases; Cholinester | 2010 |
Investigation of responders and non-responders to long-term donepezil treatment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Female; Geriatric Assessment; Huma | 2010 |
A new commercially viable synthetic route for donepezil hydrochloride: anti-Alzheimer's drug.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Technology, Pharmaceuti | 2010 |
Evaluation of the effect of donepezil on cerebral blood flow velocity in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Blood Flow Velocity; Cerebrovascul | 2010 |
Determining the minimum clinically important differences for outcomes in the DOMINO trial.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Data Interpretation, Stati | 2011 |
Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Cohort Studies; Cytochrome P-450 CYP2D6; Donepezil; Female; Genetic Variation; Hu | 2011 |
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Topics: Adult; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; ATP Binding Cassette Transporter, Subfam | 2011 |
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; | 2010 |
Early Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Early Diagnosis; Humans; Indans; Pipe | 2010 |
Plasma concentration of donepezil to the therapeutic response of Alzheimer's disease in Taiwanese.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Piperidines; Ta | 2011 |
Donepezil eliminates suppressive effects of β-amyloid peptide (1-42) on long-term potentiation in the hippocampus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Donepezil; Hippocampus; Indans; Long-Term Potenti | 2010 |
[The efficacy of donepezil hydrochloride on the Apathy scale in Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Apathy; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 2010 |
FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Benzamides; Cholinesterase Inhibitors; Cognition; Discrimination Learnin | 2011 |
Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cues; Donepezil; Fem | 2010 |
Report of the task force on designing clinical trials in early (predementia) AD.
Topics: Advisory Committees; Alzheimer Disease; Amyloidogenic Proteins; Biomarkers; Clinical Trials as Topic | 2011 |
Modulatory effects of vitamin E, acetyl-L-carnitine and α-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model.
Topics: Alzheimer Disease; Animals; Antioxidants; Biomarkers; Brain; Carnitine; Cholinesterase Inhibitors; D | 2012 |
Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation follow-up study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Follow-Up | 2011 |
Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Donepezil; Galantamine; Human | 2011 |
Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Dopamine Agents; | 2011 |
Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept).
Topics: Alzheimer Disease; Animals; Attention; Conditioning, Operant; Disease Models, Animal; Donepezil; Hum | 2011 |
[Effects of early intervention with Huannao Yicong formula effective components on behavior and cholinergic system of β-amyloid precursor protein transgenic mice].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cholinergic Agents; Di | 2011 |
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
Topics: Alzheimer Disease; Caregivers; Cognition Disorders; Cost-Benefit Analysis; Disease Progression; Done | 2012 |
[Prescription differences of dementia drugs in urban and rural areas in Germany].
Topics: Aged; Alzheimer Disease; Ambulatory Care; Donepezil; Galantamine; General Practice; Germany; Humans; | 2011 |
Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice.
Topics: Alzheimer Disease; Animals; Choline O-Acetyltransferase; Cognition Disorders; Conditioning, Psycholo | 2011 |
FDA is criticised for licensing high dose donepezil.
Topics: Alzheimer Disease; Donepezil; Dose-Response Relationship, Drug; Drug Approval; Humans; Indans; Licen | 2011 |
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Butyrylcholinesterase; Cholinesterase | 2011 |
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; P | 2011 |
1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cohort Studies; Donepezil; Female; Hu | 2011 |
"Reversible" Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Atrophy; Cohort Studies; Combined Modality Therapy; Donepezil; Female; Fluo | 2011 |
Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice.
Topics: Alzheimer Disease; Animals; Blood Pressure; Cells, Cultured; Cholinesterase Inhibitors; Donepezil; E | 2011 |
A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apoptosis; Behavi | 2011 |
Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cognition Disorders; Donepezil; Do | 2011 |
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Disease Progression; Donepezil; Fema | 2012 |
Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Aryldialkylphosphatase; Cholinesterase Inhibitors; DNA; | 2011 |
Significant dose differences in donepezil purchased from the United States and Canada.
Topics: Alzheimer Disease; Canada; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Prescr | 2011 |
The impact of patient and public involvement in the work of the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN): case studies.
Topics: Alzheimer Disease; Biomedical Research; Community Participation; Dementia; Donepezil; Humans; Indans | 2013 |
Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease.
Topics: Academies and Institutes; Alzheimer Disease; Cholinesterase Inhibitors; Cooperative Behavior; Data M | 2011 |
Evaluation of therapeutic response to donepezil by positron emission tomography.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Chi-Square Distribution; Cholinesterase Inhibitor | 2011 |
AChE inhibitor: a regio- and stereo-selective 1,3-dipolar cycloaddition for the synthesis of novel substituted 5,6-dimethoxy spiro[5.3']-oxindole-spiro-[6.3″]-2,3-dihydro-1H-inden-1″-one-7-(substituted aryl)-tetrahydro-1H-pyrrolo[1,2-c][1,3]thiazole.
Topics: Acetylcholinesterase; Alzheimer Disease; Azo Compounds; Chemistry, Pharmaceutical; Cholinesterase In | 2012 |
Characterization of oral disintegrating film containing donepezil for Alzheimer disease.
Topics: Administration, Oral; Alzheimer Disease; Chemistry, Pharmaceutical; Donepezil; Double-Blind Method; | 2012 |
Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs.
Topics: Alleles; Alzheimer Disease; Biotransformation; Cytochrome P-450 CYP2D6; Donepezil; Drug Resistance; | 2011 |
Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.
Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Cholinergic Fibers; Cholinesterase Inhibitors; | 2012 |
Withdrawal syndrome after donepezil cessation in a patient with dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Delirium; Dementia; Donepezil; Female; Humans; Indans; | 2012 |
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Ger | 2012 |
Discontinuing donepezil or starting memantine for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Female; | 2012 |
Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug Syner | 2012 |
How the FDA forgot the evidence: the case of donepezil 23 mg.
Topics: Alzheimer Disease; Donepezil; Drug Approval; Drug Labeling; Evidence-Based Medicine; Humans; Indans; | 2012 |
Case report: Post-traumatic memories triggered by donepezil in a dose-dependent pattern.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationsh | 2012 |
Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Catalase; Cholinesterase Inhibitors; Donepezil; Female; | 2012 |
Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cytochrome P-450 CYP2D6; DNA | 2012 |
Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Body Mass Index; Case-Control Stud | 2012 |
GOOD or BAD responder? Behavioural and neuroanatomical markers of clinical response to donepezil in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Biomarkers; Brain; Cholinesterase Inhibitors; D | 2012 |
Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2012 |
Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Cholinesterase Inhibitors; Donepezil; Fe | 2012 |
Novel object recognition as a facile behavior test for evaluating drug effects in AβPP/PS1 Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Donepezil; Drug | 2012 |
Cautious notification and continual monitoring of patients with mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Combin | 2012 |
[Interaction of donepezil with rocuronium].
Topics: Alzheimer Disease; Androstanols; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Humans; In | 2012 |
[Donepezil].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 2011 |
Combination therapy no advantage in Alzheimer's treatment.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; | 2012 |
[Instrumental ADL and basic ADL].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Femal | 2011 |
Continuing donepezil produces cognitive benefits in Alzheimer's.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Neuropsychological Tests; P | 2012 |
Electron density study of the anti-Alzheimer's disease drug donepezil from conventional x-ray data and invariom database application.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; E | 2012 |
Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Functional | 2012 |
Cholinergic gating of hippocampal auditory evoked potentials in freely moving rats.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Biperiden; Cholinergic Neurons; Cholinesterase Inhibit | 2013 |
Efficacy of a high dosage of donepezil for Alzheimer's disease as examined by single-photon emission computed tomography imaging.
Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cholinesterase Inhibitors; Donepezil; D | 2012 |
Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein S | 2012 |
Acute Pisa syndrome after administration of a single dose of donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dystonia; Female; Humans; Indans; Mem | 2012 |
Cervical dystonia in an Alzheimer's disease patient treated with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Piperidines; | 2013 |
Application of the VSRAD, a specific and sensitive voxel-based morphometry, to comparison of entorhinal cortex atrophy between dementia with Lewy bodies and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Data Interpretation, Statistical; Donepezil; En | 2012 |
Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cyclic AMP Response Element-Binding Pr | 2013 |
Nobiletin-rich Citrus reticulata peels, a kampo medicine for Alzheimer's disease: a case series.
Topics: Aged; Alzheimer Disease; Antioxidants; Chromatography, High Pressure Liquid; Citrus; Disease Progres | 2013 |
Trace analysis of acetylcholinesterase inhibitors with antipsychotic drugs for Alzheimer's disease by capillary electrophoresis with on column field-amplified sample injection.
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Electrophoresis, Capi | 2013 |
Extrapyramidal side-effect due to drug combination of risperidone and donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Donepezil; | 2002 |
Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Donepezil; Eponyms; Female; Germany; History, 19th Century; History, 20th C | 2002 |
Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Brain; Carbamates; Case-Control Studies; Cerebrovascular Circulation; Choli | 2002 |
[The efficacy of donepezil in Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Piperidines | 2002 |
Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Electroence | 2002 |
Comparison of functional and cognitive donepezil effects in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 2002 |
The impact of journal advertisements on prescribers of cholinesterase inhibitors.
Topics: Advertising; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions | 2002 |
[Acetylcholinesterase inhibitor. Helpful not just in Alzheimer dementia].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Parkinson Disease; Piperidi | 2002 |
Use of artificial networks in clinical trials: a pilot study to predict responsiveness to donepezil in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dis | 2002 |
A case series of D-cycloserine added to donepezil in the treatment of Alzheimer's disease.
Topics: Adolescent; Adult; Alzheimer Disease; Antimetabolites; Child; Cholinesterase Inhibitors; Cognition D | 2002 |
Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Mid | 2002 |
[Many Alzheimer patients untreated].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Germany; Humans; | 2002 |
Responses to donepezil in Alzheimer's disease and Parkinson's disease.
Topics: Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Donepezil; Humans; Indans | 2002 |
Assessing the efficacy of cholinesterase inhibitor drugs.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2003 |
Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease.
Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dement | 2003 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihy | 2002 |
An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibi | 2003 |
Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Event-Related Pote | 2003 |
Neuroleptic malignant-like syndrome due to donepezil and maprotiline.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Cholinesterase Inhibitors; Donepe | 2003 |
The lowdown on Ginkgo biloba.
Topics: Acetylcarnitine; Acetylcholine; Alzheimer Disease; Animals; Antioxidants; Brain; Candy; Cognition; D | 2003 |
'Awakenings' in demented patients.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Awareness; Cholinesterase Inhibitors; Delusions; Depr | 2003 |
Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Heart Rate | 2003 |
The value of the managed entry of new drugs: a case study of donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Decision Making; Donepezil; Dru | 2003 |
[Interaction of donepezil and muscular blockers in Alzheimer's disease].
Topics: Acetylcholine; Aged; Alzheimer Disease; Anesthesia, General; Atracurium; Cholinesterase Inhibitors; | 2003 |
Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community.
Topics: Aged; Alzheimer Disease; Caregivers; Chi-Square Distribution; Cholinesterase Inhibitors; Cross-Secti | 2003 |
Donepezil and athetosis in an elderly patient with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Athetosis; Donepezil; Humans; Indans; Male; Nootropic Agents; Piperidines | 2003 |
Anticholinesterases in the treatment of Alzheimer's dementia--the first year's experience in Argyll & Clyde.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Protocols; | 2000 |
[Characteristics of MRI features in Alzheimer's disease patients predicting response to donepezil treatment].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Donepezil; Female; Hippocampus; Humans; Indans; M | 2003 |
Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Atrophy; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Logi | 2003 |
Aggressive behaviour associated with donepezil treatment: a case report.
Topics: Aged; Aggression; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Male; Pip | 2003 |
Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
Topics: Aged; Alzheimer Disease; Cost-Benefit Analysis; Donepezil; France; Health Expenditures; Humans; Inda | 2004 |
[Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
Topics: Activities of Daily Living; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Dopami | 2003 |
Alzheimer's drug delays move to nursing home.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Institutionalization; Nursi | 2003 |
Donepezil in the treatment of mild to moderate Alzheimer's disease: report of a Belgian multicenter study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Belgium; Cholinesterase Inhibitors; Cognition; | 2003 |
Effect of donepezil on EEG spectral analysis in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Electroencephalogr | 2003 |
Galantamine vs donepezil in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Huma | 2003 |
[A case of acute cholinergic adverse effects induced by donepezil overdose: a follow-up of clinical course and plasma concentration of donepezil].
Topics: Aged; Alzheimer Disease; Arrhythmia, Sinus; Bradycardia; Cholinesterase Inhibitors; Donepezil; Drug | 2003 |
Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brain; Carbamates; Cholinesterase Inhibitors; Diagnos | 2004 |
Ignoring the controversies: newspaper reports on Alzheimer's disease treatments.
Topics: Alzheimer Disease; Canada; Donepezil; Humans; Indans; Newspapers as Topic; Nootropic Agents; Piperid | 2003 |
No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
Topics: Aged; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Neuroprotective Agents | 2003 |
[Significance of treatment and adequate care in dementia--including point of medical comments in health care insurance system for elderly people by doctors].
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Health Services for the Aged; Humans; Indans; Insuranc | 2003 |
Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Female; Humans; Indans; Mal | 2004 |
Technical issues in the determination of cerebrovascular reserve in elderly subjects using 15O-water PET imaging.
Topics: Acetazolamide; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Attention; Blood Flow Velocity; Br | 2004 |
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2004 |
Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Donepezil; Femal | 2003 |
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Inda | 2003 |
Academic highlights: emerging therapeutic strategies in Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; D | 2004 |
Enhanced cutaneous vascular response in AD subjects under donepezil therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Donepezil; Drug Synergism; Female; | 2004 |
[A study of the effect of donepezil hydrochloride on cognitive function in patients with dementia of Alzheimer's type using WAIS-R].
Topics: Aged; Alzheimer Disease; Cognition Disorders; Donepezil; Female; Humans; Indans; Male; Nootropic Age | 2004 |
Memantine for patients with Alzheimer disease.
Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine | 2004 |
Another advertisement for donepezil.
Topics: Advertising; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Donepezil; Humans; Indans; In | 2004 |
Donepezil's effects remain uncertain.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Follow-Up Studies; Hum | 2004 |
Donepezil delay to nursing home placement study is flawed.
Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Donep | 2004 |
The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil.
Topics: Administration, Oral; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Chromatog | 2004 |
Effects of donepezil on motor function in patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Donepezil; Female; Humans; Indans; | 2004 |
Donepezil use in US nursing homes.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Drug Utilization; Female; Humans; Indans; Mal | 2004 |
Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain Chemistry; Carbama | 2004 |
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cognition Disorders; Donep | 2004 |
Delay in nursing home placement with donepezil.
Topics: Aged; Alzheimer Disease; Bias; Cholinesterase Inhibitors; Data Interpretation, Statistical; Disease | 2004 |
AD2000: donepezil in Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cost-Benefit An | 2004 |
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Top | 2004 |
Mortality in donepezil-treated patients.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 2004 |
Donepezil therapy for neuropsychiatric symptoms in AD: methods make the message.
Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Nootropic Agents; Patient Dropout | 2004 |
Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Comorbidity; Dementia, Vascular; Donepezil; Female; H | 2004 |
[Significance of treatment and adequate care in dementia--including point of medical comments in health care insurance system for elderly people by doctors].
Topics: Aged; Alzheimer Disease; Cognition; Donepezil; Female; Humans; Indans; Insurance, Health; Neuropsych | 2003 |
Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinergic Agents; Cholinesterase Inhibitors; Don | 2004 |
Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cerebral Cortex; Cholineste | 2004 |
9th International Conference on AD and related disorders (ICAD).
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Donepezil; Humans; Hypoglycemic Agents | 2004 |
Delaying Alzheimer's. In a new study, Aricept held it off for 18 months. Is this drug right for you?
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Placebos; Randomized Co | 2004 |
Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey.
Topics: Activities of Daily Living; Affect; Aged; Alzheimer Disease; Attention; Behavior; Cholinesterase Inh | 2004 |
[Limited efficacy of cholinesterase inhibitors in Alzheimer's dementia].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Pip | 2004 |
[Efficacy, efficiency and evidence -- studies on donepezil].
Topics: Aged; Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 2004 |
Donepezil and cardiac syncope: case report.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Electrocardiography, Ambulatory; Fema | 2004 |
Switching from donepezil or rivastigmine to galantamine in clinical practice.
Topics: Alzheimer Disease; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; | 2004 |
Drug therapy in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Humans; Indans; Pipe | 2004 |
Alzheimer's drugs: are they worth it?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Treatment Outc | 2004 |
Impact of rivastigmine use on the risk of nursing home placement in a US sample.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Databases, Fa | 2004 |
Common Alzheimer's drug flunks test of effectiveness. Initial improvements in cognitive ability made by cholinesterase inhibitors soon disappear.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Piperidin | 2004 |
One-year change in cerebral glucose metabolism in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain Chemistry; Brain Mapping; Disease Progression; Donepezil; Female; Flu | 2004 |
[Nightmares in patients with Alzheimer's disease caused by donepezil. Therapeutic effect depends on the time of intake].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dreams; Drug Administration Schedule; Female; | 2005 |
Not all head-to-head trials are created equal: results from an open-label, short-term study seem inconsistent with previous donepezil literature.
Topics: Aged; Alzheimer Disease; Caregivers; Cognition; Donepezil; Galantamine; Humans; Indans; Nootropic Ag | 2005 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Di | 2005 |
Does donepezil improve well-being for dementia due to Alzheimer's disease?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Piperidines; Qual | 2005 |
NICE proposes to withdraw Alzheimer's drugs from NHS.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Drug Costs; England; | 2005 |
Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Endothelium, Vascular; Female; Hemost | 2005 |
Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Cells, Cultured; Cholinesterase Inhibitors; Cytokines | 2005 |
Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cholinesterase Inhibit | 2005 |
Treating dementia patients with vascular lesions with donepezil: a preliminary analysis.
Topics: Aged; Alzheimer Disease; Blood Vessels; Brain; Dementia; Dementia, Vascular; Donepezil; Female; Huma | 2005 |
Searching for methods to detect, prevent, and treat Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepez | 2005 |
Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Drug Administration S | 2005 |
Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Humans; Indans; Neuropharmacology; Nootropic Ag | 2005 |
Mild cognitive impairment--no benefit from vitamin E, little from donepezil.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Cognition Disord | 2005 |
[Protective effect of Danzhi-xiaoyao San on rat brain energy or material metabolism (correction of matebolism) dealt with D-galactose].
Topics: Aldehyde Reductase; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, An | 2005 |
Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzothiazoles; Cells, Cultured; C | 2005 |
[Post-marketing observational study of donepezil].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Therap | 2005 |
Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Chemokine CCL2; Chemokine CCL5; Cholinesterase Inhibitors; Donepezil; Femal | 2005 |
Combination drug therapies for AD: progress is slow, but we must keep trying.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinesterase Inhibitors; | 2005 |
[Donepezil in patients with Alzheimer's disease--a critical appraisal of the AD2000 study].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; H | 2005 |
Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Ger | 2005 |
One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; | 2005 |
Drug may temporarily slow progression of mild cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Donepezil; Female; Humans; Indans; Nootropic Agents; Piperid | 2005 |
Quantitative electroencephalogram analysis in dementia with Lewy bodies and Alzheimer's disease.
Topics: Aged; Algorithms; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Electroencephalography; F | 2005 |
Causes of syncope in patients with Alzheimer's disease treated with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2005 |
Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2005 |
Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cohort Studies; Cross-Sectional Studies; Databases, Fact | 2005 |
Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Attention; Cholinesterase In | 2005 |
Angle-closure glaucoma after discontinuing donepezil hydrochloride (Aricept).
Topics: Alzheimer Disease; Donepezil; Female; Glaucoma, Angle-Closure; Humans; Indans; Middle Aged; Nootropi | 2005 |
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Dementi | 2005 |
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Data Interpretat | 2005 |
Evidence of acetylcholinesterase inhibitors in treating Alzheimer's disease in very old patients is uncertain.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Research | 2005 |
Another data/rhetoric mismatch on donepezil.
Topics: Aged; Alzheimer Disease; Bias; Case-Control Studies; Cholinesterase Inhibitors; Donepezil; Homes for | 2005 |
UK government guidance on Alzheimer's drugs postponed.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Excitatory Amino Aci | 2005 |
Mild cognitive impairment: to treat or not to treat.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Disease | 2005 |
Rationalizing therapeutic approaches in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; I | 2005 |
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Topics: Acetylcholinesterase; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Carb | 2006 |
Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Mapping; Cerebral Cortex; Cholinesterase Inhibitor | 2005 |
[Concerning the contribution by Thomas Kaiser, Christiane Florack, Heinrich Franz, Peter Sawicki: donepezil in patients with Alzheimer's dementia. The AD2000 study. Med Klin 2005;100:157-60].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Piperidin | 2005 |
Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2006 |
Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; | 2006 |
Donepezil-induced nightmares in mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Donepezil; Dreams; Female; Follow-Up Studies; Humans; | 2006 |
SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cerebrovascular Circulation; Chi-S | 2006 |
[Treatment of Alzheimer's disease: clinicians's lecture].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Piperidin | 2006 |
Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepez | 2006 |
Appeals system and its outcomes in national health insurance in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Middle A | 2006 |
Donepezil for severe Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; | 2006 |
Alzheimer's drug helps brain function after radiotherapy.
Topics: Alzheimer Disease; Brain Neoplasms; Cognition Disorders; Donepezil; Humans; Indans; Nootropic Agents | 2006 |
[Advances in Alzheimer's disease treatment].
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezi | 2006 |
Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Cholinesterase Inhibitors; Coho | 2006 |
[Cholinesterase inhibitor therapy in long term care settings].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Follow-Up Studies; Galantamine; Humans; Ind | 2006 |
Pain with donepezil.
Topics: Aged, 80 and over; Alzheimer Disease; Caregivers; Donepezil; Female; Humans; Indans; Nootropic Agent | 2006 |
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cytochrome P-450 CYP2D6; Done | 2006 |
Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil.
Topics: Aged, 80 and over; Alzheimer Disease; Cardiac Pacing, Artificial; Cholinesterase Inhibitors; Donepez | 2006 |
Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Respon | 2006 |
Donepezil for severe Alzheimer's disease.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Cognition; Donepezil; Heart Block; Humans | 2006 |
Donepezil for severe Alzheimer's disease.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Donepezil; Genot | 2006 |
Donepezil for severe Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Donepezil; Hu | 2006 |
Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia.
Topics: Adult; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Female; Humans | 2006 |
Do lesions involving the cortical cholinergic pathways help or hinder efficacy of donepezil in patients with Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cholinergic Fibers; Cholinesterase Inhi | 2006 |
Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Combined Modality | 2007 |
Mayo Clinic office visit. Mild cognitive impairment. An interview with Ronald Petersen, M.D., Ph.D.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Humans; Indans; Memory Disorders; Nootropic A | 2006 |
Alcohol abuse in an elderly woman taking donepezil for Alzheimer disease.
Topics: Aged, 80 and over; Alcohol Drinking; Alcoholism; Alzheimer Disease; Cholinesterase Inhibitors; Compu | 2006 |
Donepezilium oxalate trihydrate, a therapeutic agent for Alzheimer's disease.
Topics: Alzheimer Disease; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Crystallography, X-Ray; Don | 2006 |
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Butyrylcholinesterase; C | 2007 |
In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Capsules; Cholinesterase Inhibitors; Cognition Disorders; Delayed-Action | 2007 |
Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Nootropi | 2007 |
"This is the kind of information we need".
Topics: Alzheimer Disease; British Columbia; Clinical Pharmacy Information Systems; Cognition Disorders; Don | 2007 |
Drug may slow brain shrinkage in pre-Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Cognition Disorders; Disease Progression; Donepezil; Humans | 2006 |
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 2007 |
Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Blotting, Western; Donepezil; Female; Humans; Indans; | 2007 |
3DSRT evaluation of responses of Alzheimer type dementia to donepezil hydrochloride therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cholinesterase Inhib | 2006 |
Donepezil induces a cholinergic sprouting in basocortical degeneration.
Topics: Acetylcholine; Alzheimer Disease; Animals; Basal Nucleus of Meynert; Cerebral Cortex; Cholinergic Fi | 2007 |
NICE faces legal challenge over Alzheimer's drug.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Referral and Consultati | 2007 |
Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Data Interpretation, Statis | 2007 |
Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2007 |
Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clinical Trials, Phase III as Topic; Cost-Benefit Analys | 2007 |
Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Drug Costs; Fema | 2008 |
Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study.
Topics: Adaptation, Physiological; Aged; Alzheimer Disease; Brain Mapping; Cerebrovascular Circulation; Chol | 2007 |
Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Nootropic Agents | 2007 |
Donepezil in Alzheimer's disease: a clinical observational study evaluating individual treatment response.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Nootropic Agent | 2007 |
Do extrapyramidal features in Alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Disease Progr | 2007 |
Exacerbation of myoclonus by memantine in a patient with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Donepezil; Excitatory Amino Acid Antagonists; Female; Humans; Indans; Meman | 2007 |
Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Circulation; Choline | 2007 |
Alzheimer's disease: will advances made in the past turn the tide?
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Cholinest | 2007 |
Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Assisted Living Facilities; Cholin | 2008 |
Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Phenylc | 2007 |
Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezi | 2008 |
Methodological matters on an Alzheimer's dementia trial: is a double-blind randomized controlled study design sufficient to draw strong conclusions on treatment? Reply to Dr Mazza and colleagues.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Double-Blind Method; Ginkgo bilob | 2007 |
Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Double-Blind Method; Ginkgo bilob | 2007 |
The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2007 |
NICE judgement leaves behind a nasty taste.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Formularies as Topic; | 2007 |
Treatment of neuropsychiatric symptoms in patients with dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Humans; Indans; | 2007 |
alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Azetidines; Brain; Cholinesterase Inhibitors; Donepezil; | 2008 |
Intraoperative floppy-iris syndrome associated with chronic intake of donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Intraoperative Compli | 2007 |
Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; California; Cholinesterase Inhibitors; Clinical P | 2007 |
Donepezil-induced chorea in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Chorea; Donepezil; Humans; In | 2007 |
Camptocormia in Alzheimer's disease: an association?
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Male; Pi | 2008 |
In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Oral; Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitor | 2008 |
Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Behavior; Benzodiazepines | 2007 |
Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Animals; Brain; Celecoxib; Disease Mo | 2008 |
For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; I | 2008 |
Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.
Topics: Aging; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Choice Behavior; Choline | 2008 |
Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2008 |
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Association Learning; Cognition; Disease Models, | 2008 |
Estimated pre-morbid IQ effects on cognitive and functional outcomes in Alzheimer disease: a longitudinal study in a treated cohort.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Donepezil; Female; Follow-Up Studies | 2008 |
Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer-Aided De | 1994 |
Alzheimer's disease: new pharmacological perspectives.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Humans; Indan | 1996 |
From the Food and Drug Administration.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Computer Communication Networks; Donepezil; Drug Appro | 1997 |
From mechanisms to drugs in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Dioxoles; Donepezil; Humans; Indans; Memory, | 1997 |
New drug available for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 1997 |
Drug treatments for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Protocols; Donepezil; Ethics, Medical; Humans | 1997 |
Advertisements for donepezil (Aricept) in the BMJ. Advertisement suggests an unrealistic improvement in mental status.
Topics: Advertising; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines | 1997 |
Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions; Humans; Indans; P | 1997 |
Donepezil (Aricept) for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Costs and Cost An | 1997 |
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Amnesia; Animals; Butyrylcholinesterase; C | 1997 |
Donepezil (Aricept) therapy for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Tacrine | 1997 |
Donepezil, Alzheimer's disease and suxamethonium.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Humans; Indans; Neuromus | 1997 |
A request for the 'Alzheimer's drug'.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Decision Making; Donepezil; Humans; Indans; Male | 1997 |
Aricept-induced nightmares in Alzheimer's disease: 2 case reports.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dreams; Female; Hu | 1998 |
Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation.
Topics: Adult; Alzheimer Disease; Brain Injuries; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; D | 1998 |
Drug and Therapeutics Bulletin defends its stance over donepezil.
Topics: Advertising; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Industry; Humans; Indans; | 1998 |
Questions about donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; P | 1998 |
Drug treatment for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Estrogen Replace | 1998 |
New drug treatments for Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Multicenter Studies as Topi | 1998 |
Donepezil for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 1998 |
Improving functioning in patients with Alzheimer's.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Treatment Outcome | 1998 |
Emerging antidementia drugs: a preliminary ethical view.
Topics: Aged; Alzheimer Disease; Beneficence; Cholinesterase Inhibitors; Dementia; Donepezil; Ethics, Medica | 1998 |
Advances in diagnosing and treating Alzheimer's disease.
Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Ta | 1998 |
New drug treatment for Alzheimer's disease. Doctors want to offer more than sympathy.
Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Female; Humans; Indans; Male; Nootropic Agen | 1998 |
The amnestic prodrome of Alzheimer's disease.
Topics: Alzheimer Disease; Cognition; Donepezil; Education, Medical; Humans; Indans; Nootropic Agents; Piper | 1998 |
Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Co | 1998 |
Alzheimer's disease management.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Mi | 1998 |
Visual form of Alzheimer's disease and its response to anticholinesterase therapy.
Topics: Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Middle Aged; | 1998 |
[50th Annual Meeting of the American Academy of Neurology (AAN). Minneapolis, 25 April--2 May 1998. 151st Annual Meeting of the American Psychiatric Association (APA). Toronto, 31 May--3 June 1998].
Topics: Alzheimer Disease; Dementia; Diagnosis, Differential; Donepezil; Humans; Indans; Neurology; Nootropi | 1998 |
Violent behavior-associated with donepezil.
Topics: Aged; Aggression; Alzheimer Disease; Cholinesterase Inhibitors; Domestic Violence; Donepezil; Humans | 1998 |
Behavioral complications associated with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Mental Disorders; Pip | 1998 |
New drug treatment for Alzheimer's disease. Effects of drugs can be variable.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Treatment Outcome | 1998 |
New drug treatment for Alzheimer's disease. Drugs should not need to show cost effectiveness to justify their prescription.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Drug Costs; Humans; Indans; Nootropic Agents; P | 1998 |
New drug treatment for Alzheimer's disease. SMAC's advice on use of donepezil is contradictory.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Practice Guidelines as | 1998 |
New drug treatment for Alzheimer's disease. Treatment with metrifonate warrants multicentre trials.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; M | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car | 1998 |
[Alzheimer's disease. Foreword].
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Humans; Inda | 1998 |
Efficacy of donepezil in Alzheimer's disease: fact or artifact?
Topics: Alzheimer Disease; Artifacts; Clinical Trials as Topic; Donepezil; Humans; Indans; Nootropic Agents; | 1999 |
Treating Alzheimer's disease with cholinergic drugs, Part 2.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Trichlorfon | 1999 |
Donepezil for postoperative delirium associated with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Delirium; Donepezil; Geriatric Assessment; Humans; Indans; Male; Nootropic | 1999 |
Convulsions induced by donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Male; Piperidines; Se | 1999 |
Disease, drugs, decisions, and dollars.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Decision Making; Donepezil; Health Care Costs; Humans; Ind | 1999 |
Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Costs and Cost Analysis; Diseas | 1999 |
Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
Topics: Aged; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Cost-Benefit Analysis; Decision Support | 1999 |
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Cholinesterase Inhibitors; Crystall | 1999 |
Brain injury, cognitive impairment, and donepezil.
Topics: Alzheimer Disease; Brain Injuries; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans | 1999 |
Effectiveness of donepezil in treating Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Drug Monitoring; Humans; Indans; Interview, Psychological; Mental Stat | 1999 |
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Data Collection; Donepezil; Humans; Indans; Marko | 1999 |
Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Down Syndrome; Female; H | 1999 |
Evidence-based psychopharmacology 1. Appraising a single therapeutic trial: what is the evidence for treating early Alzheimer's disease with donepezil?
Topics: Aged; Alzheimer Disease; Donepezil; Evidence-Based Medicine; Humans; Indans; Male; Nootropic Agents; | 1999 |
The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Humans; | 1999 |
Prescribing. Short rations.
Topics: Aged; Alzheimer Disease; Donepezil; Drug Utilization; Ethics, Medical; Health Care Rationing; Health | 1999 |
Mania associated with donepezil.
Topics: Aged; Alzheimer Disease; Bipolar Disorder; Donepezil; Female; Humans; Indans; Male; Nootropic Agents | 1999 |
[Cholinergic hypothesis and Alzheimer's disease: the place of donepezil (Aricept)].
Topics: Aged; Alzheimer Disease; Choline Deficiency; Cholinesterase Inhibitors; Clinical Trials as Topic; Do | 1999 |
The cholinergic hypothesis of Alzheimer's disease: a review of progress.
Topics: Alzheimer Disease; Cholinergic Fibers; Cholinesterase Inhibitors; Donepezil; Indans; Piperidines | 1999 |
New drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Donepezil; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperi | 1999 |
Calculation of the natural history line in the long-term extension trial and the use of the 'intent-to-treat' (ITT) principle in donepezil treatment.
Topics: Alzheimer Disease; Bias; Disease Progression; Donepezil; Humans; Indans; Nootropic Agents; Piperidin | 1999 |
Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents | 2000 |
Donepezil use in managed Medicare: effect on health care costs and utilization.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions | 1999 |
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Topics: Administration, Oral; Alzheimer Disease; Animals; Benzazepines; Brain; Carbamates; Cholinesterase In | 2000 |
Update on Alzheimer's disease: recent findings and treatments.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Risk Factors; | 2000 |
Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease.
Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Cholinesterase Inhibi | 2000 |
Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
Topics: Algorithms; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Caregivers; Ch | 2000 |
Prescribing donepezil in clinical practice.
Topics: Alzheimer Disease; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 1999 |
Use of donepezil in elderly patients with Alzheimer's disease--a Hawaii based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cholinesterase Inhibitors; Donepezil; Fema | 2000 |
The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cost of Illness; Donepezil; Humans; Indans; | 2000 |
Primary vs subspecialty care: a structured follow-up of dementia patients and their caregivers.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cohort Studies; Consumer Behavior; Donepezil | 2000 |
Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Light; Piperidines; Pupil; | 2000 |
[Extra-pyramidal syndrome induced by donepezil].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Basal Ganglia Diseases; Cholinesterase Inhibitors; Donep | 2000 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dys | 2000 |
Urinary incontinence: an unrecognised adverse effect with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Nootropic Agent | 2000 |
Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil | 2000 |
Donepezil in the treatment of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Quality | 2000 |
[Delaying Alzheimer dementia. Patient and family relieved--costs lowered].
Topics: Aged; Alzheimer Disease; Cost of Illness; Cost Savings; Donepezil; Germany; Humans; Indans; National | 2000 |
Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease.
Topics: Alzheimer Disease; Contrast Media; Cost-Benefit Analysis; Decision Trees; Donepezil; Health Care Cos | 2000 |
Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Donepezil; Drug U | 2000 |
Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Animals; Basal Nucleus of Meynert; Blood Vessels; Bra | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Ga | 2000 |
Impact of donepezil on caregiving burden for patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cost of Illness; Donepezil; Female; | 2000 |
Abnormal movements with donepezil in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Hum | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantam | 2000 |
Hypnopompic hallucinations with donepezil.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; | 2000 |
Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Alzheimer Disease; Bilirubin; Biopsy; Chemical and Dr | 2000 |
Donepezil for Down's syndrome.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Co | 2001 |
Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Donepezil; Female; Humans; Indans; Male; Middl | 2001 |
Carers' assessment of patients on donepezil--how reliable?
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidin | 2000 |
Donepezil and Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Costs; Evidence-Based Medicine; | 2000 |
[Treatment of the elderly dementia patients].
Topics: Aged; Alzheimer Disease; Benzazepines; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; In | 2000 |
Adverse effects associated with the use of donepezil in general practice in England.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Drug Prescriptions; E | 2000 |
[Early recognition not hopeless. Alzheimer disease can be delayed].
Topics: Aged; Alzheimer Disease; Donepezil; Humans; Indans; Mental Status Schedule; Nootropic Agents; Piperi | 2001 |
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Animals; Benzazepines; Brain; Butyrylcholi | 2000 |
Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease.
Topics: Alzheimer Disease; Bayes Theorem; Cost-Benefit Analysis; Decision Theory; Disease Progression; Donep | 2001 |
Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Cholinesterase Inhibitors; Computer | 2001 |
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Galant | 2001 |
Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Admini | 2001 |
Pharmacokinetic rationale for switching from donepezil to galantamine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Models, | 2001 |
Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation.
Topics: Alkaloids; Alzheimer Disease; Animals; Cell Size; Cell Survival; Cholinesterase Inhibitors; Donepezi | 2001 |
Equity in the new NHS: hard lessons from implementing a local healthcare policy on donepezil.
Topics: Aged; Alzheimer Disease; Donepezil; Drug Costs; Health Services Accessibility; Humans; Indans; Nootr | 2001 |
Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dystonia; Humans; Indans; Male; Middle Aged | 2001 |
Medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Donepezil; Estrogen Replacem | 2001 |
Featured CME topic: dementia. Medication update.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Contraindications; Donepezil; Drug Interac | 2001 |
Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inh | 2001 |
Maintaining functional and behavioral abilities in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; | 2001 |
[Relief for caregivers. Anti-dementia drug saves costs].
Topics: Aged; Alzheimer Disease; Caregivers; Cost Control; Cost of Illness; Donepezil; Humans; Indans; Nootr | 2001 |
EEG changes during long-term treatment with donepezil in Alzheimer's disease patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinestera | 2001 |
Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
Topics: Alzheimer Disease; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Donepezil; Drug Costs | 2002 |
[Effectiveness of donepezil on several cognitive functions in patients with Alzheimer's disease over 12 months].
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies | 2001 |
Unsafe prescription medication switching recommendations.
Topics: Alzheimer Disease; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Nootropic Agents; Pipe | 2001 |
Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Donepezil; Female; Gastrointestinal Diseases; H | 2002 |
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Confidence Intervals; Donepezil; Galantami | 2001 |
[Alzheimer dementia. Intervening as early as possible].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Prognosi | 2002 |
Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Choline O-Acetyltransferase; Cognition; Donepezil; D | 2001 |
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Humans; Indans; Piperidines; P | 2002 |
Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female | 2002 |
The effect of donepezil therapy on health costs in a Medicare managed care plan.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Case-Control Studies; Cost of Illness; Cost-Ben | 2002 |
Delirium caused by donepezil: a case study.
Topics: Aged; Alzheimer Disease; Atrophy; Cerebral Cortex; Delirium; Donepezil; Humans; Indans; Male; Nootro | 2002 |
Pharmacological treatment of cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Diarrhea; Donepezil; Humans; Indans; Nausea; Nootropic Agents; Piperidines; Vomit | 2002 |
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Cholinesterase Inhibit | 2001 |
ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Ap | 2002 |
New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Kidney Failure, Chron | 2002 |
Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia.
Topics: Alzheimer Disease; Animals; Brain Infarction; Brain Ischemia; Cell Death; Cholinesterase Inhibitors; | 2002 |